


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2020**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2020

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**Cumulative Supplement 9
September 2020**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

40th EDITION

**CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2020**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACP NIMBLE BUYER INC (ACP NIMBLE)	COSETTE PHARMACEUTICALS INC (COSETTE)
AMNEAL PHARMACEUTICALS CO GMBH (AMNEAL PHARMS CO)	AMNEAL EU LTD (AMNEAL EU)
AMERICAN ANTIBIOTICS INC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)

AMERICAN ANTIBIOTICS LLC (AM ANTIBIOTICS)	BELCHER PHARMACEUTICALS INC (BELCHER PHARMS)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	PHARMACEUTICS INTERNATIONAL INC (PII)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
LUPIN ATLANTIS HOLDINGS SA (LUPIN ATLANTIS)	LUPIN INC (LUPIN)
SHIRE DEVELOPMENT INC (SHIRE)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE DEV LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SHIRE DEVELOPMENT LLC (SHIRE LLC)	TAKEDA PHARMACEUTICALS USA INC (TAKEDA PHARMS USA)
SUVEN LIFE SCIENCES LTD (SUVEN LIFE)	SUVEN PHARMACEUTICALS LTD (SUVEN PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route

of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2019</u>	<u>MAR</u> <u>2020</u>	<u>JUN</u> <u>2020</u>	<u>SEP</u> <u>2020</u>	<u>DEC</u> <u>2020</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20567 2743 (13.3%)	20367 2635 (12.9%)	20382 2660 (13.1%)	20495 2652 (12.9%)	
MULTISOURCE	17824 (86.7%)	17732 (87.1%)	17722 (86.9%)	17843 (87.1%)	
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)	17649 (86.6%)	17770 (86.7%)	
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)	54 (0.3%)	
NEW MOLECULAR ENTITIES APPROVED	17	24	25	12	
NUMBER OF APPLICANTS	1162	1166	1189	1175	

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

TABLET;ORAL

ABACAVIR SULFATE

@ APOTEX INC

EQ 300MG BASE

A201570 001 Dec 17, 2012 Aug DISC

ABAMETAPIR

LOTION;TOPICAL

KEGLYZE

+! DR REDDYS LABS SA

0.74%

N206966 001 Jul 24, 2020 Jul NEWA

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB DR REDDYS LABS LTD

250MG

A208416 001 May 18, 2020 May NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@ EMCURE PHARMS LTD

25MG

A202271 001 Feb 07, 2012 Mar DISC

@

50MG

A202271 002 Feb 07, 2012 Mar DISC

@

100MG

A202271 003 Feb 07, 2012 Mar DISC

AB HANGZHOU ZHONGMEI

25MG

A213821 001 Aug 18, 2020 Aug NEWA

AB

50MG

A213821 002 Aug 18, 2020 Aug NEWA

AB

100MG

A213821 003 Aug 18, 2020 Aug NEWA

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP MYLAN

1GM/100ML (10MG/ML)

A213255 001 Aug 07, 2020 Jul NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA ! LGM PHARMA

300MG;50MG

A090956 001 Aug 23, 2011 Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA ! LGM PHARMA

300MG;50MG;40MG

A040885 001 Nov 16, 2009 Aug CAHN

AA TARO PHARM INDS LTD

300MG;50MG;40MG

A213046 001 Jul 01, 2020 Jun NEWA

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ HIKMA PHARMS

325MG;50MG;40MG

A089718 001 Jun 12, 1995 Feb DISC

AA LGM PHARMA

325MG;50MG;40MG

A209587 001 Oct 31, 2018 Aug CAHN

AA NESHER PHARMS

325MG;50MG;40MG

A211543 001 Jul 17, 2020 Jul NEWA

@ SPECGX LLC

325MG;50MG;40MG

A087804 001 Jan 24, 1985 May DISC

>A> AA STRIDES PHARMA

325MG;50MG;40MG

A203647 001 Sep 21, 2020 Sep NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

LGM PHARMA

300MG;50MG;40MG;30MG

A076560 002 Jul 19, 2012 Aug CAHN

AB

325MG;50MG;40MG;30MG

A076560 001 Jun 10, 2004 Aug CAHN

AB STRIDES PHARMA

325MG;50MG;40MG;30MG

A204649 001 Jul 08, 2020 Jul NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA WOCKHARDT BIO AG

120MG/5ML;12MG/5ML

A087006 001 Sep DISC

>A>

@

120MG/5ML;12MG/5ML

A087006 001 Sep DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A> AA NOSTRUM LABS INC

300MG;15MG

A088627 001 Mar 06, 1985 Sep CAHN

>A>

AA

300MG;30MG

A088628 001 Mar 06, 1985 Sep CAHN

>A>

!

AA

300MG;60MG

A088629 001 Mar 06, 1985 Sep CAHN

>D>

AA

TEVA

300MG;15MG

A088627 001 Mar 06, 1985 Sep CAHN

>D>

AA

AA

300MG;30MG

A088628 001 Mar 06, 1985 Sep CAHN

>D>

AA

!

AA

300MG;60MG

A088629 001 Mar 06, 1985 Sep CAHN

ACETAZOLAMIDE SODIUMINJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP ! XGEN PHARMS EQ 500MG BASE/VIAL A040784 001 Dec 10, 2008 Feb CAHN

ACETIC ACID, GLACIALSOLUTION/DROPS; OTIC
ACETIC ACID

AT SAPTALIS PHARMS 2% A040607 001 Feb 24, 2005 Mar CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONESOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

AT COSETTE 2%;1% A040609 001 Feb 06, 2006 May CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE; ORAL
SEMPREX-D

+ @ AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 Aug DISC

ACYCLOVIRCAPSULE; ORAL
ACYCLOVIR>A> AB @ DAVA PHARMS INC 200MG A074833 001 Apr 22, 1997 May DISC
YILING 200MG A212173 001 Sep 14, 2020 Sep NEWACREAM; TOPICAL
ACYCLOVIR

AB ! PERRIGO UK FINCO 5% A208702 001 Feb 04, 2019 Jan CHRS

AB + BAUSCH 5% N021478 001 Dec 30, 2002 Jan CHRS

OINTMENT; TOPICAL
ACYCLOVIR

>A> AB ANDA REPOSITORY 5% A206437 001 Jul 31, 2017 Sep CAHN

AB SOLARIS PHARMA CORP 5% A212495 001 Apr 07, 2020 Mar NEWA

>D> AB TOLMAR 5% A206437 001 Jul 31, 2017 Sep CAHN

AB XIROMED 5% A201501 001 Jan 29, 2020 Jan NEWA

SUSPENSION; ORAL
ACYCLOVIR

AB HERITAGE PHARMS INC 200MG/5ML A212718 001 Apr 23, 2020 Apr NEWA

AB NOVITIUM PHARMA 200MG/5ML A212252 001 Jul 10, 2020 Jul NEWA

TABLET; ORAL
ACYCLOVIR

AB ! HETERO LABS LTD V 800MG A203834 002 Oct 29, 2013 Jan CHRS

ZOVIRAX

+ @ MYLAN 400MG N020089 001 Apr 30, 1991 Jan DISC

+ @ 800MG N020089 002 Apr 30, 1991 Jan DISC

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP EXELA PHARMA EQ 50MG BASE/ML A207919 001 Jun 17, 2020 Jun NEWA

ADAPALENEGEL; TOPICAL
ADAPALENE

AB ALEOR DERMACEUTICALS 0.3% A213508 001 Jun 18, 2020 Jun NEWA

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

@ MYLAN LABS LTD 3MG/ML A078640 001 Mar 21, 2014 Apr DISC

AIR POLYMER-TYPE AFOAM; INTRAUTERINE
EXEM FOAM KIT

+ @ GISKIT 10ML N212279 001 Nov 07, 2019 Jul CAHN

+ @ 10ML N212279 001 Nov 07, 2019 Jul CAHN

+ @ 10ML N212279 001 Nov 07, 2019 Jun DISC

ALBENDAZOLE

TABLET; ORAL
ALBENDAZOLE

AB LUPIN LTD 200MG A211636 001 Jun 10, 2020 Jun NEWA

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
ALBUTEROL SULFATE

AB1 CIPLA EQ 0.09MG BASE/INH A209959 001 Apr 08, 2020 Mar NFTG
>A> AB2 LUPIN EQ 0.09MG BASE/INH A209954 001 Aug 24, 2020 Sep CAHN
>D> AB2 LUPIN ATLANTIS EQ 0.09MG BASE/INH A209954 001 Aug 24, 2020 Sep CAHN
AB2 EQ 0.09MG BASE/INH A209954 001 Aug 24, 2020 Aug NEWA
AB2 PERRIGO PHARMS CO EQ 0.09MG BASE/INH A203760 001 Feb 24, 2020 Mar CTEC
AB EQ 0.09MG BASE/INH A203760 001 Feb 24, 2020 Feb NFTG
PROAIR HFA
AB2 +! TEVA BRANDED PHARM EQ 0.09MG BASE/INH N021457 001 Oct 29, 2004 Mar CTEC
AB +! EQ 0.09MG BASE/INH N021457 001 Oct 29, 2004 Feb CFTG
PROVENTIL-HFA
AB1 +! 3M DRUG DELIVERY EQ 0.09MG BASE/INH N020503 001 Aug 15, 1996 Mar CFTG
AB1 +! KINDEVA EQ 0.09MG BASE/INH N020503 001 Aug 15, 1996 May CAHN

SOLUTION; INHALATION
ALBUTEROL SULFATE

AN AUROBINDO PHARMA LTD EQ 0.021% BASE A211888 001 Apr 20, 2020 Apr NEWA
AN EQ 0.042% BASE A211888 002 Apr 20, 2020 Apr NEWA
@ BAUSCH AND LOMB EQ 0.5% BASE A075050 001 Jun 18, 1998 Feb DISC
AN ! NEPHRON EQ 0.5% BASE A075664 001 Jun 26, 2001 Feb CHRS

SYRUP; ORAL

ALBUTEROL SULFATE
@ VISTAPHARM

EQ 2MG BASE/5ML A077788 001 Jun 26, 2007 Jul DISC

TABLET; ORAL

ALBUTEROL SULFATE
@ ARISE

EQ 2MG BASE A210948 001 Mar 15, 2019 Jul DISC

@ EQ 4MG BASE A210948 002 Mar 15, 2019 Jul DISC

AB AUROBINDO PHARMA LTD EQ 2MG BASE A213657 001 May 14, 2020 May NEWA

AB EQ 4MG BASE A213657 002 May 14, 2020 May NEWA

AB RISING EQ 2MG BASE A207046 001 Jun 29, 2018 Jul CAHN

AB EQ 4MG BASE A207046 002 Jun 29, 2018 Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

VOLMAX

+ @ MURO EQ 4MG BASE N019604 002 Dec 23, 1992 Mar CRLD

+ @ EQ 8MG BASE N019604 001 Dec 23, 1992 Mar CRLD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN AUROBINDO PHARMA LTD EQ 0.083% BASE; 0.017% A206532 001 Jul 08, 2020 Jul NEWA

@ WATSON LABS TEVA EQ 0.083% BASE; 0.017% A077063 001 Dec 31, 2007 Apr DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

@ EYWA PHARMA EQ 0.5MG BASE A211621 001 Sep 16, 2019 Apr DISC

@ EQ 1MG BASE A211621 002 Sep 16, 2019 Apr DISC

AB MANKIND PHARMA EQ 0.5MG BASE A213614 001 Sep 09, 2020 Aug NEWA

AB EQ 1MG BASE A213614 002 Sep 09, 2020 Aug NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ DAVA INTL INC 0.25MG A074174 001 Oct 19, 1993 Feb DISC

@ 0.5MG A074174 002 Oct 19, 1993 Feb DISC

@ 1MG A074174 003 Oct 19, 1993 Feb DISC

@ 2MG A074174 004 Oct 19, 1993 Feb DISC

@ OXFORD PHARMS 0.25MG A078491 001 Sep 25, 2008 Jun DISC

@ 0.5MG A078491 002 Sep 25, 2008 Jun DISC

@ 1MG A078491 003 Sep 25, 2008 Jun DISC

@ 2MG A078491 004 Dec 12, 2008 Jun DISC

XANAX

AB + UPJOHN 0.25MG N018276 001 Apr CAHN

AB + 0.5MG N018276 002 Apr CAHN

AB +! 1MG N018276 003 Apr CAHN

		TABLET;ORAL							
		XANAX							
AB	+		2MG	N018276	004	Nov 27, 1985	Apr	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		XANAX XR							
AB	+	UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN	
AB	+		1MG	N021434	002	Jan 17, 2003	Apr	CAHN	
AB	+		2MG	N021434	003	Jan 17, 2003	Apr	CAHN	
AB	+!		3MG	N021434	004	Jan 17, 2003	Apr	CAHN	
<u>ALVIMOPAN</u>									
		CAPSULE;ORAL							
		ALVIMOPAN							
		@ WATSON LABS TEVA		12MG	A208295	001	Dec 19, 2019	Jun	DISC
		ENTEREG							
		+! CUBIST PHARMS		12MG	N021775	001	May 20, 2008	Jun	CTEC
<u>AMANTADINE HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		AMANTADINE HYDROCHLORIDE							
AB	!	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jun	CHRS	
>D>	AB	INVATECH	100MG	A210129	001	Mar 02, 2020	Sep	CAHN	
	AB		100MG	A210129	001	Mar 02, 2020	Feb	NEWA	
>A>	AB	NOVELGENIX THERAPS	100MG	A210129	001	Mar 02, 2020	Sep	CAHN	
	AB	RUBICON	100MG	A212044	001	May 21, 2020	May	NEWA	
	AB	SANDOZ	100MG	A071293	001	Feb 18, 1987	Jun	CHRS	
		TABLET;ORAL							
		AMANTADINE HYDROCHLORIDE							
>D>	AB	INVATECH	100MG	A210215	001	Mar 10, 2020	Sep	CAHN	
	AB		100MG	A210215	001	Mar 10, 2020	Feb	NEWA	
>A>	AB	NOVELGENIX THERAPS	100MG	A210215	001	Mar 10, 2020	Sep	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		OSMOLEX ER							
>D>	+	OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Sep	DISC	
>A>	+	@	EQ 161MG BASE	N209410	004	Apr 22, 2020	Sep	DISC	
	+		EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr	NEWA	
<u>AMIKACIN SULFATE</u>									
		INJECTABLE;INJECTION							
		AMIKACIN SULFATE							
AP		TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar	CMFD	
<u>AMILORIDE HYDROCHLORIDE</u>									
		TABLET;ORAL							
		AMILORIDE HYDROCHLORIDE							
>A>	AB	ANDA REPOSITORY	5MG	A204180	001	Aug 07, 2015	Sep	CAHN	
>D>	AB	WINDLAS HLTHCARE	5MG	A204180	001	Aug 07, 2015	Sep	CAHN	
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL</u>									
		EMULSION;INTRAVENOUS							
		PERIKABIVEN IN PLASTIC CONTAINER							
		+! FRESENIUS KABI USA		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan	CHRS
<u>AMINOCAPROIC ACID</u>									
		SYRUP;ORAL							
		AMINOCAPROIC ACID							
AA		TULEX PHARMS INC	1.25GM/5ML	A212494	001	Aug 11, 2020	Jul	NEWA	
AA		VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA	
<u>AMIODARONE HYDROCHLORIDE</u>									
		TABLET;ORAL							
		AMIODARONE HYDROCHLORIDE							
AB		UNICHEM	200MG	A213446	001	Jul 21, 2020	Jul	NEWA	
AB	!	UPSHER SMITH LABS	200MG	A075315	001	Dec 23, 1998	Aug	CAHN	
AB			400MG	A075315	002	Jun 30, 2000	Aug	CAHN	

AMISULPRIDESOLUTION; INTRAVENOUS
BARHEMSYS

	+!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020	Feb NEWA
>A>	+!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		SANDOZ	10MG	A085968	004		Jan CMS1
AB	!		25MG	A085968	002		Jan CMS1
AB			75MG	A085968	006		Jan CMS1
AB			100MG	A085968	003		Jan CMS1
AB			150MG	A085968	005		Jan CMS1
	@	UPSHER SMITH LABS	25MG	A212654	001	Apr 07, 2020	May DISC
AB			25MG	A212654	001	Apr 07, 2020	Mar NEWA

AMLODIPINE BENZOATE

SUSPENSION; ORAL

KATERZIA

	+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	May CAHN
--	----	---------	----------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	HEBEI CHANGSHAN	EQ 2.5MG BASE	A076692	001	Jul 20, 2007	Sep CAHN
>D>	AB		EQ 5MG BASE	A076692	002	Jul 20, 2007	Sep CAHN
>D>	AB		EQ 10MG BASE	A076692	003	Jul 20, 2007	Sep CAHN
	@	HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007	Feb DISC
	@		EQ 5MG BASE	A077262	002	Jul 09, 2007	Feb DISC
	@		EQ 10MG BASE	A077262	003	Jul 09, 2007	Feb DISC
>D>	AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Sep DISC
>A>	@		EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Sep DISC
>D>	AB		EQ 5MG BASE	A077771	002	Apr 12, 2011	Sep DISC
>A>	@		EQ 5MG BASE	A077771	002	Apr 12, 2011	Sep DISC
>D>	AB		EQ 10MG BASE	A077771	003	Apr 12, 2011	Sep DISC
>A>	@		EQ 10MG BASE	A077771	003	Apr 12, 2011	Sep DISC
	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	May DISC
	@		EQ 10MG BASE	A201380	002	Apr 13, 2012	May DISC
	@	MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Jul DISC
	@		EQ 5MG BASE	A076418	002	Oct 03, 2005	Jul DISC
	@		EQ 10MG BASE	A076418	003	Oct 03, 2005	Jul DISC
	@	WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007	Apr DISC
	@		EQ 5MG BASE	A077671	002	Jul 19, 2007	Apr DISC
	@		EQ 10MG BASE	A077671	003	Jul 19, 2007	Apr DISC
>A>	AB	YILING	EQ 2.5MG BASE	A076692	001	Jul 20, 2007	Sep CAHN
>A>	AB		EQ 5MG BASE	A076692	002	Jul 20, 2007	Sep CAHN
>A>	AB		EQ 10MG BASE	A076692	003	Jul 20, 2007	Sep CAHN
		NORVASC					
AB	+	UPJOHN	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jun CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jun CAHN
AB	+!		EQ 10MG BASE	N019787	003	Jul 31, 1992	Jun CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb CMFD
AB			EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb CMFD
AB			EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb CMFD
AB			EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CMFD
AB			EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CMFD
		CADUET					
AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	May CAHN
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	May CAHN
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	May CAHN

TABLET; ORAL
CADUET

AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	May CAHN
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	May CAHN
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	May CAHN
AB	+	PHARMACIA	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	May CAHN
AB	+		EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Aug CAHN
AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Aug CAHN
AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Aug CAHN
AB	+		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Aug CAHN
AB	+		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Aug CAHN
AB	+		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Aug CAHN
AB	+		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Aug CAHN
AB	+		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Aug CAHN
AB	+		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Aug CAHN
AB	+		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Aug CAHN
AB	+		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Aug CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	PAR PHARM	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	May DISC
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	May DISC
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	May DISC
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	May DISC
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	May DISC
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	May DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul CMFD
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul CMFD
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul CMFD
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul CMFD
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul CMFD

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar CPOT
AB		EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar CPOT
AB	LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar CPOT
AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar CPOT
AB		EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar CPOT
AB	@ PAR PHARM	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar CPOT
AB	@	EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	May DISC
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar CPOT
AB	@	EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar CPOT
AB	@	EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar CPOT
AB	@	EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	May DISC
AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar CPOT
AB	@ TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar CPOT
AB	@	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar CPOT
AB	@	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar CPOT
AB	@	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar CPOT
AB	@	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar CPOT
AB	@ TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar CPOT
AB	@	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar CPOT
AB	@	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar CPOT
AB	@	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar CPOT
AB	@	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar CPOT

TABLET; ORAL
EXFORGE HCT

AB	+	NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar CPOT
AB	+		EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar CPOT
AB	+		EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar CPOT
AB	+		EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar CPOT
AB	+	!	EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar CPOT

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL
AMLODIPINE BESYLATE AND VALSARTAN

	@	PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun DISC
	@		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun DISC
	@		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun DISC
	@		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP		CARDINAL HLTH 414	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203700	001	Feb 25, 2013	May CAHN
AP		UNIV WISCONSIN	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A211740	001	Sep 09, 2020	Aug NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

	@	WATSON LABS INC	EQ 12% BASE	A076829	001	Feb 07, 2006	Apr DISC
--	---	-----------------	-------------	---------	-----	--------------	----------

LOTION; TOPICAL

	@	WATSON LABS INC	EQ 12% BASE	A075575	001	Jun 11, 2002	Apr DISC
--	---	-----------------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET; ORAL

	@	WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989	Jan CMS1
	@		50MG	A072419	001	Aug 01, 1989	Jan CMS1

AMOXICILLIN

CAPSULE; ORAL

	@	DAVA PHARMS INC	250MG	A062884	001	Feb 25, 1988	Jul DISC
	@		500MG	A062881	001	Feb 25, 1988	Jul DISC

TABLET, CHEWABLE; ORAL

		HIKMA	125MG	A205274	001	Jun 25, 2020	Jun NEWA
			250MG	A205274	002	Jun 25, 2020	Jun NEWA
		TEVA	125MG	A064013	002	Sep 11, 1995	Jun CTEC
		!	250MG	A064013	001	Dec 22, 1992	Jun CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	+	NEOPHARMA	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Jul CMFD
--	---	-----------	------------------------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

>D>	AB	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Sep CHRS	
>A>	!		1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Sep CTEC	
>A>	AB	!	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010	Sep CHRS	
>D>		AUGMENTIN XR						
>D>	AB	+!	NEOPHARMA	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Sep DISC
>A>		+ @		1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	Sep DISC

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

		ANI PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan CAHN
			2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan CAHN
			3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan CAHN
			5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan CAHN
			6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan CAHN
			7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan CAHN
		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037	001	Dec 11, 2019	May CAHN
			2.5MG;2.5MG;2.5MG;2.5MG	A212037	002	Dec 11, 2019	May CAHN

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	May	CAHN		
AB		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	May	CAHN		
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	May	CAHN		
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	May	CAHN		
AB	MYLAN	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211876	001	Jun 24, 2020	Jun	NEWA		
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211876	002	Jun 24, 2020	Jun	NEWA		
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211876	003	Jun 24, 2020	Jun	NEWA		
AB		5MG; 5MG; 5MG; 5MG	A211876	004	Jun 24, 2020	Jun	NEWA		
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211876	005	Jun 24, 2020	Jun	NEWA		
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211876	006	Jun 24, 2020	Jun	NEWA		
	@ NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019	Jan	DISC		
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019	Jan	DISC		
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019	Jan	DISC		
	@	5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019	Jan	DISC		
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019	Jan	DISC		
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019	Jan	DISC		
AB	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Apr	CMFD		
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Apr	CMFD		
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Apr	CMFD		
AB		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Apr	CMFD		
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Apr	CMFD		
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Apr	CMFD		
	@ TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr	DISC		
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr	DISC		
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr	DISC		
	@	5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr	DISC		
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr	DISC		
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr	DISC		
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
	@ BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Apr	DISC		
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Apr	DISC		
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Apr	DISC		
	@	5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013	Apr	DISC		
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013	Apr	DISC		
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013	Apr	DISC		

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE									
AB	BIONPHARMA INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Mar	NEWA		
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Mar	NEWA		
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Mar	NEWA		
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Mar	NEWA		
AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Mar	NEWA		
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Mar	NEWA		
AB	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211352	001	Dec 07, 2018	May	CAHN		
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A211352	002	Dec 07, 2018	May	CAHN		
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211352	003	Dec 07, 2018	May	CAHN		
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211352	004	Dec 07, 2018	May	CAHN		
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211352	005	Dec 07, 2018	May	CAHN		
AB		5MG; 5MG; 5MG; 5MG	A211352	006	Dec 07, 2018	May	CAHN		
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211352	007	Dec 07, 2018	May	CAHN		

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan	NEWA		
AA		10MG	A212582	002	Feb 04, 2020	Jan	NEWA		
AA	HAVIX	5MG	A212901	001	May 22, 2020	May	NEWA		
AA		10MG	A212901	002	May 22, 2020	May	NEWA		
AA	MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jul	NEWA		
AA		10MG	A213898	002	Jul 14, 2020	Jul	NEWA		
>A>	AA	NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Sep	CAHN	
>A>	AA		10MG	A213763	002	Aug 24, 2020	Sep	CAHN	
AA	PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb	NEWA		
AA		10MG	A211861	002	Mar 11, 2020	Feb	NEWA		
>D>	AA	RICONPHARMA LLC	5MG	A213763	001	Aug 24, 2020	Sep	CAHN	
AA		5MG	A213763	001	Aug 24, 2020	Aug	NEWA		
>D>	AA		10MG	A213763	002	Aug 24, 2020	Sep	CAHN	
AA		10MG	A213763	002	Aug 24, 2020	Aug	NEWA		

AMPHOTERICIN BINJECTABLE; INJECTION
AMPHOTERICIN B

! XGEN PHARMS 50MG/VIAL A063206 001 Apr 29, 1992 Feb CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM@ PHARM ASSOC EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL A065316 001 Jun 29, 2007 Jan CAHN
@ EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL A065316 002 Jun 29, 2007 Jan CAHNAMPICILLIN/AMPICILLIN TRIHYDRATECAPSULE; ORAL
AMPICILLIN TRIHYDRATE@ DAVA PHARMS INC EQ 250MG BASE A062883 001 Feb 25, 1988 Aug DISC
@ EQ 500MG BASE A062882 001 Feb 25, 1988 Mar DISC
SANDOZ EQ 250MG BASE A064082 001 Aug 29, 1995 Aug CTEC
! EQ 500MG BASE A064082 002 Aug 29, 1995 Mar CHRSFOR SUSPENSION; ORAL
AMPICILLIN TRIHYDRATE@ DAVA PHARMS INC EQ 125MG BASE/5ML A062982 001 Feb 10, 1989 Jul DISC
@ EQ 250MG BASE/5ML A062982 002 Feb 10, 1989 Jul DISCANAGRELIDE HYDROCHLORIDECAPSULE; ORAL
ANAGRELIDE HYDROCHLORIDE@ BARR EQ 0.5MG BASE A076530 001 Apr 18, 2005 Apr DISC
@ EQ 1MG BASE A076530 002 Apr 18, 2005 Apr DISCANASTROZOLETABLET; ORAL
ANASTROZOLEAB @ APOTEX INC 1MG A200654 001 May 11, 2012 Feb DISC
>D> AB EUGIA PHARMA 1MG A212434 001 Jul 24, 2020 Jul NEWA
>A> AB HIKMA 1MG A078485 001 Jun 28, 2010 Sep DISC
>A> @ 1MG A078485 001 Jun 28, 2010 Sep DISC
@ MYLAN 1MG A091051 001 Jun 28, 2010 Jan DISCAPIXABANTABLET; ORAL
APIXABANAB ACCORD HLTHCARE 2.5MG A210180 001 Jul 28, 2020 Jul NEWA
AB 5MG A210180 002 Jul 28, 2020 Jul NEWA
@ BIONPHARMA INC 2.5MG A210152 001 Apr 08, 2020 Jul DISC
AB 2.5MG A210152 001 Apr 08, 2020 Mar NEWA
@ 5MG A210152 002 Apr 08, 2020 Jul DISC
AB 5MG A210152 002 Apr 08, 2020 Mar NEWA
>A> AB INDOCO 2.5MG A209898 001 Sep 11, 2020 Sep NEWA
>A> AB 5MG A209898 002 Sep 11, 2020 Sep NEWA
@ MICRO LABS 2.5MG A210013 001 Dec 23, 2019 Jun DISC
@ 5MG A210013 002 Dec 23, 2019 Jun DISC
@ MYLAN 2.5MG A210128 001 Dec 23, 2019 Jan DISC
@ 5MG A210128 002 Dec 23, 2019 Jan DISC
ELIQUIS
>D> + BRISTOL MYERS SQUIBB 2.5MG N202155 001 Dec 28, 2012 Sep CTEC
>A> AB + 2.5MG N202155 001 Dec 28, 2012 Sep CTEC
+ 2.5MG N202155 001 Dec 28, 2012 Jul CTEC
>D> +! 5MG N202155 002 Dec 28, 2012 Sep CTEC
>A> AB +! 5MG N202155 002 Dec 28, 2012 Sep CTEC
+! 5MG N202155 002 Dec 28, 2012 Jul CTECAPOMORPHINE HYDROCHLORIDEFILM; SUBLINGUAL
KYNMOBI+ SUNOVION PHARMS INC 10MG N210875 001 May 21, 2020 May NEWA
+ 15MG N210875 002 May 21, 2020 May NEWA
+ 20MG N210875 003 May 21, 2020 May NEWA
+ 25MG N210875 004 May 21, 2020 May NEWA
+! 30MG N210875 005 May 21, 2020 May NEWA

INJECTABLE; SUBCUTANEOUS

APOKYN

	@ MDD US	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004	Jul	CAHN
+	!	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Jul	CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	+	!	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CHRS
AP	+			250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CRLD

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

	@ TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar	DISC
--	-------------------	----------------------	---------	-----	--------------	-----	------

ARTESUNATE

POWDER; INTRAVENOUS

ARTESUNATE

+	!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	May	NEWA
---	---	--------	------------	---------	-----	--------------	-----	------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

+	!	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971	002	Mar 30, 2006	Aug	CMS1
+	!		4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

+		ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan	CMS1
---	--	----------	---------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	AA	!	HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Sep	DISC
>A>		@		325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Sep	DISC
>D>	AA		STRIDES PHARMA	325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Sep	CHRS
>A>		!		325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Sep	CTEC
>A>	AA	!		325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Sep	CHRS
	AA			325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Mar	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		LGM PHARMA	325MG; 50MG; 40MG; 30MG	A075231	001	Nov 30, 2001	Aug	CAHN
----	--	------------	-------------------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC FORTE

!		GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Jul	CMFD
---	--	-------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

	@	HERITAGE PHARMS INC	325MG; 200MG	A089594	001	Mar 31, 1989	May	DISC
	@	NOVAST LABS	325MG; 200MG	A040832	001	Jan 07, 2010	May	DISC
	@	SANDOZ	325MG; 200MG	A040116	001	Apr 25, 1996	May	DISC

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

	@	STEVENS J	325MG; 400MG	A081145	001	Jan 31, 1995	Jul	DISC
--	---	-----------	--------------	---------	-----	--------------	-----	------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	@	ACTAVIS LABS FL INC	325MG; 4.8355MG	A090084	001	Mar 22, 2011	Jun	DISC
AA		EPIC PHARMA LLC	325MG; 4.8355MG	A040910	001	Jul 16, 2020	Jul	NEWA

ASPIRIN; PRAVASTATIN SODIUM

TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)

	@ BRISTOL MYERS SQUIBB	81MG;20MG	N021387	001	Jun 24, 2003	May CPOT
	@	81MG,N/A;N/A,20MG	N021387	001	Jun 24, 2003	May CDFR
	@	81MG;40MG	N021387	002	Jun 24, 2003	May CPOT
	@	81MG,N/A;N/A,40MG	N021387	002	Jun 24, 2003	May CDFR
	@	81MG;80MG	N021387	003	Jun 24, 2003	May CPOT
	@	81MG,N/A;N/A,80MG	N021387	003	Jun 24, 2003	May CDFR
	@	325MG;20MG	N021387	004	Jun 24, 2003	May CPOT
	@	325MG,N/A;N/A,20MG	N021387	004	Jun 24, 2003	May CDFR
	@	325MG;40MG	N021387	005	Jun 24, 2003	May CPOT
	@	325MG,N/A;N/A,40MG	N021387	005	Jun 24, 2003	May CDFR
	@	325MG;80MG	N021387	006	Jun 24, 2003	May CPOT
	@	325MG,N/A;N/A,80MG	N021387	006	Jun 24, 2003	May CDFR

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

	@ AMNEAL	EQ 100MG BASE	A209717	001	Jun 01, 2020	Aug DISC
AB		EQ 100MG BASE	A209717	001	Jun 01, 2020	May NEWA
AB		EQ 150MG BASE	A209717	002	Jun 01, 2020	May NEWA
AB		EQ 200MG BASE	A209717	003	Jun 01, 2020	May NEWA
AB		EQ 300MG BASE	A209717	004	Jun 01, 2020	May NEWA
	@ MYLAN	EQ 150MG BASE	A208177	001	Sep 24, 2018	Feb DISC
	@	EQ 200MG BASE	A208177	002	Sep 24, 2018	Feb DISC
	@	EQ 300MG BASE	A208177	003	Sep 24, 2018	Feb DISC
AB	ZYDUS PHARMS	EQ 150MG BASE	A210575	001	Jun 04, 2020	Jun NEWA
AB		EQ 200MG BASE	A210575	002	Jun 04, 2020	Jun NEWA
AB		EQ 300MG BASE	A210575	003	Jun 04, 2020	Jun NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	HLTHCARE	25MG	A073026	002	May 01, 1992	Jun CMS1
AB		50MG	A073026	003	Sep 17, 1991	Jun CMS1

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

	@ MYLAN	50MG;25MG	A074203	001	Oct 31, 1993	May DISC
	@	100MG;25MG	A074203	002	Oct 31, 1993	May DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Jan CMFD
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Jan CMFD
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Jan CMFD
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Jan CMFD
	@ PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020	Jul DISC
AB		EQ 10MG BASE	A208478	001	Jun 23, 2020	Jun NEWA
	@	EQ 20MG BASE	A208478	002	Jun 23, 2020	Jul DISC
AB		EQ 20MG BASE	A208478	002	Jun 23, 2020	Jun NEWA
AB	UMEDICA LABS PVT LTD	EQ 10MG BASE	A213853	001	Aug 19, 2020	Aug NEWA
AB		EQ 20MG BASE	A213853	002	Aug 19, 2020	Aug NEWA
AB		EQ 40MG BASE	A213853	003	Aug 19, 2020	Aug NEWA
AB		EQ 80MG BASE	A213853	004	Aug 19, 2020	Aug NEWA
	LIPITOR					
AB	+ UPJOHN	EQ 10MG BASE	N020702	001	Dec 17, 1996	Jun CAHN
AB	+	EQ 20MG BASE	N020702	002	Dec 17, 1996	Jun CAHN
AB	+	EQ 40MG BASE	N020702	003	Dec 17, 1996	Jun CAHN
AB	+	EQ 80MG BASE	N020702	004	Apr 07, 2000	Jun CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	@ SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr DISC
		EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Mar CAHN
	@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr DISC
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Mar CAHN
	@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr DISC

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Mar	CAHN
	@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr	DISC
	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Mar	CAHN

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

>A>	+	!	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Sep	NEWA
>A>	+	!		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	Sep	NEWA
	+	!	HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug	CTNA
	+	!		0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Aug	CDFR
	+	@		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug	CTNA
	+	@		0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Aug	CDFR
	+	!		0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Aug	CTNA
	+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug	CTNA
	+	!		1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Aug	CDFR
>D>	+	!		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Sep	CFTG
>A>	AA	+		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Sep	CFTG
		+		1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Aug	CTNA
>A>	AA		INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Sep	NEWA

SOLUTION/DROPS;OPHTHALMIC

ISOPTO ATROPINE

	+	!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb	CRLD
		!		1%	N208151	001	Dec 01, 2016	Feb	CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA			LEADING PHARMA LLC	0.025MG;2.5MG	A213413	001	Feb 20, 2020	Feb	NEWA
AA			MAYNE PHARMA INC	0.025MG;2.5MG	A210789	001	Jun 03, 2020	May	NEWA
		@	PAR PHARM	0.025MG;2.5MG	A040357	001	May 02, 2000	May	DISC
>A>	AA		SPECGX LLC	2.5MG;0.025MG	A213335	001	Oct 06, 2020	Sep	NEWA

LOMOTIL

>D>	AA	+	GD SEARLE LLC	0.025MG;2.5MG	N012462	001		Sep	CAHN
>A>	AA	+	PFIZER	0.025MG;2.5MG	N012462	001		Sep	CAHN

AVAPRITINIB

TABLET;ORAL

AYVAKIT

	+		BLUEPRINT MEDICINES	100MG	N212608	001	Jan 09, 2020	Jan	NEWA
	+			200MG	N212608	002	Jan 09, 2020	Jan	NEWA
	+	!		300MG	N212608	003	Jan 09, 2020	Jan	NEWA

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP			EUROHLTH INTL SARL	100MG/VIAL	A209337	001	Jun 08, 2020	Jun	NEWA
----	--	--	--------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

ONUREG

>A>		+	CELGENE CORP	200MG	N214120	001	Sep 01, 2020	Sep	NEWA
>A>		+		300MG	N214120	002	Sep 01, 2020	Sep	NEWA

AZATHIOPRINE

TABLET;ORAL

AZATHIOPRINE

AB			ALKEM LABS LTD	25MG	A208687	001	Mar 27, 2020	Mar	NEWA
AB				50MG	A208687	002	Mar 27, 2020	Mar	NEWA
AB				75MG	A208687	003	Mar 27, 2020	Mar	NEWA
AB				100MG	A208687	004	Mar 27, 2020	Mar	NEWA
AB			RISING	50MG	A075568	001	Dec 13, 1999	May	CAHN

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

AZELAIC ACID

>A>	AB		TEVA PHARMS USA	15%	A210928	001	Oct 07, 2020	Sep	NFTG
-----	----	--	-----------------	-----	---------	-----	--------------	-----	------

FINACEA

>D>		+	LEO PHARMA AS	15%	N207071	001	Jul 29, 2015	Sep	CFTG
>A>	AB	+		15%	N207071	001	Jul 29, 2015	Sep	CFTG

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC		AZELASTINE HYDROCHLORIDE					
AT	GLAND PHARMA LTD	0.05%		A210092	001	Feb 25, 2020	Feb NEWA
SPRAY, METERED;NASAL		AZELASTINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY		A212289	001	May 08, 2020	Apr NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL		AZITHROMYCIN					
	@ TARO	EQ 200MG BASE/5ML		A211521	001	Dec 11, 2019	May DISC
	@ TEVA PHARMS	EQ 100MG BASE/5ML		A065419	001	Jun 24, 2008	Apr DISC
	@	EQ 200MG BASE/5ML		A065419	002	Jun 24, 2008	Apr DISC
INJECTABLE;INJECTION		AZITHROMYCIN					
	@ HIKMA	EQ 500MG BASE/VIAL		A065265	001	Jan 18, 2007	Mar CAHN
	@ MYLAN LABS LTD	EQ 500MG BASE/VIAL		A204732	001	Jan 26, 2017	Mar DISC
TABLET;ORAL		AZITHROMYCIN					
AB	ALEMBIC PHARMS LTD	EQ 250MG BASE		A211791	001	Jan 28, 2020	Jan NEWA
AB		EQ 500MG BASE		A211792	001	Jan 28, 2020	Jan NEWA
AB		EQ 600MG BASE		A211793	001	Jan 27, 2020	Jan NEWA
	@ MYLAN	EQ 600MG BASE		A065360	001	Jan 08, 2007	Jan DISC
	@ YUNG SHIN PHARM	EQ 600MG BASE		A211068	001	May 08, 2020	Jun DISC
AB		EQ 600MG BASE		A211068	001	May 08, 2020	Apr NEWA

BACITRACIN

INJECTABLE;INJECTION

BACIIM

	@ X GEN PHARMS	50,000 UNITS/VIAL		A064153	001	May 09, 1997	Mar DISC
BACITRACIN							
	@ AKORN	50,000 UNITS/VIAL		A206719	001	Oct 20, 2017	Mar DISC
	@ FRESENIUS KABI USA	50,000 UNITS/VIAL		A065116	001	Dec 03, 2002	Mar DISC
	@ PHARMACIA AND UPJOHN	50,000 UNITS/VIAL		A060733	002		Aug DISC
!	XELLIA PHARMS APS	50,000 UNITS/VIAL		A203177	001	Aug 25, 2014	Aug CHRS
		50,000 UNITS/VIAL		A203177	001	Aug 25, 2014	Aug CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	+ CASPER PHARMA LLC	EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM		N050417	001		May CTNA
----	---------------------	--	--	---------	-----	--	----------

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

	@ MAIA PHARMS INC	0.5MG/ML		A210048	001	Sep 11, 2019	Mar DISC
	@	2MG/ML		A210048	002	Sep 11, 2019	Mar DISC

TABLET;ORAL

BACLOFEN

	@ MYLAN	20MG		A077121	002	Jul 29, 2005	Jan DISC
	@ MYLAN PHARMS INC	10MG		A090334	001	Feb 18, 2010	Apr DISC
	@	20MG		A090334	002	Feb 18, 2010	Apr DISC
AB	RUBICON	5MG		A209102	001	Nov 28, 2017	Apr CTEC
AB	UNICHEM	10MG		A212067	001	Jul 09, 2020	Jul NEWA
AB		20MG		A212067	002	Jul 09, 2020	Jul NEWA
AB	ZYDUS	5MG		A211659	003	Apr 17, 2020	Apr NEWA

BARIUM SULFATE

SUSPENSION;ORAL

ENTERO VU 24%

+	BRACCO	24% (144GM/600ML)		N208143	008	May 29, 2020	Jun NEWA
---	--------	-------------------	--	---------	-----	--------------	----------

BEDAQUILINE FUMARATE

TABLET;ORAL

SIRTURO

+	JANSSEN THERAP	EQ 20MG BASE		N204384	002	May 27, 2020	May NEWA
---	----------------	--------------	--	---------	-----	--------------	----------

BEMPEDOIC ACIDTABLET;ORAL
NEXLETOL

+! ESPERION THERAPS INC 180MG N211616 001 Feb 21, 2020 Feb NEWA

BEMPEDOIC ACID; EZETIMIBETABLET;ORAL
NEXLIZET

+! ESPERION THERAPS INC 180MG;10MG N211617 001 Feb 26, 2020 Feb NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE

>A>	AB	ANNORA PHARMA	5MG	A077128	001	Mar 08, 2006	Sep	CAHN
>A>	AB		10MG	A077128	002	Mar 08, 2006	Sep	CAHN
>A>	AB		20MG	A077128	003	Mar 08, 2006	Sep	CAHN
>A>	AB		40MG	A077128	004	Mar 08, 2006	Sep	CAHN
>D>	AB	COREPHARMA	5MG	A077128	001	Mar 08, 2006	Sep	CAHN
	AB		5MG	A077128	001	Mar 08, 2006	Feb	CAHN
>D>	AB		10MG	A077128	002	Mar 08, 2006	Sep	CAHN
	AB		10MG	A077128	002	Mar 08, 2006	Feb	CAHN
>D>	AB		20MG	A077128	003	Mar 08, 2006	Sep	CAHN
	AB		20MG	A077128	003	Mar 08, 2006	Feb	CAHN
>D>	AB		40MG	A077128	004	Mar 08, 2006	Sep	CAHN
	AB		40MG	A077128	004	Mar 08, 2006	Feb	CAHN
		@ MYLAN	5MG	A076430	001	Feb 11, 2004	Jul	DISC
		@	10MG	A076430	002	Feb 11, 2004	Jul	DISC
		@	20MG	A076430	003	Feb 11, 2004	Jul	DISC
		@	40MG	A076430	004	Feb 11, 2004	Jul	DISC

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014	Jun	DISC
@		10MG;12.5MG	A078794	002	Aug 21, 2014	Jun	DISC
@		20MG;12.5MG	A078794	003	Aug 21, 2014	Jun	DISC
@		20MG;25MG	A078794	004	Aug 21, 2014	Jun	DISC

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%;0.3% N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

@	EMCURE PHARMS LTD	50MG	A202061	001	Jan 27, 2012	Mar	DISC
@	SPECGX LLC	50MG	A040773	001	Apr 25, 2007	Apr	DISC
@	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Apr	DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

@ MYLAN 1.5% A206220 001 Mar 18, 2019 Feb DISC

BEPREVE

+! BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB ! GLENMARK GENERICS EQ 0.05% BASE A078930 001 Sep 23, 2008 Feb CHRS

DIPROLENE AF

+ @ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987 Feb DISC

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

@ ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC

>A> @ INVATECH EQ 0.05% BASE A070274 001 Aug 12, 1985 Sep CAHN

>D> @ PHARMADERM EQ 0.05% BASE A070274 001 Aug 12, 1985 Sep CAHN

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	CADILA	EQ 0.05% BASE	A214048	001	Jul 14, 2020	Jul	CAHN
AB	ZYDUS PHARMS	EQ 0.05% BASE	A214048	001	Jul 14, 2020	Jul	NEWA

SPRAY;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	@ TARO PHARMS	EQ 0.05% BASE/SPRAY	A211722	001	Jun 17, 2020	Jun	DISC
		EQ 0.05% BASE/SPRAY	A211722	001	Jun 17, 2020	Jun	NFTG
	SERNIVO						
	+! ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Jun	CTEC
AB	+!	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Jun	CFTG

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

CREAM;TOPICAL

WYNZORA

	+! MC2	0.064%;0.005%	N213422	001	Jul 20, 2020	Jul	NEWA
--	--------	---------------	---------	-----	--------------	-----	------

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TARO PHARMS	0.064%;0.005%	A213269	001	Sep 02, 2020	Aug	NEWA
AB	TOLMAR	0.064%;0.005%	A210765	001	May 11, 2020	Apr	NFTG
	CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE						
>A>	AB PERRIGO UK FINCO	0.064%;0.005%	A212367	001	Sep 11, 2020	Sep	NEWA
	TACLONEX						
AB	+! LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Apr	CFTG

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	! AMNEAL PHARM	5MG	A040855	001	Nov 21, 2007	Jan	CHRS
AA	!	10MG	A040855	002	Nov 21, 2007	Jan	CHRS
AA	!	25MG	A040855	003	Nov 21, 2007	Jan	CHRS
AA	!	50MG	A040855	004	Nov 21, 2007	Jul	CHRS
>A>	AA DISCOVERY THERAP	5MG	A040728	002	Oct 26, 2007	Sep	CAHN
>A>	AA	10MG	A040728	003	Oct 26, 2007	Sep	CAHN
>A>	AA	25MG	A040728	004	Oct 26, 2007	Sep	CAHN
>A>	AA	50MG	A040728	001	Oct 26, 2007	Sep	CAHN
>D>	AA ECI PHARMS LLC	5MG	A040728	002	Oct 26, 2007	Sep	CAHN
>D>	AA	10MG	A040728	003	Oct 26, 2007	Sep	CAHN
>D>	AA	25MG	A040728	004	Oct 26, 2007	Sep	CAHN
>D>	AA	50MG	A040728	001	Oct 26, 2007	Sep	CAHN
	@ HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Jul	DISC
	@	10MG	A091256	002	May 04, 2010	Jul	DISC
	@	25MG	A091256	003	May 04, 2010	Jul	DISC
	@	50MG	A091256	004	May 04, 2010	Jul	DISC
	@ IMPAX LABS	25MG	A040721	003	Nov 01, 2006	Jan	CMS1
	URECHOLINE						
	@ ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985	Jan	DISC
	@	10MG	A088440	001	May 29, 1984	Jan	DISC
	@	25MG	A088441	001	May 29, 1984	Jan	DISC
	@	50MG	A089096	001	Dec 19, 1985	Jul	DISC

BETRIXABAN

CAPSULE;ORAL

BEVYXXA

	+ @ PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017	Aug	DISC
	+ @	80MG	N208383	002	Jun 23, 2017	Aug	DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB	ANI PHARMS INC	75MG	A209861	001	May 08, 2018	Jan	CAHN
AB	HIKMA	75MG	A203663	001	Jun 16, 2020	Jun	NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

	@ MYLAN	50MG	A079185	001	Jul 06, 2009	Jan	DISC
--	---------	------	---------	-----	--------------	-----	------

BIMATOPROST

		IMPLANT;OPHTHALMIC					
		DURYSTA					
	+!	ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020	Mar NEWA
		SOLUTION/DROPS;OPHTHALMIC					
		BIMATOPROST					
AT		MICRO LABS	0.03%	A202505	001	Sep 08, 2020	Aug NEWA
		SOLUTION/DROPS;TOPICAL					
		BIMATOPROST					
AT		ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan NEWA

BISOPROLOL FUMARATE

		TABLET;ORAL					
		BISOPROLOL FUMARATE					
AB		RUBICON	5MG	A075643	001	Nov 16, 2000	Aug CAHN
AB			10MG	A075643	002	Nov 16, 2000	Aug CAHN
	@	TEVA PHARMS	5MG	A075644	001	Jun 26, 2001	Apr DISC
	@		10MG	A075644	002	Jun 26, 2001	Apr DISC

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

		TABLET;ORAL					
		BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE					
AB		EDENBRIDGE PHARMS	2.5MG;6.25MG	A212678	001	Jul 09, 2020	Jul NEWA
AB			5MG;6.25MG	A212678	002	Jul 09, 2020	Jul NEWA
AB			10MG;6.25MG	A212678	003	Jul 09, 2020	Jul NEWA

BIVALIRUDIN

		INJECTABLE;INTRAVENOUS					
		BIVALIRUDIN					
	@	APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb DISC
>D>	AP	CIPLA	250MG/VIAL	A091602	001	Jul 16, 2018	Sep CAHN
>A>	AP	HONG KONG	250MG/VIAL	A091602	001	Jul 16, 2018	Sep CAHN

BOSENTAN

		TABLET;ORAL					
		BOSENTAN					
AB		ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan NEWA
AB			125MG	A211461	002	Jan 23, 2020	Jan NEWA
	@	CIPLA	62.5MG	A210342	001	Jan 03, 2020	Jun DISC
	@		125MG	A210342	002	Jan 03, 2020	Jun DISC
	@	MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan DISC
	@		125MG	A205173	002	Jan 15, 2020	Jan DISC

BREMELANOTIDE ACETATE

		SOLUTION;SUBCUTANEOUS					
		VYLEESI (AUTOINJECTOR)					
	+!	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jul CAHN

BRIMONIDINE TARTRATE

		SOLUTION/DROPS;OPHTHALMIC					
		QOLIANA					
AT	+!	SANDOZ INC	0.15%	N021764	001	May 22, 2006	Jun CHRS
AT	+		0.15%	N021764	001	May 22, 2006	Jun CRLD

BROMFENAC SODIUM

		SOLUTION/DROPS;OPHTHALMIC					
		BROMFENAC SODIUM					
AT2		GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar NEWA

BROMOCRIPTINE MESYLATE

		TABLET;ORAL					
		BROMOCRIPTINE MESYLATE					
	@	MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004	Jun DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

		SYRUP;ORAL					
		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA		ALKEM LABS LTD	2MG/5ML;10MG/5ML;30MG/5ML	A210647	001	Jul 14, 2020	Jul NEWA
>A>	AA	BRECKENRIDGE	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	Sep NEWA
>A>	AA	EYWA	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep CAHN

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	LANNETT CO INC	2MG/5ML;10MG/5ML;30MG/5ML	A213125	001	Apr 17, 2020	Apr	NEWA
	@ PHARM ASSOC	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Aug	CAHN
>D> AA	WES PHARMA INC	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep	CAHN
AA		2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Jun	NEWA

BUDESONIDEAEROSOL, FOAM;RECTAL
UCERIS

+! SALIX 2MG/ACTUATION N205613 001 Oct 07, 2014 Feb CAHN

CAPSULE;ORAL
BUDESONIDE

AB RISING 3MG A207367 001 Apr 07, 2017 Jul CAHN

TABLET, EXTENDED RELEASE;ORAL
BUDESONIDE

>A> AB MYLAN 9MG A208851 001 Sep 17, 2020 Sep NEWA

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATEAEROSOL, METERED;INHALATION
BREZTRI AEROSPHERE+! ASTRAZENECA AB 0.16MG/INH;0.0048MG/INH;0.009MG/INH N212122 001 Jul 23, 2020 Jul NEWA
HBUMETANIDETABLET;ORAL
BUMETANIDE

AB RISING 0.5MG A212019 001 Dec 12, 2019 Jan CAHN

AB 1MG A212019 002 Dec 12, 2019 Jan CAHN

AB 2MG A212019 003 Dec 12, 2019 Jan CAHN

BUPIVACAINE HYDROCHLORIDEIMPLANT;IMPLANTATION
XARACOLL

+! INNOCOLL PHARMS 100MG N209511 001 Aug 28, 2020 Aug NEWA

BUPRENORPHINEFILM, EXTENDED RELEASE;TRANSDERMAL
BUPRENORPHINE

AB AMNEAL 5MCG/HR A211586 001 Apr 14, 2020 Mar NEWA

AB 7.5MCG/HR A211586 002 Apr 14, 2020 Mar NFTG

AB 10MCG/HR A211586 003 Apr 14, 2020 Mar NEWA

AB 15MCG/HR A211586 004 Apr 14, 2020 Mar NEWA

AB 20MCG/HR A211586 005 Apr 14, 2020 Mar NEWA

AB + BUTRANS PURDUE PHARMA LP 7.5MCG/HR N021306 005 Jun 30, 2014 Mar CFTG

BUPRENORPHINE HYDROCHLORIDETABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB RUBICON EQ 2MG BASE A090279 001 Jun 10, 2015 Aug CAHN

AB EQ 8MG BASE A090279 002 Jun 10, 2015 Aug CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM;BUCCAL
BUNAVAIL

+ @ BDSI EQ 2.1MG BASE;EQ 0.3MG BASE N205637 001 Jun 06, 2014 Jun DISC

+ @ EQ 4.2MG BASE;EQ 0.7MG BASE N205637 002 Jun 06, 2014 Jun DISC

+ @ EQ 6.3MG BASE;EQ 1MG BASE N205637 003 Jun 06, 2014 Jun DISC

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB MYLAN TECHNOLOGIES EQ 2MG BASE;EQ 0.5MG BASE A211785 001 Apr 17, 2020 Apr NEWA

AB EQ 4MG BASE;EQ 1MG BASE A211785 002 Apr 17, 2020 Apr NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB MAYNE PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE A206953 001 Jul 17, 2020 Jul NEWA

AB EQ 8MG BASE;EQ 2MG BASE A206953 002 Jul 17, 2020 Jul NEWA

AB RHODES PHARMS EQ 2MG BASE;EQ 0.5MG BASE A205601 001 Mar 30, 2020 Mar NEWA

AB EQ 8MG BASE;EQ 2MG BASE A205601 002 Mar 30, 2020 Mar NEWA

AB WES PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE A209069 001 Jul 17, 2020 Jul NEWA

AB EQ 8MG BASE;EQ 2MG BASE A209069 002 Jul 17, 2020 Jul NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan	NEWA
AB		100MG	A208606	002	Jan 16, 2020	Jan	NEWA
AB	MICRO LABS	75MG	A207403	001	Apr 17, 2020	Apr	NEWA
AB		100MG	A207403	002	Apr 17, 2020	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB3	ADAPTIS	150MG	A211020	001	Jan 28, 2019	Sep	CAHN
>A>	AB3		300MG	A211020	002	Jan 28, 2019	Sep	CAHN
>D>	AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Sep	CAHN
>D>	AB3		300MG	A211020	002	Jan 28, 2019	Sep	CAHN
		@ JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb	DISC
		@	150MG	A202774	002	Oct 11, 2013	Feb	DISC
		@	150MG	A202775	001	Oct 11, 2013	Feb	DISC
		@	150MG	A207459	001	Jun 30, 2017	Feb	DISC
		@	200MG	A202774	003	Oct 11, 2013	Feb	DISC
		@	300MG	A207459	002	Jun 30, 2017	Feb	DISC
		@ WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr	DISC
		@	150MG	A077455	002	Mar 12, 2008	Apr	DISC
		@	200MG	A077455	003	Jul 19, 2010	Apr	DISC
AB1	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Jun	CMFD	
AB1		150MG	A211347	002	Oct 16, 2018	Jun	CMFD	
AB1		200MG	A211347	003	Oct 16, 2018	Jun	CMFD	
AB3	ZHEJIANG JUTAI PHARM	150MG	A211200	002	Apr 29, 2020	Jun	NEWA	

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONTRAVE

+	!	NALPROPION	90MG; 8MG	N200063	001	Sep 10, 2014	Jan	CAHN
---	---	------------	-----------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	7.5MG	A078246	005	Feb 21, 2020	Jun	NEWA
AB	! MYLAN	7.5MG	A075467	002	Mar 28, 2001	Jun	CHRS
AB	OXFORD PHARMS	5MG	A075388	001	May 09, 2002	Jul	CMFD
AB		10MG	A075388	002	May 09, 2002	Jul	CMFD
AB		15MG	A075388	003	May 09, 2002	Jul	CMFD

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Apr	CTNA
	@ MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb	DISC

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

+	@	MYLAN SPECIALITY LP	30MG	N000793	004		May	DISC
---	---	---------------------	------	---------	-----	--	-----	------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

	@	MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan	DISC
--	---	-------	-------	---------	-----	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

>D>	AP	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009	Sep	DISC
>A>		@	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009	Sep	DISC

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

>D>	AA	HIKMA INTL PHARMS	100MG; 1MG	A040510	001	Sep 17, 2004	Sep	DISC
>A>		@	100MG; 1MG	A040510	001	Sep 17, 2004	Sep	DISC

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Mar	CMFD
AB		0.5MCG	A204556	002	Feb 21, 2019	Mar	CMFD

INJECTABLE;INJECTION

CALCITRIOL

AP	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan	CTEC
AP	GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

@	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan	DISC
---	--------------------	-------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	004	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	004	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	001	Aug 19, 1992	Aug	CHRS
AT	+		18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	001	Aug 19, 1992	Aug	CRLD

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	005	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	005	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	002	Aug 19, 1992	Aug	CHRS
AT	+		18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	002	Aug 19, 1992	Aug	CRLD

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	006	Nov 30, 1984	Aug	CHRS
AT	+		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018883	006	Nov 30, 1984	Aug	CRLD

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+!	FRESENIUS MEDCL	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	003	Aug 19, 1992	Aug	CHRS
AT	+		18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020171	003	Aug 19, 1992	Aug	CRLD

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION;ORAL

XYWAV

+!	JAZZ	0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020	Aug	CPOT
+!		0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020	Jul	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	RELIANCE LIFE	150MG	A211724	001	Apr 27, 2020	Apr	NEWA
AB		500MG	A211724	002	Apr 27, 2020	Apr	NEWA

CAPMATINIB HYDROCHLORIDE

TABLET; ORAL

TABRECTA

+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020	May	NEWA
+	!	EQ 200MG BASE	N213591	002	May 06, 2020	May	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

>A>	@ ANNORA PHARMA	12.5MG	A074737	001	Oct 28, 1998	Sep	CAHN
>A>	@	25MG	A074737	002	Oct 28, 1998	Sep	CAHN
>A>	@	50MG	A074737	003	Oct 28, 1998	Sep	CAHN
>A>	@	100MG	A074737	004	Oct 28, 1998	Sep	CAHN
>D>	@ COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Sep	CAHN
	@	12.5MG	A074737	001	Oct 28, 1998	Feb	CAHN
>D>	@	25MG	A074737	002	Oct 28, 1998	Sep	CAHN
	@	25MG	A074737	002	Oct 28, 1998	Feb	CAHN
>D>	@	50MG	A074737	003	Oct 28, 1998	Sep	CAHN
	@	50MG	A074737	003	Oct 28, 1998	Feb	CAHN
>D>	@	100MG	A074737	004	Oct 28, 1998	Sep	CAHN
	@	100MG	A074737	004	Oct 28, 1998	Feb	CAHN
	@ SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	May	DISC
	@	25MG	A212223	002	Oct 30, 2019	May	DISC
	@	50MG	A212223	003	Oct 30, 2019	May	DISC
	@	100MG	A212223	004	Oct 30, 2019	May	DISC
	@ TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr	DISC
	@	25MG	A074322	002	Feb 13, 1996	Apr	DISC
	@	50MG	A074322	003	Feb 13, 1996	Apr	DISC
	@	100MG	A074322	004	Feb 13, 1996	Apr	DISC
	@ WATSON LABS	12.5MG	A074386	001	May 23, 1996	Apr	DISC
	@	25MG	A074386	002	May 23, 1996	Apr	DISC
	@	50MG	A074386	003	May 23, 1996	Apr	DISC
	@	100MG	A074386	004	May 23, 1996	Apr	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	May	CMFD
AB		200MG	A076697	002	May 20, 2011	May	CMFD
AB		300MG	A076697	003	May 20, 2011	May	CMFD

TABLET; ORAL

CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
AB	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar	NEWA
AB		200MG	A207798	002	Apr 15, 2020	Mar	NEWA

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	! TARO PHARM INDS	100MG	A075687	001	Oct 24, 2000	Aug	CHRS
	TEGRETOL						
+	@ NOVARTIS	100MG	N018281	001		Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	UNIQUE PHARM	100MG	A211623	001	Apr 24, 2020	Apr	NEWA
AB		200MG	A211623	002	Apr 24, 2020	Apr	NEWA
AB		400MG	A211623	003	Apr 24, 2020	Apr	NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>D>	AB	MYLAN	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020	Sep	DISC
>A>		@	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020	Sep	DISC
	AB		12.5MG;200MG;50MG	A203424	001	Aug 13, 2020	Jul	NEWA
>D>	AB		18.75MG;200MG;75MG	A203424	002	Aug 13, 2020	Sep	DISC
>A>		@	18.75MG;200MG;75MG	A203424	002	Aug 13, 2020	Sep	DISC
	AB		18.75MG;200MG;75MG	A203424	002	Aug 13, 2020	Jul	NEWA
>D>	AB		25MG;200MG;100MG	A203424	003	Aug 13, 2020	Sep	DISC
>A>		@	25MG;200MG;100MG	A203424	003	Aug 13, 2020	Sep	DISC
	AB		25MG;200MG;100MG	A203424	003	Aug 13, 2020	Jul	NEWA
>D>	AB		31.25MG;200MG;125MG	A203424	004	Aug 13, 2020	Sep	DISC
>A>		@	31.25MG;200MG;125MG	A203424	004	Aug 13, 2020	Sep	DISC
	AB		31.25MG;200MG;125MG	A203424	004	Aug 13, 2020	Jul	NEWA
>D>	AB		37.5MG;200MG;150MG	A203424	005	Aug 13, 2020	Sep	DISC
>A>		@	37.5MG;200MG;150MG	A203424	005	Aug 13, 2020	Sep	DISC
	AB		37.5MG;200MG;150MG	A203424	005	Aug 13, 2020	Jul	NEWA
>D>	AB		50MG;200MG;200MG	A203424	006	Aug 13, 2020	Sep	DISC
>A>		@	50MG;200MG;200MG	A203424	006	Aug 13, 2020	Sep	DISC
	AB		50MG;200MG;200MG	A203424	006	Aug 13, 2020	Jul	NEWA
		STALEVO 125						
>D>	AB	+ ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Sep	CTEC
>A>		+	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Sep	CTEC
	AB	+	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Jul	CTEC
		STALEVO 200						
>D>	AB	+! ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Sep	CTEC
>A>		+!	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Sep	CTEC
	AB	+!	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Jul	CTEC
		STALEVO 50						
>D>	AB	+! ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Sep	CTEC
>A>		+!	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Sep	CTEC
	AB	+!	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Jul	CTEC
		STALEVO 75						
>D>	AB	+ ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Sep	CTEC
>A>		+	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Sep	CTEC
	AB	+	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Jul	CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

		+ @ MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	DISC
--	--	-----------------------	------------	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	AP	EUGIA PHARMA	600MG/60ML (10MG/ML)	A205487	004	Aug 03, 2020	Jul	NEWA
--	----	--------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INTRAVENOUS

CARBOPLATIN

		! ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020	Jul	NEWA
>D>		@ EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Sep	CMFD
>A>	AP		50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Sep	CMFD
		@	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	DISC
>D>		@	150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Sep	CMFD
>A>	AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Sep	CMFD
		@	150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	DISC
>D>		@	450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Sep	CMFD
>A>	AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Sep	CMFD
		@	450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	DISC
>D>	AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Sep	CAHN
>D>	AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Sep	CAHN
>D>	AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Sep	CAHN
>D>	AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Sep	CAHN
>A>	AP	NOVAST LABS	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Sep	CAHN
>A>	AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Sep	CAHN
>A>	AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Sep	CAHN
>A>	AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Sep	CAHN
		@ PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	Apr	DISC
		@	150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	Apr	DISC
		@	450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	Apr	DISC
		@	600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	Apr	DISC
		@ TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May	DISC

INJECTABLE; INTRAVENOUS
CARBOPLATIN

@	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May	DISC
@	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May	DISC
@	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May	DISC

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

>D>	AP	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Sep	DISC
>A>		@	30MG/VIAL	A211185	001	Mar 20, 2020	Sep	DISC
	AP		30MG/VIAL	A211185	001	Mar 20, 2020	Mar	NFTG
>D>	AP		60MG/VIAL	A209425	001	Mar 16, 2020	Sep	DISC
>A>		@	60MG/VIAL	A209425	001	Mar 16, 2020	Sep	DISC
	AP		60MG/VIAL	A209425	001	Mar 16, 2020	Mar	NEWA
KYPROLIS								
>D>	AP	+ ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Sep	CTEC
>A>		+	30MG/VIAL	N202714	002	Jun 03, 2016	Sep	CTEC
	AP	+	30MG/VIAL	N202714	002	Jun 03, 2016	Mar	CFTG

CARGLUMIC ACIDTABLET, FOR SUSPENSION; ORAL
CARBAGLU

+!	RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	Aug	CDFR
----	----------------	-------	---------	-----	--------------	-----	------

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

	@	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb	DISC
>A>	AA	NOSTRUM LABS INC	350MG	A207237	002	Sep 21, 2020	Sep	NEWA
	AA	OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997	Apr	CMFD

CEDAZURIDINE; DECITABINETABLET; ORAL
INQOVI

+!	OTSUKA	100MG; 35MG	N212576	001	Jul 07, 2020	Jul	NEWA
----	--------	-------------	---------	-----	--------------	-----	------

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jul	NEWA

CEFIXIMECAPSULE; ORAL
CEFIXIME

>D>	AB	ALKEM LABS LTD	400MG	A210574	001	Oct 09, 2018	Sep	CTEC
>A>		!	400MG	A210574	001	Oct 09, 2018	Sep	CHRS
>A>			400MG	A210574	001	Oct 09, 2018	Sep	CTEC
SUPRAX								
>D>	AB	+! LUPIN LTD	400MG	N203195	001	Jun 01, 2012	Sep	DISC
>A>		+ @	400MG	N203195	001	Jun 01, 2012	Sep	DISC
FOR SUSPENSION; ORAL								
SUPRAX								
	@	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Jan	DISC
TABLET; ORAL								
SUPRAX								
	@	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004	Jan	DISC

CEFOXITIN SODIUMINJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER

@	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Mar	DISC
@		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Mar	DISC

CEFPROZILFOR SUSPENSION; ORAL
CEFPROZIL

@	TEVA PHARMS	125MG/5ML	A065236	001	Dec 08, 2005	Apr	DISC
@		250MG/5ML	A065236	002	Dec 08, 2005	Apr	DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	NANJING	200MG	A213598	001	May 13, 2020	Apr	NEWA
AB	QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Aug	CMFD
	@	50MG	A208856	001	Aug 07, 2019	May	DISC
AB		100MG	A208856	002	Aug 07, 2019	Aug	CMFD
	@	100MG	A208856	002	Aug 07, 2019	May	DISC
AB		200MG	A208856	003	Aug 07, 2019	Aug	CMFD
	@	200MG	A208856	003	Aug 07, 2019	May	DISC
AB		400MG	A208856	004	Aug 07, 2019	Aug	CMFD
	@	400MG	A208856	004	Aug 07, 2019	May	DISC
AB	TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb	NEWA
AB		100MG	A207872	002	Feb 25, 2020	Feb	NEWA
AB		200MG	A207872	003	Feb 25, 2020	Feb	NEWA
AB		400MG	A207872	004	Feb 25, 2020	Feb	NEWA
AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan	CDFR
AB		100MG	A210628	002	Nov 27, 2019	Jan	CDFR
AB		200MG	A210628	003	Nov 27, 2019	Jan	CDFR
AB		400MG	A210628	004	Nov 27, 2019	Jan	CDFR
>A>	@ YILING	50MG	A211412	001	Mar 06, 2020	Sep	DISC
>A>	@	100MG	A211412	002	Mar 06, 2020	Sep	DISC
>A>	@	200MG	A211412	003	Mar 06, 2020	Sep	DISC
>A>	@	400MG	A211412	004	Mar 06, 2020	Sep	DISC
>D>	AB YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Sep	DISC
	AB	50MG	A211412	001	Mar 06, 2020	Feb	NEWA
>D>	AB	100MG	A211412	002	Mar 06, 2020	Sep	DISC
	AB	100MG	A211412	002	Mar 06, 2020	Feb	NEWA
>D>	AB	200MG	A211412	003	Mar 06, 2020	Sep	DISC
	AB	200MG	A211412	003	Mar 06, 2020	Feb	NEWA
>D>	AB	400MG	A211412	004	Mar 06, 2020	Sep	DISC
	AB	400MG	A211412	004	Mar 06, 2020	Feb	NEWA

SOLUTION;ORAL

>D>	ELYXYB						
>D>	+! DR REDDYS	25MG/ML	N212157	001	May 05, 2020	Sep	DISC
>A>	+ @	25MG/ML	N212157	001	May 05, 2020	Sep	DISC
	+!	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
	+!	25MG/ML	N212157	001	May 05, 2020	May	NEWA

CENOBAMATE

TABLET;ORAL

XCOPRI

+	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Mar	NEWA
+		25MG	N212839	002	Mar 10, 2020	Mar	NEWA
+		50MG	N212839	003	Mar 10, 2020	Mar	NEWA
+		100MG	N212839	004	Mar 10, 2020	Mar	NEWA
+		150MG	N212839	005	Mar 10, 2020	Mar	NEWA
+	!	200MG	N212839	006	Mar 10, 2020	Mar	NEWA

CHENODIOL

TABLET;ORAL

CHENODIOL

!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009	Aug	CAHN
---	------------	-------	---------	-----	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	MISEMER	5MG;2.5MG	A210579	001	Jul 29, 2020	Jul	NEWA
>A>	AB NUVO PHARMS INC	5MG;2.5MG	A211421	001	Jul 07, 2020	Sep	CAHN
>D>	AB SUNRISE PHARM INC	5MG;2.5MG	A211421	001	Jul 07, 2020	Sep	CAHN
	AB	5MG;2.5MG	A211421	001	Jul 07, 2020	Jul	NFTG
	LIBRAX						
AB	+! BAUSCH	5MG;2.5MG	N012750	001		Jul	CFTG
	+!	5MG;2.5MG	N012750	001		Jun	CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

+	@ SANOFI AVENTIS US	500MG	N006002	001		Apr	CPOT
	@ HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb	DISC
	@	250MG	A083082	001		Apr	CPOT

TABLET;ORAL

CHLOROQUINE PHOSPHATE

>D>	AA		500MG	A083082	002	Sep 17, 1999	Sep	DISC
>A>	@		500MG	A083082	002	Sep 17, 1999	Sep	DISC
	AA		500MG	A083082	002	Sep 17, 1999	Apr	CPOT
	@	IMPAX LABS	250MG	A080880	001		Apr	CPOT
	@		500MG	A040516	001	Aug 29, 2003	Apr	CPOT
	AA	IPCA LABS LTD	250MG	A090610	001	Dec 03, 2009	Apr	CPOT
	AA		500MG	A090249	001	Dec 03, 2009	Apr	CPOT
	@	MD PHARM	250MG	A087228	001		Apr	CPOT
	AA	! NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb	CHRS
	AA	!	250MG	A091621	001	Jan 21, 2011	Apr	CPOT
	AA	!	500MG	A090612	001	Jan 21, 2011	Apr	CPOT
	@	PUREPAC PHARM	250MG	A080886	001		Apr	CPOT
	@	TEVA	250MG	A087504	001	Jan 13, 1982	Apr	CPOT
	@	WATSON LABS	250MG	A087979	001	Dec 21, 1982	Apr	CPOT
	@		500MG	A088030	001	Dec 21, 1982	Apr	CPOT

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	25MG/ML	A211816	001	Jul 07, 2020	Jul	NEWA
AP	!	WEST-WARD PHARMS INT	25MG/ML	A083329	001		Jul	CTEC

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Aug	NEWA
AB			25MG	A213590	002	Aug 31, 2020	Aug	NEWA
AB			50MG	A213590	003	Aug 31, 2020	Aug	NEWA
AB			100MG	A213590	004	Aug 31, 2020	Aug	NEWA
AB			200MG	A213590	005	Aug 31, 2020	Aug	NEWA
AB		ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan	NEWA
AB			25MG	A213368	002	Jan 17, 2020	Jan	NEWA
AB			50MG	A213368	003	Jan 17, 2020	Jan	NEWA
AB			100MG	A213368	004	Jan 17, 2020	Jan	NEWA
AB			200MG	A213368	005	Jan 17, 2020	Jan	NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan	NEWA
AB			50MG	A213412	002	Feb 11, 2020	Jan	NEWA
AB		DR REDDYS	25MG	A210742	001	Oct 12, 2018	Aug	CAHN
AB			50MG	A210742	002	Oct 12, 2018	Aug	CAHN
AB		VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb	CAHN
AB			50MG	A211063	002	Feb 26, 2019	Feb	CAHN

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		AUROBINDO PHARMA LTD	500MG	A089853	001	May 04, 1988	Aug	CAHN
AA		AUROLIFE PHARMA LLC	500MG	A089853	001	May 04, 1988	Jun	CMFD
AB		GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020	May	NEWA
AB			750MG	A212185	002	May 26, 2020	May	NEWA
>A>	AB	I3 PHARMS	375MG	A212053	001	Sep 14, 2020	Sep	NEWA
>A>	AB		750MG	A212053	002	Sep 14, 2020	Sep	NEWA
	AB	MAYNE PHARMA	375MG	A211849	001	Jul 21, 2020	Jul	NEWA
	AA		500MG	A211849	002	Jul 21, 2020	Jul	NEWA
	AB		750MG	A211849	003	Jul 21, 2020	Jul	NEWA
	AB	TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Jun	NEWA
	AB		750MG	A212898	002	Jun 17, 2020	Jun	NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar	NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar	NEWA
		LOCHOLEST						
>D>	@	ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Sep	CAHN
	@		EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb	CAHN
>D>	@		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Sep	CAHN
	@		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb	CAHN
>A>	@	CHARTWELL RX	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Sep	CAHN
>A>	@		EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Sep	CAHN

POWDER;ORAL

LOCHOLEST

@ INVATECH

EQ 4GM RESIN/PACKET

A 074561 001 Aug 15, 1996 Jan CAHN

@

EQ 4GM RESIN/SCOOPFUL

A 074561 002 Aug 15, 1996 Jan CAHN

LOCHOLEST LIGHT

@ ALLIED

EQ 4GM RESIN/PACKET

A 074562 001 Aug 15, 1996 Feb CAHN

@

EQ 4GM RESIN/SCOOPFUL

A 074562 002 Aug 15, 1996 Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB MICRO LABS

EQ 45MG FENOFIBRIC ACID

A 213450 001 Jun 16, 2020 Jun NEWA

AB

EQ 135MG FENOFIBRIC ACID

A 213450 002 Jun 16, 2020 Jun NEWA

AB TWI PHARMS

EQ 45MG FENOFIBRIC ACID

A 210469 001 Jul 05, 2019 Mar CMFD

AB

EQ 135MG FENOFIBRIC ACID

A 210469 002 Jul 05, 2019 Mar CMFD

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB CHARTWELL RX

50MG

A 077831 002 Sep 24, 2012 Aug CMS1

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>D> AB HIKMA

200MG

A 074890 001 Dec 18, 1998 Sep DISC

>A>

@

200MG

A 074890 001 Dec 18, 1998 Sep DISC

>D> AB

300MG

A 074890 002 Dec 18, 1998 Sep DISC

>A>

@

300MG

A 074890 002 Dec 18, 1998 Sep DISC

>D> AB

400MG

A 074890 003 Dec 18, 1998 Sep DISC

>A>

@

400MG

A 074890 003 Dec 18, 1998 Sep DISC

>D> AB

800MG

A 074890 004 Dec 18, 1998 Sep DISC

>A>

@

800MG

A 074890 004 Dec 18, 1998 Sep DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ DAVA PHARMS INC

EQ 300MG BASE/2ML

A 074428 001 Apr 25, 1996 May DISC

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB ACCORD HLTHCARE

EQ 30MG BASE

A 211892 001 May 15, 2020 May NEWA

AB

EQ 60MG BASE

A 211892 002 May 15, 2020 May NEWA

AB

EQ 90MG BASE

A 211892 003 May 15, 2020 May NEWA

AB ACME LABS

EQ 30MG BASE

A 213325 001 May 18, 2020 May NEWA

AB

EQ 60MG BASE

A 213325 002 May 18, 2020 May NEWA

AB

EQ 90MG BASE

A 213325 003 May 18, 2020 May NEWA

>A> AB DR REDDYS

EQ 30MG BASE

A 208368 001 Sep 18, 2020 Sep NEWA

>A> AB

EQ 60MG BASE

A 208368 002 Sep 18, 2020 Sep NEWA

>A> AB

EQ 90MG BASE

A 208368 003 Sep 18, 2020 Sep NEWA

>A> AB

HETERO LABS LTD V

EQ 30MG BASE

A 209403 001 Oct 07, 2020 Sep NEWA

>A> AB

EQ 60MG BASE

A 209403 002 Oct 07, 2020 Sep NEWA

>A> AB

EQ 90MG BASE

A 209403 003 Oct 07, 2020 Sep NEWA

@ LUPIN LTD

EQ 30MG BASE

A 210548 001 Jun 28, 2019 Jan DISC

@

EQ 60MG BASE

A 210548 002 Jun 28, 2019 Jan DISC

@

EQ 90MG BASE

A 210548 003 Jun 28, 2019 Jan DISC

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

AB +! NOVARTIS

0.3%;0.1%

N 021537 001 Jul 18, 2003 Jul CFTG

CIPROFLOXACIN AND DEXAMETHASONE

AB DR REDDYS LABS LTD

0.3%;0.1%

A 205548 001 Aug 10, 2020 Jul NFTG

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP AUROBINDO PHARMA LTD

EQ 2MG BASE/ML

A 209144 001 May 08, 2020 Apr NEWA

AP

HOSPIRA INC

EQ 2MG BASE/ML

A 203238 001 Mar 30, 2018 Jan CMFD

AP

PIRAMAL HLTHCARE UK

EQ 2MG BASE/ML

A 212190 001 May 04, 2020 Apr NEWA

AP

ZYDUS PHARMS

EQ 2MG BASE/ML

A 213527 001 Aug 31, 2020 Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar	DISC
@		EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar	DISC
@		EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar	DISC

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL; VAGINAL

PHEXXI

+!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May	NEWA
----	------------	--------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

>D>	AB	HIKMA	250MG	A065178	002	May 25, 2004	Sep	DISC
>A>		@	250MG	A065178	002	May 25, 2004	Sep	DISC
>D>	AB		500MG	A065178	001	May 25, 2004	Sep	DISC
>A>		@	500MG	A065178	001	May 25, 2004	Sep	DISC

CLASCOTERONE

CREAM; TOPICAL

WINLEVI

+!	CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Aug	NEWA
----	---------------	----	---------	-----	--------------	-----	------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

!	GENUS	EQ 0.5MG BASE/5ML	A073399	001	Jun 30, 1994	Jul	CAHN
---	-------	-------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

	@	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	May	DISC
AT			1%	A210004	001	Mar 11, 2020	Feb	NEWA

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Jul	NEWA
----	--	---------------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	@	ALVOGEN	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul	DISC
--	---	---------	------------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AT	FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Sep	DISC	
>A>		@	EQ 1% BASE	A065254	001	Feb 14, 2006	Sep	DISC	
		@	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jul	DISC
		@	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	Jun	DISC

SWAB; TOPICAL

CLEOCIN

>D>	AT	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	002	Feb 22, 1994	Sep	CHRS
>A>	AT	+!	EQ 1% BASE	N050537	002	Feb 22, 1994	Sep	CHRS

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

AB		HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb	NEWA	
AB		LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr	NEWA	
		@	TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr	DISC
AB			2.5MG/ML	A211032	001	Jan 31, 2020	Jan	NEWA	

TABLET; ORAL

CLOBAZAM

AB		APOTEX	10MG	A209853	001	Jun 09, 2020	Jun	NEWA
AB			20MG	A209853	002	Jun 09, 2020	Jun	NEWA

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan	NEWA
AB1		ENCUBE	0.05%	A212982	001	Aug 28, 2020	Aug	NEWA

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ANI PHARMS INC	0.05%	A075733	001	Aug 22, 2001	Jun CAHN
AB2	INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	May CAHN

LOTION;TOPICAL

IMPEKLO

+	MYLAN	0.05%	N213691	001	May 19, 2020	Jun CAHN
+	MYLAN LABS INC	0.05%	N213691	001	May 19, 2020	May NEWA

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR DERMACEUTICALS	0.05%	A213290	001	May 18, 2020	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

>D>	@ ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Sep CMFD
>A>	AT	0.05%	A211191	001	Oct 02, 2019	Sep CMFD
	@	0.05%	A211191	001	Oct 02, 2019	Jan DISC

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

AB	TARO	0.1%	A206370	001	Apr 21, 2020	Apr NFTG
AB	+! CLODERM					
AB	+! EPI HLTH	0.1%	N017765	001		Apr CFTG

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

>D>	AP	INGENUS PHARMS LLC	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Sep CAHN
>A>	AP	NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Sep CAHN

CLOMIPHENE CITRATE

TABLET;ORAL

MILOPHENE

@	GRANATA BIO	50MG	A072196	001	Dec 20, 1988	Jul CAHN
---	-------------	------	---------	-----	--------------	----------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

>A>	AB	AJANTA PHARMA LTD	25MG	A213897	001	Oct 02, 2020	Sep NEWA
>A>	AB		50MG	A213897	002	Oct 02, 2020	Sep NEWA
>A>	AB		75MG	A213897	003	Oct 02, 2020	Sep NEWA
	AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan NEWA
	AB		50MG	A211364	002	Feb 07, 2020	Jan NEWA
	AB		75MG	A211364	003	Feb 07, 2020	Jan NEWA
	AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan CMFD
	AB		50MG	A211767	002	Apr 08, 2019	Jan CMFD
	AB		75MG	A211767	003	Apr 08, 2019	Jan CMFD
	AB	MICRO LABS	25MG	A213219	001	Jun 22, 2020	Jun NEWA
	AB		50MG	A213219	002	Jun 22, 2020	Jun NEWA
	AB		75MG	A213219	003	Jun 22, 2020	Jun NEWA
		@ TEVA	25MG	A074958	001	Aug 26, 1997	Feb DISC
		@	50MG	A074958	002	Aug 26, 1997	Feb DISC
		@	75MG	A074958	003	Aug 26, 1997	Feb DISC
	AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar NEWA
	AB		50MG	A210653	002	Apr 03, 2020	Mar NEWA
	AB		75MG	A210653	003	Apr 03, 2020	Mar NEWA
	AB	UNIQUE PHARM LABS	25MG	A212285	001	Aug 07, 2020	Jul NEWA
	AB		50MG	A212285	002	Aug 07, 2020	Jul NEWA
	AB		75MG	A212285	003	Aug 07, 2020	Jul NEWA
>D>	AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	Sep DISC
>A>		@	25MG	A213221	001	Jun 22, 2020	Sep DISC
	AB		25MG	A213221	001	Jun 22, 2020	Jun NEWA
>D>	AB		50MG	A213221	002	Jun 22, 2020	Sep DISC
>A>		@	50MG	A213221	002	Jun 22, 2020	Sep DISC
	AB		50MG	A213221	002	Jun 22, 2020	Jun NEWA
>D>	AB		75MG	A213221	003	Jun 22, 2020	Sep DISC
>A>		@	75MG	A213221	003	Jun 22, 2020	Sep DISC
	AB		75MG	A213221	003	Jun 22, 2020	Jun NEWA

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

@	MYLAN	0.5MG	A075150	001	Oct 05, 1998	May	DISC
@		1MG	A075150	002	Oct 05, 1998	Jun	DISC
@		2MG	A075150	003	Oct 05, 1998	May	DISC

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb	CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb	CAHN

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May	CAHN	
@		0.2MG	A070886	001	Aug 31, 1988	May	CAHN	
@		0.3MG	A070886	003	Aug 31, 1988	May	CAHN	
>D>	AB	MYLAN	0.1MG	A070317	002	Jul 09, 1987	Sep	DISC
>A>		@	0.1MG	A070317	002	Jul 09, 1987	Sep	DISC
>D>	AB		0.2MG	A070317	003	Jun 09, 1987	Sep	DISC
>A>		@	0.2MG	A070317	003	Jun 09, 1987	Sep	DISC
>D>	AB		0.3MG	A070317	001	Jun 09, 1987	Sep	DISC
>A>		@	0.3MG	A070317	001	Jun 09, 1987	Sep	DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	Feb	CMFD
-----	-------------------	-------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>A>	AB	ADAPTIS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Sep	CAHN
AB	!	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	May	CHRS
	@	CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jun	DISC
	@		EQ 300MG BASE	A202266	002	Nov 20, 2012	Jun	DISC
>D>	AB	GRAVITI PHARMS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Sep	CAHN
AB			EQ 75MG BASE	A204359	001	Feb 02, 2017	Apr	CAHN
AB		POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Jul	NEWA
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020	Jul	NEWA
		PLAVIX						
AB	+	SANOFI AVENTIS US	EQ 300MG BASE	N020839	002	Sep 20, 2007	May	CHRS

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG	A072112	002	Aug 26, 1988	Feb	CMS1
@		7.5MG	A072112	003	Aug 26, 1988	Feb	CMS1

COCAINE HYDROCHLORIDE

SOLUTION; NASAL

NUMBRINO

	CODY LABS INC	4%	N209575	001	Jan 10, 2020	Jan	NEWA
--	---------------	----	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		PHARM ASSOC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Jun	CAHN
AA	!	NOSTRUM LABS INC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984	Jun	CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE

@	PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Jun	CAHN
@	VINTAGE	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006	Apr	DISC

COLCHICINE

TABLET; ORAL

COLCHICINE

AB	AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan	CMFD
AB	GRANULES PHARMS	0.6MG	A210425	001	Feb 05, 2020	Jan	NEWA
	ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019	Jul	NEWA

	TABLET;ORAL							
	COLCHICINE							
AB		0.6MG		A211519	001	Feb 19, 2019	Jul	CMFD
	<u>COLESEVELAM HYDROCHLORIDE</u>							
	BAR, CHEWABLE;ORAL							
	WELCHOL							
	+ @	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Jun	DISC
	FOR SUSPENSION;ORAL							
	COLESEVELAM HYDROCHLORIDE							
AB		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Aug	CTEC
AB		WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Aug	NEWA
AB			3.75GM/PACKET	A202178	002	Sep 01, 2020	Aug	NEWA
	TABLET;ORAL							
	COLESEVELAM HYDROCHLORIDE							
AB		INVAGEN PHARMS	625MG	A212602	001	Apr 20, 2020	Apr	NEWA
AB		WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Aug	NEWA
AB		ZHEJIANG JINGXIN	625MG	A209946	001	Jul 15, 2020	Jul	NEWA
	<u>COLISTIMETHATE SODIUM</u>							
	INJECTABLE;INJECTION							
	COLISTIMETHATE SODIUM							
	@	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Aug	DISC
AP		XGEN PHARMS	EQ 150MG BASE/VIAL	A064216	001	Feb 26, 1999	Feb	CAHN
>A>	<u>COPPER DOTATATE CU-64</u>							
>A>	SOLUTION;INTRAVENOUS							
>A>	DETECTNET							
>A>	+!	RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020	Sep	NEWA
	<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE</u>							
	SOLUTION;INTRAVENOUS							
	TRALEMENT							
	+!	AM REGENT	EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Jul	NEWA
	<u>CYANOCOBALAMIN</u>							
	INJECTABLE;INJECTION							
	CYANOCOBALAMIN							
>A>	AP	GLAND PHARMA LTD	1MG/ML	A214390	001	Sep 24, 2020	Sep	NEWA
	SPRAY, METERED;NASAL							
	CYANOCOBALAMIN							
AB		PERRIGO UK FINCO	0.5MG/SPRAY	A212458	001	Sep 09, 2020	Aug	NFTG
	NASCOBAL							
AB	+!	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Aug	CFTG
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	CYCLOBENZAPRINE HYDROCHLORIDE							
AB		MYLAN PHARMS INC	10MG	A073144	001	May 30, 1991	Jun	CHRS
AB	!	RUBICON	10MG	A208170	003	May 31, 2017	Jun	CHRS
AB		UNICHEM	5MG	A213324	001	Jul 06, 2020	Jul	NEWA
AB			7.5MG	A213324	002	Jul 06, 2020	Jul	NEWA
AB			10MG	A213324	003	Jul 05, 2020	Jul	NEWA
	<u>CYCLOPHOSPHAMIDE</u>							
	CAPSULE;ORAL							
	CYCLOPHOSPHAMIDE							
AB		ANI PHARMS INC	25MG	A207014	001	Mar 19, 2018	Jan	CAHN
AB			50MG	A207014	002	Mar 19, 2018	Jan	CAHN
	SOLUTION;INTRAVENOUS							
	CYCLOPHOSPHAMIDE							
	+!	INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jul	NEWA
	+!		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jul	NEWA
	TABLET;ORAL							
	CYTOXAN							
	+	BAXTER HLTHCARE	25MG	N012141	002		Aug	CMFD
	+!		50MG	N012141	001		Aug	CMFD

CYCLOSPORINEINJECTABLE; INJECTION
CYCLOSPORINE

AP	PADDOCK LABS LLC	50MG/ML	A065151	001	Oct 07, 2003	Aug	CAHN
----	------------------	---------	---------	-----	--------------	-----	------

CYPROHEPTADINE HYDROCHLORIDETABLET; ORAL
CYPROHEPTADINE HYDROCHLORIDE

>D>	AA	APEX PHARMS INC	4MG	A207783	001	Dec 29, 2016	Sep	CAHN
	AA	APPCO	4MG	A206553	001	Nov 29, 2016	Mar	CAHN
		@ PAR PHARM	4MG	A087129	001		May	DISC
>A>	AA	RISING	4MG	A207783	001	Dec 29, 2016	Sep	CAHN

CYSTEAMINE BITARTRATEGRANULE; ORAL
PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Feb	NEWA
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Feb	NEWA

GRANULE, DELAYED RELEASE; ORAL
PROCYSBI

+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	Jul	CDFR
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	Jul	CDFR

CYSTEAMINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CYSTADROPS

+	!	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020	Aug	NEWA
---	---	----------------	---------------	---------	-----	--------------	-----	------

CYSTEINE HYDROCHLORIDESOLUTION; INTRAVENOUS
NOURESS

+	@	AVADEL LEGACY	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May	CRLD
	@		500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	May	DISC
+	@	EXELA PHARMA	500MG/10ML (50MG/ML)	N212535	001	Dec 13, 2019	Jul	CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP	HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Jun	NEWA
----	-----------	---------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATECAPSULE; ORAL
DABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb	NFTG	
AB		EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb	NFTG	
AB	HETERO LABS LTD III	EQ 75MG BASE	A207961	001	May 06, 2020	Apr	NEWA	
AB		EQ 150MG BASE	A207961	002	May 06, 2020	Apr	NEWA	
		PRADAXA						
AB	+	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb	CFTG
AB	+	!	EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb	CFTG

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

AP	XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

	@	MYLAN	10MG	A206858	001	Jul 06, 2020	Jul	DISC
AB			10MG	A206858	001	Jul 06, 2020	Jul	NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION
REVONTO

AP	USWM	20MG/VIAL	A078378	001	Jul 24, 2007	Jun	CAHN
----	------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR

	+ @	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	Aug	DISC
	+ @		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	Aug	DISC
	+ @		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	Aug	DISC
	+ @		10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	Aug	DISC

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

>D>	@	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Sep	CAHN
>A>	@	WOODWARD	0.5%	A204902	001	May 30, 2019	Sep	CAHN

DAPSONE

GEL;TOPICAL
ACZONE

AB	+!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun	CTEC
----	----	----------	------	---------	-----	--------------	-----	------

DAPSONE

AB		TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb	NEWA
----	--	-------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

DAPSONE

>A>	AB	RISING	100MG	A207165	001	May 08, 2019	Sep	CAHN
>D>	AB	SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Sep	CAHN

DAPTOMYCIN

POWDER;IV (INFUSION)
DAPTOMYCIN

AP		BE PHARMS	350MG/VIAL	A213425	001	Aug 20, 2020	Aug	NEWA
AP		DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	Aug	NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

	@	ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Apr	DISC
	@		EQ 15MG BASE	A209571	001	Oct 22, 2019	Apr	DISC
	@	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb	DISC
	@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb	DISC

DEFERASIROX

GRANULE;ORAL
DEFERASIROX

AB		ALKEM LABS LTD	90MG	A213374	001	Jul 14, 2020	Jul	NFTG
AB			180MG	A213374	002	Jul 14, 2020	Jul	NFTG
AB			360MG	A213374	003	Jul 14, 2020	Jul	NFTG

JADENU SPRINKLE

AB	+	NOVARTIS	90MG	N207968	001	May 18, 2017	Jul	CFTG
AB	+		180MG	N207968	002	May 18, 2017	Jul	CFTG
AB	+!		360MG	N207968	003	May 18, 2017	Jul	CFTG

TABLET;ORAL

DEFERASIROX

AB		ALEMBIC PHARMS LTD	180MG	A211824	003	Jun 15, 2020	Jun	NEWA
AB		ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar	NEWA
AB			180MG	A210555	003	Jul 02, 2020	Jul	NEWA
AB			360MG	A210555	002	Mar 30, 2020	Mar	NEWA
AB		AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb	CAHN
AB			180MG	A210727	003	Jun 15, 2020	Jun	NEWA
AB			360MG	A210727	002	Dec 27, 2019	Feb	CAHN
AB		CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA
AB			180MG	A211852	003	Jun 15, 2020	Jun	NEWA
AB			360MG	A211852	002	Feb 11, 2020	Jan	NEWA
AB		MSN	180MG	A210945	003	Jun 16, 2020	Jun	NEWA
AB		PIRAMAL HLTHCARE UK	180MG	A212995	003	Jun 15, 2020	Jun	NEWA
AB		SUN PHARM	180MG	A211641	003	Jun 15, 2020	Jun	NEWA
AB		TEVA PHARMS USA	180MG	A209223	003	Apr 24, 2020	Apr	NEWA
AB		ZYDUS PHARMS	180MG	A211383	003	Jun 15, 2020	Jun	NEWA

DEFERIPRONE

	SOLUTION; ORAL								
	FERRIPROX								
	+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN	
	+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN	
	TABLET; ORAL								
	DEFERIPRONE								
AB		TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	Aug	CMFD	
	FERRIPROX								
	+	!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CAHN
	+		1GM	N021825	002	Jul 25, 2019	Mar	CAHN	
	+	!	1GM	N212269	001	May 19, 2020	May	NEWA	

DEFEROXAMINE MESYLATE

	INJECTABLE; INJECTION								
	DEFEROXAMINE MESYLATE								
AP	!	HOSPIRA	2GM/VIAL	A076019	002	Mar 17, 2004	Jul	CHRS	
	DESFERAL								
	+	@	NOVARTIS	2GM/VIAL	N016267	002	May 25, 2000	Jul	DISC

DELAVIRDINE MESYLATE

	TABLET; ORAL								
	RESCRIPTOR								
	+	@	VIIV HLHCARE	200MG	N020705	002	Jul 14, 1999	Mar	DISC

DESIPRAMINE HYDROCHLORIDE

	TABLET; ORAL							
	DESIPRAMINE HYDROCHLORIDE							
	@	ANI PHARMS INC	10MG	A205153	001	Oct 28, 2016	Aug	DISC
	@		25MG	A205153	002	Oct 28, 2016	Aug	DISC
	@		50MG	A205153	003	Oct 28, 2016	Aug	DISC
	@		75MG	A205153	004	Oct 28, 2016	Aug	DISC
	@		100MG	A205153	005	Oct 28, 2016	Aug	DISC
	@		150MG	A205153	006	Oct 28, 2016	Aug	DISC

DESMOPRESSIN ACETATE

	INJECTABLE; INJECTION							
	DESMOPRESSIN ACETATE							
AP		UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb	NEWA
>A> AP			0.004MG/ML	A210223	001	Sep 17, 2020	Sep	NEWA
	TABLET; ORAL							
	DESMOPRESSIN ACETATE							
	@	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	DISC
	@		0.2MG	A077122	002	Jan 25, 2006	Aug	DISC
	@	MYLAN	0.1MG	A200653	001	Jun 27, 2014	Jul	DISC
	@		0.2MG	A200653	002	Jun 27, 2014	Jul	DISC

DESOGESTREL; ETHINYL ESTRADIOL

	TABLET; ORAL-28							
	DESOGESTREL AND ETHINYL ESTRADIOL							
AB		NAARI PTE LTD	0.15MG, N/A; 0.02MG, 0.01MG	A209170	001	Jun 05, 2017	Jun	CAHN
	@		0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Jun	CAHN
	EMOQUETTE							
	@	VINTAGE PHARMS LLC	0.15MG; 0.03MG	A076675	001	Feb 25, 2011	Apr	DISC
	SIMLIYA							
AB		AUROBINDO PHARMA LTD	0.15MG, N/A; 0.02MG, 0.01MG	A206853	001	Mar 22, 2017	Mar	CTNA

DESONIDE

	GEL; TOPICAL								
	DESONATE								
AB	+	!	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Apr	CFTG
	DESONIDE								
AB			CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Aug	CAHN
AB			TERESINA	0.05%	A202470	001	May 11, 2020	Apr	NFTG
	LOTION; TOPICAL								
	DESONIDE								
AB			ALEOR DERMACEUTICALS	0.05%	A213632	001	Aug 24, 2020	Aug	NEWA

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

AB	CADILA	0.25%	A205620	001	Sep 28, 2018	Mar	CMFD
AB	COSETTE	0.25%	A209595	001	Mar 04, 2020	Feb	NEWA

OINTMENT; TOPICAL
DESOXIMETASONE

AB	CADILA	0.25%	A205206	001	Sep 19, 2017	Aug	CAHN
----	--------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE

>D>	+	!	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Sep	CHRS
>A>	+			50MG	N204150	001	Mar 04, 2013	Sep	CHRS

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

	@	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Feb	DISC		
AB		RUBICON	EQ 50MG BASE	A204028	001	Jun 29, 2015	Aug	CAHN		
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Aug	CAHN		
AB		YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Jun	CMFD		
AB			EQ 100MG BASE	A210014	002	Oct 01, 2018	Jun	CMFD		
		PRISTIQ								
>D>	AB	+	!	PF PRISM CV	EQ 50MG BASE	N021992	001	Feb 29, 2008	Sep	CHRS
>A>	AB	+			EQ 50MG BASE	N021992	001	Feb 29, 2008	Sep	CHRS

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP		AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210966	001	Jun 05, 2020	Jun	NEWA
>D>		@	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	Sep	CMFD
>A>	AP		EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	Sep	CMFD

DEXAMETHASONE; TOBRAMYCINSUSPENSION/DROPS; OPHTHALMIC
TOBRADEX ST

	+	!	EYEVANCE	0.05%; 0.3%	N050818	001	Feb 13, 2009	Feb	CAHN
--	---	---	----------	-------------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551	001	May 20, 2020	May	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551	002	May 20, 2020	May	NEWA	
>D>		@	CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Sep	CAHN
AP		GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307	001	Jun 03, 2020	May	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307	002	Jun 03, 2020	May	NEWA	
AP		HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA	
>A>		@	HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Sep	CAHN
AP		JIANGSU HENGRUI MED	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A209065	002	Jun 12, 2020	Jun	NEWA	
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jun	CTNA	
AP			EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A209065	001	Sep 19, 2017	Jan	CTNA	
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209065	003	Jun 12, 2020	Jun	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209065	004	Jun 12, 2020	Jun	NEWA	
AP		MYLAN LABS LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212571	001	Aug 27, 2020	Aug	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212571	002	Aug 27, 2020	Aug	NEWA	
>A>	AP		PAR STERILE PRODUCTS	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A208266	001	Sep 15, 2020	Sep	NEWA
>A>	AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A208266	002	Sep 15, 2020	Sep	NEWA

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE
BASE/ML)

PRECEDEX

+!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	Jun	NEWA
----	---------	--	---------	-----	--------------	-----	------

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	GRANULES PHARMS	5MG	A213813	001	Sep 09, 2020	Aug	NEWA
AB		10MG	A213813	002	Sep 09, 2020	Aug	NEWA
AB		15MG	A213813	003	Sep 09, 2020	Aug	NEWA
AB		20MG	A213813	004	Sep 09, 2020	Aug	NEWA
AB		25MG	A213813	005	Sep 09, 2020	Aug	NEWA
AB		30MG	A213813	006	Sep 09, 2020	Aug	NEWA
AB		35MG	A213813	007	Sep 09, 2020	Aug	NEWA
AB		40MG	A213813	008	Sep 09, 2020	Aug	NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>D>	AB	BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Sep	DISC
>A>		@	5MG	A209754	001	Mar 24, 2020	Sep	DISC
	AB		5MG	A209754	001	Mar 24, 2020	Mar	NEWA
>D>	AB		10MG	A209754	002	Mar 24, 2020	Sep	DISC
>A>		@	10MG	A209754	002	Mar 24, 2020	Sep	DISC
	AB		10MG	A209754	002	Mar 24, 2020	Mar	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

	@	PII	5MG	A205077	001	Jun 21, 2019	Jan	DISC
	@		10MG	A205077	002	Jun 21, 2019	Jan	DISC
	@		15MG	A205077	003	Jun 21, 2019	Jan	DISC
	@	STRIDES PHARMA	5MG	A205077	001	Jun 21, 2019	Aug	CAHN
	@		10MG	A205077	002	Jun 21, 2019	Aug	CAHN
	@		15MG	A205077	003	Jun 21, 2019	Aug	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA	!	SLATE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Mar	CMFD
		@	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Feb	CAHN
			PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
AA		AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Mar	CMFD
		@ HI TECH PHARMA	15MG/5ML; 6.25MG/5ML	A040027	001	Jul 31, 1996	Mar	DISC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

>A>	AP	FRESENIUS KABI USA	5GM/100ML; 75MG/100ML	A212346	001	Sep 10, 2020	Sep	NEWA
			DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
>D>	+	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML	N017634	004		Sep	CTEC
>A>	AP	+	5GM/100ML; 75MG/100ML	N017634	004		Sep	CTEC
			DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
>A>	AP	FRESENIUS KABI USA	5GM/100ML; 150MG/100ML	A212346	002	Sep 10, 2020	Sep	NEWA

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	@	FRESENIUS KABI USA	2.5GM/100ML; 450MG/100ML	A211190	001	Dec 20, 2019	Jun	DISC	
			DEXTROSE 5% AND SODIUM CHLORIDE 0.225%						
>A>	AP	FRESENIUS KABI USA	5GM/100ML; 225MG/100ML	A211221	001	Sep 15, 2020	Sep	NFTG	
			DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
>D>	+	ICU MEDICAL INC	5GM/100ML; 225MG/100ML	N017606	001		Sep	CFTG	
>A>	AP	+	5GM/100ML; 225MG/100ML	N017606	001		Sep	CFTG	
			DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
	AP	FRESENIUS KABI USA	5GM/100ML; 300MG/100ML	A211194	001	Aug 26, 2020	Aug	NFTG	
	AP	+	ICU MEDICAL INC	5GM/100ML; 300MG/100ML	N017799	001		Aug	CFTG
			DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
>A>	AP	FRESENIUS KABI USA	5GM/100ML; 450MG/100ML	A211276	001	Sep 15, 2020	Sep	NEWA	
			DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
>A>	AP	FRESENIUS KABI USA	5GM/100ML; 900MG/100ML	A211211	001	Sep 14, 2020	Sep	NEWA	

DIAZEPAMINJECTABLE; INJECTION
DIAZEPAM

>D>	AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Sep	CHRS
>A>	!		10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Sep	CHRS
>D>	AP	! HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Sep	DISC
>A>	@		10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Sep	DISC
		SPRAY; NASAL						
		VALTOCO						
	+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA
	+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA
	+	!	10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA

DIAZOXIDESUSPENSION; ORAL
DIAZOXIDE

AB		NOVITIUM PHARMA	50MG/ML	A210799	001	Jul 08, 2020	Jul	NEWA
----	--	-----------------	---------	---------	-----	--------------	-----	------

DICLOFENAC EPOLAMINESYSTEM; TOPICAL
FLECTOR

+	!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb	CDFR
		LICART						
+	!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Apr	CHRS
+			1.3%	N206976	001	Dec 19, 2018	Apr	CMFD

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

@		STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Jun	DISC
---	--	----------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
CATAFLAM

+	@	NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD
		DICLOFENAC POTASSIUM						
>D>	AB	AMICI	50MG	A076561	001	Mar 18, 2004	Sep	CAHN
>A>	AB	ANDA REPOSITORY	50MG	A076561	001	Mar 18, 2004	Sep	CAHN
	AB	RUBICON	50MG	A075229	001	Nov 20, 1998	Aug	CAHN

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		ENCUBE	1%	A210986	001	Jan 27, 2020	Jan	NEWA
----	--	--------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

>A>	@	NOVAST LABS	1.5%	A206715	001	Aug 07, 2017	Sep	CAHN
>D>	@	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Sep	CAHN

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

@		RUBICON	0.1%	A077600	001	Nov 13, 2008	Jul	CAHN
---	--	---------	------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

@		MICRO LABS USA	50MG	A074986	001	Feb 26, 1999	Mar	CAHN
@			75MG	A074986	002	Feb 26, 1999	Mar	CAHN
>D>	AB	MYLAN PHARMS INC	50MG	A075281	002	Feb 12, 2002	Sep	DISC
>A>	@		50MG	A075281	002	Feb 12, 2002	Sep	DISC
>D>	AB		75MG	A075281	003	Feb 12, 2002	Sep	DISC
>A>	@		75MG	A075281	003	Feb 12, 2002	Sep	DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	+	PFIZER	50MG; 0.2MG	N020607	001	Dec 24, 1997	Aug	CAHN
AB	+	!	75MG; 0.2MG	N020607	002	Dec 24, 1997	Aug	CAHN

DICLOFENAC SODIUM AND MISOPROSTOL

AB		YUNG SHIN PHARM	50MG; 0.2MG	A205143	001	Feb 19, 2020	Feb	NEWA
AB			75MG; 0.2MG	A205143	002	Feb 19, 2020	Feb	NEWA

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

AA	!	GENERICS	10MG/5ML	A040169	001	Mar 24, 2005	May	CTEC
AA		HIKMA	10MG/5ML	A212286	001	May 22, 2020	May	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

		AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008	Jun	CTEC
			200MG	A090094	002	Sep 24, 2008	Jun	CTEC
			250MG	A090094	003	Sep 24, 2008	Jun	CTEC
	!		400MG	A090094	004	Sep 24, 2008	Jun	CHRS
			400MG	A090094	004	Sep 24, 2008	Jun	CTEC

VIDEX EC

+	@	BRISTOL MYERS SQUIBB	125MG	N021183	001	Oct 31, 2000	Jun	DISC
+	@		200MG	N021183	002	Oct 31, 2000	Jun	DISC
+	@		250MG	N021183	003	Oct 31, 2000	Jun	DISC
+	@		400MG	N021183	004	Oct 31, 2000	Jun	DISC

FOR SOLUTION;ORAL

VIDEX

+	@	BRISTOL-MYERS SQUIBB	10MG/ML	N020156	001	Oct 09, 1991	Jun	DISC
---	---	----------------------	---------	---------	-----	--------------	-----	------

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

+	@	NOSTRUM LABS INC	25MG	N011722	002		Mar	CAHN
---	---	------------------	------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

+	@	NOSTRUM LABS INC	75MG	N012546	001		Mar	CAHN
---	---	------------------	------	---------	-----	--	-----	------

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

DIHYDROERGOTAMINE MESYLATE

AB		CIPLA	0.5MG/SPRAY	A212907	001	May 20, 2020	May	NEWA
AB		CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb	NFTG
AB	+	!	BAUSCH	N020148	001	Dec 08, 1997	Feb	CFTG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2		ACCORD HLTHCARE	120MG	A206997	001	Apr 28, 2020	Apr	NEWA
AB2			180MG	A206997	002	Apr 28, 2020	Apr	NEWA
AB2			240MG	A206997	003	Apr 28, 2020	Apr	NEWA
AB2		APOTEX	120MG	A074943	003	Dec 19, 2000	Apr	CTEC
		DILTZAC						
	@	APOTEX	120MG	A076395	001	Feb 01, 2006	Apr	DISC
	@		180MG	A076395	002	Feb 01, 2006	Apr	DISC
	@		240MG	A076395	003	Feb 01, 2006	Apr	DISC
	@		300MG	A076395	004	Feb 01, 2006	Apr	DISC
	@		360MG	A076395	005	Feb 01, 2006	Apr	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

>A>	AB	ACCORD HLTHCARE	120MG	A210499	001	Sep 24, 2020	Sep	NEWA
>A>	AB		240MG	A210499	002	Sep 24, 2020	Sep	NEWA
>A>	AB	ALKEM LABS LTD	120MG	A210440	001	Sep 24, 2020	Sep	NEWA
>A>	AB		240MG	A210440	002	Sep 24, 2020	Sep	NEWA
>A>	AB	AMNEAL	120MG	A210402	001	Sep 24, 2020	Sep	NEWA
>A>	AB		240MG	A210402	002	Sep 24, 2020	Sep	NEWA
>A>	AB	CIPLA	120MG	A210305	001	Sep 24, 2020	Sep	NEWA
>A>	AB		240MG	A210305	002	Sep 24, 2020	Sep	NEWA
>A>	AB	GLENMARK PHARMS LTD	120MG	A210309	001	Oct 06, 2020	Sep	NEWA
>A>	AB		240MG	A210309	002	Oct 06, 2020	Sep	NEWA
>A>	AB	HETERO LABS LTD III	120MG	A210500	001	Sep 24, 2020	Sep	NEWA
>A>	AB		240MG	A210500	002	Sep 24, 2020	Sep	NEWA
>A>	AB	LUPIN ATLANTIS	120MG	A210226	001	Oct 05, 2020	Sep	NEWA
>A>	AB		240MG	A210226	002	Oct 05, 2020	Sep	NEWA
>A>	AB	MSN	120MG	A210460	001	Sep 24, 2020	Sep	NEWA

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

>A>	AB		240MG	A210460	002	Sep 24, 2020	Sep NEWA
	AB	MYLAN	120MG	A210531	001	Aug 17, 2020	Aug NFTG
	AB		240MG	A210531	002	Aug 17, 2020	Aug NFTG
>A>	AB	ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Sep NEWA
>A>	AB		240MG	A210538	002	Sep 24, 2020	Sep NEWA
		TECFIDERA					
	AB	+ BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013	Aug CFTG
	AB	+!	240MG	N204063	002	Mar 27, 2013	Aug CFTG

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

>D>	AP	HOSPIRA	50MG/ML	A040140	001	Nov 20, 1998	Sep DISC
>A>		@	50MG/ML	A040140	001	Nov 20, 1998	Sep DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL
NORPACE

	AB	+ PFIZER	EQ 100MG BASE	N017447	001		Jul CAHN
	AB	+!	EQ 150MG BASE	N017447	002		Jul CAHN

CAPSULE, EXTENDED RELEASE;ORAL
NORPACE CR

		+ PFIZER	EQ 100MG BASE	N018655	001	Jul 20, 1982	Jul CAHN
		+!	EQ 150MG BASE	N018655	002	Jul 20, 1982	Jul CAHN

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL
DIVALPROEX SODIUM

	AB	AJANTA PHARMA LTD	EQ 125MG VALPROIC ACID	A213181	001	Mar 02, 2020	Feb NEWA
		@ MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Jan DISC

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

		@ MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jan DISC
		@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jan DISC
		@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jan DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

		@ IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009	Aug DISC
		@	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009	Aug DISC
>D>		@ LUPIN LTD	EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019	Sep CMFD
>A>	AB		EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019	Sep CMFD
		@	EQ 250MG VALPROIC ACID	A209286	001	Oct 18, 2019	Apr DISC
>D>		@	EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019	Sep CMFD
>A>	AB		EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019	Sep CMFD
		@	EQ 500MG VALPROIC ACID	A209286	002	Oct 18, 2019	Apr DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 12.5MG BASE/ML	A074086	001	Nov 29, 1993	Sep CHRS
>A>	AP	!	EQ 12.5MG BASE/ML	A074086	001	Nov 29, 1993	Sep CHRS
>D>	AP	!	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Sep DISC
>A>		@	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995	Sep DISC

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>D>		@ CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Sep CAHN
>D>		@	80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Sep CAHN
>D>		@	160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Sep CAHN
>A>		@ HONG KONG	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Sep CAHN
>A>		@	80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Sep CAHN
>A>		@	160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Sep CAHN
	AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	Jan CMFD
	AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	Jan CMFD
	AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	Jan CMFD

DOFETILIDECAPSULE;ORAL
DOFETILIDE

AB	ACCORD HLTHCARE	0.125MG	A213338	001	Jun 19, 2020	Jun	NEWA
AB		0.25MG	A213338	002	Jun 19, 2020	Jun	NEWA
AB		0.5MG	A213338	003	Jun 19, 2020	Jun	NEWA
AB	MSN	0.125MG	A213220	001	Jan 29, 2020	Jan	NEWA
AB		0.25MG	A213220	002	Jan 29, 2020	Jan	NEWA
AB		0.5MG	A213220	003	Jan 29, 2020	Jan	NEWA

DOLUTEGRAVIR SODIUMTABLET, FOR SUSPENSION;ORAL
TIVICAY PD

+!	VIIV HLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020	Jun	NEWA
----	---------------	-------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDETABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB	GRAVITI PHARMS	5MG	A202114	001	Jul 05, 2013	Apr	CAHN
AB		10MG	A202114	002	Jul 05, 2013	Apr	CAHN
	@ HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	Jul	DISC
	@	10MG	A077344	002	May 31, 2011	Jul	DISC
	@ MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011	Mar	DISC
	@	10MG	A090521	002	May 31, 2011	Mar	DISC
AB	RISING	5MG	A202114	001	Jul 05, 2013	Aug	CAHN
AB		10MG	A202114	002	Jul 05, 2013	Aug	CAHN

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@	INDOCO	EQ 2% BASE	A202053	001	Sep 11, 2014	Aug	CAHN
---	--------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@	INDOCO	EQ 2% BASE;EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug	CAHN
AT	MICRO LABS	EQ 2.0% BASE;EQ 0.5% BASE	A204777	001	May 28, 2020	May	NEWA

DOXAZOSIN MESYLATETABLET;ORAL
CARDURA

AB	+! UPJOHN	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jun	CAHN
AB	+	EQ 2MG BASE	N019668	002	Nov 02, 1990	Jun	CAHN
AB	+	EQ 4MG BASE	N019668	003	Nov 02, 1990	Jun	CAHN
AB	+	EQ 8MG BASE	N019668	004	Nov 02, 1990	Jun	CAHN

DOXAZOSIN MESYLATE

@	ANI PHARMS INC	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan	DISC
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan	DISC
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan	DISC
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan	DISC
@	DAVA PHARMS INC	EQ 1MG BASE	A076161	001	Jun 10, 2004	Jul	DISC
@		EQ 2MG BASE	A076161	002	Jun 10, 2004	Jul	DISC
@		EQ 4MG BASE	A076161	003	Jun 10, 2004	Jul	DISC
@		EQ 8MG BASE	A076161	004	Jun 10, 2004	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+	UPJOHN	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jun	CAHN
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jun	CAHN

DOXEPIIN HYDROCHLORIDECAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB	CONTRACT PHARMACAL	EQ 10MG BASE	A213474	001	Jul 28, 2020	Jul	NEWA
AB		EQ 25MG BASE	A213474	002	Jul 28, 2020	Jul	NEWA
AB		EQ 50MG BASE	A213474	003	Jul 28, 2020	Jul	NEWA
AB		EQ 75MG BASE	A213474	004	Jul 28, 2020	Jul	NEWA
AB		EQ 100MG BASE	A213474	005	Jul 28, 2020	Jul	NEWA
AB	LANNETT CO INC	EQ 10MG BASE	A212997	001	Jul 24, 2020	Jul	NEWA
AB		EQ 25MG BASE	A212997	002	Jul 24, 2020	Jul	NEWA
AB		EQ 50MG BASE	A212997	003	Jul 24, 2020	Jul	NEWA
AB		EQ 75MG BASE	A212997	004	Jul 24, 2020	Jul	NEWA

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		EQ 100MG BASE	A212997	005	Jul 24, 2020	Jul	NEWA
AB	TARO PHARM INDS LTD	EQ 10MG BASE	A213063	001	Jul 01, 2020	Jun	NEWA
AB		EQ 25MG BASE	A213063	002	Jul 01, 2020	Jun	NEWA
AB		EQ 50MG BASE	A213063	003	Jul 01, 2020	Jun	NEWA
AB		EQ 75MG BASE	A213063	004	Jul 01, 2020	Jun	NEWA
AB		EQ 100MG BASE	A213063	005	Jul 01, 2020	Jun	NEWA
AB	UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug	NEWA
AB		EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug	NEWA
AB		EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug	NEWA
AB		EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug	NEWA
AB		EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug	NEWA

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

AA	! LANNETT CO INC	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998	May	CHRS
	@ TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987	May	DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jul	NEWA
AB		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jul	NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

>A>	AB	AVET	0.5MCG	A205360	001	Sep 15, 2020	Sep	NEWA
>A>	AB		1MCG	A205360	002	Sep 15, 2020	Sep	NEWA
>A>	AB		2.5MCG	A205360	003	Sep 15, 2020	Sep	NEWA

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Feb	CAHN
AP	NANJING KING-FRIEND	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

>A>	AB	ZYDUS	20MG/10ML (2MG/ML)	A212299	001	Sep 10, 2020	Sep	NEWA
>A>	AB		50MG/25ML (2MG/ML)	A212299	002	Sep 10, 2020	Sep	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

@ MYLAN PHARMS INC

EQ 150MG BASE

A202778 001 Jun 08, 2012 Jan DISC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020	Sep	DISC
>A>		@	EQ 50MG BASE	A212610	001	Mar 31, 2020	Sep	DISC
	AB		EQ 50MG BASE	A212610	001	Mar 31, 2020	Mar	NEWA
>D>	AB		EQ 100MG BASE	A212610	002	Mar 31, 2020	Sep	DISC
>A>		@	EQ 100MG BASE	A212610	002	Mar 31, 2020	Sep	DISC
	AB		EQ 100MG BASE	A212610	002	Mar 31, 2020	Mar	NEWA

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

+! DEN-MAT

50MG

N050751 001 Sep 03, 1998 Jul CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	AJANTA PHARMA LTD	EQ 75MG BASE	A211584	001	Jun 01, 2020	May	NEWA	
AB		EQ 150MG BASE	A211584	002	Jun 01, 2020	May	NEWA	
AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A210537	001	Mar 03, 2020	Feb	NEWA	
AB		EQ 75MG BASE	A211744	001	Jun 30, 2020	Jun	NEWA	
AB		EQ 100MG BASE	A210536	001	May 14, 2020	May	NEWA	
AB		EQ 150MG BASE	A211744	002	Jun 30, 2020	Jun	NEWA	
AB	! CARIBE HOLDINGS	EQ 100MG BASE	A062269	002	Nov 08, 1982	Jul	CHRS	
	@ HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	Jul	DISC	
AB	HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Jul	CHRS	
>A>	AB	MYLAN	EQ 75MG BASE	A209987	001	Oct 05, 2020	Sep	NEWA
>A>	AB		EQ 150MG BASE	A209987	002	Oct 05, 2020	Sep	NEWA
>D>	AB	OAKLOCK LLC	EQ 100MG BASE	A210664	001	Mar 16, 2020	Sep	DISC
>A>		@	EQ 100MG BASE	A210664	001	Mar 16, 2020	Sep	DISC
	AB		EQ 100MG BASE	A210664	001	Mar 16, 2020	Mar	NEWA

TABLET, DELAYED RELEASE;ORAL
DORYX

	+ @	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Jul	DISC
	+		EQ 80MG BASE	N050795	004	Apr 11, 2013	Mar	CMFD
AB		DOXYCYCLINE HYCLATE PRINSTON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019	Feb	NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

AB		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE MYLAN PHARMS INC	10MG;10MG	A207825	001	Jul 06, 2020	Jul	NEWA
----	--	---	-----------	---------	-----	--------------	-----	------

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		ASCENT PHARMS INC	2.5MG	A207421	001	Feb 07, 2020	Jan	NEWA
AB			5MG	A207421	002	Feb 07, 2020	Jan	NEWA
AB			10MG	A207421	003	Feb 07, 2020	Jan	NEWA

MARINOL

AB	+	ALKEM LABS LTD	2.5MG	N018651	001	May 31, 1985	Jan	CAHN
AB	+	!	5MG	N018651	002	May 31, 1985	Jan	CAHN
AB	+		10MG	N018651	003	May 31, 1985	Jan	CAHN

SOLUTION;ORAL

SYNDROS

>D>	+	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017	Sep	CAHN
	+	!	5MG/ML	N205525	001	Mar 23, 2017	Feb	CAHN
>A>	+	GUA ZHUANG	5MG/ML	N205525	001	Mar 23, 2017	Sep	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ALLIED	3MG;0.02MG	A203291	001	Jul 18, 2017	Jan	CAHN
----	--	--------	------------	---------	-----	--------------	-----	------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	@	APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016	Jul	DISC
AB		HETERO LABS LTD	3MG;0.03MG	A213034	001	Jan 24, 2020	Jan	NEWA
AB		NAARI PTE LTD	3MG;0.03MG	A207245	001	Nov 22, 2016	Jun	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

>D>	@	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Sep	CMFD
>A>	AB		EQ 20MG BASE	A210599	001	Apr 17, 2019	Sep	CMFD
	@		EQ 20MG BASE	A210599	001	Apr 17, 2019	May	DISC
>D>	@		EQ 30MG BASE	A210599	002	Apr 17, 2019	Sep	CMFD
>A>	AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Sep	CMFD
	@		EQ 30MG BASE	A210599	002	Apr 17, 2019	May	DISC
>D>	@		EQ 60MG BASE	A210599	003	Apr 17, 2019	Sep	CMFD
>A>	AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Sep	CMFD
	@		EQ 60MG BASE	A210599	003	Apr 17, 2019	May	DISC
	@	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Mar	DISC
	@		EQ 30MG BASE	A207219	002	Aug 16, 2019	Mar	DISC
	@		EQ 60MG BASE	A207219	003	Aug 16, 2019	Mar	DISC

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB		ACELLA	0.5MG	A206373	001	Mar 17, 2016	Jul	CAHN
	@	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Jan	DISC
	@	APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Feb	DISC
AB		AUROBINDO PHARMA LTD	0.5MG	A202660	001	Nov 20, 2015	May	CAHN
	@	HIKMA	0.5MG	A202204	001	Nov 23, 2015	Feb	DISC
	@	STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018	Mar	CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB		TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018	Aug	CMFD
----	--	-----------------	-------------------	---------	-----	--------------	-----	------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS LABS LTD	400MG;300MG;300MG	A213038	001	May 14, 2020	May	NFTG
AB			600MG;300MG;300MG	A212786	001	May 14, 2020	May	NFTG
		SYMFI						
AB	+	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	May	CFTG
		SYMFI LO						
AB	+	MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018	May	CFTG

ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE; ORAL

ORIAHNN (COPACKAGED)

	+	ABBVIE INC	EQ 300MG BASE, 1MG, 0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020	May	NEWA
--	---	------------	--	---------	-----	--------------	-----	------

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

		@ YUNG SHIN PHARM		EQ 20MG BASE	A209680	001	Jul 13, 2020	Aug	DISC
AB				EQ 20MG BASE	A209680	001	Jul 13, 2020	Jul	NEWA
		@		EQ 40MG BASE	A209680	002	Jul 13, 2020	Aug	DISC
AB				EQ 40MG BASE	A209680	002	Jul 13, 2020	Jul	NEWA
		RELPAK							
AB	+	UPJOHN		EQ 20MG BASE	N021016	001	Dec 26, 2002	Jul	CAHN
AB	+			EQ 40MG BASE	N021016	002	Dec 26, 2002	Jul	CAHN

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIJARDY XR

	+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan	NEWA
	+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan	NEWA
	+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan	NEWA
	+		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		AMNEAL PHARMS CO	200MG;300MG	A209721	004	Aug 22, 2018	Aug	CMFD
>D>	AB	MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Sep	DISC
>A>		@	200MG;300MG	A203442	001	May 15, 2020	Sep	DISC
AB			200MG;300MG	A203442	001	May 15, 2020	May	NEWA
		@ MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb	DISC
AB		ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb	NEWA

ENALAPRIL MALEATE

SOLUTION; ORAL

EPANED

	+	AZURITY	1MG/ML	N208686	001	Sep 20, 2016	May	CAHN
--	---	---------	--------	---------	-----	--------------	-----	------

ENTECAVIR

TABLET; ORAL

ENTECAVIR

		@ MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan	DISC
		@	1MG	A206226	002	Mar 26, 2019	Jan	DISC
AB		PHARMADAX INC	0.5MG	A212106	001	Aug 10, 2020	Jul	NEWA
AB			1MG	A212106	002	Aug 10, 2020	Jul	NEWA
AB		SUNSHINE	0.5MG	A211978	001	May 20, 2020	May	NEWA
AB			1MG	A211978	002	May 20, 2020	May	NEWA
		@ YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Apr	DISC
		@	1MG	A212201	002	Nov 04, 2019	Apr	DISC

ENZALUTAMIDE

TABLET; ORAL

XTANDI

	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020	Aug	NEWA
	+		80MG	N213674	002	Aug 04, 2020	Aug	NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP	+!	EXELA PHARMA	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Jul	CAHN
		EMERPHED						
	+!	NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Apr	NEWA
		EPHEDRINE SULFATE						
AP		ANDERSEN	50MG/ML (50MG/ML)	A209646	001	Aug 04, 2020	Jul	NEWA
>A>	AP	DR REDDYS LABS LTD	50MG/ML (50MG/ML)	A212649	001	Oct 03, 2020	Sep	NEWA
AP		FRESENIUS KABI USA	50MG/ML (50MG/ML)	A209646	001	Aug 04, 2020	Aug	CAHN

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+!	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr	CFTG
		EPINEPHRINE						
AP		INTL MEDICATION SYS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A211880	001	Apr 24, 2020	Apr	NFTG

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>D>		@ ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep	CAHN
>A>		@	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep	CAHN
>D>		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep	CAHN
>A>		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep	CAHN

EPLERENONE

TABLET; ORAL

EPLERENONE

AB		COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb	CAHN
AB			50MG	A078482	002	Jul 30, 2008	Feb	CAHN
AB		PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Jul	NEWA
AB			50MG	A212765	002	Aug 10, 2020	Jul	NEWA

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

@ MYLAN PHARMS INC

@

EQ 400MG BASE

EQ 600MG BASE

A202012	001	Nov 16, 2011	Apr	DISC
A202012	002	Nov 16, 2011	Apr	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

>D>	AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	Sep	DISC
>A>		@	2MG/ML	A205581	001	Dec 08, 2016	Sep	DISC
>D>	AP		75MG/100ML	A205581	002	Dec 08, 2016	Sep	DISC
>A>		@	75MG/100ML	A205581	002	Dec 08, 2016	Sep	DISC
>D>	AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Sep	DISC
>A>		@	2MG/ML	A207864	001	Mar 20, 2020	Sep	DISC
	AP		2MG/ML	A207864	001	Mar 20, 2020	Mar	NEWA
>D>	AP		75MG/100ML	A207864	002	Mar 20, 2020	Sep	DISC
>A>		@	75MG/100ML	A207864	002	Mar 20, 2020	Sep	DISC
	AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar	NEWA

ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS

XERAVA

+!	TETRAPHASE PHARMS	EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020	Jun	NEWA
----	-------------------	--------------------	---------	-----	--------------	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 25MG BASE	A211083	001	Jul 02, 2020	Jul	NEWA
AB			EQ 100MG BASE	A211083	002	Jul 02, 2020	Jul	NEWA
AB			EQ 150MG BASE	A211083	003	Jul 02, 2020	Jul	NEWA
AB		ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr	NEWA
AB			EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr	NEWA
AB			EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr	NEWA

ERYTHROMYCIN

TABLET; ORAL

ERYTHROMYCIN

AB	TORRENT	250MG	A212015	001	Jul 06, 2020	Jul	NEWA
AB		500MG	A212015	002	Jul 06, 2020	Jul	NEWA

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

>A>	AP	EXELA PHARMA	EQ 500MG BASE/VIAL	A211086	001	Sep 17, 2020	Sep	NEWA
-----	----	--------------	--------------------	---------	-----	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan	CAHN
AA	! HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr	CHRS
	LEXAPRO						
	+ @ ALLERGAN	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr	DISC

TABLET; ORAL

ESCITALOPRAM OXALATE

>D>	AB	HIKMA PHARMS	EQ 5MG BASE	A078766	001	Sep 11, 2012	Sep	DISC
>A>	@		EQ 5MG BASE	A078766	001	Sep 11, 2012	Sep	DISC
>D>	AB		EQ 10MG BASE	A078766	002	Sep 11, 2012	Sep	DISC
>A>	@		EQ 10MG BASE	A078766	002	Sep 11, 2012	Sep	DISC
>D>	AB		EQ 20MG BASE	A078766	003	Sep 11, 2012	Sep	DISC
>A>	@		EQ 20MG BASE	A078766	003	Sep 11, 2012	Sep	DISC
	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	May	DISC
	@		EQ 10MG BASE	A202210	002	Sep 11, 2012	May	DISC
	@		EQ 20MG BASE	A202210	003	Sep 11, 2012	May	DISC
	AB	RISING	EQ 5MG BASE	A078777	001	Sep 11, 2012	Aug	CAHN
	AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Aug	CAHN
	AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Aug	CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	CISEN	EQ 20MG BASE	A213158	001	Sep 22, 2020	Sep	NEWA
>A>	AB		EQ 40MG BASE	A213158	002	Sep 22, 2020	Sep	NEWA
>A>	AB	CSPC OUYI	EQ 20MG BASE	A212949	001	Oct 02, 2020	Sep	NEWA
>A>	AB		EQ 40MG BASE	A212949	002	Oct 02, 2020	Sep	NEWA
	AB	HETERO LABS LTD III	EQ 20MG BASE	A211977	001	Jun 02, 2020	May	NEWA
	AB		EQ 40MG BASE	A211977	002	Jun 02, 2020	May	NEWA

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

	AB	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar	NFTG
	AB		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar	NFTG
	AB		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar	NFTG
		NEXIUM						
	AB	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
	AB	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
	AB	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A204206	001	Feb 18, 2020	Feb	NEWA
	AB		EQ 20MG BASE; 500MG	A204206	002	Feb 18, 2020	Feb	NEWA
		VIMOVO						
	AB	+ HORIZON	EQ 20MG BASE; 375MG	N022511	002	Apr 30, 2010	Feb	CTEC
	AB	+	EQ 20MG BASE; 500MG	N022511	001	Apr 30, 2010	Feb	CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

	AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar	NEWA
	AP		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar	NEWA

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

>D>	+ @	BELCHER	24.65MG	N202342	001	Aug 06, 2013	Sep CAHN
>A>	+ @		24.65MG	N202342	001	Aug 06, 2013	Sep CAHN
	+ @		24.65MG	N202342	001	Aug 06, 2013	Mar CAHN
>D>	+ @		49.3MG	N202342	002	Aug 06, 2013	Sep CAHN
>A>	+ @		49.3MG	N202342	002	Aug 06, 2013	Sep CAHN
	+ @		49.3MG	N202342	002	Aug 06, 2013	Mar CAHN

ESTAZOLAMTABLET;ORAL
ESTAZOLAM

AB		NOVITIUM PHARMA	1MG	A074826	001	Jul 03, 1997	Jul CAHN
AB			2MG	A074826	002	Jul 03, 1997	Jul CAHN
AB		PAR PHARM	1MG	A074826	001	Jul 03, 1997	Aug CAHN
AB			2MG	A074826	002	Jul 03, 1997	Aug CAHN

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

>A>	AB3	AMNEAL	0.025MG/24HR	A211396	001	Sep 28, 2020	Sep NEWA
>A>	AB3		0.0375MG/24HR	A211396	002	Sep 28, 2020	Sep NEWA
>A>	AB3		0.05MG/24HR	A211396	003	Sep 28, 2020	Sep NEWA
>A>	AB3		0.075MG/24HR	A211396	004	Sep 28, 2020	Sep NEWA
>A>	AB3		0.1MG/24HR	A211396	005	Sep 28, 2020	Sep NEWA

ESTRADIOL VALERATEINJECTABLE;INJECTION
DELESTROGEN

AO	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr CTEC
		ESTRADIOL VALERATE					
AO		HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr NEWA
AO			20MG/ML	A203723	002	Apr 21, 2020	Apr NEWA
AO			40MG/ML	A203723	003	Apr 21, 2020	Apr NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

@ NAARI PTE LTD 1MG;0.5MG
@ TEVA PHARMS USA 0.5MG;0.1MGA210233 001 Feb 28, 2018 Jun CAHN
A200747 001 Mar 08, 2012 Jan DISCESTROPIPATE

TABLET;ORAL

ESTROPIPATE

@ MYLAN 0.75MG
@ 1.5MGA040359 001 Aug 26, 1999 Jan DISC
A040359 002 Aug 26, 1999 Jan DISCESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ HIKMA 1MG
@ 2MG
@ 3MGA091153 001 Apr 15, 2014 Feb DISC
A091153 002 Apr 15, 2014 Feb DISC
A091153 003 Apr 15, 2014 Feb DISCETHACRYNATE SODIUMINJECTABLE;INJECTION
ETHACRYNATE SODIUM

AP VPI PHARMS INC EQ 50MG BASE/VIAL A208663 001 Jun 09, 2020 Jun NEWA

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

AB UPSHER SMITH LABS 25MG A212417 001 Feb 19, 2020 Feb NEWA

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE

@ PFIZER 0.035MG;75MG;1MG

N018926 001 Jul 18, 1986 Jul CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

		SYSTEM; TRANSDERMAL							
		TWIRLA							
		+! AGILE	0.03MG/24HR; 0.12MG/24HR	N204017	001	Feb 14, 2020	Feb	NEWA	
		TABLET; ORAL							
		BALCOLTRA							
		+! AVION PHARMS	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan	CHRS	
		+	0.02MG; 0.1MG	N208612	001	Jan 09, 2018	Jan	CRLD	
>A>		TYBLUME							
>A>		+! EXELTIS USA INC	0.02MG; 0.1MG	N209405	001	Mar 30, 2020	Sep	CDFR	
		TABLET; ORAL-28							
		ELIFEMME							
		@ XIROMED	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Mar	DISC	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
>D>	AB	ACCORD HLTHCARE	0.02MG; 0.1MG	A207065	001	Aug 17, 2020	Sep	CAHN	
	AB		0.02MG; 0.1MG	A207065	001	Aug 17, 2020	Aug	NEWA	
		@ MYLAN LABS LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	Feb	DISC	
>A>	AB	NAARI PTE LTD	0.02MG; 0.1MG	A207065	001	Aug 17, 2020	Sep	CAHN	
		ORSYTHIA							
		@ VINTAGE PHARMS LLC	0.02MG; 0.1MG	A077099	001	May 11, 2011	Jun	DISC	
>D>		TABLET, CHEWABLE; ORAL							
>D>		TYBLUME							
>D>		+! EXELTIS USA INC	0.02MG; 0.1MG	N209405	001	Mar 30, 2020	Sep	CDFR	
		+!	0.02MG; 0.1MG	N209405	001	Mar 30, 2020	Jun	CTNA	
		+!	0.02MG; 0.1MG	N209405	001	Mar 30, 2020	Mar	NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE

		TABLET; ORAL-28							
		BREVICON 28-DAY							
		@ ALLERGAN	0.035MG; 0.5MG	N017743	001		Aug	DISC	
		DASETTA 7/7/7							
AB	!	NOVAST LABS LTD	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	A090946	001	Dec 22, 2011	Aug	CHRS	
		NORETHINDRONE AND ETHINYL ESTRADIOL							
AB		NAARI PTE LTD	0.035MG; 1MG	A206864	001	Apr 28, 2017	Jun	CAHN	
		ORTHO-NOVUM 7/7/7-28							
		+ @ JANSSEN PHARMS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG	N018985	002	Apr 04, 1984	Aug	DISC	
		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		NAARI PTE LTD	0.035MG; 0.4MG	A207066	001	Mar 29, 2017	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

		TABLET; ORAL							
		LOESTRIN 24 FE							
AB	+	TEVA BRANDED PHARM	0.02MG; 1MG	N021871	001	Feb 17, 2006	Jan	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
		@ MYLAN LABS LTD	0.02MG; 1MG	A202742	001	Oct 30, 2014	Jun	DISC	
		TABLET; ORAL-21							
		GILDESS 1.5/30							
		@ VINTAGE PHARMS LLC	0.03MG; 1.5MG	A077075	002	Jul 24, 2012	Jun	DISC	
		LOESTRIN 21 1.5/30							
AB	+	TEVA BRANDED PHARM	0.03MG; 1.5MG	N017875	001		Jan	CAHN	
		LOESTRIN 21 1/20							
AB	+	TEVA BRANDED PHARM	0.02MG; 1MG	N017876	001		Jan	CAHN	
		LOESTRIN FE 1.5/30							
AB	+!	TEVA BRANDED PHARM	0.03MG; 1.5MG	N017355	001		Jan	CAHN	
		TABLET; ORAL-28							
		CHABELINA FE							
AB		NOVAST LABS	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A202962	001	Apr 15, 2020	Mar	NEWA	
		GILDESS FE 1.5/30							
		@ VINTAGE PHARMS LLC	0.03MG; 1.5MG	A077075	001	Apr 28, 2005	Jun	DISC	
		LOESTRIN FE 1/20							
AB	+	TEVA BRANDED PHARM	0.02MG; 1MG	N017354	001		Jan	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
		@ MYLAN LABS LTD	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb	DISC	

TABLET, CHEWABLE;ORAL

FINZALA

	@ TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jul	DISC
AB		0.02MG;1MG	A210087	001	Apr 07, 2020	Mar	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	!	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Aug	CHRS
AB	!	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016	Jul	CHRS
		ORTHO TRI-CYCLEN						
+	@	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N019697	001	Jul 03, 1992	Aug	DISC
		ORTHO TRI-CYCLEN LO						
+	@	JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	N021241	001	Aug 22, 2002	Jul	DISC
		TRI-PREVIFEM						
	@	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335	001	Mar 26, 2004	Jun	DISC

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB		PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Mar	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE;ORAL

ETODOLAC

>D>		@ ECI PHARMS LLC	300MG	A074929	001	Jan 30, 1998	Sep	CAHN
>A>		@ PHARMA LIFE	300MG	A074929	001	Jan 30, 1998	Sep	CAHN

TABLET;ORAL

ETODOLAC

>D>		@ ECI PHARMS LLC	400MG	A074927	001	Oct 30, 1997	Sep	CAHN
>D>		@ INVATECH	400MG	A074839	001	Jul 11, 1997	Sep	CAHN
>D>		@	400MG	A074846	001	Feb 28, 1997	Sep	CAHN
>A>		@ PHARMA LIFE	400MG	A074927	001	Oct 30, 1997	Sep	CAHN
>A>		@ PHARMGEN	400MG	A074839	001	Jul 11, 1997	Sep	CAHN
>A>		@	400MG	A074846	001	Feb 28, 1997	Sep	CAHN
		@ TEVA	400MG	A075009	001	Nov 26, 1997	Feb	DISC
		@	500MG	A075009	002	Dec 28, 1999	Feb	DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

	@	MYLAN LABS LTD	2MG/ML	A078289	001	Jan 02, 2009	Feb	DISC
--	---	----------------	--------	---------	-----	--------------	-----	------

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB		HIKMA	2.5MG	A207486	001	Jun 08, 2020	Jun	NEWA
AB			5MG	A207486	002	Jun 08, 2020	Jun	NEWA
AB			7.5MG	A207486	003	Jun 08, 2020	Jun	NEWA
AB		MYLAN	2.5MG	A212936	001	Jun 08, 2020	Jun	NEWA
AB			5MG	A212936	002	Jun 08, 2020	Jun	NEWA
AB			7.5MG	A212936	003	Jun 08, 2020	Jun	NEWA
AB			10MG	A212936	004	Jun 08, 2020	Jun	NEWA
AB		TEVA PHARMS USA	2.5MG	A210050	001	Dec 09, 2019	Jun	CMFD
	@		2.5MG	A210050	001	Dec 09, 2019	Jun	DISC
AB			5MG	A210050	002	Dec 09, 2019	Jun	CMFD
	@		5MG	A210050	002	Dec 09, 2019	Jun	DISC
AB			7.5MG	A210050	003	Dec 09, 2019	Jun	CMFD
	@		7.5MG	A210050	003	Dec 09, 2019	Jun	DISC
	@		10MG	A210050	004	Dec 09, 2019	Jun	DISC
		ZORTRESS						
AB	+	NOVARTIS	0.75MG	N021560	003	Apr 20, 2010	Jul	CHRS
	+	!	1MG	N021560	004	Aug 10, 2018	Jul	CHRS

EXEMESTANETABLET; ORAL
EXEMESTANE

	@ MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jan	DISC
AB	QILU	25MG	A213547	001	Apr 13, 2020	Mar	NEWA

EZETIMIBETABLET; ORAL
EZETIMIBE

	@ MYLAN	10MG	A201790	001	Apr 26, 2019	Feb	DISC
	@ TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	Mar	DISC

FAMCICLOVIRTABLET; ORAL
FAMCICLOVIR

>D>	AB	HIKMA	125MG	A090128	001	Mar 21, 2011	Sep	DISC
>A>		@	125MG	A090128	001	Mar 21, 2011	Sep	DISC
>D>	AB		250MG	A090128	002	Mar 21, 2011	Sep	DISC
>A>		@	250MG	A090128	002	Mar 21, 2011	Sep	DISC
>D>	AB		500MG	A090128	003	Mar 21, 2011	Sep	DISC
>A>		@	500MG	A090128	003	Mar 21, 2011	Sep	DISC

FAMOTIDINETABLET; ORAL
FAMOTIDINE

AB	!	AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan	CHRS
		@ MYLAN	20MG	A075704	001	Apr 16, 2001	Feb	DISC
		@ TEVA	20MG	A075311	001	Apr 16, 2001	Mar	DISC
		@	40MG	A075311	002	Apr 16, 2001	Mar	DISC
		PEPCID						
	+	@ VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan	DISC
	+	@	40MG	N019462	002	Oct 15, 1986	Jan	DISC

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB		SUNSHINE	40MG	A213069	001	Jun 02, 2020	May	NEWA
AB			80MG	A213069	002	Jun 02, 2020	May	NEWA

FENFLURAMINE HYDROCHLORIDESOLUTION; ORAL
FINTEPLA

	+!	ZOGENIX INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020	Jun	NEWA
--	----	-------------	------------------	---------	-----	--------------	-----	------

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB		ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan	CAHN
AB			134MG	A209504	002	Apr 30, 2018	Jan	CAHN
AB			200MG	A209504	003	Apr 30, 2018	Jan	CAHN
		@ MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013	Mar	DISC
		@	130MG	A202579	002	Jan 10, 2013	Mar	DISC

TABLET; ORAL
FENOFIBRATE

AB		ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan	NEWA
AB			160MG	A213252	002	Jan 17, 2020	Jan	NEWA
AB		APPCO	54MG	A210670	001	Sep 06, 2019	Jan	CAHN
AB			160MG	A210670	002	Sep 06, 2019	Jan	CAHN
AB		DR REDDYS	54MG	A210670	001	Sep 06, 2019	Aug	CAHN
AB			160MG	A210670	002	Sep 06, 2019	Aug	CAHN
AB		GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar	NEWA
AB			54MG	A210606	001	Aug 17, 2018	Jan	CMFD
AB			145MG	A211122	002	Mar 18, 2020	Mar	NEWA
AB			160MG	A210606	002	Aug 17, 2018	Jan	CMFD
AB		MANKIND PHARMA	54MG	A213864	001	Jun 12, 2020	Jun	NEWA
AB			160MG	A213864	002	Jun 12, 2020	Jun	NEWA

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

+ @ ATHENA 35MG N022418 001 Aug 14, 2009 Jul DISC

FENTANYLFILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100>D> AB LAVIPHARM LABS 100MCG/HR A077051 004 Aug 04, 2006 Sep DISC
>A> @ 100MCG/HR A077051 004 Aug 04, 2006 Sep DISC

FENTANYL-25

>D> AB LAVIPHARM LABS 25MCG/HR A077051 001 Aug 04, 2006 Sep DISC
>A> @ 25MCG/HR A077051 001 Aug 04, 2006 Sep DISC

FENTANYL-37

AB SPECGX LLC 37.5MCG/HR A077154 006 Jan 14, 2020 Jul NEWA

FENTANYL-50

>D> AB LAVIPHARM LABS 50MCG/HR A077051 002 Aug 04, 2006 Sep DISC
>A> @ 50MCG/HR A077051 002 Aug 04, 2006 Sep DISC

FENTANYL-62

AB MYLAN TECHNOLOGIES 62.5MCG/HR A076258 007 Dec 29, 2014 Jul CTEC
AB SPECGX LLC 62.5MCG/HR A077154 007 Jan 14, 2020 Jul NEWA

FENTANYL-75

>D> AB LAVIPHARM LABS 75MCG/HR A077051 003 Aug 04, 2006 Sep DISC
>A> @ 75MCG/HR A077051 003 Aug 04, 2006 Sep DISC

FENTANYL-87

AB MYLAN TECHNOLOGIES 87.5MCG/HR A076258 008 Dec 29, 2014 Jul CTEC

FENTANYL CITRATEINJECTABLE;INJECTION
FENTANYL CITRATEAP FRESENIUS KABI USA EQ 0.05MG BASE/ML A212086 001 Sep 01, 2020 Aug NEWA
FENTANYL CITRATE PRESERVATIVE FREE

AP +! HIKMA EQ 0.05MG BASE/ML N019101 001 Jul 11, 1984 Feb CAHN

FERRIC DERISOMALTOSESOLUTION;INTRAVENOUS
MONOFERRIC+ @ PHARMACOSMOS AS 100MG/ML (100MG/ML) N208171 001 Jan 16, 2020 Jun DISC
+! 100MG/ML (100MG/ML) N208171 001 Jan 16, 2020 Jan NEWA
+ @ 500MG/5ML (100MG/ML) N208171 002 Jan 16, 2020 Jun DISC
+! 500MG/5ML (100MG/ML) N208171 002 Jan 16, 2020 Jan NEWA
+! 1GM/10ML (100MG/ML) N208171 003 Jan 16, 2020 Jan NEWA>D> FERRIC MALTOL>D> CAPSULE;ORAL
>D> ACCRUFER>D> +! SHIELD TX 30MG IRON N212320 001 Jul 25, 2019 Sep DISC
>A> + @ 30MG IRON N212320 001 Jul 25, 2019 Sep DISCFERRIC PYROPHOSPHATE CITRATESOLUTION;INTRAVENOUS
TRIFERIC AVNU

+! ROCKWELL MEDICAL INC 6.75MG IRON/4.5ML (1.5MG IRON/ML) N212860 001 Mar 27, 2020 Mar NEWA

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE@ DR REDDYS LABS LTD 4MG A204975 001 Aug 13, 2019 Feb DISC
@ 8MG A204975 002 Aug 13, 2019 Feb DISCFEXOFENADINE HYDROCHLORIDETABLET;ORAL
FEXOFENADINE HYDROCHLORIDE@ BARR 30MG A076191 001 Aug 31, 2005 Mar DISC
@ 60MG A076191 002 Aug 31, 2005 Mar DISC
@ 180MG A076191 003 Aug 31, 2005 Mar DISC

FIDAXOMICINFOR SUSPENSION; ORAL
DIFICID

+! CUBIST PHARMS LLC 40MG/ML N213138 001 Jan 24, 2020 Jan NEWA

FINASTERIDETABLET; ORAL
FINASTERIDE

@ TEVA 1MG A076905 001 Nov 05, 2013 Mar DISC

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

	@ BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Jun DISC
AB	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Jun NEWA
AB	HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	May NEWA
AB	STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Jun NEWA
AB	TEVA PHARMS USA	EQ 0.5MG BASE	A208008	001	Jul 02, 2020	Jul NEWA

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>A>	AB	BEXIMCO PHARMS USA	50MG	A210683	001	Sep 16, 2020	Sep NEWA
>A>	AB		100MG	A210683	002	Sep 16, 2020	Sep NEWA
>A>	AB		150MG	A210683	003	Sep 16, 2020	Sep NEWA

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS

TAUVID

+!	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	May NEWA
+!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	May NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

	@ HIKMA	50MG/5ML	A076246	001	Jul 29, 2004	Feb DISC
	@	200MG/5ML	A076246	002	Jul 29, 2004	Feb DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@ HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Mar DISC
	@	400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Mar DISC
	@ HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar DISC
	@	400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar DISC
	@ WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Mar DISC
	@	400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Mar DISC

TABLET; ORAL

FLUCONAZOLE

AB	ANI PHARMS INC	50MG	A078423	001	Mar 07, 2011	Jul CAHN
AB		100MG	A078423	002	Mar 07, 2011	Jul CAHN
AB		150MG	A078423	003	Mar 07, 2011	Jul CAHN
AB		200MG	A078423	004	Mar 07, 2011	Jul CAHN
	@ MYLAN	50MG	A076351	001	Jul 29, 2004	Jan DISC
	@	100MG	A076351	002	Jul 29, 2004	Jan DISC
	@	150MG	A076351	003	Jul 29, 2004	Jan DISC
	@	200MG	A076351	004	Jul 29, 2004	Jan DISC
	@ TEVA	50MG	A074681	001	Jul 29, 2004	Mar DISC
	@	100MG	A074681	002	Jul 29, 2004	Mar DISC
	@	150MG	A074681	003	Jul 29, 2004	Mar DISC
	@	200MG	A074681	004	Jul 29, 2004	Mar DISC

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

AB	AUROBINDO PHARMA LTD	250MG	A213665	001	May 01, 2020	Apr NEWA
AB		500MG	A213665	002	May 01, 2020	Apr NEWA
AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Apr NEWA
AB		500MG	A212632	002	Apr 17, 2020	Apr NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
 FLUDEOXYGLUCOSE F18
 @ UNIV TX SW MEDCTR 20-200mCi/ML A210265 001 Feb 06, 2020 May DISC
 AP 20-200mCi/ML A210265 001 Feb 06, 2020 Jan NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL
 FLUDROCORTISONE ACETATE
 >D> AB HIKMA PHARMS 0.1MG A091302 001 Jul 22, 2011 Sep DISC
 >A> @ 0.1MG A091302 001 Jul 22, 2011 Sep DISC

FLUNISOLIDE

SPRAY, METERED; NASAL
 FLUNISOLIDE
 ! APOTEX 0.029MG/SPRAY A077436 001 Aug 09, 2007 Mar CHRS
 0.029MG/SPRAY A077436 001 Aug 09, 2007 Mar CMFD
 NASALIDE
 + @ IVAX RES 0.025MG/SPRAY N018148 001 Aug CRLD

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
 FLUOCINOLONE ACETONIDE
 AT AMNEAL 0.01% A201759 001 Oct 17, 2011 Aug CAHN
 AT 0.01% A201764 001 Oct 17, 2011 Aug CAHN
 OIL/DROPS; OTIC
 FLUOCINOLONE ACETONIDE
 AT AMNEAL 0.01% A091306 001 Oct 17, 2011 Aug CAHN

FLUOCINONIDE

CREAM; TOPICAL
 FLUOCINONIDE
 AB1 AMNEAL 0.05% A210554 001 Aug 21, 2018 Apr CMFD
 AB CADILA 0.1% A208989 001 Feb 10, 2020 Feb CAHN
 AB ZYDUS PHARMS 0.1% A208989 001 Feb 10, 2020 Jan NEWA
 SOLUTION; TOPICAL
 FLUOCINONIDE
 @ TEVA 0.05% A072511 001 Feb 07, 1989 Mar DISC

FLUORODOPA F-18

SOLUTION; INTRAVENOUS
 FLUORODOPA F18
 + @ FEINSTEIN 0.42-8.33mCi/ML N200655 001 Oct 10, 2019 Aug DISC

FLUOROESTRADIOL F-18

SOLUTION; INTRAVENOUS
 CERIANNA
 +! ZIONEXA 50ML (4-100mCi/ML) N212155 001 May 20, 2020 May NEWA

FLUOROURACIL

INJECTABLE; INJECTION
 FLUOROURACIL
 >D> @ INGENUS PHARMS LLC 500MG/10ML (50MG/ML) A209219 001 Dec 12, 2019 Sep CAHN
 @ 500MG/10ML (50MG/ML) A209219 001 Dec 12, 2019 Apr DISC
 >D> @ 500MG/10ML (50MG/ML) A209271 001 Dec 11, 2019 Sep CAHN
 @ 500MG/10ML (50MG/ML) A209271 001 Dec 11, 2019 Apr DISC
 >D> @ 1GM/20ML (50MG/ML) A209219 002 Dec 12, 2019 Sep CAHN
 @ 1GM/20ML (50MG/ML) A209219 002 Dec 12, 2019 Apr DISC
 >D> @ 2.5GM/50ML (50MG/ML) A209271 002 Dec 11, 2019 Sep CAHN
 @ 2.5GM/50ML (50MG/ML) A209271 002 Dec 11, 2019 Apr DISC
 >A> @ NOVAST LABS 500MG/10ML (50MG/ML) A209219 001 Dec 12, 2019 Sep CAHN
 >A> @ 500MG/10ML (50MG/ML) A209271 001 Dec 11, 2019 Sep CAHN
 >A> @ 1GM/20ML (50MG/ML) A209219 002 Dec 12, 2019 Sep CAHN
 >A> @ 2.5GM/50ML (50MG/ML) A209271 002 Dec 11, 2019 Sep CAHN
 SOLUTION; TOPICAL
 EFUDEX
 + @ BAUSCH 5% N016831 002 Aug DISC
 FLUOROURACIL
 ! TARO 5% A076526 002 Nov 05, 2003 Aug CTEC
 AT ! 5% A076526 002 Nov 05, 2003 Mar CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Aug	NEWA
AB1		EQ 20MG BASE	A202729	002	Aug 27, 2020	Aug	NEWA
AB		EQ 40MG BASE	A202729	003	Aug 27, 2020	Aug	NEWA
	@ BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002	Mar	DISC
	@	EQ 20MG BASE	A074803	001	Aug 02, 2001	Mar	DISC
	@ SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002	May	DISC
	@	EQ 20MG BASE	A075658	002	Jan 29, 2002	May	DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Mar	CMFD
	@ SPECGX LLC	EQ 20MG BASE/5ML	A075920	001	Jan 29, 2002	May	DISC

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar	NEWA
AB		EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar	NEWA
AB		EQ 60MG BASE	A213265	001	Jun 10, 2020	Jun	NEWA
	SARAFEM						
+	@ APIL	EQ 15MG BASE	N021860	002	May 19, 2006	Jul	DISC
+		EQ 15MG BASE	N021860	002	May 19, 2006	Apr	CTEC
	SELFEMRA						
	@ TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Apr	DISC
	@	EQ 15MG BASE	A200151	002	Feb 03, 2014	Apr	DISC
	@	EQ 20MG BASE	A200151	003	Feb 03, 2014	Apr	DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	AMNEAL	1MG	A213647	001	Jul 09, 2020	Jul	NEWA
AB		2.5MG	A213647	002	Jul 09, 2020	Jul	NEWA
AB		5MG	A213647	003	Jul 09, 2020	Jul	NEWA
AB		10MG	A213647	004	Jul 09, 2020	Jul	NEWA
	@ SANDOZ	1MG	A089586	002	Oct 16, 1987	Mar	DISC
	@	2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
	@	5MG	A089586	004	Oct 16, 1987	Mar	DISC
	@	10MG	A089586	001	Oct 16, 1987	Mar	DISC

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

+	@ ALMIRALL	0.025%	N012806	003		Aug	DISC
---	------------	--------	---------	-----	--	-----	------

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

>D>	MYLAN	50MG	A074358	001	Jun 20, 1994	Sep	DISC
>A>	@	50MG	A074358	001	Jun 20, 1994	Sep	DISC
>D> AB	!	100MG	A074358	002	Jun 20, 1994	Sep	DISC
>A>	@	100MG	A074358	002	Jun 20, 1994	Sep	DISC
>D> AB	TEVA	100MG	A074431	001	May 31, 1995	Sep	CHRS
>A>	!	100MG	A074431	001	May 31, 1995	Sep	CTEC
>A> AB	!	100MG	A074431	001	May 31, 1995	Sep	CHRS

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

TRELEGY ELLIPTA

>A>	+!	GLAXOSMITHKLINE	0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	002	Sep 09, 2020	Sep	NEWA
-----	----	-----------------	--	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER; INHALATION

ARMONAIR DIGIHALER

+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Mar	NEWA
+		0.113MG/INH	N208798	005	Feb 20, 2020	Mar	NEWA
+	!	0.232MG/INH	N208798	006	Feb 20, 2020	Mar	NEWA

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE;ORAL
FLUVOXAMINE MALEATE

>A>	AB	BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Sep	NEWA
	AB		150MG	A212182	001	May 11, 2020	Apr	NEWA
		TABLET;ORAL						
		FLUVOXAMINE MALEATE						
>D>	@	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	Sep	CAHN
>D>	@		50MG	A075900	002	Feb 23, 2006	Sep	CAHN
>D>	@		100MG	A075900	003	Feb 23, 2006	Sep	CAHN
>A>	@	PHARMA LIFE	25MG	A075900	001	Feb 23, 2006	Sep	CAHN
>A>	@		50MG	A075900	002	Feb 23, 2006	Sep	CAHN
>A>	@		100MG	A075900	003	Feb 23, 2006	Sep	CAHN
	@	TEVA	25MG	A075893	001	Sep 10, 2002	Mar	DISC
	@		50MG	A075893	002	Sep 10, 2002	Mar	DISC
	@		100MG	A075893	003	Sep 10, 2002	Mar	DISC

FOLIC ACIDINJECTABLE;INJECTION
FOLIC ACID

AP		X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan	CAHN
AP		XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019	Feb	CAHN
		TABLET;ORAL						
		FOLIC ACID						
>D>	AA	HIKMA	1MG	A080600	001		Sep	DISC
>A>	@	HIKMA PHARMS	1MG	A080600	001		Sep	DISC
	@	VINTAGE	1MG	A040756	001	Jun 04, 2010	Jun	DISC

FOSAPREPITANT DIMEGLUMINEPOWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

AP		ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	Aug	NEWA
AP		NAVINTA LLC	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Aug	NEWA
AP		QILU	EQ 150MG BASE/VIAL	A213106	001	Sep 08, 2020	Aug	NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

>A>		FOSFOMYCIN TROMETHAMINE						
>A>	AA	XIROMED	EQ 3GM BASE/PACKET	A212548	001	Oct 06, 2020	Sep	NFTG
		MONUROL						
>D>	+	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996	Sep	CFTG
>A>	AA	+	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996	Sep	CFTG

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	!	AUROBINDO PHARMA	20MG;12.5MG	A079245	002	Jul 09, 2009	Apr	CHRS
	@	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Apr	DISC
	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Apr	DISC

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDEPOWDER;INTRAVENOUS
AKYNZEO

+	!	HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018	May	CMS1
---	---	------------------	---	---------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS
AKYNZEO

+	!	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020	May	NEWA
---	---	------------------	---	---------	-----	--------------	-----	------

FOSPHENYTOIN SODIUMINJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

>D>	AP	AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Sep	DISC
>A>	@		EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Sep	DISC

FOSTEMSAVIR TROMETHAMINE

TABLET, EXTENDED RELEASE;ORAL
RUKOBIA

+! VIIV HLTHCARE EQ 600MG BASE N212950 001 Jul 02, 2020 Jul NEWA

FULVESTRANT

INJECTABLE;INTRAMUSCULAR
FULVESTRANT

AO CHIA TAI TIANQING 50MG/ML A211422 001 Feb 07, 2020 Jan NEWA
AO DR REDDYS 50MG/ML A209246 001 Aug 07, 2020 Jul NEWA

FUROSEMIDE

INJECTABLE;INJECTION
FUROSEMIDE

>D> AP AMNEAL PHARMS CO 10MG/ML A207552 001 Jul 20, 2016 Sep DISC
>A> @ 10MG/ML A207552 001 Jul 20, 2016 Sep DISC
AP GLAND PHARMA LTD 10MG/ML A213902 001 Jul 01, 2020 Jun NEWA

TABLET;ORAL
FUROSEMIDE

@ AVET 20MG N018413 001 Nov 30, 1983 Jan DISC
@ 40MG N018413 002 Nov 30, 1983 Jan DISC

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

AB CSPC OUYI 100MG A075477 001 Mar 23, 2005 Jan CMFD
AB 300MG A075477 002 Mar 23, 2005 Jan CMFD
AB 400MG A075477 003 Mar 23, 2005 Jan CMFD
@ JIANGSU HENGRUI MED 100MG A091008 001 Oct 26, 2017 May DISC
@ 300MG A091008 002 Oct 26, 2017 May DISC
@ 400MG A091008 003 Oct 26, 2017 May DISC
@ TEVA PHARMS 100MG A075435 001 Oct 08, 2004 Mar DISC
@ 300MG A075435 002 Oct 08, 2004 Mar DISC
@ 400MG A075435 003 Oct 08, 2004 Mar DISC
AB ZHEJIANG YONGTAI 100MG A213603 001 Aug 17, 2020 Aug NEWA
AB 300MG A213603 002 Aug 17, 2020 Aug NEWA
AB 400MG A213603 003 Aug 17, 2020 Aug NEWA
NEURONTIN
AB + UPJOHN 100MG N020235 001 Dec 30, 1993 Jun CAHN
AB + 300MG N020235 002 Dec 30, 1993 Jun CAHN
AB +! 400MG N020235 003 Dec 30, 1993 Jun CAHN

SOLUTION;ORAL
GABAPENTIN

@ VISTAPHARM 250MG/5ML A211330 001 Dec 03, 2019 May DISC

NEURONTIN

AA +! UPJOHN 250MG/5ML N021129 001 Mar 02, 2000 Jun CAHN

TABLET;ORAL

GABAPENTIN

@ MYLAN PHARMS INC 600MG A090335 001 Jun 01, 2010 Mar DISC
@ 800MG A090335 002 Jun 01, 2010 Mar DISC
@ TEVA PHARMS USA 600MG A205807 001 Mar 10, 2017 Mar DISC
@ 800MG A205807 002 Mar 10, 2017 Mar DISC

GRALISE

BX +! ALMATICA 300MG N022544 001 Jan 28, 2011 Jan CAHN
BX +! 600MG N022544 002 Jan 28, 2011 Jan CAHN

NEURONTIN

AB + UPJOHN 600MG N020882 001 Oct 09, 1998 Jun CAHN
AB +! 800MG N020882 002 Oct 09, 1998 Jun CAHN

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS
CLARISCAN

>A> AP GE HEALTHCARE 37.69GM/100ML (376.9MG/ML) A210016 004 Aug 04, 2020 Sep NFTG
DOTAREM
>D> +! GUERBET 37.69GM/100ML (376.9MG/ML) N204781 001 Mar 20, 2013 Sep CFTG
>A> AP +! 37.69GM/100ML (376.9MG/ML) N204781 001 Mar 20, 2013 Sep CFTG

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

@	HIKMA	EQ 4MG BASE	A 077608	001	Feb 11, 2009	Feb	DISC
@		EQ 8MG BASE	A 077608	002	Feb 11, 2009	Feb	DISC
@		EQ 12MG BASE	A 077608	003	Feb 11, 2009	Feb	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

@	APOTEX	200MG/5.26ML (38MG/ML)	A 206776	001	May 23, 2017	Feb	DISC	
@		1GM/26.3ML (38MG/ML)	A 206776	002	May 23, 2017	Feb	DISC	
@		2GM/52.6ML (38MG/ML)	A 206776	003	May 23, 2017	Feb	DISC	
@	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A 202063	001	Sep 11, 2012	Aug	DISC	
@		EQ 1GM BASE/VIAL	A 202063	002	Sep 11, 2012	Aug	DISC	
>D>	@	INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A 210383	001	Feb 14, 2019	Sep	CAHN
>D>	@		1GM/26.3ML (38MG/ML)	A 210383	002	Feb 14, 2019	Sep	CAHN
>D>	@		2GM/52.6ML (38MG/ML)	A 210383	003	Feb 14, 2019	Sep	CAHN
@	MYLAN LABS LTD	EQ 200MG BASE/VIAL	A 200145	001	Jul 25, 2011	Jul	DISC	
@		EQ 1GM BASE/VIAL	A 200145	002	Jul 25, 2011	May	DISC	
@		EQ 2GM BASE/VIAL	A 200145	003	Jul 25, 2011	Mar	DISC	
>A>	@	NOVAST LABS	200MG/5.26ML (38MG/ML)	A 210383	001	Feb 14, 2019	Sep	CAHN
>A>	@		1GM/26.3ML (38MG/ML)	A 210383	002	Feb 14, 2019	Sep	CAHN
>A>	@		2GM/52.6ML (38MG/ML)	A 210383	003	Feb 14, 2019	Sep	CAHN
AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A 207575	001	Feb 22, 2019	Jan	CMFD	
AP		EQ 1GM BASE/VIAL	A 207575	002	Feb 22, 2019	Jan	CMFD	
@	TEVA PHARMS	EQ 200MG BASE/VIAL	A 077983	002	Jan 25, 2011	Mar	DISC	
@		EQ 1GM BASE/VIAL	A 077983	001	Jan 25, 2011	Mar	DISC	

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	CADILA	600MG	A 204189	001	Aug 28, 2018	Feb	CAHN	
>D>	AB	HIKMA PHARMS	600MG	A 078599	001	Aug 16, 2010	Sep	DISC
>A>	@		600MG	A 078599	001	Aug 16, 2010	Sep	DISC
@	TEVA	600MG	A 074256	001	Oct 31, 1993	Feb	DISC	

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@	MYLAN	1MG	A 077624	001	Nov 28, 2005	Apr	DISC
@		2MG	A 077624	002	Nov 28, 2005	Apr	DISC
@		4MG	A 077624	003	Nov 28, 2005	Apr	DISC

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB1	ORIENT PHARMA CO LTD	1.25MG	A 206483	001	Feb 22, 2019	May	CMFD	
AB1		2.5MG	A 206483	002	Feb 22, 2019	May	CMFD	
AB1		5MG	A 206483	003	Feb 22, 2019	May	CMFD	
>D>	AB1	PHARMADAX INC	1.25MG	A 203581	001	Apr 14, 2016	Sep	CAHN
>D>	AB1		2.5MG	A 203581	002	Apr 14, 2016	Sep	CAHN
>D>	AB1		5MG	A 203581	003	Apr 14, 2016	Sep	CAHN
>A>	AB1	SWISS PHARM	1.25MG	A 203581	001	Apr 14, 2016	Sep	CAHN
>A>	AB1		2.5MG	A 203581	002	Apr 14, 2016	Sep	CAHN
>A>	AB1		5MG	A 203581	003	Apr 14, 2016	Sep	CAHN
		GLYBURIDE (MICRONIZED)						
@	MYLAN	1.5MG	A 074792	001	Jun 26, 1998	Jan	DISC	
@		3MG	A 074792	002	Jun 26, 1998	Jan	DISC	
@		6MG	A 074792	003	Aug 17, 1999	Jan	DISC	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	ACCORD HLTHCARE	0.2MG/ML	A 213238	001	Jul 08, 2020	Jul	NEWA
AP	RICONPHARMA LLC	0.2MG/ML	A 210083	001	Feb 21, 2020	Feb	NEWA

POWDER; INHALATION

SEEBRI

+	@	NOVARTIS	15.6MCG/INH	N 207923	001	Oct 29, 2015	Mar	CAHN
+	@	SUNOVION PHARMS INC	15.6MCG/INH	N 207923	001	Oct 29, 2015	Mar	DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS								
GLYRX-PF								
	EXELA PHARMA	1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020	Apr	NEWA	
TABLET;ORAL								
GLYCOPYRROLATE								
	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Aug	CAHN	
<u>GLYCOPYRROLATE; INDACATEROL MALEATE</u>								
POWDER; INHALATION								
UTIBRON								
	+ @ NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	CAHN	
	+ @ SUNOVION PHARMS INC	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Mar	DISC	
<u>GRANISETRON HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
GRANISETRON HYDROCHLORIDE								
	@ MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017	Apr	DISC	
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017	Apr	DISC	
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017	Mar	DISC	
AP	PUNISKA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May	CAHN	
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May	CAHN	
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May	CAHN	
	@ YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Apr	DISC	
AP		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647	001	Mar 06, 2020	Feb	NEWA	
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Aug	DISC	
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648	001	Jun 29, 2020	Jun	NEWA	
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Aug	DISC	
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648	002	Jun 29, 2020	Jun	NEWA	
TABLET;ORAL								
GRANISETRON HYDROCHLORIDE								
	@ MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008	Jan	DISC	
<u>GRISEOFULVIN, MICROSIZE</u>								
SUSPENSION;ORAL								
GRISEOFULVIN								
AB	COSETTE	125MG/5ML	A065438	001	Oct 08, 2010	May	CAHN	
<u>GRISEOFULVIN, ULTRAMICROSIZE</u>								
TABLET;ORAL								
GRIS-PEG								
AB	+ BAUSCH	125MG	N050475	001		Aug	CAHN	
AB	+ BAUSCH	250MG	N050475	002		Aug	CAHN	
AB	+ VALEANT PHARMS INC	250MG	N050475	002		Jul	CHRS	
GRISEOFULVIN, ULTRAMICROSIZE								
AB	! MOUNTAIN	250MG	A204371	002	Jan 09, 2014	Jul	CHRS	
<u>GUANIDINE HYDROCHLORIDE</u>								
TABLET;ORAL								
GUANIDINE HYDROCHLORIDE								
>D>	MERCK SHARP DOHME	125MG	N001546	001		Sep	DISC	
>A>	@	125MG	N001546	001		Sep	DISC	
<u>HALCINONIDE</u>								
SOLUTION;TOPICAL								
HALOG								
	! SUN PHARM INDS INC	0.1%	N017823	001		Mar	CMFD	
<u>HALOBETASOL PROPIONATE</u>								
LOTION;TOPICAL								
HALOBETASOL PROPIONATE								
AB	@ PERRIGO ISRAEL	0.05%	A211464	001	Jun 03, 2020	Jun	DISC	
		0.05%	A211464	001	Jun 03, 2020	May	NFTG	
ULTRAVATE								
	+! SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	Jun	CTEC	
AB	+!	0.05%	N208183	001	Nov 06, 2015	May	CFTG	
OINTMENT;TOPICAL								
HALOBETASOL PROPIONATE								
>A>	AB QUAGEN	0.05%	A213560	001	Oct 06, 2020	Sep	NEWA	

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	UPSHER SMITH LABS	0.5MG	A211061	001	Jan 08, 2020	Jun	CAHN
AB		1MG	A211061	002	Jan 08, 2020	Jun	CAHN
AB		2MG	A211061	003	Jan 08, 2020	Jun	CAHN
AB		5MG	A211061	004	Jan 08, 2020	Jun	CAHN
AB		10MG	A211061	005	Jan 08, 2020	Jun	CAHN
AB		20MG	A211061	006	Jan 08, 2020	Jun	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Aug	CMFD
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Mar	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	GLAND PHARMA LTD	1,000 UNITS/ML	A205323	002	Nov 18, 2019	Apr	NEWA
AP	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Jul	NEWA
AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020	Feb	NEWA
	+ @ PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011	Jun	DISC
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Jul	NEWA
	HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020	Apr	NEWA
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Jul	NEWA
	HEPARIN SODIUM PRESERVATIVE FREE						
AP	+! FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	CTEC
>D>	! HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Sep	DISC
>A>	@	10,000 UNITS/ML	A089522	001	May 04, 1987	Sep	DISC
AP	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

@ NOSTRUM LABS INC 1.5MG/5ML; 5MG/5ML

A210663 001 Jun 11, 2019 Apr CAHN

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	! NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Jan	CHRS
	TUSSIGON						
	@ KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Jan	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

>A>	AP	I3 PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN
>D>	AP	XGEN PHARMS	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN
	AP		20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@ STRIDES PHARMA 10MG

A200770 004 Jun 25, 2019 Jan DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ IVAX SUB TEVA PHARMS 12.5MG

A077005 001 Jul 13, 2005 Mar DISC

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	HIKMA INTL PHARMS	50MG	A084878	001		Sep	DISC
>A>	@		50MG	A084878	001		Sep	DISC
	@ MYLAN PHARMS INC	25MG	A040735	002	Jan 23, 2007	Jan	DISC	
	@	50MG	A040735	003	Jan 23, 2007	Jan	DISC	

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

	@	COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004	Feb	CAHN
	@		12.5MG;20MG	A076674	002	Oct 05, 2004	Feb	CAHN
	@		25MG;20MG	A076674	003	Oct 05, 2004	Feb	CAHN
>D>	AB	HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002	Sep	DISC
>A>		@	12.5MG;10MG	A076265	001	Jul 08, 2002	Sep	DISC
>D>	AB		12.5MG;20MG	A076265	002	Jul 08, 2002	Sep	DISC
>A>		@	12.5MG;20MG	A076265	002	Jul 08, 2002	Sep	DISC
>D>	AB		25MG;20MG	A076265	003	Jul 08, 2002	Sep	DISC
>A>		@	25MG;20MG	A076265	003	Jul 08, 2002	Sep	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	HIKMA	12.5MG;50MG	A077732	002	Oct 06, 2010	Sep	DISC
>A>		@	12.5MG;50MG	A077732	002	Oct 06, 2010	Sep	DISC
>D>	AB		12.5MG;100MG	A077732	001	Apr 06, 2010	Sep	DISC
>A>		@	12.5MG;100MG	A077732	001	Apr 06, 2010	Sep	DISC
>D>	AB		25MG;100MG	A077732	003	Oct 06, 2010	Sep	DISC
>A>		@	25MG;100MG	A077732	003	Oct 06, 2010	Sep	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

>D>	AB	+!	US PHARMS HOLDINGS I	25MG;100MG	N018303	002	Dec 31, 1984	Sep	DISC
>A>		+ @		25MG;100MG	N018303	002	Dec 31, 1984	Sep	DISC
			METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE						
>D>	AB		ALEMBIC PHARMS LTD	25MG;100MG	A202870	002	Nov 06, 2013	Sep	CHRS
>A>	AB	!		25MG;100MG	A202870	002	Nov 06, 2013	Sep	CHRS

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMS INC 12.5MG;7.5MG
 @ 12.5MG;15MG
 @ 25MG;15MG

A202150 001 Mar 07, 2014 Apr DISC
 A202150 002 Mar 07, 2014 Apr DISC
 A202150 003 Mar 07, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB ACCORD HLTHCARE 12.5MG;20MG
 AB 12.5MG;40MG
 AB 25MG;40MG
 AB UMEDICA LABS PVT LTD 12.5MG;20MG
 @ 12.5MG;20MG
 AB 12.5MG;40MG
 @ 12.5MG;40MG
 AB 25MG;40MG
 @ 25MG;40MG

A209281 001 Feb 07, 2019 Jul CMFD
 A209281 002 Feb 07, 2019 Jul CMFD
 A209281 003 Feb 07, 2019 Jul CMFD
 A208847 001 Sep 17, 2019 May CMFD
 A208847 001 Sep 17, 2019 Mar DISC
 A208847 003 Sep 17, 2019 May CMFD
 A208847 003 Sep 17, 2019 Mar DISC
 A208847 002 Sep 17, 2019 May CMFD
 A208847 002 Sep 17, 2019 Mar DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

AB + PFIZER 25MG;25MG
 +! 50MG;50MG

N012616 004 Dec 30, 1982 Jul CAHN
 N012616 005 Dec 30, 1982 Jul CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@ MACLEODS PHARMS LTD 12.5MG;40MG
 @ 12.5MG;80MG
 @ 25MG;80MG
 @ MYLAN 12.5MG;40MG
 @ 12.5MG;80MG
 @ 25MG;80MG

A204169 001 Nov 02, 2015 May DISC
 A204169 002 Nov 02, 2015 May DISC
 A204169 003 Nov 02, 2015 May DISC
 A091648 001 Feb 25, 2014 Apr DISC
 A091648 002 Feb 25, 2014 Apr DISC
 A091648 003 Feb 25, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
AB	CADILA	25MG;37.5MG		A208358	001	Feb 11, 2019	Feb CAHN
	@ DURAMED PHARMS BARR	25MG;37.5MG		A075052	001	Jun 18, 1999	Mar DISC
TABLET;ORAL		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
	@ PLIVA	25MG;37.5MG		A074026	001	Apr 26, 1996	Mar DISC

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL		HYDROCODONE BITARTRATE					
AB	ALVOGEN	10MG		A206986	001	Jan 21, 2020	Jan NFTG
AB		15MG		A206986	002	Jan 21, 2020	Jan NFTG
AB		20MG		A206986	003	Jan 21, 2020	Jan NFTG
AB		30MG		A206986	004	Jan 21, 2020	Jan NFTG
AB		40MG		A206986	005	Jan 21, 2020	Jan NFTG
AB		50MG		A206986	006	Jan 21, 2020	Jan NFTG
ZOHYDRO ER							
AB	+! PERSION	10MG		N202880	001	Oct 25, 2013	Jan CFTG
AB	+	15MG		N202880	002	Oct 25, 2013	Jan CFTG
AB	+	20MG		N202880	003	Oct 25, 2013	Jan CFTG
AB	+	30MG		N202880	004	Oct 25, 2013	Jan CFTG
AB	+	40MG		N202880	005	Oct 25, 2013	Jan CFTG
AB	+	50MG		N202880	006	Oct 25, 2013	Jan CFTG

HYDROCORTISONE

ENEMA;RECTAL		HYDROCORTISONE					
	@ TEVA PHARMS	100MG/60ML		A074171	001	May 27, 1994	Mar DISC
GRANULE;ORAL		ALKINDI SPRINKLE					
>A>	+	ETON	0.5MG	N213876	001	Sep 29, 2020	Sep NEWA
>A>	+		1MG	N213876	002	Sep 29, 2020	Sep NEWA
>A>	+		2MG	N213876	003	Sep 29, 2020	Sep NEWA
>A>	+!		5MG	N213876	004	Sep 29, 2020	Sep NEWA
LOTION;TOPICAL		HYDROCORTISONE					
	@ FOUGERA PHARMS	2.5%		A040351	001	Jul 25, 2000	Apr DISC
	STIE-CORT						
AT	! PERRIGO CO	2.5%		A089074	001	Nov 26, 1985	Apr CHRS
OINTMENT;TOPICAL		HYDROCORTISONE					
	@ ACTAVIS MID ATLANTIC	1%		A087796	001	Oct 13, 1982	Mar DISC
TABLET;ORAL		HYDROCORTISONE					
>D>	AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Sep DISC
>A>		@	5MG	A083365	002	Feb 23, 2015	Sep DISC
>D>	AB		10MG	A083365	003	Feb 23, 2015	Sep DISC
>A>		@	10MG	A083365	003	Feb 23, 2015	Sep DISC
>D>	AB		20MG	A083365	001		Sep DISC
>A>		@	20MG	A083365	001		Sep DISC
AB		STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb CAHN
AB			10MG	A207029	002	Apr 27, 2017	Feb CAHN
AB			20MG	A207029	003	Apr 27, 2017	Feb CAHN
	@ VINTAGE		5MG	A040761	001	Jul 16, 2007	Aug DISC
	@		10MG	A040761	002	Jul 16, 2007	Aug DISC
	@		20MG	A040761	003	Jul 16, 2007	Aug DISC

HYDROCORTISONE ACETATE

CREAM;TOPICAL		CARMOL HC					
	@ FOUGERA PHARMS	1%		A080505	001		Aug CAIN
HYDROCORTISONE ACETATE		U-CORT					
	@ IMPERIUM	2.5%		A040259	001	Jul 29, 1999	Jun CAHN
	TARO	1%		A089472	001	Jun 13, 1988	Aug CAIN

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB	COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb	NEWA
----	---------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

	+	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Jan	NEWA
>D>	AP	+	1MG/ML	N019034	003	Apr 30, 2009	Sep	CTEC
>A>		+	1MG/ML	N019034	003	Apr 30, 2009	Sep	CTEC

HYDROMORPHONE HYDROCHLORIDE

	@	BARR	10MG/ML	A076444	001	Apr 25, 2003	Mar	DISC
>D>	AP	HOSPIRA INC	1MG/ML	N200403	001	Dec 01, 2011	Sep	DISC
>A>		@	1MG/ML	N200403	001	Dec 01, 2011	Sep	DISC
>D>	AP		2MG/ML	N200403	002	Dec 01, 2011	Sep	DISC
>A>		@	2MG/ML	N200403	002	Dec 01, 2011	Sep	DISC

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	AB	ASCENT PHARMS INC	8MG	A212133	001	Sep 23, 2020	Sep	NEWA
>A>	AB		12MG	A212133	002	Sep 23, 2020	Sep	NEWA
>A>	AB		16MG	A212133	003	Sep 23, 2020	Sep	NEWA
>A>	AB		32MG	A212133	004	Sep 23, 2020	Sep	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar	NEWA	
>D>	AB	APPCO	200MG	A210441	001	May 01, 2018	Sep	CAHN
	AB		200MG	A210441	001	May 01, 2018	Mar	CAHN
>A>	AB	DR REDDYS	200MG	A210441	001	May 01, 2018	Sep	CAHN
	AB	HAVIX	200MG	A212902	001	May 14, 2020	May	NEWA
>D>	AB	HIKMA	200MG	A040760	001	Aug 15, 2007	Sep	DISC
>A>		@ HIKMA PHARMS	200MG	A040760	001	Aug 15, 2007	Sep	DISC
	AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar	CMFD
	AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar	CMFD

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

	@	AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
AP1			1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ VINTAGE PHARMS 10MG/5ML

A040391	001	Apr 10, 2002	May	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@	AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May	CAHN
	@		25MG	A087871	003	Dec 20, 1982	May	CAHN
	@		50MG	A087871	001	Dec 20, 1982	May	CAHN
>A>	AB	DISCOVERY THERAP	10MG	A040804	001	Jun 30, 2008	Sep	CAHN
>A>	AB		25MG	A040804	002	Jun 30, 2008	Sep	CAHN
>A>	AB		50MG	A040804	003	Jun 30, 2008	Sep	CAHN
>D>	AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	Sep	CAHN
>D>	AB		25MG	A040804	002	Jun 30, 2008	Sep	CAHN
>D>	AB		50MG	A040804	003	Jun 30, 2008	Sep	CAHN
>A>	AB	NUVO PHARMS INC	10MG	A207121	002	Mar 29, 2017	Sep	CMS1
>A>	AB		50MG	A207121	003	Mar 29, 2017	Sep	CMS1

HYDROXYZINE PAMOATECAPSULE;ORAL
VISTARIL

AB	+	PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002		Jul	CMFD
AB	+		EQ 50MG HYDROCHLORIDE	N011459	004		Jul	CMFD

IBANDRONATE SODIUMINJECTABLE;INTRAVENOUS
BONIVA

>D>	AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Sep	DISC
>A>		+	@	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Sep	DISC
			IBANDRONATE SODIUM						
>D>	AP		APOTEX	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015	Sep	CHRS
>A>	AP		!	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015	Sep	CHRS

IBUPROFENTABLET;ORAL
IBUPROFEN

AB		AUROBINDO PHARMA LTD	400MG	A213794	001	May 08, 2020	Apr	NEWA
AB			600MG	A213794	002	May 08, 2020	Apr	NEWA
AB			800MG	A213794	003	May 08, 2020	Apr	NEWA

IBUPROFEN LYSINEINJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP		XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN
----	--	-------------	------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDETABLET;ORAL
COMBUNOX

		+	@ FOREST LABS	400MG;5MG	N021378	001	Nov 26, 2004	Apr	CRLD
			OXYCODONE HYDROCHLORIDE AND IBUPROFEN						
			ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008	Apr	CTEC
			@ BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007	Apr	DISC

ICATIBANT ACETATEINJECTABLE;SUBCUTANEOUS
ICATIBANT ACETATE

AP		CIPLA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A212446	001	Jul 13, 2020	Jul	NEWA	
>A>	AP		DR REDDYS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	Sep	NEWA
AP		FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A208317	001	Jun 18, 2020	Jun	NEWA	
AP		JIANGSU HANSO PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211021	001	Mar 09, 2020	Feb	NEWA	
AP		SLAYBACK PHARMA LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A211501	001	Sep 01, 2020	Aug	NEWA	

ICOSAPENT ETHYLCAPSULE;ORAL
ICOSAPENT ETHYL

AB		DR REDDYS	1GM	A209499	001	Aug 07, 2020	Jul	NEWA	
AB		HIKMA	1GM	A209457	001	May 21, 2020	May	NFTG	
>A>	AB		TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Sep	NFTG
>A>	AB			1GM	A209525	002	Sep 11, 2020	Sep	NEWA
			VASCEPA						
>D>		+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Sep	CFTG
>A>	AB	+		500MG	N202057	002	Feb 16, 2017	Sep	CFTG
AB		+	!	1GM	N202057	001	Jul 26, 2012	May	CFTG

IMATINIB MESYLATETABLET;ORAL
IMATINIB MESYLATE

AB		EUGIA PHARMA	EQ 100MG BASE	A212773	001	Jul 23, 2020	Jul	NEWA
AB			EQ 400MG BASE	A212773	002	Jul 23, 2020	Jul	NEWA
AB		ZYDUS PHARMS	EQ 100MG BASE	A210658	001	Apr 08, 2020	Mar	NEWA
AB			EQ 400MG BASE	A210658	002	Apr 08, 2020	Mar	NEWA

IMIPRAMINE HYDROCHLORIDETABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB		OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Apr	CMFD
AB			25MG	A040751	002	Feb 28, 2008	Apr	CMFD
AB			50MG	A040751	001	Feb 28, 2008	Apr	CMFD

INDACATEROL MALEATEPOWDER; INHALATION
ARCAPTA NEOHALER

+ @	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	CAHN
+ @	SUNOVION PHARMS INC	EQ 75MCG BASE	N022383	001	Jul 01, 2011	Mar	DISC

INDINAVIR SULFATECAPSULE; ORAL
CRIXIVAN

+ @	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996	Mar	DISC
+ @		EQ 400MG BASE	N020685	001	Mar 13, 1996	Aug	DISC

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

	@	HERITAGE	25MG	N018851	001	May 18, 1984	Jul	DISC
AB			25MG	N018851	001	May 18, 1984	Jan	CAHN
	@		50MG	N018851	002	May 18, 1984	Jul	DISC
AB			50MG	N018851	002	May 18, 1984	Jan	CAHN
	@	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Apr	DISC
	@		50MG	A070756	001	Feb 12, 1986	Mar	DISC

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

@	MYLAN	75MG	A202139	001	Mar 20, 2014	May	DISC
---	-------	------	---------	-----	--------------	-----	------

SUPPOSITORY; RECTAL
INDOMETHACIN

!	COSETTE	50MG	A073314	001	Aug 31, 1992	Jul	CAHN
---	---------	------	---------	-----	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

INGENOL MEBUTATE

@	PERRIGO UK FINCO	0.015%	A209018	001	Jan 07, 2019	Jun	DISC
@		0.05%	A209019	001	Jan 09, 2019	Jun	DISC

PICATO

+!	LEO LABS	0.015%	N202833	001	Jan 23, 2012	Jun	CTEC
+!		0.05%	N202833	002	Jan 23, 2012	Jun	CTEC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

@	WATSON LABS	0.02%	A076291	001	May 09, 2005	Apr	DISC
---	-------------	-------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

AB		APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Jan	CMFD
----	--	------------	---------------	---------	-----	--------------	-----	------

IRBESARTAN

TABLET; ORAL

IRBESARTAN

@	HIKMA	75MG	A090201	001	Oct 15, 2012	Feb	DISC
@		150MG	A090201	002	Oct 15, 2012	Feb	DISC
@		300MG	A090201	003	Oct 15, 2012	Feb	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

	@	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Apr	DISC
	@		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Apr	DISC
>D>	AP	INGENUS PHARMS LLC	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	Sep	CAHN
>D>	AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	Sep	CAHN
>A>	AP	NOVAST LABS	40MG/2ML (20MG/ML)	A206935	001	May 26, 2017	Sep	CAHN
>A>	AP		100MG/5ML (20MG/ML)	A206935	002	May 26, 2017	Sep	CAHN
	@	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122	001	Oct 31, 2008	Apr	DISC
	@		100MG/5ML (20MG/ML)	A078122	002	Oct 31, 2008	Apr	DISC
>A>	AP	SHILPA MEDICARE LTD	300MG/15ML (20MG/ML)	A208718	003	Aug 16, 2019	Sep	NEWA
>D>	AP	ZENNOVA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Sep	CAHN
>A>	AP		40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Sep	CAHN
>D>	AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Sep	CAHN
>A>	AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Sep	CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

>D>	AB	HIKMA INTL PHARMS	30MG	A 040591	001	Jan 10, 2007	Sep	DISC
>A>		@	30MG	A 040591	001	Jan 10, 2007	Sep	DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

>D>	AB	HIKMA	20MG	A 075361	001	Oct 05, 2000	Sep	DISC
>A>		@ HIKMA PHARMS	20MG	A 075361	001	Oct 05, 2000	Sep	DISC

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

		@ HIKMA INTL PHARMS	30MG	A 076813	002	Mar 30, 2006	Feb	DISC
		@	60MG	A 076813	001	Jan 07, 2005	Feb	DISC
>D>	AB	VINTAGE PHARMS	30MG	A 090598	001	Aug 11, 2010	Sep	DISC
>A>		@	30MG	A 090598	001	Aug 11, 2010	Sep	DISC
>D>	AB		60MG	A 090598	002	Aug 11, 2010	Sep	DISC
>A>		@	60MG	A 090598	002	Aug 11, 2010	Sep	DISC
>D>	AB		120MG	A 090598	003	Aug 11, 2010	Sep	DISC
>A>		@	120MG	A 090598	003	Aug 11, 2010	Sep	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA LD

		+ @ SUN PHARM	20MG	N 211913	003	Nov 05, 2019	Jun	DISC
		+ @	28MG	N 211913	005	Nov 05, 2019	Jun	DISC

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB		STRIDES PHARMA	100MG	A 206410	001	Jul 02, 2019	Aug	CAHN
----	--	----------------	-------	----------	-----	--------------	-----	------

SOLUTION; ORAL

ITRACONAZOLE

AA		ANNORA PHARMA	10MG/ML	A 212239	001	Sep 01, 2020	Aug	NEWA
		@ APOTEX	10MG/ML	A 208481	001	Aug 02, 2019	Feb	DISC

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

AB		@ PERRIGO UK FINCO	1%	A 210225	001	Apr 13, 2020	Jul	DISC
			1%	A 210225	001	Apr 13, 2020	Mar	NEWA

LOTION; TOPICAL

IVERMECTIN

AB		TARO	0.5%	A 210720	001	May 06, 2020	Apr	NFTG
AB		+! ARBOR PHARMS LLC	0.5%	N 202736	001	Feb 07, 2012	Apr	CFTG

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

AB		HAVIX	200MG	A 075912	001	Jan 10, 2002	Apr	CMFD
----	--	-------	-------	----------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

>D>	AP	AMPHASTAR PHARM	15MG/ML	A 076209	001	Jul 21, 2004	Sep	DISC
>A>		@	15MG/ML	A 076209	001	Jul 21, 2004	Sep	DISC
>D>	AP		30MG/ML	A 076209	002	Jul 21, 2004	Sep	DISC
>A>		@	30MG/ML	A 076209	002	Jul 21, 2004	Sep	DISC
>D>	AP	HOSPIRA	15MG/ML	A 074993	001	Jan 27, 1999	Sep	DISC
>A>		@	15MG/ML	A 074993	001	Jan 27, 1999	Sep	DISC
>D>	AP		30MG/ML	A 074993	002	Jan 27, 1999	Sep	DISC
>A>		@	30MG/ML	A 074993	002	Jan 27, 1999	Sep	DISC
AP		NEPHRON	30MG/ML	A 211445	001	Aug 20, 2020	Aug	NEWA

TABLET; ORAL

KETOROLAC TROMETHAMINE

AB		MYLAN	10MG	A 074761	001	May 16, 1997	Feb	CHRS
		@ PLIVA	10MG	A 075284	001	Jun 23, 1999	Apr	DISC
AB		! TEVA	10MG	A 074754	001	May 16, 1997	Feb	CHRS

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
NORMODYNE

+ @ SCHERING 5MG/ML N018686 001 Aug 01, 1984 Jan CRLD

TABLET; ORAL

LABETALOL HYDROCHLORIDE

>D>	AB	ATHEM	100MG	A207863	001	Feb 04, 2019	Sep CAHN
>D>	AB		200MG	A207863	002	Feb 04, 2019	Sep CAHN
>D>	AB		300MG	A207863	003	Feb 04, 2019	Sep CAHN
>A>	AB	EPIC PHARMA LLC	100MG	A212990	001	Sep 30, 2020	Sep NEWA
>A>	AB		200MG	A212990	002	Sep 30, 2020	Sep NEWA
>A>	AB		300MG	A212990	003	Sep 30, 2020	Sep NEWA
>A>	AB	EYWA	100MG	A207863	001	Feb 04, 2019	Sep CAHN
>A>	AB		200MG	A207863	002	Feb 04, 2019	Sep CAHN
>A>	AB		300MG	A207863	003	Feb 04, 2019	Sep CAHN
	AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb CMFD
	AB		200MG	A074787	002	Aug 03, 1998	Feb CMFD

LACTITOL

FOR SOLUTION; ORAL
PIZENSY

+	@	BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020	Aug DISC
+	!		10GM	N211281	001	Feb 12, 2020	Feb NEWA
+			10GM/PACKET	N211281	001	Feb 12, 2020	Feb NEWA

LACTULOSE

SOLUTION; ORAL
LACTULOSE

>A>	AA	CHARTWELL RX	10GM/15ML	A209517	001	Nov 23, 2018	Sep CAHN
>D>	AA	HIKMA	10GM/15ML	A073591	001	May 29, 1992	Sep DISC
>A>		@	10GM/15ML	A073591	001	May 29, 1992	Sep DISC
>D>	AA	LIFEPHARMA	10GM/15ML	A209517	001	Nov 23, 2018	Sep CAHN

SOLUTION; ORAL, RECTAL

ENULOSE

@ ACTAVIS MID ATLANTIC 10GM/15ML

A071548 001 Aug 15, 1988 Jul DISC

LACTULOSE

AA ! FRESENIUS KABI 10GM/15ML

A090502 001 Jan 25, 2012 Jul CHRS

LAMIVUDINE

TABLET; ORAL
LAMIVUDINE

>A>	AB	BIOPHARM	150MG	A203586	001	Nov 21, 2016	Sep CAHN
>D>	AB	ECI PHARMS LLC	150MG	A203586	001	Nov 21, 2016	Sep CAHN
>A>	AB	PHARMA LIFE	150MG	A203586	001	Nov 21, 2016	Sep CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
TEMIXYS

+	!	CELLTRION	300MG; 300MG	N211284	001	Nov 16, 2018	May CHRS
+			300MG; 300MG	N211284	001	Nov 16, 2018	May CRLD

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

@ MYLAN LABS LTD 150MG; 300MG

A079079 001 Aug 12, 2019 Apr CAHN

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

@	CIPLA	25MG
@		100MG
@		150MG
@		200MG
@	MYLAN	25MG
@		100MG
@		150MG
@		200MG

A077783	001	Nov 01, 2010	Aug DISC
A077783	002	Nov 01, 2010	Aug DISC
A077783	003	Nov 01, 2010	Aug DISC
A077783	004	Nov 01, 2010	Aug DISC
A077420	001	Jan 27, 2009	Mar DISC
A077420	002	Jan 27, 2009	Mar DISC
A077420	003	Jan 27, 2009	Mar DISC
A077420	004	Jan 27, 2009	Mar DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	DR REDDYS LABS LTD	250MG
AB	ZYDUS PHARMS	25MG

A202383	006	Sep 06, 2018	Mar NEWA
A207763	001	Apr 01, 2020	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

AB		50MG	A207763	002	Apr 01, 2020	Mar	NEWA
AB		100MG	A207763	003	Apr 01, 2020	Mar	NEWA
AB		200MG	A207763	004	Apr 01, 2020	Mar	NEWA
AB		250MG	A207763	005	Apr 01, 2020	Mar	NEWA
AB		300MG	A207763	006	Apr 01, 2020	Mar	NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	HETERO LABS LTD III	15MG	A203083	001	May 18, 2020	May	NEWA
AB		30MG	A203083	002	May 18, 2020	May	NEWA

LANTHANUM CARBONATE

POWDER;ORAL
FOSRENOL

+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014	Jul	CAHN
+	!	EQ 1GM BASE	N204734	002	Sep 24, 2014	Jul	CAHN

TABLET, CHEWABLE;ORAL
FOSRENOL

AB	@ TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004	Jul	CAHN
AB	+	EQ 500MG BASE	N021468	002	Oct 26, 2004	Jul	CAHN
AB	+	EQ 750MG BASE	N021468	003	Nov 23, 2005	Jul	CAHN
AB	+	EQ 1GM BASE	N021468	004	Nov 23, 2005	Jul	CAHN

LAPATINIB DITOSYLATE

TABLET;ORAL

>A>	LAPATINIB DITOSYLATE							
>A>	AB	NATCO PHARMA LTD	EQ 250MG BASE	A203007	001	Sep 29, 2020	Sep	NFTG
		TYKERB						
>D>	+	NOVARTIS	EQ 250MG BASE	N022059	001	Mar 13, 2007	Sep	CFTG
>A>	AB	+	EQ 250MG BASE	N022059	001	Mar 13, 2007	Sep	CFTG

LASMIDITAN SUCCINATE

TABLET;ORAL
REYVOW

+	ELI LILLY AND CO	50MG	N211280	001	Jan 31, 2020	Jan	NEWA
+	!	100MG	N211280	002	Jan 31, 2020	Jan	NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

	@ AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Mar	DISC		
AT	+	!	UPJOHN	0.005%	N020597	001	Jun 05, 1996	Jun	CAHN

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

	@ BARR	10MG	A077083	001	Sep 13, 2005	Apr	DISC
	@	20MG	A077083	002	Sep 13, 2005	Apr	DISC
AB	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Aug	CMFD
AB		20MG	A077087	002	Sep 13, 2005	Aug	CMFD
AB	LUPIN LTD	10MG	A211863	001	Feb 04, 2020	Jan	NEWA
AB		20MG	A211863	002	Feb 04, 2020	Jan	NEWA
	@ TEVA PHARMS	10MG	A077084	001	Sep 13, 2005	Apr	DISC
	@	20MG	A077084	002	Sep 13, 2005	Apr	DISC

LEMBOREXANT

TABLET;ORAL
DAYVIGO

+	EISAI INC	5MG	N212028	001	Apr 07, 2020	Apr	NEWA
+	!	10MG	N212028	002	Apr 07, 2020	Apr	NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE

>D>	AB	HIKMA	2.5MG	A090838	001	Jun 03, 2011	Sep	DISC
>A>		@	2.5MG	A090838	001	Jun 03, 2011	Sep	DISC
>D>	AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	Sep	DISC
>A>		@	2.5MG	A203796	001	Jun 03, 2016	Sep	DISC

TABLET;ORAL

LETROZOLE

@	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	May	DISC
@	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Jul	DISC

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

AB	EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	Mar	CMFD
AB		EQ 25MG BASE	A074544	002	Aug 28, 1997	Mar	CMFD
AB	HIKMA	EQ 10MG BASE	A072734	001	Feb 22, 1993	Jul	CTEC
AB		EQ 15MG BASE	A072735	001	Feb 22, 1993	Jul	CTEC
>A>	AB	NOVAST LABS	EQ 5MG BASE	A211132	001	Jul 30, 2020	Sep CAHN
>A>	AB		EQ 10MG BASE	A211132	002	Jul 30, 2020	Sep CAHN
>A>	AB		EQ 15MG BASE	A211132	003	Jul 30, 2020	Sep CAHN
>A>	AB		EQ 25MG BASE	A211132	004	Jul 30, 2020	Sep CAHN
>D>	AB	RICONPHARMA LLC	EQ 5MG BASE	A211132	001	Jul 30, 2020	Sep CAHN
	AB		EQ 5MG BASE	A211132	001	Jul 30, 2020	Jul NEWA
>D>	AB		EQ 10MG BASE	A211132	002	Jul 30, 2020	Sep CAHN
	AB		EQ 10MG BASE	A211132	002	Jul 30, 2020	Jul NEWA
>D>	AB		EQ 15MG BASE	A211132	003	Jul 30, 2020	Sep CAHN
	AB		EQ 15MG BASE	A211132	003	Jul 30, 2020	Jul NEWA
>D>	AB		EQ 25MG BASE	A211132	004	Jul 30, 2020	Sep CAHN
	AB		EQ 25MG BASE	A211132	004	Jul 30, 2020	Jul NEWA

LEUPROLIDE ACETATE

INJECTABLE;INJECTION

LUPRON DEPOT-PED KIT

+	@	ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May CTNA
+	@		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May CTNA
+	!		7.5MG/VIAL	N020263	002	Apr 16, 1993	May CTNA
+	!		11.25MG/VIAL	N020263	005	Jan 21, 1994	May CTNA
+	!		11.25MG/VIAL	N020263	007	Aug 15, 2011	May CTNA
+	!		15MG/VIAL	N020263	006	Jan 21, 1994	May CTNA
+	!		30MG/VIAL	N020263	008	Aug 15, 2011	May CTNA

INJECTABLE;SUBCUTANEOUS

ELIGARD KIT

+	!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002	May CTNA
+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May CTNA
+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May CTNA
+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May CTNA

POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+	@	ABBVIE ENDOCRINE INC	3.75MG, 7.5MG	N020263	003	Apr 16, 1993	May CPOT
+	@		3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May CDFR
+	!		7.5MG	N020263	002	Apr 16, 1993	May CPOT
+	!		7.5MG/VIAL	N020263	002	Apr 16, 1993	May CDFR
+	@		7.5MG, 7.5MG	N020263	004	Apr 16, 1993	May CPOT
+	@		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May CDFR
+	!		11.25MG	N020263	005	Jan 21, 1994	May CPOT
+	!		11.25MG/VIAL	N020263	005	Jan 21, 1994	May CDFR
+	!		11.25MG	N020263	007	Aug 15, 2011	May CPOT
+	!		11.25MG/VIAL	N020263	007	Aug 15, 2011	May CDFR
+	!		15MG	N020263	006	Jan 21, 1994	May CPOT
+	!		15MG/VIAL	N020263	006	Jan 21, 1994	May CDFR
+	!		30MG	N020263	008	Aug 15, 2011	May CPOT
+	!		30MG/VIAL	N020263	008	Aug 15, 2011	May CDFR

POWDER;SUBCUTANEOUS

ELIGARD KIT

+	!	TOLMAR THERAP	7.5MG	N021343	001	Jan 23, 2002	May CPOT
+	!		7.5MG/VIAL	N021343	001	Jan 23, 2002	May CDFR
+	!		22.5MG	N021379	001	Jul 24, 2002	May CPOT
+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May CDFR
+	!		30MG	N021488	001	Feb 13, 2003	May CPOT
+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May CDFR
+	!		45MG	N021731	001	Dec 14, 2004	May CPOT
+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May CDFR

FENSOLVI KIT

+	!	TOLMAR	45MG	N213150	001	May 01, 2020	May NEWA
---	---	--------	------	---------	-----	--------------	----------

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ @ CSPC OUYI EQ 1.25MG BASE N212895 001 Dec 19, 2019 May DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

	@ FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A 090813	001	May 26, 2010	Jul	DISC
AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A 091485	001	Aug 05, 2011	Feb	CAHN
	LEVETIRACETAM IN SODIUM CHLORIDE						
AP	NEXUS PHARMS	500MG/100ML (5MG/ML)	A 213532	001	Jul 06, 2020	Jul	NEWA
AP		1000MG/100ML (10MG/ML)	A 213532	002	Jul 06, 2020	Jul	NEWA
AP		1500MG/100ML (15MG/ML)	A 213532	003	Jul 06, 2020	Jul	NEWA

SOLUTION; ORAL

LEVETIRACETAM

AA ACI HEALTHCARE LTD 100MG/ML A 078582 001 Jan 15, 2009 Jun CMFD

TABLET; ORAL

LEVETIRACETAM

	@ TEVA PHARMS	250MG	A 078101	001	Jan 15, 2009	Apr	DISC
	@	500MG	A 078101	002	Jan 15, 2009	Apr	DISC
	@	750MG	A 078101	003	Jan 15, 2009	Apr	DISC
	@	1GM	A 078101	004	Jan 15, 2009	Apr	DISC
AB	VIWIT PHARM	250MG	A 078869	001	Mar 13, 2009	Mar	CAHN
AB		250MG	A 078869	001	Mar 13, 2009	Mar	CAHN
AB		500MG	A 078869	002	Mar 13, 2009	Mar	CAHN
AB		500MG	A 078869	002	Mar 13, 2009	Mar	CAHN
AB		750MG	A 078869	003	Mar 13, 2009	Mar	CAHN
AB		750MG	A 078869	003	Mar 13, 2009	Mar	CAHN
AB		1GM	A 078869	004	Mar 13, 2009	Mar	CAHN
AB		1GM	A 078869	004	Mar 13, 2009	Mar	CAHN
AB	VKT PHARMA	250MG	A 090767	001	Jul 28, 2010	Jul	CAHN
AB		500MG	A 090767	002	Jul 28, 2010	Jul	CAHN
AB		750MG	A 090767	003	Jul 28, 2010	Jul	CAHN
AB		1GM	A 090767	004	Jul 28, 2010	Jul	CAHN
AB	ZHEJIANG JINGXIN	250MG	A 091491	001	Dec 14, 2010	Jun	CAHN
AB		500MG	A 091491	002	Dec 14, 2010	Jun	CAHN
AB		750MG	A 091491	003	Dec 14, 2010	Jun	CAHN
AB		1GM	A 091491	004	Dec 14, 2010	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	@ ACTAVIS ELIZABETH	500MG	A 091557	001	Sep 12, 2011	Apr	DISC
	@	750MG	A 091557	002	Sep 12, 2011	Apr	DISC
>D>	AB DEXCEL PHARMA	500MG	A 202167	001	Sep 04, 2015	Sep	CAHN
>D>	AB	750MG	A 202167	002	Sep 04, 2015	Sep	CAHN
>D>	AB ECI PHARMS LLC	500MG	A 204754	001	Aug 26, 2016	Sep	CAHN
>D>	AB	750MG	A 204754	002	Aug 26, 2016	Sep	CAHN
>A>	AB FLORIDA	500MG	A 202167	001	Sep 04, 2015	Sep	CAHN
>A>	AB	750MG	A 202167	002	Sep 04, 2015	Sep	CAHN
	AB OVERSEAS	750MG	A 212688	001	Jun 11, 2020	Jun	NEWA
>A>	AB PHARMA LIFE	500MG	A 204754	001	Aug 26, 2016	Sep	CAHN
>A>	AB	750MG	A 204754	002	Aug 26, 2016	Sep	CAHN
	@ TEVA PHARMS	500MG	A 091430	001	Sep 12, 2011	Apr	DISC
	@	750MG	A 091430	002	Sep 12, 2011	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 2.5MG/5ML A 202915 001 Aug 21, 2014 Feb DISC

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 5MG A 203027 001 Feb 13, 2015 Feb DISC

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A 205540	001	Apr 22, 2020	Apr	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A 205540	002	Apr 22, 2020	Apr	NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

@ RUBICON 0.5% A 078282 001 Dec 20, 2010 Jul CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

>A>	AB	RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Sep NEWA
-----	----	---------------	-----------	---------	-----	--------------	----------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOMYCIN

AP		XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb CAHN
----	--	-------------	------------------	---------	-----	--------------	----------

LINEZOLID

TABLET; ORAL

LINEZOLID

		@ GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Apr DISC
		@ TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May DISC

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

AP		XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb CAHN
----	--	-------------	-------------------	---------	-----	--------------	----------

TABLET; ORAL

LIOTHYRONINE SODIUM

AB		SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan CMFD
AB			EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan CMFD
AB			EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan CMFD
AB		TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Jul CMFD
AB			EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Jul CMFD
AB			EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Jul CMFD

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

+		TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014	Jul CAHN
+			20MG	N021977	004	Dec 10, 2007	Jul CAHN
+			30MG	N021977	001	Feb 23, 2007	Jul CAHN
+			40MG	N021977	005	Dec 10, 2007	Jul CAHN
+			50MG	N021977	002	Feb 23, 2007	Jul CAHN
+			60MG	N021977	006	Dec 10, 2007	Jul CAHN
+	!		70MG	N021977	003	Feb 23, 2007	Jul CAHN

TABLET, CHEWABLE; ORAL

VYVANSE

+		TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017	Jul CAHN
+			20MG	N208510	002	Jan 28, 2017	Jul CAHN
+			30MG	N208510	003	Jan 28, 2017	Jul CAHN
+			40MG	N208510	004	Jan 28, 2017	Jul CAHN
+			50MG	N208510	005	Jan 28, 2017	Jul CAHN
+	!		60MG	N208510	006	Jan 28, 2017	Jul CAHN

LISINAPRIL

SOLUTION; ORAL

QBRELIS

+	!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016	May CAHN
---	---	---------	--------	---------	-----	--------------	----------

TABLET; ORAL

LISINAPRIL

		@ ASCENT PHARMS INC	2.5MG	A075903	001	Jul 01, 2002	Jul CAHN
		@	5MG	A075903	002	Jul 01, 2002	Jul CAHN
		@	10MG	A075903	003	Jul 01, 2002	Jul CAHN
		@	20MG	A075903	004	Jul 01, 2002	Jul CAHN
		@	30MG	A075903	005	Jul 01, 2002	Jul CAHN
		@	40MG	A075903	006	Jul 01, 2002	Jul CAHN
AB		COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb CAHN
AB			5MG	A076102	002	Sep 30, 2002	Feb CAHN
AB			10MG	A076102	003	Sep 30, 2002	Feb CAHN
AB			20MG	A076102	004	Sep 30, 2002	Feb CAHN
AB			30MG	A076102	005	Sep 30, 2002	Feb CAHN
AB			40MG	A076102	006	Sep 30, 2002	Feb CAHN
>D>		@ INVATECH	2.5MG	A075999	001	Jul 01, 2002	Sep CAHN
>D>		@	5MG	A075999	002	Jul 01, 2002	Sep CAHN
>D>		@	10MG	A075999	003	Jul 01, 2002	Sep CAHN
>D>		@	20MG	A075999	004	Jul 01, 2002	Sep CAHN
>D>		@	30MG	A075999	005	Jul 01, 2002	Sep CAHN

TABLET; ORAL
LISINOPRIL

>D>	@	40MG	A 075999	006	Jul 01, 2002	Sep CAHN
>A>	@ PHARMGEN	2.5MG	A 075999	001	Jul 01, 2002	Sep CAHN
>A>	@	5MG	A 075999	002	Jul 01, 2002	Sep CAHN
>A>	@	10MG	A 075999	003	Jul 01, 2002	Sep CAHN
>A>	@	20MG	A 075999	004	Jul 01, 2002	Sep CAHN
>A>	@	30MG	A 075999	005	Jul 01, 2002	Sep CAHN
>A>	@	40MG	A 075999	006	Jul 01, 2002	Sep CAHN
>A> AB	YILING	2.5MG	A 212041	001	Sep 15, 2020	Sep NEWA
>A> AB		5MG	A 212041	002	Sep 15, 2020	Sep NEWA
>A> AB		10MG	A 212041	003	Sep 15, 2020	Sep NEWA

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE

AB	+	HIKMA	150MG	N 017812	002	Jan 28, 1987	Jan CAHN
AB	+		300MG	N 017812	001		Jan CAHN
AB	+	!	600MG	N 017812	003	Jan 28, 1987	Jan CAHN
	@	MYLAN	150MG	A 076243	002	Feb 24, 2003	Jan DISC
	@		300MG	A 076243	001	Jun 27, 2002	Jan DISC

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE

AA	+	!	HIKMA	EQ 300MG CARBONATE/5ML	N 018421	001	Jan CAHN
----	---	---	-------	------------------------	----------	-----	----------

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL
LUCEMYRA

+	!	USWM	EQ 0.18MG BASE	N 209229	001	May 16, 2018	Jun CAHN
---	---	------	----------------	----------	-----	--------------	----------

LOMITAPIDE MESYLATE

CAPSULE; ORAL
JUXTAPID

+		AMRYT	EQ 5MG BASE	N 203858	001	Dec 21, 2012	May CAHN
+			EQ 10MG BASE	N 203858	002	Dec 21, 2012	May CAHN
+			EQ 20MG BASE	N 203858	003	Dec 21, 2012	May CAHN
+			EQ 30MG BASE	N 203858	004	Apr 23, 2015	May CAHN
>D>	+		EQ 40MG BASE	N 203858	005	Apr 23, 2015	Sep DISC
>A>	+	@	EQ 40MG BASE	N 203858	005	Apr 23, 2015	Sep DISC
	+		EQ 40MG BASE	N 203858	005	Apr 23, 2015	May CAHN
>D>	+	!	EQ 60MG BASE	N 203858	006	Apr 23, 2015	Sep DISC
>A>	+	@	EQ 60MG BASE	N 203858	006	Apr 23, 2015	Sep DISC
	+	!	EQ 60MG BASE	N 203858	006	Apr 23, 2015	May CAHN

LORAZEPAM

INJECTABLE; INJECTION
LORAZEPAM

>D> AP		HOSPIRA	2MG/ML	A 074243	001	Apr 12, 1994	Sep DISC
>A>	@		2MG/ML	A 074243	001	Apr 12, 1994	Sep DISC

TABLET; ORAL
LORAZEPAM

@	MYLAN	0.5MG	A 077657	001	Mar 16, 2006	Mar DISC
@		1MG	A 077657	002	Mar 16, 2006	Mar DISC
@		2MG	A 077657	003	Mar 16, 2006	Mar DISC

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

@	HIKMA	25MG	A 077459	001	Oct 06, 2010	Feb DISC
@		50MG	A 077459	002	Oct 06, 2010	Feb DISC
@		100MG	A 077459	003	Oct 06, 2010	Feb DISC

LOVASTATIN

TABLET; ORAL
LOVASTATIN

AB		COREPHARMA	10MG	A 077748	001	Feb 28, 2007	Feb CAHN
AB			20MG	A 077748	002	Feb 28, 2007	Feb CAHN
AB			40MG	A 077748	003	Feb 28, 2007	Feb CAHN

LURBINECTEDINPOWDER; INTRAVENOUS
ZEPZELCA

+! JAZZ 4MG/VIAL N213702 001 Jun 15, 2020 Jun NEWA

MAFENIDE ACETATECREAM; TOPICAL
SULFAMYLON

+! RISING EQ 85MG BASE/GM N016763 001 May CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP BAXTER HLTHCARE CORP 1GM/100ML A211965 001 Aug 11, 2020 Jul NEWA

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML) A211966 001 Jun 01, 2020 May NEWA

AP 4GM/50ML (80MG/ML) A211966 002 Jun 01, 2020 May NEWA

AP 4GM/100ML (40MG/ML) A211966 003 Jun 01, 2020 May NEWA

AP GLAND PHARMA LTD 2GM/50ML (40MG/ML) A213917 001 Jul 10, 2020 Jul NEWA

AP 4GM/100ML (40MG/ML) A213917 002 Jul 10, 2020 Jul NEWA

MAZINDOLTABLET; ORAL
SANOREX

+ @ NOVARTIS 1MG N017247 001 Jan CAHN

+ @ 2MG N017247 002 Jan CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

! LGM PHARMA 2.5MG A204054 001 Mar 19, 2013 Aug CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA ANNORA PHARMA 25MG A087128 001 Aug CAHN

AA INDICUS PHARMA 50MG A205136 003 Feb 22, 2019 Jun CTEC

@ MYLAN PHARMS INC 12.5MG A202640 001 Sep 17, 2012 Jan DISC

@ 25MG A202640 002 Sep 17, 2012 Jan DISC

AA ZYDUS 12.5MG A213957 001 Jun 23, 2020 Jun NEWA

AA 25MG A213957 002 Jun 23, 2020 Jun NEWA

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

>A> AB STRIDES PHARMA 250MG A209209 001 Sep 18, 2020 Sep NEWA

PONSTEL

AB +! AVION PHARMS 250MG N015034 003 Jul CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

! BARR 250MG A076392 001 Dec 29, 2003 Feb CTEC

@ HIKMA 250MG A076523 001 Oct 01, 2004 Feb DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB @ HIKMA 40MG/ML A075997 001 Feb 15, 2002 Feb DISC

! PAR PHARM 40MG/ML A075671 001 Jul 25, 2001 Feb CHRS

@ TEVA PHARMS 40MG/ML A075681 001 May 05, 2003 Apr DISC

TABLET; ORAL

MEGESTROL ACETATE

>D> AB HIKMA 20MG A074458 001 Sep 29, 1995 Sep DISC

>A> @ 20MG A074458 001 Sep 29, 1995 Sep DISC

>D> AB 40MG A074458 002 Sep 29, 1995 Sep DISC

>A> @ 40MG A074458 002 Sep 29, 1995 Sep DISC

MELOXICAM

SOLUTION; INTRAVENOUS
ANJESO

+! BAUDAX 30MG/ML (30MG/ML) N210583 001 Feb 20, 2020 Feb NEWA
TABLET, ORALLY DISINTEGRATING; ORAL

QMIIZ ODT
+ @ TERSERA 7.5MG N211210 001 Oct 19, 2018 Apr DISC
+ @ 15MG N211210 002 Oct 19, 2018 Apr DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
MELPHALAN HYDROCHLORIDE

@ ALVOGEN EQ 50MG BASE/VIAL A204817 001 May 17, 2019 May DISC
AP BPI LABS LLC EQ 50MG BASE/VIAL A209197 001 May 08, 2020 Apr NEWA
AP INGENUS PHARMS LLC EQ 50MG BASE/VIAL A210947 001 Feb 18, 2020 Feb NEWA
@ PAR STERILE PRODUCTS EQ 50MG BASE/VIAL A204773 001 Aug 22, 2016 Feb DISC
@ TWI PHARMS EQ 50MG BASE/VIAL A211463 001 Sep 13, 2019 Jan DISC
@ USWM EQ 50MG BASE/VIAL A207032 001 May 03, 2019 Jun CAHN

POWDER; INTRAVENOUS
EVOMELA

+! ACROTECH EQ 50MG BASE/VIAL N207155 001 Mar 10, 2016 Mar CTEC
AP +! EQ 50MG BASE/VIAL N207155 001 Mar 10, 2016 Feb CFTG
MELPHALAN HYDROCHLORIDE
@ ACTAVIS LLC EQ 50MG BASE/VIAL A209323 001 Mar 06, 2020 Mar DISC
AP EQ 50MG BASE/VIAL A209323 001 Mar 06, 2020 Feb NFTG

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MEMANTINE HYDROCHLORIDE

AB ANI PHARMS INC 7MG A205365 001 Feb 28, 2020 Feb NEWA
AB 14MG A205365 002 Feb 28, 2020 Feb NEWA
AB 21MG A205365 003 Feb 28, 2020 Feb NEWA
AB 28MG A205365 004 Feb 28, 2020 Feb NEWA

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

>D> AA MEDLEY PHARMS 2MG/ML A210319 001 Aug 31, 2020 Sep CAHN
AA 2MG/ML A210319 001 Aug 31, 2020 Aug NEWA
>A> AA SAPTALIS PHARMS 2MG/ML A210319 001 Aug 31, 2020 Sep CAHN

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@ CHARTWELL 5MG A090244 001 Jul 11, 2018 Mar CAHN
@ 10MG A090244 002 Jul 11, 2018 Mar CAHN
AB HIKMA 5MG A208173 001 Feb 28, 2020 Feb NEWA
AB 10MG A208173 002 Feb 28, 2020 Feb NEWA
AB NINGBO 5MG A212947 001 Apr 03, 2020 Apr CAHN
AB 5MG A212947 001 Apr 03, 2020 Mar NEWA
AB 10MG A212947 002 Apr 03, 2020 Apr CAHN
AB 10MG A212947 002 Apr 03, 2020 Mar NEWA
@ TEVA PHARMS 5MG A090052 001 Oct 25, 2011 Apr DISC
@ 10MG A090052 002 Oct 25, 2011 Apr DISC

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA ! EPIC PHARMA 50MG A040331 001 May 28, 1999 Feb CHRS
AA ! 100MG A040331 002 May 28, 1999 Feb CHRS
@ HIKMA 50MG A040110 001 Mar 12, 1997 Feb DISC
@ 100MG A040110 002 Mar 12, 1997 Feb DISC

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ ACELLA 400MG A084153 001 Aug CAHN

MESALAMINE

SUPPOSITORY; RECTAL

MESALAMINE

AB ACTAVIS MID ATLANTIC 1GM A205654 001 Aug 14, 2020 Aug NEWA
AB ANNORA PHARMA 1GM A213377 001 Mar 19, 2020 Mar NEWA
>A> AB APTAPHARMA INC 1GM A207448 001 Apr 19, 2019 Sep CAHN
>D> AB PHARM SOURCING 1GM A207448 001 Apr 19, 2019 Sep CAHN

SUPPOSITORY;RECTAL
MESALAMINE

AB	ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan NEWA
----	--------------	-----	---------	-----	--------------	----------

METAXALONE

TABLET;ORAL
METAXALONE

AB	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar CTEC
AB	RISING	800MG	A208774	001	Sep 24, 2018	Jul CAHN
AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL
METFORMIN HYDROCHLORIDE

AB	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb NFTG
AB	+! RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb CFTG
	+!	500MG/5ML	N021591	001	Sep 11, 2003	Jan CAHN

TABLET;ORAL
METFORMIN HYDROCHLORIDE

	@ HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar DISC
	@	850MG	A075978	002	Jan 25, 2002	Mar DISC
	@	1GM	A075978	003	Nov 05, 2002	Mar DISC
	@ MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	May DISC
	@	850MG	A205330	002	Oct 31, 2017	May DISC
	@	1GM	A205330	003	Oct 31, 2017	May DISC
	@ MYLAN	500MG	A075976	001	Jan 24, 2002	Jan DISC
	@	850MG	A075976	002	Jan 24, 2002	Jan DISC
	@	1GM	A075976	003	Jan 24, 2002	Jan DISC

TABLET, EXTENDED RELEASE;ORAL
FORTAMET

>D>	+ @ ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Sep CMFD
>A>	AB2 +	1GM	N021574	002	Apr 27, 2004	Sep CMFD
	METFORMIN HYDROCHLORIDE					
AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar NEWA
AB2		1GM	A213651	002	Apr 09, 2020	Mar NEWA
	@ APOTEX	750MG	A076706	002	Dec 29, 2005	May DISC
	@ BARR	750MG	A076863	001	Oct 14, 2004	Apr DISC
>D>	@ MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	Sep CMFD
>A>	AB1	500MG	A206955	001	Dec 07, 2016	Sep CMFD
	@	500MG	A206955	001	Dec 07, 2016	May DISC
>D>	@	750MG	A206955	002	Dec 07, 2016	Sep CMFD
>A>	AB	750MG	A206955	002	Dec 07, 2016	Sep CMFD
	@	750MG	A206955	002	Dec 07, 2016	May DISC
AB1	YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Jun CMFD
AB		750MG	A211052	002	Sep 24, 2018	Jun CMFD

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL
METHADONE HYDROCHLORIDE

AA	SPECGX LLC	10MG/ML	A207368	001	Aug 22, 2019	May CAHN
	SOLUTION;ORAL					
	METHADONE HYDROCHLORIDE					
AA	SPECGX LLC	5MG/5ML	A207537	001	Oct 02, 2019	May CAHN
AA		10MG/5ML	A207537	002	Oct 01, 2019	May CAHN

TABLET;ORAL
DOLOPHINE HYDROCHLORIDE

	+ @ HIKMA	5MG	N006134	002		Jun DISC
	+ @	10MG	N006134	010		Jun DISC
	METHADONE HYDROCHLORIDE					
AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar CAHN
AA		5MG	A210484	001	Aug 02, 2018	Mar CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar CAHN
AA	ROXANE	5MG	A088108	001	Mar 08, 1983	May CMFD
AA		10MG	A088109	001	Mar 08, 1983	May CMFD
AA	! SPECGX LLC	5MG	A040517	001	Apr 27, 2004	Jun CHRS
AA	!	10MG	A040517	002	Apr 27, 2004	Jun CHRS
>A>	AA THEPHARMANETWORK LLC	5MG	A090635	002	Sep 22, 2020	Sep NEWA
AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar NEWA
	METHADOSE					
	@ SPECGX LLC	5MG	A040050	001	Apr 15, 1993	May DISC

	TABLET;ORAL								
	METHADOSE								
	@	10MG		A 040050	002	Apr 15, 1993		May	DISC
	<u>METHAZOLAMIDE</u>								
	TABLET;ORAL								
	METHAZOLAMIDE								
>A>	@ ATHEM	25MG		A 040102	001	Aug 28, 1996		Sep	CAHN
>A>	@	50MG		A 040102	002	Aug 28, 1996		Sep	CAHN
	@ BAUSCH	25MG		A 207438	001	Oct 05, 2018		Jul	CAHN
	@	50MG		A 207438	002	Oct 05, 2018		Jul	CAHN
>D>	@ INVATECH	25MG		A 040102	001	Aug 28, 1996		Sep	CAHN
>D>	@	50MG		A 040102	002	Aug 28, 1996		Sep	CAHN
	<u>METHENAMINE HIPPURATE</u>								
	TABLET;ORAL								
	METHENAMINE HIPPURATE								
	@ IMPAX LABS INC	1GM		A 076411	001	Jun 20, 2003		Jul	DISC
	<u>METHIMAZOLE</u>								
	TABLET;ORAL								
	METHIMAZOLE								
>A>	AB DISCOVERY THERAP	5MG		A 040547	001	Feb 18, 2005		Sep	CAHN
>A>	AB	10MG		A 040547	002	Feb 18, 2005		Sep	CAHN
>A>	@	15MG		A 040619	003	Jul 12, 2005		Sep	CAHN
>A>	@	20MG		A 040547	004	Feb 18, 2005		Sep	CAHN
>D>	AB ECI PHARMS LLC	5MG		A 040547	001	Feb 18, 2005		Sep	CAHN
>D>	AB	10MG		A 040547	002	Feb 18, 2005		Sep	CAHN
>D>	@	15MG		A 040619	003	Jul 12, 2005		Sep	CAHN
>D>	@	20MG		A 040547	004	Feb 18, 2005		Sep	CAHN
	<u>METHOCARBAMOL</u>								
	TABLET;ORAL								
	METHOCARBAMOL								
AA	AUROBINDO PHARMA LTD	750MG		A 213967	001	Aug 12, 2020		Jul	NEWA
	@ HIKMA INTL PHARMS	500MG		A 085159	001			Feb	DISC
	@	750MG		A 085123	001			Feb	DISC
	<u>METHOHEXITAL SODIUM</u>								
	INJECTABLE;INJECTION								
	BREVITAL SODIUM								
	+ @ PAR STERILE PRODUCTS	2.5GM/VIAL		N 011559	002			Jul	DISC
	<u>METHOTREXATE</u>								
>D>	SOLUTION;INTRAVENOUS								
>D>	METHOTREXATE								
>D>	+! ACCORD HLTHCARE	5GM/50ML (100MG/ML)		N 214121	001	Aug 24, 2020		Sep	DISC
>A>	+ @	5GM/50ML (100MG/ML)		N 214121	001	Aug 24, 2020		Sep	DISC
	+!	5GM/50ML (100MG/ML)		N 214121	001	Aug 24, 2020		Aug	NEWA
	<u>METHOTREXATE SODIUM</u>								
	INJECTABLE;INJECTION								
	METHOTREXATE SODIUM PRESERVATIVE FREE								
	@ MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)		A 201529	001	Mar 29, 2012		Jan	DISC
	@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)		A 201529	002	Mar 29, 2012		Jan	DISC
	@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)		A 201529	003	Mar 29, 2012		Jan	DISC
	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)		A 040843	003	Feb 27, 2012		Jan	CTEC
	SOLUTION;ORAL								
	XATMEP								
	+! AZURITY	EQ 2MG BASE/ML		N 208400	001	Apr 25, 2017		May	CAHN
	+!	EQ 2.5MG BASE/ML		N 208400	001	Apr 25, 2017		Jul	C POT
	TABLET;ORAL								
	METHOTREXATE SODIUM								
AB	ACCORD HLTHCARE	EQ 2.5MG BASE		A 213343	001	Jan 24, 2020		Jan	NEWA
	+ @ DAVA PHARMS INC	EQ 2.5MG BASE		N 008085	002			Mar	DISC
AB	EUGIA PHARMA	EQ 2.5MG BASE		A 210454	001	Jan 30, 2020		Jan	NEWA
AB	! HIKMA	EQ 2.5MG BASE		A 040054	001	Aug 01, 1994		Mar	CHRS

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Apr	CTEC
AA	!	5MG	A200602	002	Sep 24, 2012	Apr	CTEC
AA	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Apr	CMFD
AA		5MG	A040642	002	Dec 06, 2011	Apr	CMFD

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Apr	DISC
@		500MG	A070343	001	Feb 20, 1986	Apr	DISC
@	WATSON LABS	500MG	A070625	001	Jun 06, 1986	Apr	DISC

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+	!	PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630	002	Jul 18, 2019	Jun	NEWA
---	---	----------------	-------------------	---------	-----	--------------	-----	------

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	TULEX PHARMS INC	0.2MG	A212233	001	May 01, 2020	Apr	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jul	CTEC
AB	+	8.6MG	N205489	001	Jun 19, 2017	Jun	CFTG
+		17.3MG	N205489	002	Jun 19, 2017	Jul	CTEC
AB	+	17.3MG	N205489	002	Jun 19, 2017	Jun	CFTG
+	!	25.9MG	N205489	003	Jun 19, 2017	Jul	CTEC
AB	+	25.9MG	N205489	003	Jun 19, 2017	Jun	CFTG
+	!	25.9MG	N205489	003	Jun 19, 2017	Jun	CHRS

METHYLPHENIDATE

@	ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020	Jul	DISC
AB		8.6MG	A210924	001	Jun 19, 2020	Jun	NFTG
@		17.3MG	A210924	002	Jun 19, 2020	Jul	DISC
AB		17.3MG	A210924	002	Jun 19, 2020	Jun	NFTG
@		25.9MG	A210924	003	Jun 19, 2020	Jul	DISC
AB		25.9MG	A210924	003	Jun 19, 2020	Jun	NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ADHANSIA XR

>D>	+	PURDUE PHARMA LP	85MG	N212038	006	Feb 27, 2019	Sep	CHRS
>A>	+	!	85MG	N212038	006	Feb 27, 2019	Sep	CHRS

JORNAY PM

>D>	+	IRONSHORE PHARMS	100MG	N209311	005	Aug 08, 2018	Sep	CHRS
>A>	+	!	100MG	N209311	005	Aug 08, 2018	Sep	CHRS

METHYLPHENIDATE HYDROCHLORIDE

@	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Apr	DISC
@		20MG	A079031	001	Jul 13, 2012	Apr	DISC
@		30MG	A079031	002	Jul 13, 2012	Apr	DISC
@		40MG	A079031	003	Jul 13, 2012	Apr	DISC

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ALKEM LABS LTD	5MG/5ML	A211647	001	Mar 30, 2020	Mar	NEWA	
AA		10MG/5ML	A211647	002	Mar 30, 2020	Mar	NEWA	
AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Jul	CAHN	
AA		10MG/5ML	A210764	002	Apr 10, 2020	Jul	CAHN	
>A>	AA	EYWA	5MG/5ML	A210139	001	Oct 03, 2018	Sep	CAHN
>A>	AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep	CAHN
>D>	AA	NOVELGENIX THERAPS	5MG/5ML	A210139	001	Oct 03, 2018	Sep	CAHN
>D>	AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep	CAHN
AA	PATRIN PHARMA INC	5MG/5ML	A210764	001	Apr 10, 2020	Mar	NEWA	
AA		10MG/5ML	A210764	002	Apr 10, 2020	Mar	NEWA	
AA	QUAGEN	5MG/5ML	A213567	001	Jun 04, 2020	Jun	NEWA	
AA		10MG/5ML	A213567	002	Jun 04, 2020	Jun	NEWA	

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Aug CAHN
AB		10MG	A207587	002	Mar 03, 2017	Aug CAHN
AB		20MG	A207587	003	Mar 03, 2017	Aug CAHN
AB	PRINSTON INC	5MG	A212697	001	Jul 23, 2020	Jul NEWA
AB		10MG	A212697	002	Jul 23, 2020	Jul NEWA
AB		20MG	A212697	003	Jul 23, 2020	Jul NEWA
	@ WATSON LABS	5MG	A040220	001	Aug 29, 1997	Apr DISC
	@	10MG	A040220	002	Aug 29, 1997	Apr DISC
	@	20MG	A040220	003	Aug 29, 1997	Apr DISC

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018	Jul CMFD
	@	18MG	A076772	001	Mar 22, 2018	Mar DISC
AB		27MG	A076772	002	Mar 22, 2018	Jul CMFD
	@	27MG	A076772	002	Mar 22, 2018	Mar DISC
AB		36MG	A076772	003	Mar 22, 2018	Jul CMFD
	@	36MG	A076772	003	Mar 22, 2018	Mar DISC
AB		54MG	A076655	001	Mar 21, 2018	Jul CMFD
	@	54MG	A076655	001	Mar 21, 2018	Mar DISC
>A> AB	ALKEM LABS LTD	20MG	A212288	001	Oct 06, 2020	Sep NEWA
	@ ANI PHARMS INC	18MG	A208607	001	Jul 14, 2017	Aug DISC
	@	27MG	A208607	002	Jul 14, 2017	Aug DISC
	@	36MG	A208607	003	Jul 14, 2017	Aug DISC
	@	54MG	A208607	004	Jul 14, 2017	Aug DISC
AB	DR REDDYS	18MG	A213473	001	Jul 29, 2020	Jul NEWA
AB		27MG	A213473	002	Jul 29, 2020	Jul NEWA
AB		36MG	A213473	003	Jul 29, 2020	Jul NEWA
AB		54MG	A213473	004	Jul 29, 2020	Jul NEWA
AB	SUN PHARM INDS INC	18MG	A205135	001	Aug 19, 2020	Aug NEWA
AB		27MG	A205135	002	Aug 19, 2020	Aug NEWA
AB		36MG	A205135	003	Aug 19, 2020	Aug NEWA
AB		54MG	A205135	004	Aug 19, 2020	Aug NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

>D>	@ DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar DISC
>A> AB	@ NOVAST LABS	4MG	A210985	001	Jan 09, 2019	Sep CMFD
		4MG	A210985	001	Jan 09, 2019	Sep CMFD

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul CMFD
AB		80MG/ML	A210043	002	May 20, 2019	Jul CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

TESTRED

>A> AB	! BAUSCH	10MG	A083976	001		Sep CAHN
>D> AB	! VALEANT PHARM INTL	10MG	A083976	001		Sep CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SPRAY, METERED;NASAL

GIMOTI

+!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020	Jun NEWA
----	------------------	--------------------	---------	-----	--------------	----------

METOLAZONE

TABLET;ORAL

METOLAZONE

@	ANI PHARMS INC	2.5MG	A075543	001	Jan 06, 2004	May CMS1
@		5MG	A075543	002	Mar 01, 2004	May CMS1

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar DISC
@		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar DISC
@		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar DISC
@		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar DISC

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

	@	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC
	@		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan DISC
	@		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan DISC
AB		PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar NEWA
AB			EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar NEWA
AB			EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar NEWA
AB			EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

	@	HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb DISC
	@		100MG	A074141	002	Jan 31, 1995	Feb DISC
AB		YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan NEWA
AB			50MG	A208955	002	Feb 05, 2020	Jan NEWA
AB			100MG	A208955	003	Feb 05, 2020	Jan NEWA

METRONIDAZOLE

CAPSULE;ORAL

FLAGYL

AB	+	PFIZER	375MG	N020334	001	May 03, 1995	Aug CAHN
----	---	--------	-------	---------	-----	--------------	----------

GEL;VAGINAL

VANDAZOLE

>D>	BX	TEVA PHARMS	0.75%	N021806	001	May 20, 2005	Sep CHRS
>A>	BX	!	0.75%	N021806	001	May 20, 2005	Sep CHRS

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP		GLAND PHARMA LTD	500MG/100ML	A212435	001	Aug 03, 2020	Jul NEWA
	@	MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017	Jun DISC

TABLET;ORAL

FLAGYL

AB	+	PFIZER	250MG	N012623	001		Aug CAHN
AB	+	!	500MG	N012623	003		Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

FLAGYL ER

	+	@	PFIZER	750MG	N020868	001	Nov 26, 1997	Aug CAHN
--	---	---	--------	-------	---------	-----	--------------	----------

METYROSINE

CAPSULE;ORAL

DEMSER

AB	+	BAUSCH	250MG	N017871	001		Jul CFTG
----	---	--------	-------	---------	-----	--	----------

METYROSINE

AB		AMNEAL	250MG	A213734	001	Jul 24, 2020	Jul NFTG
----	--	--------	-------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A074450	001	May 16, 1996	Jun CMFD
AB			200MG	A074450	002	May 16, 1996	Jun CMFD
AB			250MG	A074450	003	May 16, 1996	Jun CMFD
AB		CROSSMEDIKA SA	150MG	A213500	001	Jul 22, 2020	Jul NEWA
AB			200MG	A213500	002	Jul 22, 2020	Jul NEWA
AB			250MG	A213500	003	Jul 22, 2020	Jul NEWA
AB		TEVA	150MG	A074377	001	May 16, 1995	Jun CTEC
AB			200MG	A074377	002	May 16, 1995	Jun CTEC
AB		!	250MG	A074377	003	May 16, 1995	Jun CTEC

MICONAZOLE

TABLET;BUCCAL

ORAVIG

>D>		+	FORTOVIA	50MG	N022404	001	Apr 16, 2010	Sep DISC
>A>		+	@	50MG	N022404	001	Apr 16, 2010	Sep DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002	Sep DISC
>A>		@	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002	Sep DISC

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ MYLAN ASI

EQ 1MG BASE/ML

A 090315 001 Nov 29, 2010 Jan DISC

@

EQ 5MG BASE/ML

A 090315 002 Nov 29, 2010 Jan DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	2.5MG	A 212774	001	Aug 10, 2020	Jul	NEWA
AB		5MG	A 212774	002	Aug 10, 2020	Jul	NEWA
AB		10MG	A 212774	003	Aug 10, 2020	Jul	NEWA
>A>	CEROVENE INC	2.5MG	A 207849	001	Oct 01, 2020	Sep	NEWA
>A>		5MG	A 207849	002	Oct 01, 2020	Sep	NEWA
>A>		10MG	A 207849	003	Oct 01, 2020	Sep	NEWA
AB	ZYDUS	2.5MG	A 213055	001	Sep 01, 2020	Aug	NEWA
AB		5MG	A 213055	002	Sep 01, 2020	Aug	NEWA
AB		10MG	A 213055	003	Sep 01, 2020	Aug	NEWA

MIFEPRISTONE

TABLET; ORAL

KORLYM

AB	+! CORCEPT THERAP	300MG	N 202107	001	Feb 17, 2012	Jul	CFTG
AB	MIFEPRISTONE						
AB	TEVA PHARMS USA INC	300MG	A 211436	001	Aug 03, 2020	Jul	NFTG

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

>D>	AB	AMERIGEN PHARMS LTD	100MG	A 208342	001	Apr 17, 2018	Sep	CAHN
>A>	AB	ANI PHARMS INC	100MG	A 208342	001	Apr 17, 2018	Sep	CAHN
	AB	EDENBRIDGE PHARMS	100MG	A 209821	001	Aug 06, 2020	Jul	NEWA

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

>A>	@	ANDA REPOSITORY	12.5MG	A 205071	001	Jan 27, 2016	Sep	CAHN
>A>	@		25MG	A 205071	002	Jan 27, 2016	Sep	CAHN
>A>	@		50MG	A 205071	003	Jan 27, 2016	Sep	CAHN
>A>	@		100MG	A 205071	004	Jan 27, 2016	Sep	CAHN
>D>	@	USPHARMA WINDLAS	12.5MG	A 205071	001	Jan 27, 2016	Sep	CAHN
>D>	@		25MG	A 205071	002	Jan 27, 2016	Sep	CAHN
>D>	@		50MG	A 205071	003	Jan 27, 2016	Sep	CAHN
>D>	@		100MG	A 205071	004	Jan 27, 2016	Sep	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	MEITHEAL	EQ 1MG BASE/ML	A 211671	001	Mar 24, 2020	Apr	CAHN
AP	NANJING KING-FRIEND	EQ 1MG BASE/ML	A 211671	001	Mar 24, 2020	Mar	NEWA
	MILRINONE LACTATE IN DEXTROSE 5%						
AP	AUROBINDO PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 209666	001	Sep 03, 2020	Aug	NEWA
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 209666	002	Sep 03, 2020	Aug	NEWA
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	GLAND PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 213585	001	Jul 16, 2020	Jul	NEWA
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 213585	002	Jul 16, 2020	Jul	NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

ZILXI

+!	FOAMIX	EQ 1.5% BASE	N 213690	001	May 28, 2020	May	NEWA
----	--------	--------------	----------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

JOURNEY

@		EQ 45MG BASE	N 201922	001	Jul 11, 2012	Feb	CAHN
@		EQ 67.5MG BASE	N 201922	002	Jul 11, 2012	Feb	CAHN
@		EQ 90MG BASE	N 201922	003	Jul 11, 2012	Feb	CAHN
@		EQ 112.5MG BASE	N 201922	004	Jul 11, 2012	Feb	CAHN
@		EQ 135MG BASE	N 201922	005	Jul 11, 2012	Feb	CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 50MG BASE	A213662	001	May 01, 2020	Apr	NEWA
AB		EQ 75MG BASE	A213662	002	May 01, 2020	Apr	NEWA
AB		EQ 100MG BASE	A213662	003	May 01, 2020	Apr	NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

	@ SAWAI USA	25MG	A209446	001	Dec 27, 2019	Jan	DISC
	MYRBETRIQ						
+	! APGDI	25MG	N202611	001	Jun 28, 2012	Jan	CTEC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

	@ IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005	Jul	DISC
	@	30MG	A076901	002	Jun 28, 2005	Jul	DISC
	@	45MG	A076901	003	Jun 28, 2005	Jul	DISC

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	+	PFIZER	0.1MG	N019268	003	Sep 21, 1990	Aug	CAHN
AB	+	!	0.2MG	N019268	001	Dec 27, 1988	Aug	CAHN
		MISOPROSTOL						
>A>		@ ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019	Sep	CAHN
>A>		@	0.2MG	A210201	002	Jul 02, 2019	Sep	CAHN
>D>		@ ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019	Sep	CAHN
>D>		@	0.2MG	A210201	002	Jul 02, 2019	Sep	CAHN

MITOMYCIN

POWDER;PYELOALYCEAL

JELMYTO

+	!	UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020	Apr	NEWA
---	---	---------------	-----------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

>D>	AB	FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005	Sep	DISC
>A>		@	0.1%	A076171	001	Apr 08, 2005	Sep	DISC
		SPRAY, METERED;NASAL						
		MOMETASONE FUROATE						
AB		AMNEAL PHARMS	0.05MG/SPRAY	A207989	001	Apr 03, 2017	Mar	CPOT
AB		APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	Mar	CPOT
		NASONEX						
AB	+	! MERCK SHARP DOHME	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Mar	CPOT

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

+	!	BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020	Apr	NEWA
---	---	----------------------	------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE/PACKET	A213471	001	Feb 18, 2020	Feb	NEWA
----	--	----------------------	--------------------	---------	-----	--------------	-----	------

TABLET;ORAL

MONTELUKAST SODIUM

>A>	AB	ADAPTIS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep	CAHN
>D>	AB	GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep	CAHN
	AB		EQ 10MG BASE	A209012	001	Apr 24, 2017	May	CAHN
		@ HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012	Feb	DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>A>	AB	ADAPTIS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep	CAHN
>A>	AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep	CAHN
	AB	AMNEAL PHARMS	EQ 4MG BASE	A205107	001	Sep 04, 2020	Aug	NEWA
	AB		EQ 5MG BASE	A205107	002	Sep 04, 2020	Aug	NEWA
>D>	AB	GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep	CAHN
	AB		EQ 4MG BASE	A209011	001	Apr 18, 2017	Apr	CAHN
>D>	AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep	CAHN

TABLET, CHEWABLE;ORAL
MONTELUKAST SODIUM

AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Apr	CAHN
	@ JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Jan	DISC
	@	EQ 5MG BASE	A203795	002	Feb 27, 2015	Jan	DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

+	ALLERGAN	70MG	N020616	010	Jul 09, 2012	Apr	CTEC
	MORPHINE SULFATE						
	@ TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Apr	DISC
	@	30MG	A202718	002	Dec 29, 2014	Apr	DISC
	@	40MG	A202718	007	Jun 03, 2015	Apr	DISC
	@	50MG	A202718	003	Dec 29, 2014	Apr	DISC
	@	60MG	A202718	004	Dec 29, 2014	Apr	DISC
	@	70MG	A202718	008	Jun 03, 2015	Apr	DISC
	@	80MG	A202718	005	Dec 29, 2014	Apr	DISC
	@	100MG	A202718	006	Dec 29, 2014	Apr	DISC

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	HIKMA	0.5MG/ML	N018565	001	Sep 18, 1984	Feb	CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Feb	CAHN
		INFUMORPH						
AP	+	HIKMA	10MG/ML	N018565	003	Jul 19, 1991	Feb	CAHN
AP	+		25MG/ML	N018565	004	Jul 19, 1991	Feb	CAHN

MORPHINE SULFATE

>D>	AP	HIKMA	4MG/ML	A205758	001	May 21, 2015	Sep	CHRS
>A>	!		4MG/ML	A205758	001	May 21, 2015	Sep	CTEC
>A>	AP	!	4MG/ML	A205758	001	May 21, 2015	Sep	CHRS
	AP		4MG/ML	A205758	001	May 21, 2015	Feb	CAHN
>D>	AP		8MG/ML	A205758	002	May 21, 2015	Sep	CHRS
>A>	!		8MG/ML	A205758	002	May 21, 2015	Sep	CTEC
>A>	AP	!	8MG/ML	A205758	002	May 21, 2015	Sep	CHRS
	AP		8MG/ML	A205758	002	May 21, 2015	Feb	CAHN
	AP		10MG/ML	A205758	003	May 21, 2015	Feb	CAHN
	@ HOSPIRA		1MG/ML	A071850	001	May 11, 1988	May	DISC
>D>	+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011	Sep	DISC
>A>	+ @		2MG/ML	N202515	001	Nov 14, 2011	Sep	DISC
>D>	AP	+	4MG/ML	N202515	002	Nov 14, 2011	Sep	DISC
>A>	+ @		4MG/ML	N202515	002	Nov 14, 2011	Sep	DISC
>D>	AP	+	8MG/ML	N202515	003	Nov 14, 2011	Sep	DISC
>A>	+ @		8MG/ML	N202515	003	Nov 14, 2011	Sep	DISC
>D>	AP	+	10MG/ML	N202515	004	Nov 14, 2011	Sep	DISC
>A>	+ @		10MG/ML	N202515	004	Nov 14, 2011	Sep	DISC
	+ @ ICU MEDICAL INC		1MG/ML	N019916	001	Oct 30, 1992	May	DISC

SOLUTION;INTRAMUSCULAR

MORPHINE SULFATE (AUTOINJECTOR)

>D>	+	MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Sep	DISC
>A>	+ @		10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Sep	DISC
	+		10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990	Jun	CPOT
	+		15MG/ML	N019999	001	Jul 12, 1990	Jun	CTNA
	+		15MG/ML	N019999	001	Jul 12, 1990	Jun	CDFR

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND ER

+	@ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015	Aug	DISC
+	@	30MG	N206544	002	Oct 02, 2015	Aug	DISC
+	@	60MG	N206544	003	Oct 02, 2015	Aug	DISC
+	@	100MG	N206544	004	Oct 02, 2015	Aug	DISC
	MORPHINE SULFATE						
	@ NESHER PHARMS	15MG	A076733	001	May 19, 2004	Mar	DISC
	@	100MG	A077855	001	Sep 27, 2007	Mar	DISC
	@	200MG	A077855	002	Sep 27, 2007	Mar	DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1	GLAND PHARMA LTD	EQ 0.5% BASE	A208778	001	Mar 30, 2020	Mar	NEWA
AT1	MYLAN	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Mar	NEWA

TABLET;ORAL

AVELOX

+	@ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Apr	DISC
---	------------------	---------------	---------	-----	--------------	-----	------

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	!	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr	CHRS
----	---	--------------------	---------------	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CTEC
AB		TARO	EQ 2% BASE	A207116	001	Apr 27, 2020	Apr	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@ VINTAGE PHARMS LLC 250MG

A090111 001 Dec 22, 2009 Jun DISC

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB		CONCORD BIOTECH LTD	500MG	A212087	001	Jul 31, 2020	Jul	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

@ TEVA PHARMS USA 180MG

A202720 001 Oct 30, 2014 Mar DISC

@ 360MG

A202720 002 Oct 30, 2014 Mar DISC

NABILONE

CAPSULE;ORAL

CESAMET

+! BAUSCH 1MG

N018677 001 Dec 26, 1985 Mar CAHN

NABUMETONE

TABLET;ORAL

NABUMETONE

>D>	AB		IMPAX LABS INC	500MG	A075189	001	May 26, 2000	Sep	DISC
>A>		@		500MG	A075189	001	May 26, 2000	Sep	DISC
>D>	AB			750MG	A075189	002	Sep 24, 2001	Sep	DISC
>A>		@		750MG	A075189	002	Sep 24, 2001	Sep	DISC
	AB			750MG	A075189	002	Sep 24, 2001	Jul	CHRS
	AB	!	INVAGEN PHARMS	750MG	A078671	002	Mar 07, 2008	Jul	CHRS
	AB		LGM PHARMA	500MG	A203166	001	Aug 30, 2019	Aug	CAHN
	AB			750MG	A203166	002	Aug 30, 2019	Aug	CAHN
				1GM	A203166	003	Aug 30, 2019	Aug	CAHN

NADOLOL

TABLET;ORAL

CORGARD

AB	+	USWM	20MG	N018063	005	Oct 28, 1986	Jun	CAHN
AB	+		40MG	N018063	001		Jun	CAHN
AB	+!		80MG	N018063	002		Jun	CAHN
		@	120MG	N018063	003		Jun	CAHN
		@	160MG	N018063	004		Jun	CAHN

NADOLOL

@ VGYAAN 20MG

A212856 001 Sep 13, 2019 Mar DISC

@ 40MG

A212856 002 Sep 13, 2019 Mar DISC

@ 80MG

A212856 003 Sep 13, 2019 Mar DISC

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	PFIZER	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990	Jul	CAHN
--	----	--------	---------------------	---------	-----	--------------	-----	------

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

@ FRESENIUS EQ 1GM BASE/VIAL

A206682 001 Dec 10, 2019 Jul DISC

@ EQ 2GM BASE/VIAL

A206682 002 Dec 10, 2019 Jul DISC

AP			EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	May	NEWA
----	--	--	-------------------	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

>A>	AB	GENZUM	2.0%	A210038	001	Sep 22, 2020	Sep NEWA
-----	----	--------	------	---------	-----	--------------	----------

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

@ MYLAN LABS LTD 10MG/ML

A206506 001 Feb 06, 2019 Feb DISC

@ 10MG/ML

A207595 001 Jan 11, 2019 Feb DISC

@ 20MG/ML

A206506 002 Feb 06, 2019 Feb DISC

@ 20MG/ML

A207595 002 Jan 11, 2019 Feb DISC

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+ REDHILL EQ 12.5MG BASE

N204760 001 Sep 16, 2014 Jul CAHN

+! EQ 25MG BASE

N204760 002 Sep 16, 2014 Jul CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP DR REDDYS 1MG/ML

A213209 001 Mar 16, 2020 Mar NEWA

AP ! INTL MEDICATION 1MG/ML

A072076 001 Mar 24, 1988 Mar CTEC

@ PAR STERILE PRODUCTS 0.4MG/ML

A211286 001 Jan 17, 2020 Jul DISC

AP 0.4MG/ML

A211286 001 Jan 17, 2020 Jan NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO (AUTOINJECTOR)

>D> +! KALEO INC 2MG/0.4ML (2MG/0.4ML)

N209862 001 Oct 19, 2016 Sep DISC

>A> + @ 2MG/0.4ML (2MG/0.4ML)

N209862 001 Oct 19, 2016 Sep DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB CHARTWELL 50MG

A207905 001 Jul 21, 2017 Aug CAHN

NAPROXEN

SUSPENSION; ORAL

NAPROXEN

AB AMNEAL 25MG/ML

A212705 001 Jul 31, 2020 Jul NEWA

TABLET; ORAL

NAPROXEN

>D> @ FOSUN PHARMA 250MG

A074140 001 Dec 21, 1993 Sep CAHN

>D> @ 375MG

A074140 002 Dec 21, 1993 Sep CAHN

>D> @ 500MG

A074140 003 Dec 21, 1993 Sep CAHN

>A> @ GRANULES 250MG

A074140 001 Dec 21, 1993 Sep CAHN

>A> @ 375MG

A074140 002 Dec 21, 1993 Sep CAHN

>A> @ 500MG

A074140 003 Dec 21, 1993 Sep CAHN

@ MYLAN 250MG

A074121 001 Dec 21, 1993 Jan DISC

@ 375MG

A074121 002 Dec 21, 1993 Jan DISC

@ 500MG

A074121 003 Dec 21, 1993 Jan DISC

AB SCIEGEN PHARMS INC 250MG

A212517 001 Feb 21, 2020 Feb NEWA

AB 375MG

A212517 002 Feb 21, 2020 Feb NEWA

AB 500MG

A212517 003 Feb 21, 2020 Feb NEWA

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

>A> AB NUVO PHARMS INC 375MG

A091432 001 Sep 19, 2011 Sep CAHN

>A> AB 500MG

A091432 002 Sep 19, 2011 Sep CAHN

@ PLIVA 375MG

A075337 001 May 26, 1999 Mar DISC

@ 500MG

A075337 002 May 26, 1999 Mar DISC

>D> AB SUNRISE PHARM INC 375MG

A091432 001 Sep 19, 2011 Sep CAHN

>D> AB 500MG

A091432 002 Sep 19, 2011 Sep CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ TEVA EQ 250MG BASE

A074198 001 Dec 21, 1993 Mar DISC

@ EQ 500MG BASE

A074198 002 Dec 21, 1993 Mar DISC

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

	@ ALVOGEN	60MG	A205055	001	Dec 11, 2015	Mar	DISC
	@	120MG	A205055	002	Dec 11, 2015	Mar	DISC
>A>	AB	INDICUS PHARMA	60MG	A205544	001	Jun 18, 2018	Sep CAHN
>A>	AB		120MG	A205544	002	Jun 18, 2018	Sep CAHN
>D>	AB	WILSHIRE PHARMS INC	60MG	A205544	001	Jun 18, 2018	Sep CAHN
>D>	AB		120MG	A205544	002	Jun 18, 2018	Sep CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

>D>	@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Sep CAHN
>D>	@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Sep CAHN
>D>	@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Sep CAHN
>D>	@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Sep CAHN
>A>	@	ANI PHARMS INC	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Sep CAHN
>A>	@		EQ 5MG BASE	A203659	002	Apr 16, 2015	Sep CAHN
>A>	@		EQ 10MG BASE	A203659	003	Apr 16, 2015	Sep CAHN
>A>	@		EQ 20MG BASE	A203659	004	Apr 16, 2015	Sep CAHN

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

	@	BRECKENRIDGE	500MG	A065468	001	Mar 29, 2010	Apr DISC
	@	NOSTRUM LABS INC	500MG	A065468	001	Mar 29, 2010	Jul CAHN
AA		XGEN PHARMS	500MG	A065220	001	Jul 28, 2006	Feb CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Mar CMFD
AT		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A065106	001	Jan 31, 2006	Feb CAHN
AT			EQ 40MG BASE/ML; 200,000 UNITS/ML	A065108	001	Jan 31, 2006	Feb CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+	EXELA PHARMA	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Jul CAHN
AP	+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Jul CAHN

NEOSTIGMINE METHYLSULFATE

	+	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Aug CHRS
	+		3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Aug CRLD
	+		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Aug CHRS
	+		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Aug CRLD
	+		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Aug CHRS
	+		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Aug CRLD

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

	+	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017	Feb CAIN
--	---	------------------	---------------	---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

	@	MYLAN	500MG	A203742	001	Feb 22, 2019	Jan DISC
	@		750MG	A203742	002	Feb 22, 2019	Jan DISC
	@		1GM	A203742	003	Feb 22, 2019	Jan DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

		EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	Aug CTEC
	!		30MG	A074928	002	Mar 19, 1998	Aug CHRS
			30MG	A074928	002	Mar 19, 1998	Aug CTEC
	@	MYLAN	20MG	A074642	001	Jul 18, 1996	Aug DISC
	@		30MG	A074642	002	Jul 18, 1996	Aug DISC

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

	AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	May	CMFD
+	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Aug	CHRS
+		25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Aug	CRLD

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+	EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Aug	CHRS
+		20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Aug	CRLD
		20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	May	CMFD
+		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Aug	CHRS
+		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Aug	CRLD
		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	May	CMFD

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	ACELLA	10MG	A072781	001	Jul 30, 1993	Jul	CAHN
----	--------	------	---------	-----	--------------	-----	------

NIFURTIMOX

TABLET; ORAL

LAMPIT

+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020	Aug	NEWA
+		120MG	N213464	002	Aug 06, 2020	Aug	NEWA

NIMODIPINE

SOLUTION; ORAL

NYMALIZE

+	@ ARBOR PHARMS LLC	3MG/ML	N203340	001	May 10, 2013	Apr	DISC
+		3MG/ML	N203340	001	May 10, 2013	Apr	CPOT
+		6MG/ML	N203340	002	Apr 08, 2020	Apr	NEWA

NIRAPARIB TOSYLATE

CAPSULE; ORAL

ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Jan	CAHN
---	-----------------	---------------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

>D>	@ INVATECH	25MG	A074336	001	Jan 25, 1995	Sep	CAHN
>D>	@	50MG	A074336	002	Jan 25, 1995	Sep	CAHN
>D>	@	100MG	A074336	003	Jan 25, 1995	Sep	CAHN
>A>	@ PHARMGEN	25MG	A074336	001	Jan 25, 1995	Sep	CAHN
>A>	@	50MG	A074336	002	Jan 25, 1995	Sep	CAHN
>A>	@	100MG	A074336	003	Jan 25, 1995	Sep	CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITRO-DUR

BX	+	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
BX	+		0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
BX	+		0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
BX	+		0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC

TABLET; SUBLINGUAL

NITROGLYCERIN

	@ ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Mar	DISC
	@	0.4MG	A203693	002	Oct 16, 2017	Mar	DISC
	@	0.6MG	A203693	003	Oct 16, 2017	Mar	DISC

NITROSTAT

AB	+	UPJOHN	0.3MG	N021134	001	May 01, 2000	Jul	CAHN
AB	+		0.4MG	N021134	002	May 01, 2000	Jul	CAHN
AB	+		0.6MG	N021134	003	May 01, 2000	Jul	CAHN

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

	@ MYLAN PHARMS INC	150MG	A075806	001	Jul 05, 2002	May	DISC	
	@	300MG	A075806	002	Jul 05, 2002	May	DISC	
AB	!	WATSON LABS	300MG	A075616	002	Jul 09, 2002	May	CHRS

NORETHINDRONE

TABLET; ORAL-28		NOR-QD					
AB1	+! TEVA BRANDED PHARM	0.35MG		N017060	001		Jan CAHN
AB1	NAARI PTE LTD	0.35MG		A206807	001	Dec 13, 2016	Jun CAHN

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL		SPINRAZA					
	+! BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)		N209531	001	Dec 23, 2016	Jun CPOT

NYSTATIN

CREAM; TOPICAL		NYSTATIN					
	@ VINTAGE	100,000 UNITS/GM		A065315	001	May 31, 2006	Jul DISC
POWDER; TOPICAL		NYSTATIN					
AT	XGEN PHARMS	100,000 UNITS/GM		A065175	001	Dec 17, 2004	Feb CAHN
SUSPENSION; ORAL		NYSTATIN					
AA	SOCORRO	100,000 UNITS/ML		A062832	001	Dec 27, 1991	May CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	TORRENT	100,000 UNITS/GM; 0.1%		A213142	001	Jul 14, 2020	Jul NEWA
OINTMENT; TOPICAL		NYSTATIN AND TRIAMCINOLONE ACETONIDE					
AT	CADILA	100,000 UNITS/GM; 0.1%		A207764	001	Nov 08, 2018	Jun CAHN
	@ VITRUVIAS THERAP	100,000 UNITS/GM; 0.1%		A207316	001	Nov 18, 2019	May CPOT
	@	100000 UNITS/GM; 0.1%		A207316	001	Nov 18, 2019	May DISC
AT	ZYDUS PHARMS	100,000 UNITS/GM; 0.1%		A207764	001	Nov 08, 2018	Mar CMFD

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL		MYCAPSSA					
	+! CHIASMA	EQ 20MG BASE		N208232	001	Jun 26, 2020	Jun NEWA
INJECTABLE; INJECTION		OCTREOTIDE ACETATE					
	@ HERITAGE PHARMS INC	EQ 0.05MG BASE/ML		A204669	001	Dec 27, 2018	Feb DISC
	@	EQ 0.1MG BASE/ML		A204669	002	Dec 27, 2018	Feb DISC
	@	EQ 0.5MG BASE/ML		A204669	003	Dec 27, 2018	Feb DISC
SANDOSTATIN							
	+ @ NOVARTIS	EQ 0.2MG BASE/ML		N019667	004	Jun 12, 1991	May DISC
	+ @	EQ 1MG BASE/ML		N019667	005	Jun 12, 1991	May DISC
SOLUTION; SUBCUTANEOUS		BYNFEZIA PEN					
	+! SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)		N213224	001	Jan 28, 2020	Jan NEWA

OLANZAPINE

TABLET; ORAL		OLANZAPINE					
>D>	AB	HIKMA	2.5MG	A204866	001	Jun 16, 2017	Sep DISC
>A>		@	2.5MG	A204866	001	Jun 16, 2017	Sep DISC
>D>	AB		5MG	A204866	002	Jun 16, 2017	Sep DISC
>A>		@	5MG	A204866	002	Jun 16, 2017	Sep DISC
>D>	AB		7.5MG	A204866	003	Jun 16, 2017	Sep DISC
>A>		@	7.5MG	A204866	003	Jun 16, 2017	Sep DISC
>D>	AB		10MG	A204866	004	Jun 16, 2017	Sep DISC
>A>		@	10MG	A204866	004	Jun 16, 2017	Sep DISC
>D>	AB		15MG	A204866	005	Jun 16, 2017	Sep DISC
>A>		@	15MG	A204866	005	Jun 16, 2017	Sep DISC
>D>	AB		20MG	A204866	006	Jun 16, 2017	Sep DISC
>A>		@	20MG	A204866	006	Jun 16, 2017	Sep DISC
AB		INDOCO	2.5MG	A206155	001	Jul 31, 2020	Jul NEWA
AB			5MG	A206155	002	Jul 31, 2020	Jul NEWA
AB			7.5MG	A206155	003	Jul 31, 2020	Jul NEWA
AB			10MG	A206155	004	Jul 31, 2020	Jul NEWA

TABLET;ORAL
OLANZAPINE

AB		15MG	A206155	005	Jul 31, 2020	Jul	NEWA
AB		20MG	A206155	006	Jul 31, 2020	Jul	NEWA
	@ IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC
	@ JIANGSU HANSOH PHARM	2.5MG	A209399	001	Sep 24, 2018	May	DISC
	@	5MG	A209399	002	Sep 24, 2018	May	DISC
	@	10MG	A209399	003	Sep 24, 2018	May	DISC
	@ TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
	@	5MG	A076000	002	Oct 24, 2011	Jan	DISC
	@	7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
	@	10MG	A076000	004	Oct 24, 2011	Jan	DISC
	@	15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

	OLMESARTAN MEDOXOMIL						
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	NEWA
AB		20MG	A208659	002	May 18, 2020	May	NEWA
AB		40MG	A208659	003	May 18, 2020	May	NEWA
	@ JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
	@	20MG	A205482	002	Apr 24, 2017	Feb	DISC
	@	40MG	A205482	003	Apr 24, 2017	Feb	DISC
AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA
AB		20MG	A090237	002	Apr 13, 2020	Mar	NEWA
AB		40MG	A090237	003	Apr 13, 2020	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	@ CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC	
	@	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC	
>D>	AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Sep	DISC
>A>		@	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Sep	DISC
	@ WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC	
AT		EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG	
	PATADAY ONCE DAILY RELIEF							
	+! NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar	CTEC	
AT	+!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb	CFTG	

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	AKORN INC	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Aug	NEWA
AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020	Apr	NEWA
AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A212504	001	Aug 19, 2020	Aug	NEWA
AB	PURACAP PHARM LLC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210093	001	Jun 15, 2020	Jun	NEWA
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb	CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

	@ MYLAN	10MG	A205070	001	Jun 29, 2018	Feb	DISC
	@	20MG	A075876	002	May 29, 2003	Jan	DISC
	@	20MG	A205070	002	Jun 29, 2018	Feb	DISC
	@	40MG	A205070	003	Jun 29, 2018	Feb	DISC
	@ TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017	May	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Apr	NEWA
AB		40MG;1.1GM	A212587	002	Apr 30, 2020	Apr	NEWA

ONDANSETRON

FILM; ORAL

ZUPLENZ

>D>							
>D>							
>D>	+	FORTOVIA	4MG	N022524	001	Jul 02, 2010	Sep DISC
>A>	+	@	4MG	N022524	001	Jul 02, 2010	Sep DISC
	+		4MG	N022524	001	Jul 02, 2010	May CAHN
>D>	+	!	8MG	N022524	002	Jul 02, 2010	Sep DISC
>A>	+	@	8MG	N022524	002	Jul 02, 2010	Sep DISC
	+	!	8MG	N022524	002	Jul 02, 2010	May CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@ BARR

@

@ TEVA

@

	4MG	A076693	001	Jun 25, 2007	Mar	DISC
	8MG	A076693	002	Jun 25, 2007	Mar	DISC
	4MG	A076810	001	Jun 25, 2007	Mar	DISC
	8MG	A076810	002	Jun 25, 2007	Mar	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

@ EMCURE PHARMS

! GLAND PHARMA LTD

HOSPIRA

@

! QILU

	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010	May	DISC
AP	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012	Jun	CHRS
>D> AP	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Sep	DISC
>A>	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Sep	DISC
AP	EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Mar	CHRS

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN

@

@ PLIVA HRVATSKA DOO

@

@

	EQ 4MG BASE	A076930	001	Jun 25, 2007	Jan	DISC
	EQ 8MG BASE	A076930	002	Jun 25, 2007	Jan	DISC
	EQ 4MG BASE	A077112	001	Jun 25, 2007	Mar	DISC
	EQ 8MG BASE	A077112	002	Jun 25, 2007	Mar	DISC
	EQ 24MG BASE	A077112	003	Jun 25, 2007	Mar	DISC

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+ NEUROCRINE

+!

	25MG	N212489	001	Apr 24, 2020	Apr	NEWA
	50MG	N212489	002	Apr 24, 2020	Apr	NEWA

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB	MSN	EQ 30MG BASE	A212544	001	May 20, 2020	May	NEWA
AB		EQ 45MG BASE	A212544	002	May 20, 2020	May	NEWA
AB		EQ 75MG BASE	A212544	003	May 20, 2020	May	NEWA

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

AB	AJANTA PHARMA LTD	EQ 6MG BASE/ML	A212784	001	May 27, 2020	May	NEWA
----	-------------------	----------------	---------	-----	--------------	-----	------

OSILODROSTAT PHOSPHATE

TABLET; ORAL

ISTURISA

+ RECORDATI RARE

+

+!

	EQ 1MG BASE	N212801	001	Mar 06, 2020	Mar	NEWA
	EQ 5MG BASE	N212801	002	Mar 06, 2020	Mar	NEWA
	EQ 10MG BASE	N212801	003	Mar 06, 2020	Mar	NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A206199	001	Jul 27, 2020	Jul	NEWA

OXALIPLATININJECTABLE; INTRAVENOUS
OXALIPLATIN

	@ ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Aug	DISC
	@ FRESENIUS KABI USA	200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Aug	DISC
	@ GLAND PHARMA LTD	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Aug	DISC
!	QILU	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug	CMFD
@		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Aug	DISC

OXAPROZINTABLET; ORAL
DAYPRO

AB	+!	PFIZER	600MG	N018841	004	Oct 29, 1992	Jul	CAHN
		OXAPROZIN						
AB		CHARTWELL	600MG	A075987	001	Sep 02, 2004	Mar	CAHN
	@	IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002	Mar	DISC

OXAPROZIN POTASSIUMTABLET; ORAL
DAYPRO ALTA

@	PFIZER	600MG	N020776	001	Oct 17, 2002	Jul	CAHN
---	--------	-------	---------	-----	--------------	-----	------

OXAZEPAMCAPSULE; ORAL
OXAZEPAM

AB		FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Mar	CMFD
AB			15MG	A071026	003	Aug 10, 1987	Mar	CMFD
AB			30MG	A071026	001	Aug 10, 1987	Mar	CMFD

OXCARBAZEPINETABLET; ORAL
OXCARBAZEPINE

@	HIKMA	150MG	A077795	001	Oct 09, 2007	Feb	DISC
@		300MG	A077795	002	Oct 09, 2007	Feb	DISC
@		600MG	A077795	003	Oct 09, 2007	Feb	DISC

OXYBUTYNIN CHLORIDETABLET; ORAL
OXYBUTYNIN CHLORIDE

>D>	AB	ATHEM	5MG	A211062	001	Feb 06, 2019	Sep	CAHN
>A>	AB	EYWA	5MG	A211062	001	Feb 06, 2019	Sep	CAHN
	AB	LEADING PHARMA LLC	5MG	A212798	001	Apr 06, 2020	Mar	NEWA
	AB	RISING	5MG	A209025	001	Dec 21, 2017	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

@	IMPAX PHARMS	5MG	A076745	002	May 09, 2007	Jul	DISC
@		10MG	A076745	003	May 09, 2007	Jul	DISC
@		15MG	A076745	001	Nov 09, 2006	Jul	DISC
@	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan	DISC
@		15MG	A076644	002	May 10, 2007	Jan	DISC

OXYCODONE HYDROCHLORIDESOLUTION; ORAL
OXYCODONE HYDROCHLORIDE

@	ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan	DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan	NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan	NEWA
@	HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb	DISC
AA	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr	NEWA

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

@	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar	DISC
@		10MG	A077290	002	Dec 08, 2005	Mar	DISC
@		15MG	A077290	003	Dec 08, 2005	Mar	DISC
@		20MG	A077290	004	Dec 08, 2005	Mar	DISC
@		30MG	A077290	005	Dec 08, 2005	Mar	DISC

ROXYBOND

@	OHEMO LIFE	5MG	N209777	001	Apr 20, 2017	May	CAHN
@		15MG	N209777	002	Apr 20, 2017	May	CAHN
@		30MG	N209777	003	Apr 20, 2017	May	CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
UPNEEQ

+! RVL PHARMS 0.1% N212520 001 Jul 08, 2020 Jul NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar	DISC	
	@		7.5MG	A079046	001	Dec 13, 2010	Mar	DISC	
	@		10MG	A079046	004	Jul 11, 2013	Mar	DISC	
	@		15MG	A079046	002	Dec 13, 2010	Mar	DISC	
	@		20MG	A079046	005	Jul 11, 2013	Mar	DISC	
	@		30MG	A079046	006	Jul 11, 2013	Mar	DISC	
	@		40MG	A079046	007	Jul 11, 2013	Mar	DISC	
>D>	AB	HIKMA	5MG	A200822	002	Jul 15, 2013	Sep	DISC	
>A>		@	5MG	A200822	002	Jul 15, 2013	Sep	DISC	
>D>	AB		7.5MG	A200822	003	Jul 15, 2013	Sep	DISC	
>A>		@	7.5MG	A200822	003	Jul 15, 2013	Sep	DISC	
>D>	AB		10MG	A200822	004	Jul 15, 2013	Sep	DISC	
>A>		@	10MG	A200822	004	Jul 15, 2013	Sep	DISC	
>D>	AB		15MG	A200822	005	Jul 15, 2013	Sep	DISC	
>A>		@	15MG	A200822	005	Jul 15, 2013	Sep	DISC	
>D>	AB		20MG	A200822	006	Jul 15, 2013	Sep	DISC	
>A>		@	20MG	A200822	006	Jul 15, 2013	Sep	DISC	
>D>	AB		30MG	A200822	007	Jul 15, 2013	Sep	DISC	
>A>		@	30MG	A200822	007	Jul 15, 2013	Sep	DISC	
>D>	AB		40MG	A200822	001	Jul 15, 2013	Sep	DISC	
>A>		@	40MG	A200822	001	Jul 15, 2013	Sep	DISC	
>D>	AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Sep	CTEC	
>A>			5MG	A079087	001	Jun 14, 2010	Sep	CTEC	
>D>	AB		7.5MG	A079087	002	Dec 21, 2010	Sep	CTEC	
>A>			7.5MG	A079087	002	Dec 21, 2010	Sep	CTEC	
>D>	AB		10MG	A079087	003	Jun 14, 2010	Sep	CTEC	
>A>			10MG	A079087	003	Jun 14, 2010	Sep	CTEC	
>D>	AB		15MG	A079087	004	Dec 21, 2010	Sep	CTEC	
>A>			15MG	A079087	004	Dec 21, 2010	Sep	CTEC	
>D>	AB		20MG	A079087	005	Jun 14, 2010	Sep	CTEC	
>A>			20MG	A079087	005	Jun 14, 2010	Sep	CTEC	
>D>	AB		30MG	A079087	006	Jul 22, 2010	Sep	CTEC	
>A>			30MG	A079087	006	Jul 22, 2010	Sep	CTEC	
		@	SPECGX LLC	5MG	A202946	001	Jun 27, 2014	May	DISC
		@		7.5MG	A202946	002	Jun 27, 2014	May	DISC
		@		10MG	A202946	003	Jun 27, 2014	May	DISC
		@		15MG	A202946	004	Jun 27, 2014	May	DISC
		@		20MG	A202946	005	Jun 27, 2014	May	DISC
		@		30MG	A202946	006	Jun 27, 2014	May	DISC
		@		40MG	A202946	007	Jun 27, 2014	May	DISC

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL
ZEPOSIA

+	CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar	NEWA
+		0.46MG	N209899	002	Mar 25, 2020	Mar	NEWA
+!		0.92MG	N209899	003	Mar 25, 2020	Mar	NEWA

PACLITAXEL

INJECTABLE;INJECTION
PACLITAXEL

AP	MSN	6MG/ML	A213434	001	Aug 24, 2020	Aug	NEWA
----	-----	--------	---------	-----	--------------	-----	------

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	NEWA
----	--------------------	--	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM
@ TEVA PHARMS USA 30MG/10ML (3MG/ML)
@ 90MG/10ML (9MG/ML)

A076153 001 Mar 27, 2002 Mar DISC
A076153 002 Mar 27, 2002 Mar DISC

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB SUN PHARM EQ 40MG BASE
PROTONIX
AB +! WYETH PHARMS EQ 40MG BASE

A213725 001 Jun 30, 2020 Jun NFTG
N022020 001 Nov 14, 2007 Jun CFTG

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

@ MACLEODS PHARMS LTD EQ 20MG BASE
@ EQ 40MG BASE
@ TEVA EQ 20MG BASE
@ EQ 40MG BASE

A200821 001 Feb 16, 2012 May DISC
A200821 002 Feb 16, 2012 May DISC
A077056 001 Aug 02, 2007 May DISC
A077056 002 Aug 02, 2007 May DISC

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAROXETINE HYDROCHLORIDE

@ JUBILANT GENERICS EQ 10MG BASE
@ EQ 20MG BASE
@ EQ 30MG BASE
@ EQ 40MG BASE

A205528 001 Nov 27, 2015 Jan DISC
A205528 002 Nov 27, 2015 Jan DISC
A205528 003 Nov 27, 2015 Jan DISC
A205528 004 Nov 27, 2015 Jan DISC

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS
SIGNIFOR

+ RECORDATI RARE EQ 0.3MG BASE/ML (EQ 0.3MG
BASE/ML)
+ EQ 0.6MG BASE/ML (EQ 0.6MG
BASE/ML)
+! EQ 0.9MG BASE/ML (EQ 0.9MG
BASE/ML)

N200677 001 Dec 14, 2012 Feb CAHN
N200677 002 Dec 14, 2012 Feb CAHN
N200677 003 Dec 14, 2012 Feb CAHN

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR
SIGNIFOR LAR KIT

+ RECORDATI RARE EQ 10MG BASE/VIAL
+ EQ 20MG BASE/VIAL
+ EQ 30MG BASE/VIAL
+ EQ 40MG BASE/VIAL
+! EQ 60MG BASE/VIAL

N203255 004 Jun 29, 2018 Feb CAHN
N203255 001 Dec 15, 2014 Feb CAHN
N203255 005 Jun 29, 2018 Feb CAHN
N203255 002 Dec 15, 2014 Feb CAHN
N203255 003 Dec 15, 2014 Feb CAHN

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL
VOTRIENT

+ @ NOVARTIS EQ 400MG BASE

N022465 002 Oct 19, 2009 Jan CRLD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL
MACUGEN

+ @ VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML

N021756 001 Dec 17, 2004 Aug DISC

PEMETREXED

SOLUTION; INTRAVENOUS
PEMETREXED

+! ACTAVIS LLC 100MG/4ML (25MG/ML)
+! 500MG/20ML (25MG/ML)
+! 1GM/40ML (25MG/ML)
PEMFEXY
+! EAGLE PHARMS 500MG/20ML (25MG/ML)

N208419 001 Aug 21, 2020 Aug NEWA
N208419 002 Aug 21, 2020 Aug NEWA
N208419 003 Aug 21, 2020 Aug NEWA
N209472 001 Feb 08, 2020 Feb NEWA

PEMIGATINIB

TABLET; ORAL
PEMAZYRE

+ INCYTE CORP 4.5MG
+ 9MG
+! 13.5MG

N213736 001 Apr 17, 2020 Apr NEWA
N213736 002 Apr 17, 2020 Apr NEWA
N213736 003 Apr 17, 2020 Apr NEWA

PENICILLAMINE

CAPSULE;ORAL

PENICILLAMINE

AB	ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan	CAHN
AB	APOTEX	250MG	A213310	001	Apr 28, 2020	Apr	NEWA
AB	DR REDDYS	250MG	A211867	001	Aug 04, 2020	Jul	NEWA

TABLET;ORAL

PENICILLAMINE

	@ TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Aug	DISC
AB		250MG	A211497	001	Feb 13, 2020	Feb	NEWA

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

>A>	+ @ HAMELN	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Sep	DISC
>A>	+ @	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Sep	DISC
>D>	+! HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Sep	DISC

>D> PENTETATE ZINC TRISODIUM

>D> SOLUTION;INHALATION, INTRAVENOUS

>D> PENTETATE ZINC TRISODIUM

>D>	+! HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Sep	DISC
>A>	+ @	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Sep	DISC

PERMETHRIN

CREAM;TOPICAL

ELIMITE

	+ @ MYLAN	5%	N019855	001	Aug 25, 1989	Feb	DISC
AB	! PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb	CHRS

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB	ZYDUS PHARMS	2MG	A205232	001	Apr 06, 2020	Mar	NEWA
AB		4MG	A205232	002	Apr 06, 2020	Mar	NEWA
AB		8MG	A205232	003	Apr 06, 2020	Mar	NEWA
AB		16MG	A205232	004	Apr 06, 2020	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

AA	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017	Mar	CAHN
AA		35MG	A203600	001	Dec 27, 2017	Mar	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

AB	+ CONCORDIA	10MG	N008708	001		Jun	CMFD
----	-------------	------	---------	-----	--	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR 15MG

@ 30MG

A090591	001	Mar 18, 2010	Mar	DISC
A090591	002	Mar 18, 2010	Mar	DISC

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

@ BARR 37.5MG

A090470	001	Aug 31, 2009	Mar	DISC
---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Jun	NEWA
AP1	APOLLO	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jul	NEWA
AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jul	NEWA
AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jul	NEWA
AP1	CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jun	NEWA
AP1		50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jun	NEWA
AP1		100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jun	NEWA

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A211920	001	Jun 05, 2020	Jun NEWA
AP1			100MG/10ML (10MG/ML)	A211920	002	Jun 05, 2020	Jun NEWA
AP1		RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan NEWA
AP1			50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan NEWA
AP1			100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan NEWA
AP1		SAGENT PHARMS INC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jun CAHN
AP1			50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jun CAHN
AP1			100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jun CAHN
VAZCULEP							
AP1	+	EXELA PHARMA	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jul CAHN
AP1	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jul CAHN
AP1	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jul CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	PHARM ASSOC	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jun CAHN
----	---	-------------	--------------------	---------	-----	--------------	----------

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+	UPJOHN	125MG/5ML	N008762	001		Jul CAHN
		DILANTIN-30					
	@	UPJOHN	30MG/5ML	N008762	002		Jul CAHN

TABLET, CHEWABLE;ORAL

DILANTIN

AB	!	PHARMACIA	50MG	A084427	001		Aug CAHN
AB	!	UPJOHN	50MG	A084427	001		Jul CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	!	UPJOHN	30MG EXTENDED	A084349	001		Jul CAHN
AB	!		100MG EXTENDED	A084349	002		Jul CAHN
		EXTENDED PHENYTOIN SODIUM					
	@	LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Apr DISC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

>A>	AT	AMNEAL	1%	A214193	001	Sep 21, 2020	Sep NEWA
>A>	AT		2%	A214193	002	Sep 21, 2020	Sep NEWA
>A>	AT		4%	A214193	003	Sep 21, 2020	Sep NEWA

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Mar CMFD
	@		5MG	A212377	001	Aug 13, 2019	Feb DISC
AB			7.5MG	A212377	002	Aug 13, 2019	Mar CMFD
	@		7.5MG	A212377	002	Aug 13, 2019	Feb DISC
>D>	AB	INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep CAHN
>D>	AB		7.5MG	A076963	002	Feb 27, 2007	Sep CAHN
>A>	AB	MLV	5MG	A076963	001	Dec 22, 2004	Sep CAHN
>A>	AB		7.5MG	A076963	002	Feb 27, 2007	Sep CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

	@	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan DISC
	@		EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan DISC
	@		EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan DISC
AB		NOSTRUM LABS INC	EQ 15MG BASE	A078472	001	Feb 13, 2013	Jul CAHN
AB			EQ 30MG BASE	A078472	002	Feb 13, 2013	Jul CAHN
AB			EQ 45MG BASE	A078472	003	Feb 13, 2013	Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr CMFD
AP			EQ 3GM BASE/VIAL;EQ 375MG	A212287	002	Jul 29, 2019	Apr CMFD

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		BASE/VIAL EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr	CMFD
----	--	--	---------	-----	--------------	-----	------

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar	CAHN
AB		20MG	A206136	002	Jun 20, 2017	Mar	CAHN

PODOFILOX

SOLUTION; TOPICAL
CONDYLOX

AT	+! TEVA BRANDED PHARM	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN
----	-----------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	NOSTRUM LABS INC	420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT	A202060	001	Mar 08, 2017	Jul	CAHN
----	------------------	---	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
AEROSPORIN

	@ GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036	001		Jan	CMS1
	@ MYLAN ASI	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Aug	DISC
AP	XGEN PHARMS	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN

POSACONAZOLE

SUSPENSION; ORAL
NOXAFIL

AB	+! SCHERING	40MG/ML	N022003	001	Sep 15, 2006	May	CFTG
AB	HIKMA	40MG/ML	A208773	001	May 15, 2020	May	NFTG

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K

	+ @ NESHER PHARMS	8MEQ	N018238	001		May	DISC
	+ @ NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	May	DISC
AB	STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Mar	CAHN
AB		10MEQ	A205549	002	Dec 08, 2015	Mar	CAHN

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ

AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Aug	NEWA
AP		746MG/100ML	A211087	002	Sep 09, 2020	Aug	NEWA
AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Aug	NEWA
AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB1	AMNEAL	10MEQ	A212861	001	May 08, 2020	Apr	NEWA
	@	15MEQ	A212861	002	May 08, 2020	Aug	DISC
AB1		15MEQ	A212861	002	May 08, 2020	Apr	NEWA
AB1		20MEQ	A212861	003	May 08, 2020	Apr	NEWA
>D>	AB1 CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Sep	CAHN
	AB1	10MEQ	A213588	001	Aug 21, 2020	Aug	NEWA
>D>	AB1	20MEQ	A213588	002	Aug 21, 2020	Sep	CAHN
	AB1	20MEQ	A213588	002	Aug 21, 2020	Aug	NEWA
	AB2 GRANULES PHARMS	8MEQ	A211797	001	Mar 04, 2020	Feb	NEWA
	AB2	10MEQ	A211797	002	Mar 04, 2020	Feb	NEWA
	@ STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019	Feb	CAHN
	@	10MEQ	A206630	001	Mar 29, 2019	Aug	CAHN
	@	10MEQ	A206881	002	Jan 22, 2019	Feb	CAHN
	@	10MEQ	A210097	001	Jun 17, 2019	Feb	CAHN
	@	15MEQ	A206630	002	Mar 29, 2019	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	@	20MEQ	A206630	003	Mar 29, 2019	Aug	CAHN	
	@	20MEQ	A210098	001	Apr 26, 2019	Feb	CAHN	
>A>	AB1	UNICHEM	10MEQ	A213588	001	Aug 21, 2020	Sep	CAHN
>A>	AB1		20MEQ	A213588	002	Aug 21, 2020	Sep	CAHN
>A>	AB1	ZYDUS PHARMS	10MEQ	A210395	001	Sep 17, 2020	Sep	NEWA
>A>	AB1		20MEQ	A210395	002	Sep 17, 2020	Sep	NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

>A>	AP	FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Sep	NEWA
>A>	AP	FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Sep	NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Jun	NEWA
AB			15MEQ	A212799	002	Jun 29, 2020	Jun	NEWA
AB		RISING	5MEQ	A077440	001	Jun 09, 2006	Apr	CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Apr	CAHN

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE (AUTOINJECTOR)

	+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun	CTNA
>D>	+!	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983	Jun	CDFR
>A>	+!		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Sep	DISC
>A>	+ @		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Sep	DISC
	+!		600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983	Jun	CPOT

>A> PRALSETINIB

CAPSULE; ORAL

GAVRETO

>A>	+!	BLUEPRINT MEDICINES	100MG	N213721	001	Sep 04, 2020	Sep	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GRAVITI PHARMS	0.25MG	A211088	001	Oct 03, 2018	May	CAHN
AB			0.5MG	A211088	002	Oct 03, 2018	May	CAHN
AB			0.75MG	A211088	003	Oct 03, 2018	May	CAHN
AB			1MG	A211088	004	Oct 03, 2018	May	CAHN
AB			1.5MG	A211088	005	Oct 03, 2018	May	CAHN
	@	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	Apr	DISC
	@		0.25MG	A077724	002	Feb 19, 2008	Apr	DISC
	@		0.5MG	A077724	003	Feb 19, 2008	Apr	DISC
	@		1MG	A077724	004	Feb 19, 2008	Apr	DISC
	@		1.5MG	A077724	005	Feb 19, 2008	Apr	DISC
	@	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012	Jun	DISC
	@		0.25MG	A202164	002	Sep 20, 2012	Jun	DISC
	@		0.5MG	A202164	003	Sep 20, 2012	Jun	DISC
	@		1MG	A202164	004	Sep 20, 2012	Jun	DISC
	@		1.5MG	A202164	005	Sep 20, 2012	Jun	DISC
	@	MYLAN	0.125MG	A077854	001	Oct 08, 2010	Jan	DISC
	@		0.25MG	A077854	002	Oct 08, 2010	Jan	DISC
	@		0.5MG	A077854	003	Oct 08, 2010	Jan	DISC
	@		0.75MG	A090764	001	Apr 09, 2010	Jan	DISC
	@		1MG	A077854	004	Oct 08, 2010	Jan	DISC
	@		1.5MG	A077854	005	Oct 08, 2010	Jan	DISC
AB		RISING	0.25MG	A211088	001	Oct 03, 2018	Aug	CAHN
AB			0.5MG	A211088	002	Oct 03, 2018	Aug	CAHN
AB			0.75MG	A211088	003	Oct 03, 2018	Aug	CAHN
AB			1MG	A211088	004	Oct 03, 2018	Aug	CAHN
AB			1.5MG	A211088	005	Oct 03, 2018	Aug	CAHN
AB		ZENNOVA	0.125MG	A090151	001	Apr 30, 2012	Feb	CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Feb	CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Feb	CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Feb	CAHN

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		1MG	A090151	004	Apr 30, 2012	Feb	CAHN
AB		1.5MG	A090151	005	Apr 30, 2012	Feb	CAHN

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016	Jun	CAHN
----	-----------	-------	---------	-----	--------------	-----	------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

>A>	AB	ANDA REPOSITORY	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep	CAHN
>A>	AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep	CAHN
	AB	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jul	NEWA
	AB		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jul	NEWA
>D>	AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep	CAHN
>D>	AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>D>	AB	APPCO	10MG	A209869	001	Apr 13, 2018	Sep	CAHN
	AB		10MG	A209869	001	Apr 13, 2018	Jul	CAHN
>D>	AB		20MG	A209869	002	Apr 13, 2018	Sep	CAHN
	AB		20MG	A209869	002	Apr 13, 2018	Jul	CAHN
>D>	AB		40MG	A209869	003	Apr 13, 2018	Sep	CAHN
	AB		40MG	A209869	003	Apr 13, 2018	Jul	CAHN
>D>	AB		80MG	A209869	004	Apr 13, 2018	Sep	CAHN
	AB		80MG	A209869	004	Apr 13, 2018	Jul	CAHN
>A>	AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Sep	CAHN
>A>	AB		20MG	A209869	002	Apr 13, 2018	Sep	CAHN
>A>	AB		40MG	A209869	003	Apr 13, 2018	Sep	CAHN
>A>	AB		80MG	A209869	004	Apr 13, 2018	Sep	CAHN
>D>	AB	ZYDUS PHARMS USA	10MG	A077751	001	Apr 30, 2008	Sep	DISC
>A>		@	10MG	A077751	001	Apr 30, 2008	Sep	DISC

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

+	@	VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993	Apr	DISC
---	---	-----------------	------	---------	-----	--------------	-----	------

PREDNICARBATE

@ FOUGERA PHARMS

			0.1%	A077287	001	Sep 19, 2006	Apr	DISC
--	--	--	------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

DERMATOP

+	@	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb	DISC
---	---	----------------------	------	---------	-----	--------------	-----	------

PREDNICARBATE

!		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb	CTEC
---	--	----------------	------	---------	-----	--------------	-----	------

AB	!		0.1%	A077236	001	Mar 09, 2007	Feb	CHRS
----	---	--	------	---------	-----	--------------	-----	------

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

AB	+!	NOVARTIS	1%	N017469	001		Jan	CHRS
----	----	----------	----	---------	-----	--	-----	------

AB	+		1%	N017469	001		Jan	CRLD
----	---	--	----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

PHARM ASSOC

@ VINTAGE

		EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb	NEWA
--	--	------------------	---------	-----	--------------	-----	------

		EQ 15MG BASE/5ML	A079010	001	May 26, 2009	Jun	DISC
--	--	------------------	---------	-----	--------------	-----	------

PREDNISONE

TABLET;ORAL

PREDNISONE

@ AMNEAL

		1MG	A213385	001	Jun 16, 2020	Aug	DISC
--	--	-----	---------	-----	--------------	-----	------

AB		1MG	A213385	001	Jun 16, 2020	Jun	NEWA
----	--	-----	---------	-----	--------------	-----	------

	@	5MG	A213385	002	Jun 16, 2020	Aug	DISC
--	---	-----	---------	-----	--------------	-----	------

AB		5MG	A213385	002	Jun 16, 2020	Jun	NEWA
----	--	-----	---------	-----	--------------	-----	------

	@	10MG	A213386	001	Jun 24, 2020	Aug	DISC
--	---	------	---------	-----	--------------	-----	------

AB		10MG	A213386	001	Jun 24, 2020	Jun	NEWA
----	--	------	---------	-----	--------------	-----	------

TABLET;ORAL
PREDNISONE

	@	20MG	A213386	002	Jun 24, 2020	Aug	DISC	
AB		20MG	A213386	002	Jun 24, 2020	Jun	NEWA	
>D>	AB	HIKMA PHARMS	50MG	A088465	001	Jun 01, 1984	Sep	DISC
>A>	@	50MG	A088465	001	Jun 01, 1984	Sep	DISC	
AB		STRIDES PHARMA	1MG	A210785	001	Sep 02, 2020	Aug	NEWA
TABLET, DELAYED RELEASE;ORAL								
PREDNISONE								
	@	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr	DISC
	@		2MG	A204867	002	Apr 25, 2017	Apr	DISC
	@		5MG	A204867	003	Apr 25, 2017	Apr	DISC
RAYOS								
	+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr	CTEC
	+		2MG	N202020	002	Jul 26, 2012	Apr	CTEC
	+		5MG	N202020	003	Jul 26, 2012	Apr	CTEC

PREGABALIN

CAPSULE;ORAL
LYRICA

AB	+	PFIZER	25MG	N021446	001	Dec 30, 2004	Jun	CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Jun	CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Jun	CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Jun	CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Jun	CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Jun	CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Jun	CAHN
AB	+		300MG	N021446	008	Dec 30, 2004	Jun	CAHN

PREGABALIN

AB		ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Jul	NEWA
AB			50MG	A091025	002	Jul 09, 2020	Jul	NEWA
AB			75MG	A091025	003	Jul 09, 2020	Jul	NEWA
AB			100MG	A091025	004	Jul 09, 2020	Jul	NEWA
AB			150MG	A091025	005	Jul 09, 2020	Jul	NEWA
AB			200MG	A091025	006	Jul 09, 2020	Jul	NEWA
AB			225MG	A091025	007	Jul 09, 2020	Jul	NEWA
AB			300MG	A091025	008	Jul 09, 2020	Jul	NEWA
AB		CELLTRION	50MG	A212865	001	Mar 20, 2020	Mar	NEWA
AB			75MG	A212865	002	Mar 20, 2020	Mar	NEWA
AB			100MG	A212865	003	Mar 20, 2020	Mar	NEWA
AB			150MG	A212865	004	Mar 20, 2020	Mar	NEWA
AB		HIKAL	25MG	A213423	001	Mar 23, 2020	Mar	NEWA
AB			50MG	A213423	002	Mar 23, 2020	Mar	NEWA
AB			75MG	A213423	003	Mar 23, 2020	Mar	NEWA
AB			100MG	A213423	004	Mar 23, 2020	Mar	NEWA
AB			150MG	A213423	005	Mar 23, 2020	Mar	NEWA
AB			200MG	A213423	006	Mar 23, 2020	Mar	NEWA
AB			225MG	A213423	007	Mar 23, 2020	Mar	NEWA
AB			300MG	A213423	008	Mar 23, 2020	Mar	NEWA
	@	MYLAN	25MG	A091228	001	Sep 20, 2019	Feb	DISC
	@		50MG	A091228	002	Sep 20, 2019	Feb	DISC
	@		75MG	A091228	003	Sep 20, 2019	Feb	DISC
	@		100MG	A091228	004	Sep 20, 2019	Feb	DISC
	@		150MG	A091228	005	Sep 20, 2019	Feb	DISC
	@		200MG	A091228	006	Sep 20, 2019	Feb	DISC
	@		225MG	A091228	007	Sep 20, 2019	Feb	DISC
	@		300MG	A091228	008	Sep 20, 2019	Feb	DISC

SOLUTION;ORAL

LYRICA

AA	+	PFIZER	20MG/ML	N022488	001	Jan 04, 2010	Jun	CAHN
----	---	--------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

	+	PFIZER	82.5MG	N209501	001	Oct 11, 2017	Jun	CAHN
	+		165MG	N209501	002	Oct 11, 2017	Jun	CAHN
	+		330MG	N209501	003	Oct 11, 2017	Jun	CAHN

PRIMIDONE

SUSPENSION;ORAL
MYSOLINE

	+	@ NURO PHARMA	250MG/5ML	N010401	001		Aug	CRLD
--	---	---------------	-----------	---------	-----	--	-----	------

TABLET; ORAL
 PRIMIDONE
 >D> AB HIKMA INTL PHARMS 250MG A040667 002 Jul 27, 2006 Sep DISC
 >A> @ 250MG A040667 002 Jul 27, 2006 Sep DISC

PROCHLORPERAZINE MALEATE

TABLET; ORAL
 COMPAZINE
 + @ GLAXOSMITHKLINE EQ 5MG BASE N010571 001 Mar CRLD
 + @ EQ 10MG BASE N010571 002 Mar CRLD
 + @ EQ 25MG BASE N010571 003 Mar CRLD
 PROCHLORPERAZINE MALEATE
 @ SANDOZ EQ 5MG BASE A040101 001 Jul 19, 1996 Mar DISC
 @ EQ 10MG BASE A040101 002 Jul 19, 1996 Mar DISC
 PROCOMP
 AB ! JUBILANT CADISTA EQ 10MG BASE A040268 002 Feb 27, 1998 Mar CHRS

PROGESTERONE

>D> SYSTEM; VAGINAL
 >D> MILPROSA
 >D> +! FERRING PHARMS INC 1.78GM N201110 001 Apr 29, 2020 Sep DISC
 >A> + @ 1.78GM N201110 001 Apr 29, 2020 Sep DISC
 +! 1.78GM N201110 001 Apr 29, 2020 Apr NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
 PROMETHAZINE HYDROCHLORIDE
 AP XGEN PHARMS 25MG/ML A040737 001 Apr 24, 2008 Feb CAHN
 AP 50MG/ML A040737 002 Apr 24, 2008 Feb CAHN
 SUPPOSITORY; RECTAL
 PROMETHAZINE HYDROCHLORIDE
 @ WATSON LABS INC 12.5MG A040479 001 Jun 24, 2003 Mar DISC
 @ 25MG A040479 002 Jun 24, 2003 Mar DISC
 SYRUP; ORAL
 PROMETHAZINE HYDROCHLORIDE
 @ PHARM ASSOC 6.25MG/5ML A040643 001 Apr 26, 2006 Jun CAHN
 @ VINTAGE 6.25MG/5ML A040643 001 Apr 26, 2006 Jun DISC

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 PROPAFENONE HYDROCHLORIDE
 AB TWI PHARMS 225MG A212928 001 Jun 18, 2020 Jun NEWA
 AB 325MG A212928 002 Jun 18, 2020 Jun NEWA
 AB 425MG A212928 003 Jun 18, 2020 Jun NEWA
 AB UPSHER SMITH LABS 225MG A212744 001 Jun 25, 2020 Jun NEWA
 AB 325MG A212744 002 Jun 25, 2020 Jun NEWA
 AB 425MG A212744 003 Jun 25, 2020 Jun NEWA

PROPOFOL

INJECTABLE; INJECTION
 PROPOFOL
 >A> AB INNOPHARMA 10MG/ML A205576 001 Sep 16, 2020 Sep NEWA
 AB WEST-WARD PHARMS INT 10MG/ML A074848 001 Apr 19, 2005 Jul CMFD

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
 PROPRANOLOL HYDROCHLORIDE
 @ IMPAX LABS INC 10MG A071972 001 Apr 06, 1988 Jul DISC
 @ 20MG A071972 002 Apr 06, 1988 Jul DISC
 @ 40MG A071972 003 Apr 06, 1988 Jul DISC
 >D> AB ! 80MG A071976 001 Apr 06, 1988 Sep DISC
 >A> @ 80MG A071976 001 Apr 06, 1988 Sep DISC
 >D> AB WATSON LABS 80MG A070178 001 May 13, 1986 Sep CHRS
 >A> AB ! 80MG A070178 001 May 13, 1986 Sep CHRS

PYRAZINAMIDE

TABLET; ORAL
 PYRAZINAMIDE
 AB ! AKORN 500MG A081319 001 Jun 30, 1992 Jul CTEC
 ! 500MG A081319 001 Jun 30, 1992 Feb CHRS
 500MG A081319 001 Jun 30, 1992 Feb CTEC
 @ DAVA PHARMS INC 500MG A080157 001 Feb DISC

TABLET;ORAL

PYRAZINAMIDE

AB		MACLEODS PHARMS LTD	500MG	A212541	001	Jul 27, 2020	Jul NEWA
	@	NOVITIUM PHARMA	500MG	A080157	001		Jul CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

>A>	AA	ELYSIUM	60MG/5ML	A208797	001	Jan 09, 2020	Sep CAHN
>D>	AA	INVATECH	60MG/5ML	A208797	001	Jan 09, 2020	Sep CAHN

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

>D>		ELYSIUM	30MG	A211181	002	May 14, 2019	Sep CAHN
>D>	AB		60MG	A211181	001	Jul 20, 2018	Sep CAHN
>A>		EYWA	30MG	A211181	002	May 14, 2019	Sep CAHN
>A>	AB		60MG	A211181	001	Jul 20, 2018	Sep CAHN

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

AB	+	VYERA PHARMS LLC	25MG	N008578	001		Feb CFTG
AB		CEROVENE INC	25MG	A207127	001	Feb 28, 2020	Feb NFTG

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012	Feb CAHN
AB			EQ 50MG BASE	A090960	002	Mar 27, 2012	Feb CAHN
AB			EQ 100MG BASE	A090960	003	Mar 27, 2012	Feb CAHN
AB			EQ 200MG BASE	A090960	004	Mar 27, 2012	Feb CAHN
AB			EQ 300MG BASE	A090960	005	Mar 27, 2012	Feb CAHN
AB			EQ 400MG BASE	A090960	006	Mar 27, 2012	Feb CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ MYLAN

@

@

@

		EQ 5MG BASE	A076694	001	Dec 23, 2004	Mar DISC
		EQ 10MG BASE	A076694	002	Dec 23, 2004	Mar DISC
		EQ 20MG BASE	A076694	003	Dec 23, 2004	Mar DISC
		EQ 40MG BASE	A076694	004	Dec 23, 2004	Mar DISC

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

! SANDOZ

!

@ WATSON LABS

@

		200MG	A088072	002		May CHRS
		200MG	A088072	002		May CTEC
		300MG	A088072	001	Sep 26, 1983	Apr CHRS
		300MG	A088072	001	Sep 26, 1983	Apr CTEC
		200MG	A083288	001		Apr DISC
		300MG	A085583	001		Apr DISC

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		CADILA PHARMS LTD	60MG	A211324	001	Aug 18, 2020	Aug NEWA
----	--	-------------------	------	---------	-----	--------------	----------

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		GRANULES PHARMS	8MG	A213186	001	Aug 21, 2020	Aug NEWA
AB		I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ TEVA PHARMS

@

@

@

		1.25MG	A077470	001	Jun 18, 2008	Mar DISC
		2.5MG	A077470	002	Jun 18, 2008	Mar DISC
		5MG	A077470	003	Jun 18, 2008	Mar DISC
		10MG	A077470	004	Jun 18, 2008	Mar DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

	@ AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018	Jun	DISC
	@	EQ 300MG BASE	A209859	002	Sep 27, 2018	Jun	DISC
	@ APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019	May	DISC
	@	EQ 300MG BASE	A211893	002	Apr 05, 2019	May	DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@ AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008	Apr	DISC
	@ HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	May	DISC
AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Jul	CAHN
	@ TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011	May	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006	Jan	DISC	
	@	EQ 300MG BASE	A077824	002	Oct 13, 2006	Jan	DISC	
	@ HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Apr	DISC	
	@	EQ 300MG BASE	A075165	002	Sep 30, 1998	Apr	DISC	
>D>	AB	NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017	Sep	DISC
>A>		@	EQ 150MG BASE	A203694	001	Nov 30, 2017	Sep	DISC
	AB		EQ 150MG BASE	A203694	001	Nov 30, 2017	Jul	CAHN
>D>	AB		EQ 300MG BASE	A203694	002	Nov 30, 2017	Sep	DISC
>A>		@	EQ 300MG BASE	A203694	002	Nov 30, 2017	Sep	DISC
	AB		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jul	CAHN
	@ STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Apr	DISC	
	@	EQ 150MG BASE	A210010	001	Aug 01, 2018	Jan	DISC	
	@	EQ 300MG BASE	A205512	002	Aug 22, 2016	Apr	DISC	
AB	!	EQ 300MG BASE	A205512	002	Aug 22, 2016	Jan	CHRS	
	@	EQ 300MG BASE	A210010	002	Aug 01, 2018	Jan	DISC	

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		ANI PHARMS INC	500MG	A210482	001	Oct 29, 2019	Jan	CAHN
AB			1GM	A210482	002	Oct 29, 2019	Jan	CAHN
		@ CIPLA	500MG	A211291	001	May 28, 2019	Jul	DISC
		@	1GM	A211291	002	May 28, 2019	Jul	DISC
AB		MANKIND PHARMA	500MG	A212284	001	Feb 12, 2020	Jan	NEWA
AB			1GM	A212284	002	Feb 12, 2020	Jan	NEWA
AB		MICRO LABS	500MG	A211745	001	Feb 27, 2020	Feb	NEWA
AB			1GM	A211745	002	Feb 27, 2020	Feb	NEWA
>D>	AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Sep	DISC
>A>		@	500MG	A212781	001	Mar 23, 2020	Sep	DISC
	AB		500MG	A212781	001	Mar 23, 2020	Mar	NEWA
>D>	AB		1GM	A212781	002	Mar 23, 2020	Sep	DISC
>A>		@	1GM	A212781	002	Mar 23, 2020	Sep	DISC
	AB		1GM	A212781	002	Mar 23, 2020	Mar	NEWA
AB		SUNSHINE	500MG	A211865	001	Mar 23, 2020	Mar	NEWA
AB			1GM	A211865	002	Mar 23, 2020	Mar	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

	@ WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Mar	DISC
	@	EQ 1MG BASE	A201823	002	Jul 01, 2013	Mar	DISC

REMIMAZOLAM BESYLATE

POWDER; INTRAVENOUS

BYFAVO

+	!	ACACIA	EQ 20MG BASE/VIAL	N212295	001	Jul 02, 2020	Jul	CAHN
+	!	COSMO	EQ 20MG BASE/VIAL	N212295	001	Jul 02, 2020	Jul	NEWA

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

	@ ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Mar	DISC
	@	1MG	A090008	002	Jan 22, 2014	Mar	DISC
	@	2MG	A090008	003	Jan 22, 2014	Mar	DISC

RIBAVIRIN

CAPSULE; ORAL

RIBAVIRIN

@ TEVA	200MG	A076277	001	Oct 04, 2004	Mar	DISC
--------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

RIBAVIRIN

@ BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	DISC
@	400MG	A202546	002	Aug 12, 2014	Feb	DISC
@	500MG	A202546	003	Aug 12, 2014	Feb	DISC
@	600MG	A202546	004	Aug 12, 2014	Feb	DISC
@ ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb	DISC
@	500MG	A077094	004	Apr 18, 2008	Feb	DISC
@	600MG	A077094	003	Mar 16, 2007	Feb	DISC

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

@ EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	May	DISC
---------------------	------------	---------	-----	--------------	-----	------

RILUZOLE

TABLET; ORAL

RILUZOLE

AB	KENTON	50MG	A206045	001	Dec 09, 2019	Mar	CAHN
----	--------	------	---------	-----	--------------	-----	------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL

NURTEC ODT

+	BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb	NEWA
---	----------------	--------------	---------	-----	--------------	-----	------

RIPRETINIB

TABLET; ORAL

QINLOCK

+	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020	May	NEWA
---	------------------	------	---------	-----	--------------	-----	------

RISDIPLAM

FOR SOLUTION; ORAL

EVRYSDI

+	GENENTECH INC	0.75MG/ML	N213535	001	Aug 07, 2020	Aug	NEWA
---	---------------	-----------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

>D>	AB	@ MYLAN	0.25MG	A076288	001	Sep 15, 2008	Jun	DISC
>A>		@	0.5MG	A076288	002	Sep 15, 2008	Sep	DISC
>D>	AB	@	0.5MG	A076288	002	Sep 15, 2008	Sep	DISC
>D>	AB		1MG	A076288	003	Sep 15, 2008	Sep	DISC
>A>		@	1MG	A076288	003	Sep 15, 2008	Sep	DISC
>D>	AB		2MG	A076288	004	Sep 15, 2008	Sep	DISC
>A>		@	2MG	A076288	004	Sep 15, 2008	Sep	DISC
>D>	AB		3MG	A076288	005	Sep 15, 2008	Sep	DISC
>A>		@	3MG	A076288	005	Sep 15, 2008	Sep	DISC
>D>	AB		4MG	A076288	006	Sep 15, 2008	Sep	DISC
>A>		@	4MG	A076288	006	Sep 15, 2008	Sep	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

@ ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar	DISC
@	1MG	A076996	002	Apr 19, 2011	Mar	DISC
@	2MG	A076996	003	Apr 19, 2011	Mar	DISC
@	3MG	A076996	004	Apr 19, 2011	Mar	DISC
@	4MG	A076996	005	Apr 19, 2011	Mar	DISC
@ HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	Apr	DISC
@	1MG	A076908	002	Mar 12, 2012	Apr	DISC
@	2MG	A076908	003	Mar 12, 2012	Apr	DISC

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

YUTOPAR

@ ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan	CMS1
---------------	---------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

@	APOTEX INC	EQ 1.5MG BASE	A 091072	001	May 16, 2013	May	DISC
@		EQ 3MG BASE	A 091072	002	May 16, 2013	May	DISC
@		EQ 4.5MG BASE	A 091072	003	May 16, 2013	May	DISC
@		EQ 6MG BASE	A 091072	004	May 16, 2013	May	DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

>D>	AB	ECI PHARMS LLC	EQ 5MG BASE	A 202047	001	Dec 31, 2012	Sep	CAHN
>D>	AB		EQ 10MG BASE	A 202047	002	Dec 31, 2012	Sep	CAHN
>A>	AB	PHARMA LIFE	EQ 5MG BASE	A 202047	001	Dec 31, 2012	Sep	CAHN
>A>	AB		EQ 10MG BASE	A 202047	002	Dec 31, 2012	Sep	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

@	MYLAN PHARMS INC	EQ 5MG BASE	A 078173	001	Dec 31, 2012	Feb	DISC
@		EQ 10MG BASE	A 078173	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A>	AP	PIRAMAL CRITICAL	50MG/5ML (10MG/ML)	A 210437	001	Aug 13, 2019	Sep	CAHN
>A>	AP		100MG/10ML (10MG/ML)	A 210437	002	Aug 13, 2019	Sep	CAHN
>D>	AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A 210437	001	Aug 13, 2019	Sep	CAHN
>D>	AP		100MG/10ML (10MG/ML)	A 210437	002	Aug 13, 2019	Sep	CAHN
		@ TEVA PHARMS	50MG/5ML (10MG/ML)	A 078717	001	Nov 26, 2008	Mar	DISC
		@	100MG/10ML (10MG/ML)	A 078717	002	Nov 26, 2008	Mar	DISC

ROFLUMILAST

TABLET;ORAL

ROFLUMILAST

AB		@ MICRO LABS	500MCG	A 208180	001	Mar 22, 2019	Jun	DISC
		STRIDES PHARMA	500MCG	A 208247	001	Mar 30, 2020	Mar	NEWA

ROMIDEPSIN

SOLUTION;INTRAVENOUS

ROMIDEPSIN

>D>	+	TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N 208574	001	Mar 13, 2020	Sep	DISC
>A>	+	@	10MG/2ML (5MG/ML)	N 208574	001	Mar 13, 2020	Sep	DISC
	+		10MG/2ML (5MG/ML)	N 208574	001	Mar 13, 2020	Mar	NEWA
	+	!	27.5MG/5.5ML (5MG/ML)	N 208574	002	Mar 13, 2020	Mar	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

@	HIKMA	EQ 0.25MG BASE	A 077852	001	May 05, 2008	Feb	DISC
@		EQ 0.5MG BASE	A 077852	002	May 05, 2008	Feb	DISC
@		EQ 1MG BASE	A 077852	003	May 05, 2008	Feb	DISC
@		EQ 2MG BASE	A 077852	004	May 05, 2008	Feb	DISC
@		EQ 3MG BASE	A 077852	005	May 05, 2008	Feb	DISC
@		EQ 4MG BASE	A 077852	006	May 05, 2008	Feb	DISC
@		EQ 5MG BASE	A 077852	007	May 19, 2008	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

+	@	GLAXOSMITHKLINE LLC	EQ 8MG BASE	N 022008	004	Jun 13, 2008	Mar	DISC
		@ WATSON LABS INC	EQ 2MG BASE	A 200431	001	Jun 06, 2012	Mar	DISC
		@	EQ 4MG BASE	A 200431	002	Jun 06, 2012	Mar	DISC
		@	EQ 6MG BASE	A 200431	003	Jun 06, 2012	Mar	DISC
		@	EQ 8MG BASE	A 200431	004	Jun 06, 2012	Mar	DISC
		@	EQ 12MG BASE	A 200431	005	Jun 06, 2012	Mar	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		CAPLIN	40MG/20ML (2MG/ML)	A 212808	001	Apr 09, 2020	Mar	NEWA
AP			100MG/20ML (5MG/ML)	A 212808	002	Apr 09, 2020	Mar	NEWA
AP			150MG/30ML (5MG/ML)	A 212808	003	Apr 09, 2020	Mar	NEWA
AP			200MG/20ML (10MG/ML)	A 212808	004	Apr 09, 2020	Mar	NEWA

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	HIKMA	40MG/20ML (2MG/ML)	A214074	001	Jul 20, 2020	Jul	NEWA
AP		150MG/30ML (5MG/ML)	A214074	002	Jul 20, 2020	Jul	NEWA
AP		150MG/20ML (7.5MG/ML)	A214074	003	Jul 20, 2020	Jul	NEWA
AP		200MG/20ML (10MG/ML)	A214074	004	Jul 20, 2020	Jul	NEWA
>D>	AP	MYLAN ASI	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Sep DISC
>A>	@		40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Sep DISC
>D>	AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Sep DISC
>A>	@		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Sep DISC

ROSUVASTATIN CALCIUM

CAPSULE;ORAL

EZALLOR SPRINKLE

+	SUN PHARMA GLOBAL	EQ 5MG BASE	N208647	001	Dec 18, 2018	Aug	CTNA
+		EQ 10MG BASE	N208647	002	Dec 18, 2018	Aug	CTNA
+		EQ 20MG BASE	N208647	003	Dec 18, 2018	Aug	CTNA
+	!	EQ 40MG BASE	N208647	004	Dec 18, 2018	Aug	CTNA

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jun DISC
	@		10MG	A079145	002	Jul 19, 2016	Jun DISC
	@		20MG	A079145	003	Jul 19, 2016	Jun DISC
	@		40MG	A079145	004	Jul 19, 2016	Jun DISC
>A>	AB	LUPIN	5MG	A205587	001	Jul 31, 2017	Sep CAHN
>A>	AB		10MG	A205587	002	Jul 31, 2017	Sep CAHN
>A>	AB		20MG	A205587	003	Jul 31, 2017	Sep CAHN
>A>	AB		40MG	A205587	004	Jul 31, 2017	Sep CAHN
>D>	AB	LUPIN LTD	5MG	A205587	001	Jul 31, 2017	Sep CAHN
>D>	AB		10MG	A205587	002	Jul 31, 2017	Sep CAHN
>D>	AB		20MG	A205587	003	Jul 31, 2017	Sep CAHN
>D>	AB		40MG	A205587	004	Jul 31, 2017	Sep CAHN
	AB	RENATA	5MG	A207062	001	Oct 31, 2016	Jul CAHN
	AB		10MG	A207062	002	Oct 31, 2016	Jul CAHN
	AB		20MG	A207062	003	Oct 31, 2016	Jul CAHN
	AB		40MG	A207062	004	Oct 31, 2016	Jul CAHN
	AB	SUNSHINE	5MG	A210667	001	Apr 01, 2020	Mar NEWA
	AB		10MG	A210667	002	Apr 01, 2020	Mar NEWA
	AB		20MG	A210667	003	Apr 01, 2020	Mar NEWA
	AB		40MG	A210667	004	Apr 01, 2020	Mar NEWA
	@	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr DISC
	@		10MG	A212059	002	Nov 04, 2019	Apr DISC
	@		20MG	A212059	003	Nov 04, 2019	Apr DISC
	@		40MG	A212059	004	Nov 04, 2019	Apr DISC

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

+	MDD US	50MG	N207145	001	Mar 21, 2017	Jul	CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Jul	CAHN

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

AB	+	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Aug CTEC
		SAPROPTERIN DIHYDROCHLORIDE					
AB		PAR PHARM INC	500MG/PACKET	A210027	001	Aug 20, 2019	Aug CMFD
		TABLET;ORAL					
		KUVAN					
AB	+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	Aug CTEC
		SAPROPTERIN DIHYDROCHLORIDE					
AB		PAR PHARM INC	100MG	A207200	001	May 10, 2019	Aug CMFD

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

	@	DAVA PHARMS INC	5MG	A075352	001	Nov 30, 1998	Feb DISC
		TABLET;ORAL					
		SELEGILINE HYDROCHLORIDE					
	@	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Jul CAHN
	@	MLV	5MG	A074672	001	Apr 01, 1997	Mar CAHN

SELEXIPAGTABLET; ORAL
UPTRA VI

+	!	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan CHRS
+			1.6MG	N207947	008	Dec 21, 2015	Jan CHRS

SELPERCATINIBCAPSULE; ORAL
RETEVMO

+		LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020	May NEWA
+	!		80MG	N213246	002	May 08, 2020	May NEWA

SELUMETINIB SULFATECAPSULE; ORAL
KOSELUGO

+		ASTRAZENECA PHARMS	EQ 10MG BASE	N213756	001	Apr 10, 2020	Apr NEWA
+	!		EQ 25MG BASE	N213756	002	Apr 10, 2020	Apr NEWA

SEMAGLUTIDESOLUTION; SUBCUTANEOUS
OZEMPIC

+	!	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan NEWA
---	---	------	---------------------	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDECONCENTRATE; ORAL
ZOLOFT

AA	+	!	UPJOHN	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jun CAHN
----	---	---	--------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

			@ SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Jul DISC
			@	EQ 50MG BASE	A077977	002	Feb 06, 2007	Jul DISC
			@	EQ 100MG BASE	A077977	003	Feb 06, 2007	Jul DISC
			@	EQ 150MG BASE	A077977	004	Feb 06, 2007	Jul DISC
			@	EQ 200MG BASE	A077977	005	Feb 06, 2007	Jul DISC
AB			VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB				EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar CAHN
AB				EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB				EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar CAHN
AB				EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
AB				EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar CAHN
			ZOLOFT					
AB	+		UPJOHN	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jun CAHN
AB	+			EQ 50MG BASE	N019839	001	Dec 30, 1991	Jun CAHN
AB	+	!		EQ 100MG BASE	N019839	002	Dec 30, 1991	Jun CAHN
			+ @	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jun CAHN
			+ @	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jun CAHN

SEVELAMER CARBONATE

TABLET; ORAL

SEVELAMER CARBONATE

>D>	AB		ANXIN	800MG	A212970	001	Apr 09, 2020	Sep DISC
>A>			@	800MG	A212970	001	Apr 09, 2020	Sep DISC
	AB			800MG	A212970	001	Apr 09, 2020	Mar NEWA
			@ IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017	Jul DISC
>A>	AB		INDICUS PHARMA	800MG	A204451	001	Nov 29, 2018	Sep CAHN
			@ MYLAN	800MG	A201069	001	Aug 05, 2020	Aug DISC
	AB			800MG	A201069	001	Aug 05, 2020	Jul NEWA
>D>	AB		WILSHIRE PHARMS INC	800MG	A204451	001	Nov 29, 2018	Sep CAHN
	AB		ZYDUS PHARMS	800MG	A207759	001	Aug 11, 2020	Jul NEWA

SILDENAFIL CITRATEFOR SUSPENSION; ORAL
REVATIO

AB	+	!	UPJOHN	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Jun CAHN
----	---	---	--------	-----------------	---------	-----	--------------	----------

SILDENAFIL CITRATE

AB			APTAPHARMA INC	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Jul NEWA
AB			TEVA PHARMS USA	EQ 10MG BASE/ML	A211534	001	May 29, 2020	May NEWA

SOLUTION; INTRAVENOUS
REVATIO

AP	+	!	UPJOHN	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Jun CAHN
----	---	---	--------	--	---------	-----	--------------	----------

TABLET;ORAL									
REVATIO									
AB	+	UPJOHN	EQ 20MG BASE	N021845	001	Jun 03, 2005	Jun	CAHN	
SILDENAFIL CITRATE									
AB		APPCO	EQ 25MG BASE	A207178	001	Mar 02, 2020	Apr	CPOT	
AB			25MG	A207178	001	Mar 02, 2020	Feb	NEWA	
AB			EQ 50MG BASE	A207178	002	Mar 02, 2020	Apr	CPOT	
AB			50MG	A207178	002	Mar 02, 2020	Feb	NEWA	
AB			EQ 100MG BASE	A207178	003	Mar 02, 2020	Apr	CPOT	
AB			100MG	A207178	003	Mar 02, 2020	Feb	NEWA	
>D>	AB	HEBEI CHANGSHAN	EQ 20MG BASE	A202598	001	Nov 06, 2012	Sep	CAHN	
		@ PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020	Jul	DISC	
	AB		EQ 25MG BASE	A205791	001	Apr 23, 2020	Apr	NEWA	
		@	EQ 50MG BASE	A205791	002	Apr 23, 2020	Jul	DISC	
	AB		EQ 50MG BASE	A205791	002	Apr 23, 2020	Apr	NEWA	
	AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Jun	NEWA	
	AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Jun	NEWA	
	AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Jun	NEWA	
	AB	SUNSHINE	EQ 25MG BASE	A213032	001	Jun 11, 2020	Jun	NEWA	
	AB		EQ 50MG BASE	A213032	002	Jun 11, 2020	Jun	NEWA	
	AB		EQ 100MG BASE	A213032	003	Jun 11, 2020	Jun	NEWA	
	AB	UMEDICA LABS PVT LTD	EQ 50MG BASE	A209302	001	Aug 25, 2020	Aug	NEWA	
	AB		EQ 100MG BASE	A209302	002	Aug 25, 2020	Aug	NEWA	
>A>	AB	YILING	EQ 20MG BASE	A202598	001	Nov 06, 2012	Sep	CAHN	
VIAGRA									
AB	+	UPJOHN	EQ 25MG BASE	N020895	001	Mar 27, 1998	Jun	CAHN	
AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Jun	CAHN	
AB	+		EQ 100MG BASE	N020895	003	Mar 27, 1998	Jun	CAHN	
<u>SILODOSIN</u>									
CAPSULE;ORAL									
SILODOSIN									
AB		HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb	NEWA	
AB			8MG	A204793	002	Feb 14, 2020	Feb	NEWA	
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>									
SOLUTION;INTRAVENOUS									
AMMONUL									
AP	+	BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jun	CAHN	
<u>SODIUM BICARBONATE</u>									
INJECTABLE;INJECTION									
SODIUM BICARBONATE									
AP	!	EXELA PHARMA	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jul	CHRS	
AP	!		0.9MEQ/ML	A211091	002	Jun 20, 2019	Jul	CHRS	
AP	!		1MEQ/ML	A211091	003	Jun 20, 2019	Jul	CHRS	
		@ HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Jul	DISC	
		@	1MEQ/ML	A077394	002	Nov 09, 2005	Jul	DISC	
AP		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Jul	CMFD	
<u>SODIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	+	BAXTER HLTHCARE	450MG/100ML	N018016	001		Aug	CHRS	
AP	+		450MG/100ML	N018016	001		Aug	CRLD	
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP		NEPHRON	9MG/ML	A211968	001	Apr 23, 2020	Apr	NEWA	
SOLUTION;INTRAVENOUS									
SODIUM CHLORIDE 14.6%									
	+	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul	CTNA	
	+		2.5MEQ/ML	N018897	001	Jul 20, 1984	Jul	CDFR	
	+	@	50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul	DISC	
	+		50MEQ/20ML (2.5MEQ/ML)	N018897	001	Jul 20, 1984	Jul	CPOT	
	+	!	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984	Jul	NEWA	
SODIUM CHLORIDE 23.4%									
	+	!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Jul	NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	CURIUM	100uCi	A 071909	001	Feb 28, 1989	Feb	CAHN
AA		200uCi	A 071910	001	Feb 28, 1989	Feb	CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

>A>	+	JUBILANT	0.009-0.1mCi	N 021305	006	May 19, 2005	Sep	CAHN
>A>	@		2-200mCi	N 021305	004	Nov 18, 2004	Sep	CAHN
>D>	+	JUBILANT DRAXIMAGE	0.009-0.1mCi	N 021305	006	May 19, 2005	Sep	CAHN
>D>	@		2-200mCi	N 021305	004	Nov 18, 2004	Sep	CAHN

SOLUTION;ORAL

HICON

>A>	@	JUBILANT	1-250mCi/0.25ML	N 021305	002	Jan 24, 2003	Sep	CAHN
>A>	@		1-500mCi/0.5ML	N 021305	003	Jan 24, 2003	Sep	CAHN
>A>	@		1-1000mCi/ML	N 021305	005	Apr 04, 2006	Sep	CAHN
>A>	AA	+	250-1000mCi	N 021305	007	Dec 05, 2011	Sep	CAHN
>D>	@	JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N 021305	002	Jan 24, 2003	Sep	CAHN
>D>	@		1-500mCi/0.5ML	N 021305	003	Jan 24, 2003	Sep	CAHN
>D>	@		1-1000mCi/ML	N 021305	005	Apr 04, 2006	Sep	CAHN
>D>	AA	+	250-1000mCi	N 021305	007	Dec 05, 2011	Sep	CAHN
AA	+		250-1000mCi	N 021305	007	Dec 05, 2011	Jan	CFTG
AA		SODIUM IODIDE I 131						
AA		INTL ISOTOPES	250-1000mCi	A 209166	001	Feb 05, 2020	Jan	NFTG

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

+	@	HOSPIRA	5MEQ/ML	N 018947	001	Sep 05, 1984	Jun	DISC
---	---	---------	---------	----------	-----	--------------	-----	------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

>D>	AP	@	AMPHASTAR PHARMS INC	25MG/ML	A 209832	001	Dec 18, 2017	Jul	DISC
	AP		CAPLIN	25MG/ML	A 211016	001	Nov 29, 2019	Sep	CAHN
	AP		HAINAN POLY PHARM	25MG/ML	A 214199	001	Aug 25, 2020	Aug	NEWA
>A>	AP		HONG KONG	25MG/ML	A 211016	001	Nov 29, 2019	Sep	CAHN

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

>D>	AA		HIKMA	0.5GM/ML	A 202090	001	Jan 17, 2017	Sep	DISC
>A>		@		0.5GM/ML	A 202090	001	Jan 17, 2017	Sep	DISC
	AA			0.5GM/ML	A 202090	001	Jan 17, 2017	Jul	CPOT
			XYREM						
>D>	AA	+	JAZZ PHARMS	0.5GM/ML	N 021196	001	Jul 17, 2002	Sep	CTEC
>A>		+		0.5GM/ML	N 021196	001	Jul 17, 2002	Sep	CTEC
	AA	+		0.5GM/ML	N 021196	001	Jul 17, 2002	Jul	CPOT

SODIUM PHENYL BUTYRATE

TABLET;ORAL

SODIUM PHENYL BUTYRATE

@	ALVOGEN	500MG	A 090910	001	Nov 18, 2011	Jan	DISC
---	---------	-------	----------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>A>	AA		DISCOVERY THERAP	453.6GM/BOT	A 090313	001	Dec 21, 2011	Sep	CAHN
>D>	AA		ECI PHARMS LLC	453.6GM/BOT	A 090313	001	Dec 21, 2011	Sep	CAHN

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@	HIKMA	15GM/60ML	A 089049	001	Nov 17, 1986	Feb	DISC
---	-------	-----------	----------	-----	--------------	-----	------

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	200MG;50MG	N 208341	002	Mar 19, 2020	Mar	NEWA
---	---------------------	------------	----------	-----	--------------	-----	------

SOLIFENACIN SUCCINATESUSPENSION;ORAL
VESICARE LS

+! ASTELLAS 1MG/ML N209529 001 May 26, 2020 May NEWA

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	GRAVITI PHARMS	5MG	A211423	001	Dec 11, 2019	May	CAHN
AB		10MG	A211423	002	Dec 11, 2019	May	CAHN
AB	RISING	5MG	A211423	001	Dec 11, 2019	Aug	CAHN
AB		10MG	A211423	002	Dec 11, 2019	Aug	CAHN
AB	SUNSHINE	5MG	A213346	001	Apr 13, 2020	Mar	NEWA
AB		10MG	A213346	002	Apr 13, 2020	Mar	NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

+	JAZZ	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jan	CPOT
+		75MG	N211230	001	Jun 17, 2019	Jan	CAIN
+!		EQ 150MG BASE	N211230	002	Jun 17, 2019	Apr	CHRS
+		EQ 150MG BASE	N211230	002	Jun 17, 2019	Jan	CPOT
+		150MG	N211230	002	Jun 17, 2019	Jan	CAIN

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

>D>	+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	Sep	CFTG
>A>	+!		EQ 200MG BASE	N021923	001	Dec 20, 2005	Sep	CTEC
>A>	AB	+!	EQ 200MG BASE	N021923	001	Dec 20, 2005	Sep	CFTG
		SORAFENIB TOSYLATE						
>A>	@	MYLAN	EQ 200MG BASE	A207012	001	Sep 10, 2020	Sep	DISC
>A>	AB		EQ 200MG BASE	A207012	001	Sep 10, 2020	Sep	NFTG

SPIRONOLACTONE

TABLET;ORAL

ALDACTONE

AB	+	PFIZER	25MG	N012151	009	Dec 30, 1983	Jul	CAHN
AB	+		50MG	N012151	008	Dec 30, 1982	Jul	CAHN
AB	+!		100MG	N012151	010	Dec 30, 1983	Jul	CAHN

STAVUDINE

CAPSULE;ORAL

STAVUDINE

>D>	AB	AUROBINDO PHARMA	15MG	A077672	003	Dec 29, 2008	Sep	CTEC	
>A>			15MG	A077672	003	Dec 29, 2008	Sep	CTEC	
>D>	AB		20MG	A077672	004	Dec 29, 2008	Sep	CTEC	
>A>			20MG	A077672	004	Dec 29, 2008	Sep	CTEC	
>D>	AB		30MG	A077672	001	Dec 29, 2008	Sep	CTEC	
>A>			30MG	A077672	001	Dec 29, 2008	Sep	CTEC	
>D>	AB		40MG	A077672	002	Dec 29, 2008	Sep	CHRS	
>A>		!	40MG	A077672	002	Dec 29, 2008	Sep	CTEC	
>A>	AB	!	40MG	A077672	002	Dec 29, 2008	Sep	CHRS	
>D>		ZERIT							
>D>	AB	+	BRISTOL MYERS SQUIBB	15MG	N020412	002	Jun 24, 1994	Sep	DISC
>D>	AB	+		20MG	N020412	003	Jun 24, 1994	Sep	DISC
>D>	AB	+		30MG	N020412	004	Jun 24, 1994	Sep	DISC
>D>	AB	+!		40MG	N020412	005	Jun 24, 1994	Sep	DISC
>A>		+ @	BRISTOL-MYERS SQUIBB	15MG	N020412	002	Jun 24, 1994	Sep	DISC
>A>		+ @		20MG	N020412	003	Jun 24, 1994	Sep	DISC
>A>		+ @		30MG	N020412	004	Jun 24, 1994	Sep	DISC
>A>		+ @		40MG	N020412	005	Jun 24, 1994	Sep	DISC

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

! XGEN PHARMS EQ 1GM BASE/VIAL A064210 001 Jun 30, 1998 Feb CAHN

SUCCINYLMCHOLINE CHLORIDEINJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE

	+ @ HOSPIRA	50MG/ML	N008845	002		Apr	CRLD
	+ @	100MG/ML	N008845	004		Apr	CRLD
	SUCCINYLMCHOLINE CHLORIDE						
AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	May	NEWA
AP	AMPHASTAR PHARMS INC	20MG/ML	A213432	001	Jun 08, 2020	Jun	NEWA
AP	ASPIRO	20MG/ML	A213810	001	May 04, 2020	Apr	NEWA
AP	GLAND PHARMA LTD	20MG/ML	A214246	001	Jun 16, 2020	Jun	NEWA
AP	HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Jun	NEWA
AP	INDOCO	20MG/ML	A214308	001	May 22, 2020	May	NEWA
AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	May	NEWA
	SUCOSTRIN						
	+ @ APOTHECON	20MG/ML	N008847	001		Apr	CRLD
	+ @	100MG/ML	N008847	003		Apr	CRLD

SUCRALFATETABLET; ORAL
SUCRALFATE

AB	NOSTRUM LABS INC	1GM	A074415	001	Jun 08, 1998	May	CMFD
----	------------------	-----	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUMLOTION; TOPICAL
KLARON

AB	+! BAUSCH	10%	N019931	001	Dec 23, 1996	Mar	CAHN
----	-----------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991	Mar	CMFD
----	-----------------	------------------	---------	-----	--------------	-----	------

SULFASALAZINETABLET; ORAL
SULFASALAZINE

AB	NUVO PHARMS INC	500MG	A040349	001	Jan 11, 2002	Aug	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL
SULFASALAZINE

AB	NUVO PHARMS INC	500MG	A075339	001	Jan 11, 2002	Aug	CAHN
----	-----------------	-------	---------	-----	--------------	-----	------

SUMATRIPTANSPRAY; NASAL
SUMATRIPTAN

>A>	AB	PERRIGO UK FINCO	5MG/SPRAY	A213650	001	Sep 21, 2020	Sep	NEWA
>A>	AB		20MG/SPRAY	A213465	001	Sep 21, 2020	Sep	NEWA

SUMATRIPTAN SUCCINATETABLET; ORAL
SUMATRIPTAN SUCCINATE

AB	COREPHARMA	EQ 25MG BASE	A200263	001	Jun 19, 2012	Feb	CAHN
AB		EQ 50MG BASE	A200263	002	Jun 19, 2012	Feb	CAHN
AB		EQ 100MG BASE	A200263	003	Jun 19, 2012	Feb	CAHN

TADALAFILTABLET; ORAL
TADALAFIL

AB	ACCORD HLTHCARE	10MG	A209167	003	Oct 23, 2019	Jul	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

TAMOXIFEN CITRATE

>D>	SOLUTION; ORAL							
>D>	SOLTAMOX							
>D>		FORTOVIA	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Sep	DISC
>A>		@	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Sep	DISC
	TABLET; ORAL							
	TAMOXIFEN CITRATE							
AB		EUGIA PHARMA	EQ 10MG BASE	A213358	001	Aug 14, 2020	Aug	NEWA
AB			EQ 20MG BASE	A213358	002	Aug 14, 2020	Aug	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

@ ANBISON LAB

0.4MG

A211885 001 Oct 17, 2019 Apr DISC

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+ @ COLLEGIUM PHARM INC

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012 Feb CAHN

TABLET;ORAL

NUCYNTA

+ COLLEGIUM PHARM INC

EQ 50MG BASE

N022304 001 Nov 20, 2008 Feb CAHN

+ COLLEGIUM PHARM INC

EQ 75MG BASE

N022304 002 Nov 20, 2008 Feb CAHN

+! COLLEGIUM PHARM INC

EQ 100MG BASE

N022304 003 Nov 20, 2008 Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

+ COLLEGIUM PHARM INC

EQ 50MG BASE

N200533 001 Aug 25, 2011 Feb CAHN

+ COLLEGIUM PHARM INC

EQ 100MG BASE

N200533 002 Aug 25, 2011 Feb CAHN

+ COLLEGIUM PHARM INC

EQ 150MG BASE

N200533 003 Aug 25, 2011 Feb CAHN

+ COLLEGIUM PHARM INC

EQ 200MG BASE

N200533 004 Aug 25, 2011 Feb CAHN

+! COLLEGIUM PHARM INC

EQ 250MG BASE

N200533 005 Aug 25, 2011 Feb CAHN

TAZEMETOSTAT HYDROBROMIDE

TABLET;ORAL

TAZVERIK

+! EPIZYME INC

EQ 200MG BASE

N211723 001 Jan 23, 2020 Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

@ SUN PHARM INDS INC

N/A

N018467 001 Mar 16, 1982 Apr CAHN

TECHNETIUM TC-99M EXAMETAZIME KIT

POWDER;INTRAVENOUS

DRAX EXAMETAZIME

>A>

JUBILANT

N/A

N208870 001 Aug 17, 2017 Sep CAHN

>D>

JUBILANT DRAXIMAGE

N/A

N208870 001 Aug 17, 2017 Sep CAHN

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE;INJECTION

TECHNETIUM TC-99M MEBROFENIN

AP

SUN PHARM INDS INC

N/A

A078242 001 Jan 29, 2008 Apr CAHN

TECHNETIUM TC-99M MEDRONATE

INJECTABLE;INJECTION

DRAXIMAGE MDP-10

>A>

@ JUBILANT

N/A

N018035 001 Sep CAHN

>D>

@ JUBILANT DRAXIMAGE

N/A

N018035 001 Sep CAHN

DRAXIMAGE MDP-25

>A>

+! JUBILANT

N/A

N018035 002 Feb 27, 2004 Sep CAHN

>D>

+! JUBILANT DRAXIMAGE

N/A

N018035 002 Feb 27, 2004 Sep CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

CIS-MDP

SUN PHARM INDS INC

N/A

N018124 001 Apr CAHN

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNETIUM TC99M MERTIATIDE KIT

AP

SOMMER PHARMS II LLC

N/A

A206489 001 Feb 06, 2020 Jan NEWA

AP

SUN PHARM INDS INC

N/A

A208994 001 Jul 12, 2019 Apr CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE;INJECTION

CIS-PYRO

AP

SUN PHARM INDS INC

N/A

N019039 001 Jun 30, 1987 Apr CAHN

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE;INJECTION
TECHNETIUM TC 99M SESTAMIBI

AP	CURIUM	N/A		A078098	001	Sep 22, 2008	Feb	CAHN
AP	SUN PHARM INDS INC	10-30mCi		A079157	001	Jul 10, 2009	Apr	CAHN

TECHNETIUM TC-99M SULFUR COLLOID KITSOLUTION;INJECTION, ORAL
AN-SULFUR COLLOID

+!	SUN PHARM INDS INC	N/A		N017858	001		Apr	CAHN
----	--------------------	-----	--	---------	-----	--	-----	------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

	@ CELLTRION	20MG		A078710	001	Jan 08, 2014	Jul	CAHN
	@	40MG		A078710	002	Jan 08, 2014	Jul	CAHN
	@	80MG		A078710	003	Jan 08, 2014	Jul	CAHN
	@ JUBILANT GENERICS	20MG		A204164	001	Aug 22, 2016	Jan	DISC
	@	40MG		A204164	002	Aug 22, 2016	Jan	DISC
	@	80MG		A204164	003	Aug 22, 2016	Jan	DISC
AB	MICRO LABS	20MG		A207016	001	Oct 03, 2017	Apr	CMFD
AB		40MG		A207016	002	Oct 03, 2017	Apr	CMFD
AB		80MG		A207016	003	Oct 03, 2017	Apr	CMFD

TELOTTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

>D>	+!	LEXICON PHARMS INC	EQ 250MG BASE	N208794	001	Feb 28, 2017	Sep	CAHN
>A>	+!	TERSERA	EQ 250MG BASE	N208794	001	Feb 28, 2017	Sep	CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>D>	AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Sep	CAHN
>D>	AB		20MG	A203490	002	Jul 13, 2016	Sep	CAHN
>D>	AB		100MG	A203490	003	Jul 13, 2016	Sep	CAHN
>D>	AB		140MG	A203490	004	Jul 13, 2016	Sep	CAHN
>D>	AB		180MG	A203490	005	Jul 13, 2016	Sep	CAHN
>D>	AB		250MG	A203490	006	Jul 13, 2016	Sep	CAHN
>A>	AB	ANI PHARMS INC	5MG	A203490	001	Jul 13, 2016	Sep	CAHN
>A>	AB		20MG	A203490	002	Jul 13, 2016	Sep	CAHN
>A>	AB		100MG	A203490	003	Jul 13, 2016	Sep	CAHN
>A>	AB		140MG	A203490	004	Jul 13, 2016	Sep	CAHN
>A>	AB		180MG	A203490	005	Jul 13, 2016	Sep	CAHN
>A>	AB		250MG	A203490	006	Jul 13, 2016	Sep	CAHN
	AB	CHARTWELL	5MG	A206413	001	Apr 12, 2016	Jun	CAHN
	AB		20MG	A206413	002	Apr 12, 2016	Jun	CAHN
	AB		100MG	A206413	003	Apr 12, 2016	Jun	CAHN
	AB		140MG	A206413	004	Apr 12, 2016	Jun	CAHN
	AB		180MG	A206413	005	Apr 12, 2016	Jun	CAHN
	AB		250MG	A206413	006	Apr 12, 2016	Jun	CAHN

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

IBSRELA

+ @	ARDELYX INC	EQ 50MG BASE		N211801	001	Sep 12, 2019	Mar	DISC
-----	-------------	--------------	--	---------	-----	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

@	MYLAN	150MG		A206569	001	Nov 27, 2018	Feb	DISC
@		200MG		A206569	002	Nov 27, 2018	Feb	DISC
@		250MG		A206569	003	Nov 27, 2018	Feb	DISC
@		300MG		A206569	004	Nov 27, 2018	Feb	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

>D>	AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Sep	CHRS
>A>	AB	!	EQ 1MG BASE	A074823	001	Mar 30, 1998	Sep	CHRS
>D>	AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Sep	CHRS

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

>A>	AB		EQ 2MG BASE	A074823	002	Mar 30, 1998	Sep	CHRS
		@ HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb	DISC
		@	EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb	DISC
		@	EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb	DISC
		@	EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb	DISC
>D>	AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Sep	DISC
>A>		@	EQ 1MG BASE	A075498	001	Apr 12, 2001	Sep	DISC
>D>	AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Sep	DISC
>A>		@	EQ 2MG BASE	A075498	002	Apr 12, 2001	Sep	DISC
>D>	AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Sep	DISC
>A>		@	EQ 5MG BASE	A075498	003	Apr 12, 2001	Sep	DISC
>D>	AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Sep	DISC
>A>		@	EQ 10MG BASE	A075498	004	Apr 12, 2001	Sep	DISC

TERBUTALINE SULFATE

TABLET;ORAL

TERBUTALINE SULFATE

AB		TWI PHARMS	2.5MG	A211832	001	Jun 19, 2020	Jun	NEWA
AB			5MG	A211832	002	Jun 19, 2020	Jun	NEWA

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

AB		IMPAX	14MG	A209677	001	Jun 17, 2020	Jun	NEWA
		@ MYLAN	7MG	A209702	001	Feb 28, 2020	Mar	DISC
AB			7MG	A209702	001	Feb 28, 2020	Feb	NEWA
		@	14MG	A209702	002	Feb 28, 2020	Mar	DISC
AB			14MG	A209702	002	Feb 28, 2020	Feb	NEWA

TERIPARATIDE

INJECTABLE;SUBCUTANEOUS

FORTEO

+!	LILLY		0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
	@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN

SOLUTION;SUBCUTANEOUS

BONSITY

ALVOGEN

			0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
--	--	--	---------------------------	---------	-----	--------------	-----	------

FORTEO

+!	LILLY		0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR
	@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CDFR

TESTOSTERONE

GEL, METERED;TRANSDERMAL

ANDROGEL

+	@	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar	DISC
---	---	--------	-------------------------	---------	-----	--------------	-----	------

TESTOSTERONE

BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CHRS
BX			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar	CTEC
AB		XIROMED	1.62% (20.25MG/1.25GM ACTUATION)	A210835	001	Apr 16, 2020	Apr	NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB		APOTEX	12.5MG	A206093	001	Mar 17, 2020	Mar	NEWA
AB			25MG	A206093	002	Mar 17, 2020	Mar	NEWA
AB		PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan	NEWA
AB			25MG	A213316	002	Jan 22, 2020	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

>D>		@ STRIDES PHARMA	250MG	A212635	001	Mar 03, 2020	Sep	CMFD
>A>	AB		250MG	A212635	001	Mar 03, 2020	Sep	CMFD
		@	250MG	A212635	001	Mar 03, 2020	Jul	DISC
	AB		250MG	A212635	001	Mar 03, 2020	Feb	NEWA
>D>		@	500MG	A212635	002	Mar 03, 2020	Sep	CMFD
>A>	AB		500MG	A212635	002	Mar 03, 2020	Sep	CMFD
		@	500MG	A212635	002	Mar 03, 2020	Jul	DISC
	AB		500MG	A212635	002	Mar 03, 2020	Feb	NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS
THALLOUS CHLORIDE TL 201
@ CURIUM 2mCi/ML

A 077698 001 Nov 09, 2006 Feb CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE
ALEMBIC PHARMS LTD 300MG
@ HERITAGE PHARMA 300MG

A 090430 001 Oct 27, 2010 Jun CTEC
A 089763 001 Apr 30, 1990 Jun DISC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

AB MYLAN 10MG
AB 25MG
AB 50MG
AB ! 100MG
AB SUN PHARM INDUSTRIES 10MG
AB 25MG
AB 50MG
AB 100MG

A 088004 002 Mar 15, 1983 Mar CTEC
A 088004 003 Mar 15, 1983 Mar CTEC
A 088004 004 Mar 15, 1983 Mar CTEC
A 088004 001 Nov 18, 1983 Mar CTEC
A 089953 004 Aug 01, 1986 Mar CMFD
A 089953 003 Aug 01, 1986 Mar CMFD
A 089953 002 Aug 01, 1986 Mar CMFD
A 089953 001 Oct 07, 1988 Mar CMFD

THIOTEPA

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL
TEPADINA

AP +! ADIENNE SA 15MG/VIAL
AP +! 100MG/VIAL
THIOTEPA
AP MSN 15MG/VIAL
AP 100MG/VIAL

N 208264 001 Jan 26, 2017 May CPOT
N 208264 002 Jan 26, 2017 May CPOT
A 213049 001 Mar 04, 2020 May CPOT
A 213049 002 Mar 04, 2020 May CPOT

POWDER;INTRAVENOUS
TEPADINA

AP +! ADIENNE SA 15MG/VIAL
AP +! 100MG/VIAL
THIOTEPA
AP MSN 15MG/VIAL
AP 100MG/VIAL

N 208264 001 Jan 26, 2017 Feb CFTG
N 208264 002 Jan 26, 2017 Feb CFTG
A 213049 001 Mar 04, 2020 Feb NFTG
A 213049 002 Mar 04, 2020 Feb NFTG

TICAGRELOR

TABLET;ORAL
TICAGRELOR

>A> @ AMNEAL 90MG
>D> @ AMNEAL PHARMS CO 90MG
>D> AB HEC PHARM CO LTD 90MG
AB 90MG
AB SIGMAPHARM LABS LLC 90MG
>A> AB SUNSHINE 90MG

A 208531 001 Jan 23, 2019 Sep CAHN
A 208531 001 Jan 23, 2019 Sep CAHN
A 208508 001 Apr 06, 2020 Sep CAHN
A 208508 001 Apr 06, 2020 Mar NEWA
A 208596 001 Apr 07, 2020 Mar NEWA
A 208508 001 Apr 06, 2020 Sep CAHN

TIGECYCLINE

POWDER;INTRAVENOUS
TIGECYCLINE

AP +! FRESENIUS KABI USA 50MG/VIAL
AP + 50MG/VIAL

N 205645 001 Dec 01, 2016 Aug CHRS
N 205645 001 Dec 01, 2016 Aug CRLD

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

>A>
>A> AT3 AKORN INC EQ 0.5% BASE
TIMOPTIC IN OCUDOSE
>D> +! VALEANT PHARMS INTL EQ 0.5% BASE
>A> AT3 +! EQ 0.5% BASE

A 212291 001 Sep 11, 2020 Sep NFTG
N 019463 002 Nov 05, 1986 Sep CFTG
N 019463 002 Nov 05, 1986 Sep CFTG

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 6MG BASE
AB RUBICON EQ 2MG BASE
AB EQ 4MG BASE

A 213544 001 Mar 24, 2020 Mar NEWA
A 213544 002 Mar 24, 2020 Mar NEWA
A 213544 003 Mar 24, 2020 Mar NEWA
A 213798 001 May 27, 2020 May NEWA
A 213798 002 May 27, 2020 May NEWA

	CAPSULE;ORAL								
	TIZANIDINE HYDROCHLORIDE								
AB		EQ 6MG BASE		A213798	003	May 27, 2020		May	NEWA
	<u>TOBRAMYCIN</u>								
	SOLUTION; INHALATION								
	BETHKIS								
>D>	+	CHIESI	300MG/4ML	N201820	001	Oct 12, 2012		Sep	CTEC
>A>	AN	+	300MG/4ML	N201820	001	Oct 12, 2012		Sep	CTEC
		TOBRAMYCIN							
		@ MYLAN	300MG/5ML	A209554	001	Oct 13, 2017		Feb	DISC
AN		TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019		Aug	CMFD
	<u>TOBRAMYCIN SULFATE</u>								
	INJECTABLE; INJECTION								
	TOBRAMYCIN SULFATE								
AP	!	XGEN PHARMS	EQ 1.2GM BASE/VIAL	A065013	001	Aug 17, 2001		Feb	CAHN
	<u>TOFACITINIB CITRATE</u>								
>A>	SOLUTION;ORAL								
>A>	Xeljanz								
>A>	+	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020		Sep	NEWA
	<u>TOLAZAMIDE</u>								
	TABLET;ORAL								
	TOLAZAMIDE								
		@ MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986		Mar	DISC
		@	500MG	A070259	003	Mar 17, 1986		Mar	DISC
	<u>TOLCAPONE</u>								
	TABLET;ORAL								
	TOLCAPONE								
AB		ALVOGEN	100MG	A207729	001	Jul 29, 2020		Jul	NEWA
	<u>TOLTERODINE TARTRATE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	DETROL LA								
AB	+	UPJOHN	2MG	N021228	001	Dec 22, 2000		Jul	CAHN
AB	+	!	4MG	N021228	002	Dec 22, 2000		Jul	CAHN
		TOLTERODINE TARTRATE							
AB		AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020		May	NEWA
AB			4MG	A213397	002	May 19, 2020		May	NEWA
	TABLET;ORAL								
	DETROL								
AB	+	UPJOHN	1MG	N020771	001	Mar 25, 1998		Jun	CAHN
AB	+	!	2MG	N020771	002	Mar 25, 1998		Jun	CAHN
		TOLTERODINE TARTRATE							
>A>	AB	ATHEM	1MG	A210775	001	Dec 30, 2019		Sep	CAHN
>A>	AB		2MG	A210775	002	Dec 30, 2019		Sep	CAHN
>D>	AB	INVATECH	1MG	A210775	001	Dec 30, 2019		Sep	CAHN
>D>	AB		2MG	A210775	002	Dec 30, 2019		Sep	CAHN
		@ MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012		Jan	DISC
		@	2MG	A202641	002	Nov 27, 2012		Jan	DISC
AB		UNICHEM	1MG	A205399	001	Aug 05, 2020		Jul	NEWA
AB			2MG	A205399	002	Aug 05, 2020		Jul	NEWA
AB		UNIQUE PHARM LABS	1MG	A204721	001	Jan 24, 2020		Jan	NEWA
AB			2MG	A204721	002	Jan 24, 2020		Jan	NEWA
	<u>TOLVAPTAN</u>								
	TABLET;ORAL								
	SAMSCA								
AB	+	OTSUKA AMERICA PHARM	30MG	N022275	002	May 19, 2009		May	CFTG
		TOLVAPTAN							
AB		ALKEM LABS LTD	30MG	A211891	001	May 19, 2020		May	NEWA
AB			60MG	A211891	002	May 19, 2020		May	NFTG
AB		APOTEX	30MG	A207605	001	May 19, 2020		May	NFTG

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB	VIWIT PHARM	25MG	A 077733	001	Mar 27, 2009	Mar	CAHN
AB		25MG	A 077733	001	Mar 27, 2009	Mar	CAHN
AB		50MG	A 077733	002	Mar 27, 2009	Mar	CAHN
AB		50MG	A 077733	002	Mar 27, 2009	Mar	CAHN
AB		100MG	A 077733	003	Mar 27, 2009	Mar	CAHN
AB		100MG	A 077733	003	Mar 27, 2009	Mar	CAHN
AB		200MG	A 077733	004	Mar 27, 2009	Mar	CAHN
AB		200MG	A 077733	004	Mar 27, 2009	Mar	CAHN

TOREMIFENE CITRATETABLET; ORAL
TOREMIFENE CITRATE

AB	MSN	EQ 60MG BASE	A 212818	001	Aug 18, 2020	Aug	NEWA
----	-----	--------------	----------	-----	--------------	-----	------

TORSEMIDETABLET; ORAL
DEMADEX

	+ @ MYLAN SPECIALITY LP	5MG	N 020136	001	Aug 23, 1993	Aug	DISC
	+ @	10MG	N 020136	002	Aug 23, 1993	Aug	DISC
	+ @	20MG	N 020136	003	Aug 23, 1993	Aug	DISC
	+ @	100MG	N 020136	004	Aug 23, 1993	Aug	DISC
	TORSEMIDE						
AB	COREPHARMA	5MG	A 076894	001	May 31, 2005	Feb	CAHN
AB		10MG	A 076894	002	May 31, 2005	Feb	CAHN
AB		20MG	A 076894	003	May 31, 2005	Feb	CAHN
AB		100MG	A 076894	004	May 31, 2005	Feb	CAHN
AB	! PLIVA PHARM IND	20MG	A 076346	003	May 30, 2003	Aug	CHRS

TRAMADOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CONZIP

	+ @ CIPHER PHARMS INC	150MG	N 022370	004	Aug 01, 2011	Aug	DISC
>A>	SOLUTION; ORAL						
>A>	QDOLO						
>A>	+! ATHENA	5MG/ML	N 214044	001	Sep 01, 2020	Sep	NEWA
	TABLET; ORAL						
	TRAMADOL HYDROCHLORIDE						
	@ MACLEODS PHARMS LTD	50MG	A 205702	001	Sep 25, 2015	May	DISC

TRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID

	@ CAPLIN	100MG/ML	A 212360	001	Jul 17, 2019	Jan	DISC
AP	XGEN PHARMS	100MG/ML	A 201580	001	Jun 14, 2013	Feb	CAHN
	TABLET; ORAL						
	TRANEXAMIC ACID						
	@ ANI PHARMS INC	650MG	A 203256	001	Jul 25, 2016	Jan	CAHN

TRAZODONE HYDROCHLORIDETABLET; ORAL
TRAZODONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	50MG	A 204852	001	Feb 05, 2020	Jan	NEWA
AB		100MG	A 204852	002	Feb 05, 2020	Jan	NEWA
AB		150MG	A 204852	003	Feb 05, 2020	Jan	NEWA
AB		300MG	A 204852	004	Feb 05, 2020	Jan	NEWA

TREPROSTINILINJECTABLE; IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	DR REDDYS	1MG/ML	A 210214	001	May 22, 2020	May	NEWA
AP		2.5MG/ML	A 210214	002	May 22, 2020	May	NEWA
AP		5MG/ML	A 210214	003	May 22, 2020	May	NEWA
AP		10MG/ML	A 210214	004	May 22, 2020	May	NEWA

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	QUAGEN	0.025%	A213559	001	Jul 01, 2020	Jun	NEWA
AT		0.1%	A213559	002	Jul 01, 2020	Jun	NEWA
AT	SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar	CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar	CTNA
AT		0.1%	A209828	002	Nov 23, 2018	Mar	CTNA
AT		0.5%	A209828	003	Nov 23, 2018	Mar	CTNA
AT	STRIDES PHARMA	0.05%	A212356	001	Jun 01, 2020	May	NEWA
	@	0.1%	A211315	001	Mar 18, 2020	Jul	DISC
AT		0.1%	A211315	001	Mar 18, 2020	Mar	NEWA
	@	0.5%	A211315	002	Mar 18, 2020	Jul	DISC
AT		0.5%	A211315	002	Mar 18, 2020	Mar	NEWA

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ MYLAN PHARMS INC

0.125MG

A074031 001 Mar 25, 1994 Jan DISC

@

0.25MG

A074031 002 Mar 25, 1994 Jan DISC

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB	LUPIN LTD	250MG	A211637	001	May 21, 2020	May	NEWA
AB	RISING	250MG	A212238	001	Feb 20, 2020	Feb	NEWA

TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+! GALDERMA LABS LP 0.005%

N211527 001 Oct 04, 2019 May CAHN

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

>A>	@ ATHEM	EQ 1MG BASE	A040153	001	Oct 25, 1996	Sep	CAHN
>A>	@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Sep	CAHN
>A>	@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Sep	CAHN
>A>	@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Sep	CAHN
>D>	@ INVATECH	EQ 1MG BASE	A040153	001	Oct 25, 1996	Sep	CAHN
>D>	@	EQ 2MG BASE	A040153	002	Oct 25, 1996	Sep	CAHN
>D>	@	EQ 5MG BASE	A040153	003	Oct 25, 1996	Sep	CAHN
>D>	@	EQ 10MG BASE	A040153	004	Oct 25, 1996	Sep	CAHN

TRIEPTANOIN

LIQUID; ORAL

DOJOLVI

+! ULTRAGENYX PHARM INC 100% w/w N213687 001 Jun 30, 2020 Jul NEWA

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+ @ ALLEGIS EQ 50MG BASE/5ML N074973 001 Jan 24, 2000 Aug DISC

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+!	VERITY	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jul	CAHN
+!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jul	CAHN
+!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jul	CAHN

TROMETHAMINE

SOLUTION; INJECTION

THAM

+! HOSPIRA 18GM/500ML (3.6GM/100ML) N013025 002 Jun CMFD

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 TROSPIUM CHLORIDE
 AB GRANULES PHARMS 60MG A213185 001 Apr 23, 2020 Apr NEWA

TUCATINIB

TABLET;ORAL
 TUKYSA
 + SEATTLE GENETICS 50MG N213411 001 Apr 17, 2020 Apr NEWA
 +! 150MG N213411 002 Apr 17, 2020 Apr NEWA

URSODIOL

CAPSULE;ORAL
 URSODIOL
 LGM PHARMA 200MG A205789 001 May 08, 2020 Aug CAHN
 400MG A205789 002 May 08, 2020 Aug CAHN
 NEXGEN PHARMA INC 200MG A205789 001 May 08, 2020 Apr NFTG
 400MG A205789 002 May 08, 2020 Apr NFTG
 AB RISING 300MG A213200 001 Feb 12, 2020 Jan NEWA
 AB UPSHER SMITH LABS 300MG A213555 001 Aug 17, 2020 Aug NEWA
 TABLET;ORAL
 URSODIOL
 @ IMPAX LABS INC 250MG A200826 001 Dec 23, 2011 Aug DISC
 @ 500MG A200826 002 Dec 23, 2011 Aug DISC
 AB STRIDES PHARMA 250MG A213504 001 Aug 20, 2020 Aug NEWA
 AB 500MG A213504 002 Aug 20, 2020 Aug NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL
 VALACYCLOVIR HYDROCHLORIDE
 >D> AB HIKMA EQ 500MG BASE A078656 001 May 24, 2010 Sep DISC
 >A> @ EQ 500MG BASE A078656 001 May 24, 2010 Sep DISC
 >D> AB EQ 1GM BASE A078656 002 May 24, 2010 Sep DISC
 >A> @ EQ 1GM BASE A078656 002 May 24, 2010 Sep DISC
 @ TEVA PHARMS EQ 500MG BASE A077655 001 May 24, 2010 Jan DISC
 @ EQ 1GM BASE A077655 002 May 24, 2010 Jan DISC
 AB YILING EQ 500MG BASE A209553 001 Mar 18, 2020 Mar NEWA
 AB EQ 1GM BASE A209553 002 Mar 18, 2020 Mar NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL
 VALGANCICLOVIR HYDROCHLORIDE
 >D> AB GRANULES PHARMS 50MG/ML A213306 001 Jan 31, 2020 Sep DISC
 >A> @ 50MG/ML A213306 001 Jan 31, 2020 Sep DISC
 AB 50MG/ML A213306 001 Jan 31, 2020 Jan NEWA

VALPROIC ACID

CAPSULE;ORAL
 VALPROIC ACID
 >A> AB EYWA 250MG A207611 001 Aug 05, 2019 Sep CAHN
 >D> AB NOVELGENIX THERAPS 250MG A207611 001 Aug 05, 2019 Sep CAHN
 SYRUP;ORAL
 VALPROIC ACID
 >A> AA BIOPHARM 250MG/5ML A090517 001 May 28, 2010 Sep CAHN
 >D> AA ECI PHARMS LLC 250MG/5ML A090517 001 May 28, 2010 Sep CAHN
 @ NOSTRUM LABS INC 250MG/5ML A077105 001 Jul 29, 2005 Aug CAHN
 >A> AA PHARMA LIFE 250MG/5ML A090517 001 May 28, 2010 Sep CAHN

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION;ORAL
 FIRVANQ KIT
 +! AZURITY EQ 25MG BASE/ML N208910 001 Jan 26, 2018 Jun CAHN
 +! EQ 50MG BASE/ML N208910 002 Jan 26, 2018 Jun CAHN
 VANOCIN HYDROCHLORIDE
 ! ANI PHARMS INC EQ 250MG BASE/5ML A061667 002 Jul 13, 1983 Jul CHRS
 INJECTABLE;INJECTION
 VANCOMYCIN HYDROCHLORIDE
 AP HAINAN POLY PHARM EQ 500MG BASE/VIAL A212332 001 Jun 12, 2019 Jun CMFD
 AP EQ 1GM BASE/VIAL A212332 002 Jun 12, 2019 Jun CMFD
 AP HIKMA EQ 500MG BASE/VIAL A203300 001 Aug 11, 2020 Jul NEWA
 AP EQ 1GM BASE/VIAL A203300 002 Aug 11, 2020 Jul NEWA

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020	Jul	NFTG	
>A>	AP		EQ 10GM BASE/VIAL	A063076	002	Sep 14, 2020	Sep	NEWA	
	AP	!	MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Jul	CHRS
	AP		PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CAHN
	AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CAHN

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

	+	!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	May	CPOT
	+	!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	May	NEWA
	+	!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	May	CPOT
	+	!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	May	NEWA
	+	!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	May	CPOT
	+	!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	May	NEWA
	+	!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	May	CPOT

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

>D>	+	@	BAYER HLTHCARE	2.5MG	N021400	003	Aug 19, 2003	Sep	CPOT
>A>	+	@		EQ 2.5MG BASE	N021400	003	Aug 19, 2003	Sep	CPOT
>D>	AB	+		5MG	N021400	001	Aug 19, 2003	Sep	CPOT
>A>	AB	+		EQ 5MG BASE	N021400	001	Aug 19, 2003	Sep	CPOT
>D>	AB	+		10MG	N021400	002	Aug 19, 2003	Sep	CPOT
>A>	AB	+		EQ 10MG BASE	N021400	002	Aug 19, 2003	Sep	CPOT
>D>	AB	+		20MG	N021400	004	Aug 19, 2003	Sep	CPOT
>A>	AB	+		EQ 20MG BASE	N021400	004	Aug 19, 2003	Sep	CPOT

VARDENAFIL HYDROCHLORIDE

>D>	AB		ALEMBIC PHARMS LTD	2.5MG	A214031	001	Aug 04, 2020	Sep	CPOT
>A>	AB			EQ 2.5MG BASE	A214031	001	Aug 04, 2020	Sep	CPOT
	AB			2.5MG	A214031	001	Aug 04, 2020	Jul	NEWA
>D>	AB			5MG	A214031	002	Aug 04, 2020	Sep	CPOT
>A>	AB			EQ 5MG BASE	A214031	002	Aug 04, 2020	Sep	CPOT
	AB			5MG	A214031	002	Aug 04, 2020	Jul	NEWA
>D>	AB			10MG	A214031	003	Aug 04, 2020	Sep	CPOT
>A>	AB			EQ 10MG BASE	A214031	003	Aug 04, 2020	Sep	CPOT
	AB			10MG	A214031	003	Aug 04, 2020	Jul	NEWA
>D>	AB			20MG	A214031	004	Aug 04, 2020	Sep	CPOT
>A>	AB			EQ 20MG BASE	A214031	004	Aug 04, 2020	Sep	CPOT
	AB			20MG	A214031	004	Aug 04, 2020	Jul	NEWA
>D>		@	AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Sep	CPOT
>A>		@		EQ 5MG BASE	A210738	001	Oct 31, 2018	Sep	CPOT
>D>		@		10MG	A210738	002	Oct 31, 2018	Sep	CPOT
>A>		@		EQ 10MG BASE	A210738	002	Oct 31, 2018	Sep	CPOT
>D>		@		20MG	A210738	003	Oct 31, 2018	Sep	CPOT
>A>		@		EQ 20MG BASE	A210738	003	Oct 31, 2018	Sep	CPOT
>D>	AB		CROSSMEDIKA SA	2.5MG	A209057	001	Oct 31, 2018	Sep	CPOT
>A>	AB			EQ 2.5MG BASE	A209057	001	Oct 31, 2018	Sep	CPOT
>D>	AB			5MG	A209057	002	Oct 31, 2018	Sep	CPOT
>A>	AB			EQ 5MG BASE	A209057	002	Oct 31, 2018	Sep	CPOT
>D>	AB			10MG	A209057	003	Oct 31, 2018	Sep	CPOT
>A>	AB			EQ 10MG BASE	A209057	003	Oct 31, 2018	Sep	CPOT
>D>	AB			20MG	A209057	004	Oct 31, 2018	Sep	CPOT
>A>	AB			EQ 20MG BASE	A209057	004	Oct 31, 2018	Sep	CPOT
>D>	AB		MACLEODS PHARMS LTD	2.5MG	A204632	001	Oct 22, 2019	Sep	CPOT
>A>	AB			EQ 2.5MG BASE	A204632	001	Oct 22, 2019	Sep	CPOT
>D>	AB			5MG	A204632	002	Oct 22, 2019	Sep	CPOT
>A>	AB			EQ 5MG BASE	A204632	002	Oct 22, 2019	Sep	CPOT
>D>	AB			10MG	A204632	003	Oct 22, 2019	Sep	CPOT
>A>	AB			EQ 10MG BASE	A204632	003	Oct 22, 2019	Sep	CPOT
>D>	AB			20MG	A204632	004	Oct 22, 2019	Sep	CPOT
>A>	AB			EQ 20MG BASE	A204632	004	Oct 22, 2019	Sep	CPOT
>D>	AB		TEVA PHARMS	2.5MG	A091347	001	May 03, 2012	Sep	CPOT
>A>	AB			EQ 2.5MG BASE	A091347	001	May 03, 2012	Sep	CPOT
>D>	AB			5MG	A091347	002	May 03, 2012	Sep	CPOT
>A>	AB			EQ 5MG BASE	A091347	002	May 03, 2012	Sep	CPOT
>D>	AB			10MG	A091347	003	May 03, 2012	Sep	CPOT
>A>	AB			EQ 10MG BASE	A091347	003	May 03, 2012	Sep	CPOT

TABLET;ORAL

VARDENAFIL HYDROCHLORIDE

>D>	AB		20MG	A091347	004	May 03, 2012	Sep	CPOT
>A>	AB		EQ 20MG BASE	A091347	004	May 03, 2012	Sep	CPOT
>D>	AB	ZYDUS PHARMS	2.5MG	A208960	001	Oct 31, 2018	Sep	CPOT
>A>	AB		EQ 2.5MG BASE	A208960	001	Oct 31, 2018	Sep	CPOT
>D>	AB		5MG	A208960	002	Oct 31, 2018	Sep	CPOT
>A>	AB		EQ 5MG BASE	A208960	002	Oct 31, 2018	Sep	CPOT
>D>	AB		10MG	A208960	003	Oct 31, 2018	Sep	CPOT
>A>	AB		EQ 10MG BASE	A208960	003	Oct 31, 2018	Sep	CPOT
>D>	AB		20MG	A208960	004	Oct 31, 2018	Sep	CPOT
>A>	AB		EQ 20MG BASE	A208960	004	Oct 31, 2018	Sep	CPOT

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

+	!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020	Aug	NEWA
		VASOSTRICT						
+	!	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr	NEWA
+	!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	+	UPJOHN	EQ 37.5MG BASE	N020699	001	Oct 20, 1997	Jun	CAHN
AB	+		EQ 75MG BASE	N020699	002	Oct 20, 1997	Jun	CAHN
		@	EQ 100MG BASE	N020699	003	Oct 20, 1997	Jun	CAHN
AB	+		EQ 150MG BASE	N020699	004	Oct 20, 1997	Jun	CAHN

VENLAFAXINE HYDROCHLORIDE

AB		INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar	NEWA
AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar	NEWA
AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

>D>		AUROBINDO PHARMA LTD	2.5MG/ML	A212965	001	Jul 06, 2020	Sep	CHRS
>A>	!		2.5MG/ML	A212965	001	Jul 06, 2020	Sep	CHRS
			2.5MG/ML	A212965	001	Jul 06, 2020	Jul	NEWA

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

>A>	AP	AREVA PHARMS	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Sep	NEWA
	AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar	NEWA
	AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar	NEWA
	AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar	NEWA

TABLET;ORAL

CALAN

	@	PFIZER	40MG	N018817	003	Feb 23, 1988	Jul	CAHN
	+	@	80MG	N018817	001	Sep 10, 1984	Jul	CAHN
	+	@	120MG	N018817	002	Sep 10, 1984	Jul	CAHN
		@	160MG	N018817	004	Feb 23, 1988	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL

COVERA-HS

	@	PFIZER	180MG	N020552	001	Feb 26, 1996	Aug	CAHN
		@	240MG	N020552	002	Feb 26, 1996	Aug	CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA		GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020	Apr	NEWA
----	--	-----------------	--------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

	@	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Mar	DISC
	@		20MG	A208212	002	Sep 30, 2019	Mar	DISC
	@		40MG	A208212	003	Sep 30, 2019	Mar	DISC

VILTOLARSENSOLUTION; INTRAVENOUS
VILTEPSO

+! NIPPON SHINYAKU 250MG/5ML (50MG/ML) N212154 001 Aug 12, 2020 Aug NEWA

VINCRISTINE SULFATEINJECTABLE; INJECTION
VINCRISTINE SULFATE PFSAP ! HOSPIRA 1MG/ML A071484 001 Apr 19, 1988 Feb CTEC
AP TEVA PHARMS USA 1MG/ML A075493 001 Sep 01, 1999 Feb CMFDVORICONAZOLEINJECTABLE; INTRAVENOUS
VORICONAZOLE

AP GLAND PHARMA LTD 200MG/VIAL A211099 001 Mar 31, 2020 Mar NEWA

TABLET; ORAL
VORICONAZOLEAB RISING 50MG A206762 001 May 24, 2016 Jul CAHN
AB 200MG A206762 002 May 24, 2016 Jul CAHNWARFARIN SODIUMTABLET; ORAL
COUMADIN

>D>	AB	+	BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Sep	DISC
>A>		+	@	1MG	N009218	022	Mar 01, 1990	Sep	DISC
>D>	AB	+		2MG	N009218	013		Sep	DISC
>A>		+	@	2MG	N009218	013		Sep	DISC
>D>	AB	+		2.5MG	N009218	018		Sep	DISC
>A>		+	@	2.5MG	N009218	018		Sep	DISC
>D>	AB	+		3MG	N009218	025	Nov 18, 1996	Sep	DISC
>A>		+	@	3MG	N009218	025	Nov 18, 1996	Sep	DISC
>D>	AB	+		4MG	N009218	023	Aug 24, 1993	Sep	DISC
>A>		+	@	4MG	N009218	023	Aug 24, 1993	Sep	DISC
>D>	AB	+		5MG	N009218	007		Sep	DISC
>A>		+	@	5MG	N009218	007		Sep	DISC
>D>	AB	+		6MG	N009218	026	Nov 18, 1996	Sep	DISC
>A>		+	@	6MG	N009218	026	Nov 18, 1996	Sep	DISC
>D>	AB	+		7.5MG	N009218	016		Sep	DISC
>A>		+	@	7.5MG	N009218	016		Sep	DISC
>D>	AB	+	!	10MG	N009218	005		Sep	DISC
>A>		+	@	10MG	N009218	005		Sep	DISC

WARFARIN SODIUM

>D>	AB		PLIVA	10MG	A040616	008	Jul 05, 2006	Sep	CHRS
>A>	AB	!		10MG	A040616	008	Jul 05, 2006	Sep	CHRS

ZAFIRLUKASTTABLET; ORAL
ZAFIRLUKAST

>A>	AB		ANNORA PHARMA	10MG	A212475	001	Sep 10, 2020	Sep	NEWA
>A>	AB			20MG	A212475	002	Sep 10, 2020	Sep	NEWA

ZALEPLONCAPSULE; ORAL
ZALEPLON

>D>	AB		HIKMA	5MG	A078147	001	Nov 25, 2008	Sep	DISC
>D>	AB			10MG	A078147	002	Nov 25, 2008	Sep	DISC
>A>		@	HIKMA PHARMS	5MG	A078147	001	Nov 25, 2008	Sep	DISC
>A>		@		10MG	A078147	002	Nov 25, 2008	Sep	DISC
		@	TEVA PHARMS	5MG	A077239	001	Jun 06, 2008	Mar	DISC
		@		10MG	A077239	002	Jun 06, 2008	Mar	DISC

ZIDOVUDINESOLUTION; ORAL
RETROVIR

AA +! VIIV HLTHCARE 50MG/5ML N019910 001 Sep 28, 1989 Jul CDFR

ZIDOVUDINE

AA AUROBINDO 50MG/5ML A077268 001 Sep 19, 2005 Jul CDFR
AA CIPLA LTD 50MG/5ML A077981 001 Jun 26, 2008 Jul CDFRTABLET; ORAL
ZIDOVUDINE

>D> AB HIKMA 300MG A076844 001 Sep 19, 2005 Sep DISC

<u>TABLET;ORAL</u>							
ZIDOVUDINE							
>A>	@	300MG	A076844	001	Sep 19, 2005	Sep DISC	
	@ MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011	Apr CAHN	
<u>ZINC SULFATE</u>							
SOLUTION;INTRAVENOUS							
ZINC SULFATE							
	AM REAGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Apr NEWA	
<u>ZIPRASIDONE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
GEODON							
AB	+!	UPJOHN	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jun CAHN
AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001	Jun CAHN
AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001	Jun CAHN
AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001	Jun CAHN
ZIPRASIDONE HYDROCHLORIDE							
AB		CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar CMFD
AB			EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar CMFD
AB			EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar CMFD
AB			EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar CMFD
<u>ZIPRASIDONE MESYLATE</u>							
INJECTABLE;INTRAMUSCULAR							
GEODON							
AP	+!	UPJOHN	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jun CAHN
<u>ZOLEDRONIC ACID</u>							
INJECTABLE;INTRAVENOUS							
ZOLEDRONIC ACID							
	@	EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr DISC
AP		INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb NEWA
AP		PUNISKA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
<u>ZOLMITRIPTAN</u>							
TABLET;ORAL							
ZOLMITRIPTAN							
AB		APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar CAHN
AB			5MG	A206973	002	Jun 30, 2017	Mar CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
ZOLMITRIPTAN							
	@	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb DISC
	@		5MG	A202855	002	Sep 20, 2019	Feb DISC
<u>ZOLPIDEM TARTRATE</u>							
TABLET;ORAL							
ZOLPIDEM TARTRATE							
	@	VINTAGE	5MG	A078616	001	Nov 21, 2008	Jun DISC
	@		10MG	A078616	002	Nov 21, 2008	Jun DISC
	@	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007	Apr DISC
	@		10MG	A077990	002	Apr 23, 2007	Apr DISC
TABLET, EXTENDED RELEASE;ORAL							
ZOLPIDEM TARTRATE							
>A>	AB	BRECKENRIDGE	6.25MG	A213592	001	Jun 04, 2020	Sep CAHN
>A>	AB		12.5MG	A213592	002	Jun 04, 2020	Sep CAHN
>D>	AB	CENTAUR PHARMS PVT	6.25MG	A213592	001	Jun 04, 2020	Sep CAHN
	AB		6.25MG	A213592	001	Jun 04, 2020	Jun NEWA
>D>	AB		12.5MG	A213592	002	Jun 04, 2020	Sep CAHN
	AB		12.5MG	A213592	002	Jun 04, 2020	Jun NEWA
<u>ZONISAMIDE</u>							
CAPSULE;ORAL							
ZONISAMIDE							
AB		AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Mar CMFD
AB			50MG	A077645	003	Sep 29, 2006	Mar CMFD
AB			100MG	A077645	001	Dec 22, 2005	Mar CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+!	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020	Apr	CAHN
+!	PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Feb	NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar	CMS1
	P AND L	0.1%	A090962	001	Jun 02, 2010	Apr	CMS1

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	CATALENT	10MG	A213105	001	Sep 21, 2020	Sep	NEWA
-----	----------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE

>A>	AUROBINDO PHARMA LTD	10MG	A213557	001	Sep 11, 2020	Sep	NEWA
-----	----------------------	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	Mar	CMFD
--	-----------------	-----------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Aug	CMS1
	ENCUBE	1%	A210986	001	Jan 27, 2020	Aug	CMS1
	MYLAN	1%	A204306	001	May 06, 2019	Aug	CMS1
	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr	CMS1

VOLTAREN ARTHRITIS PAIN

+!	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CTNA
+!		1%	N022122	001	Oct 17, 2007	Mar	CMS1

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

>A>	GRANULES	25MG;220MG	A213663	001	Sep 24, 2020	Sep	NEWA
-----	----------	------------	---------	-----	--------------	-----	------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	HETERO LABS LTD III	EQ 20MG BASE	A208939	001	May 28, 2020	May	NEWA
		EQ 20MG BASE	A212507	001	Jun 02, 2020	May	NEWA
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020	Apr	NEWA

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

	DR REDDYS LABS LTD	EQ 20MG BASE	A211571	001	May 14, 2020	May	NEWA
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020	Jun	NEWA

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan	CMS1
@	MYLAN	10MG	A075674	001	Dec 21, 2001	Jan	DISC
@	TEVA	10MG	A075312	001	May 31, 2001	Mar	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

@	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Jul	DISC
		60MG	A212971	001	Feb 24, 2020	Feb	NEWA
@		180MG	A212971	002	Feb 24, 2020	Jul	DISC
		180MG	A212971	002	Feb 24, 2020	Feb	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

@	GRANULES	60MG	A211075	001	Oct 18, 2019	May	DISC
@		180MG	A211075	002	Oct 18, 2019	May	DISC

GUAIFENESINTABLET, EXTENDED RELEASE;ORAL
GUAIFENESIN

GRANULES	600MG	A213420	001	May 08, 2020	Apr	NEWA
	1.2GM	A213420	002	May 08, 2020	Apr	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020	Sep	DISC
>A>	@	600MG;60MG	A213203	001	Mar 25, 2020	Sep	DISC
		600MG;60MG	A213203	001	Mar 25, 2020	Mar	NEWA
>D>		1.2GM;120MG	A213203	002	Mar 25, 2020	Sep	DISC
>A>	@	1.2GM;120MG	A213203	002	Mar 25, 2020	Sep	DISC
		1.2GM;120MG	A213203	002	Mar 25, 2020	Mar	NEWA
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020	Apr	NEWA
		1.2GM;120MG	A212542	002	Apr 28, 2020	Apr	NEWA

IBUPROFEN

TABLET;ORAL

ADVIL

+!	GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984	Aug	CHRS
+		200MG	N018989	001	May 18, 1984	Aug	CRLD
>A>	IBUPROFEN						
	SHANDONG XINHUA	200MG	A207095	002	Aug 21, 2018	Sep	CMS1
	@ ULTRATAB LABS INC	200MG	A209076	001	Jan 06, 2020	Jun	DISC
	@ VINTAGE PHARMS	200MG	A071639	001	Feb 02, 1988	Jul	DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

>A>	BAUSCH	EQ 0.035% BASE	A208158	001	Sep 24, 2020	Sep	NEWA
	KETOTIFEN FUMARATE						
	BAYSHORE PHARMS LLC	EQ 0.025% BASE	A204059	001	Jun 01, 2020	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020	Apr	NEWA
	PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Feb	CMFD

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan	CMFD
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018	Jan	CAHN
	@ NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Jun	CAHN
	XIROMED	1.5MG	A205329	001	Sep 18, 2018	Feb	CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	May	CMFD
	@ STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020	Jul	DISC

SYRUP;ORAL

LORATADINE

	@ TEVA	1MG/ML	A075505	001	Nov 07, 2003	Apr	DISC
--	--------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

LORATADINE

	@ MYLAN	10MG	A075790	001	Nov 07, 2008	Jan	DISC
	@	10MG	A078447	001	Aug 12, 2011	Jan	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

>A>	FDN CONSUMER	10MG	N021375	001	Dec 19, 2002	Sep	CAHN
>D>	GLAXOSMITHKLINE	10MG	N021375	001	Dec 19, 2002	Sep	CAHN
	LORATADINE						
	@ ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003	Apr	DISC
>A>	RUBICON	10MG	A214280	001	Sep 10, 2020	Sep	NEWA
>A>	TENSHI	5MG	A212795	001	Sep 18, 2020	Sep	NEWA

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ YICHANG HUMANWELL 220MG A212033 001 Aug 30, 2019 Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

DR REDDYS LABS SA EQ 2MG BASE A212983 001 Feb 21, 2020 Feb NEWA
 EQ 2MG BASE A213233 001 Aug 04, 2020 Jul NEWA
 EQ 4MG BASE A212983 002 Feb 21, 2020 Feb NEWA
 EQ 4MG BASE A213233 002 Aug 04, 2020 Jul NEWA
 P AND L EQ 2MG BASE A212057 001 May 14, 2020 May NEWA
 EQ 4MG BASE A212057 002 May 14, 2020 May NEWA

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ @ MAYER LABS INC 1GM N018683 001 Apr 01, 1983 Mar DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

APOTEX EQ 0.1% BASE A078350 001 Dec 07, 2015 Aug CMS1
 AUROBINDO PHARMA LTD EQ 0.1% BASE A204812 001 Dec 18, 2015 Aug CMS1
 EQ 0.2% BASE A209995 001 Apr 04, 2019 Aug CMS1
 GLAND PHARMA LTD EQ 0.1% BASE A209619 001 Aug 02, 2019 Jul CMS1
 EQ 0.2% BASE A209752 001 May 20, 2020 May NFTG
 MICRO LABS LTD INDIA EQ 0.2% BASE A204620 001 Jun 16, 2020 Jun NEWA
 PATADAY ONCE DAILY RELIEF
 +! ALCON LABS INC EQ 0.2% BASE N021545 001 Dec 22, 2004 Aug CAHN
 +! EQ 0.7% BASE N206276 001 Jan 30, 2015 Aug CAHN
 +! NOVARTIS EQ 0.2% BASE N021545 001 Dec 22, 2004 Mar CTNA
 +! EQ 0.2% BASE N021545 001 Dec 22, 2004 Mar CMS1
 +! EQ 0.7% BASE N206276 001 Jan 30, 2015 Jul CTNA
 +! EQ 0.7% BASE N206276 001 Jan 30, 2015 Jul CMS1
 PATADAY TWICE DAILY RELIEF
 +! ALCON LABS INC EQ 0.1% BASE N020688 001 Dec 18, 1996 Aug CAHN
 +! NOVARTIS EQ 0.1% BASE N020688 001 Dec 18, 1996 Mar CTNA
 +! EQ 0.1% BASE N020688 001 Dec 18, 1996 Mar CMS1

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

HETERO LABS LTD III EQ 20MG BASE A211732 001 Mar 25, 2020 Mar NEWA
 P AND L EQ 20MG BASE A206582 001 Jun 01, 2020 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>D> @ ACTAVIS ELIZABETH 20MG;1.1GM A204137 001 Jul 15, 2016 Sep CAHN
 @ 20MG;1.1GM A204137 001 Jul 15, 2016 Mar DISC
 >D> PAR PHARM 20MG;1.1GM A201946 001 Jul 15, 2016 Sep DISC
 >A> @ 20MG;1.1GM A201946 001 Jul 15, 2016 Sep DISC
 >A> @ UNICORN 20MG;1.1GM A204137 001 Jul 15, 2016 Sep CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

LANNETT CO INC 17GM/PACKET A090600 001 Oct 06, 2009 Jan CMFD
 17GM/SCOOPFUL A090600 002 Oct 06, 2009 Jan CMFD
 POLYETHYLENE GLYCOL 3350
 LGM PHARMA 17GM/SCOOPFUL A090812 001 Oct 07, 2009 Aug CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ APOTEX INC EQ 75MG BASE A075167 001 May 04, 2000 May DISC
 @ EQ 150MG BASE A200172 001 May 31, 2012 Apr DISC
 @ STRIDES PHARMA EQ 75MG BASE A201745 001 Feb 29, 2012 Apr DISC
 @ EQ 75MG BASE A209160 001 Mar 05, 2018 Apr DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ EQ 150MG BASE
@ EQ 150MG BASE

A200536 001 Jun 28, 2011 Apr DISC
A209161 001 Feb 22, 2018 Apr DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2020

NO SEPTEMBER 2020 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Apr 28, 2031	U-2009			
<u>ABAMETAPIR - XEGLYZE</u>						
N 206966 001	10292389	Dec 17, 2034	DP U-2863		NCE	Jul 31, 2025
	7812163	Oct 28, 2026	DP U-2863			
	8212038	Jul 16, 2024	DP U-2863			
	9357783	Jul 16, 2024	DP			
	9839631	Jul 16, 2024	DS DP U-2863			
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115 001					CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001					NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10588895	Jul 07, 2020	U-2772		M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10588895	Jul 07, 2020	U-2772			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	RE43431	Jan 13, 2026	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	RE43431	Jan 13, 2026	DS			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134 001	10617695	Mar 19, 2027	DP U-1493			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	10646456	Jun 17, 2034	U-2808			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	10646456	Jun 17, 2034	U-2808			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	>A> 10751355	May 15, 2035	U-2414			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10695329	Oct 16, 2037	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001 >A>	9408837	Feb 28, 2030	U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002 >A>	9408837	Feb 28, 2030	U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003 >A>	9408837	Feb 28, 2030	U-2410			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 002					M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437 003					M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10624850	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10688091	Aug 17, 2035	DP			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001					NCE ODE-290	May 26, 2025 May 26, 2027
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID</u>						
A 090145 001					PC	Feb 27, 2021
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10646512	Mar 25, 2032	DP			
	>A> 10780112	Mar 09, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	>A> 10039718	Oct 06, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	>A> 8846628	Jun 03, 2030	DP U-2950			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	>A> 8846628	Jun 03, 2030	DP U-2950			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10633397	Apr 27, 2036	U-2816			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10633397	Apr 27, 2036	U-2816			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					ODE-307	May 27, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321		ODE-307	May 27, 2027
	8546428	Mar 19, 2029	DS DP U-1321			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023		U-2747	NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023		U-2747		
	9000041	Dec 23, 2023		U-2747		
	9624152	Dec 23, 2023		U-2748		
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023		U-2746	NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023		U-2746		
	9000041	Dec 23, 2023		U-2746		
	9624152	Dec 23, 2023		U-2749		
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10624918	Jun 03, 2029		U-916		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Jan 13, 2025	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP U-2627			
	10682364	Jun 10, 2031	DP			
	10688108	Jun 10, 2031		U-2627		
	10716799	Jun 10, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	10265265	Sep 27, 2027	DP		NDF	Jul 20, 2023
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
	7390791	Apr 17, 2025	DS DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024		U-2759	NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027		U-2759		
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025		U-2759		
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034		U-2759		
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6579968	Jun 28, 2021	DS DP			
	6794489	Jun 28, 2021	DS DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Apr 12, 2026	DS		Y	
	RE48059	Apr 12, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Apr 12, 2026	DS	Y		
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Apr 12, 2026	DS	Y		
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Apr 12, 2026	DS	Y		
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Apr 12, 2026	DS	Y		
	RE48059	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y		
	RE48059	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		ODE-300	May 22, 2027
	9273077	May 21, 2029	U-2837			
	9611283	Apr 10, 2034	U-2837			
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	10729653	Apr 09, 2030	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	10729653	Apr 09, 2030	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			
	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688094	Apr 30, 2032	U-2879			
	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			
	10688155	Jun 07, 2030	U-2281			
	10688155	Jun 07, 2030	U-2890			
	10688155	Jun 07, 2030	U-2891			
	10688155	Jun 07, 2030	U-2892			
	10688155	Jun 07, 2030	U-2893			
	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			
	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10660858	Sep 07, 2031	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	10716753	May 28, 2030	DP U-2889		NC	Jul 23, 2023
	8324266	May 28, 2030	U-2889			
	8703806	May 28, 2030	U-2889			
	8808713	May 28, 2030	DP U-2889			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	8815258	Mar 17, 2031	U-2889			
	9415009	May 28, 2030	U-2889			
	9463161	May 28, 2030	DP U-2889			
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001	>A> RE47826	May 20, 2029	U-2949		NP	Aug 28, 2023
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586 002					CGT	Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
	10716777	Oct 27, 2030	U-2856			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001				>A> NPP NPP		May 06, 2022 Nov 05, 2022
<u>CALCITRIOL - VECTICAL</u>						
N 022087 001				>A> NPP		Jul 17, 2023
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10195168	Jan 11, 2033	DP		NP	Jul 21, 2023
	10213400	Mar 15, 2033	U-2499			
	10675258	Jan 11, 2033	U-2938			
	8591922	Jan 11, 2033	DP			
	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
	8901173	Jan 11, 2033	DP			
	9050302	Mar 15, 2033	U-1532			
	9132107	Jan 11, 2033	DP			
	9486426	Mar 15, 2033	U-1532			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-1715			
	8680052	Mar 09, 2033	U-2869			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2780		NPP	Jul 31, 2023
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001					I-838	Jul 17, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-842	Aug 20, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002					I-842	Aug 20, 2023
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	>A> 7491704	Apr 14, 2025	U-2319		I-842	Aug 20, 2023
	>A> 7491704	Apr 14, 2025	U-2320			
	>A> 7491704	Apr 14, 2025	U-2947			
	>A> 8129346	Apr 14, 2025	U-2319			
	>A> 8129346	Apr 14, 2025	U-2320			
	>A> 8129346	Apr 14, 2025	U-2947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	>A> 8207127	Apr 14, 2025	U-2319			
	>A> 8207127	Apr 14, 2025	U-2320			
	>A> 8207127	Apr 14, 2025	U-2947			
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	8268800	Aug 22, 2030	DS U-2864		NCE	Jul 07, 2025
	8268800	Aug 22, 2030	DS U-2865			
	8268800	Aug 22, 2030	DS U-2866			
	8268800	Aug 22, 2030	DS U-2867			
	8618075	Oct 16, 2028	U-2864			
	8618075	Oct 16, 2028	U-2867			
	9567363	Oct 16, 2028	DS			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	10376527	May 27, 2036	DP U-2718		NP	May 05, 2023
	10722456	May 27, 2036	DP U-2718			
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7964592	Apr 29, 2028	DS DP			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7964592	Apr 29, 2028	DS DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
	8487093	Nov 19, 2029	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001					NP	May 22, 2023
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	10159682	Aug 14, 2028	U-2942		>A> NCE	Aug 26, 2025
	8143240	Jan 12, 2023	U-2942			
	8785427	Jul 25, 2030	DP			
	8865690	Jul 24, 2022	U-2942			
	9211295	Jul 24, 2022	DP			
	9433628	Feb 08, 2029	DP			
	9486458	Jul 24, 2028	U-2942			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500 001	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500 002	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	10039718	Oct 06, 2032	DP			
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395 001	10039718	Oct 06, 2032	DP			
	>A> 8148374	Sep 03, 2029	DS DP U-1279			
	>A> 8148374	Sep 03, 2029	DS DP U-2939			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10039718	Oct 06, 2032	DP			
	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
	7390791	Apr 17, 2025	DS DP			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	10039718	Oct 06, 2032	DP			
	7390791	Apr 17, 2025	DS DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	10039718	Oct 06, 2032	DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			
<u>COPPER DOTATATE CU-64 - DETECTNET</u>						
N 213227 001	>A> 10159759	Aug 23, 2032	U-2951		>A> NCE	Sep 03, 2025
	>A> 10383961	Aug 23, 2032	U-2951			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			NPP	Mar 23, 2023
	8168614	Jan 20, 2030		U-1932	PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			PED	Sep 23, 2023
	8501712	Feb 16, 2027		U-1932		
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027		U-1932		
	9682092*PED	Aug 16, 2027				
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001					NCE	Apr 30, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036		U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036		U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036		U-1399	M-216	Dec 22, 2020
	10328037	Aug 16, 2036		U-1399	PED	Jun 22, 2021
	10548859	Aug 16, 2036		U-1399		
	8026284	Sep 22, 2027		U-1399		
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027		U-1399		
	9198882	Jan 26, 2027		U-1399		
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP	U-1399		
	9925157	Jan 26, 2027	DP	U-1399		
	9925158	Jan 26, 2027	DP	U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036		U-1399	M-216	Dec 22, 2020
	10328037	Aug 16, 2036		U-1399	PED	Jun 22, 2021
	10548859	Aug 16, 2036		U-1399		
	8026284	Sep 22, 2027		U-1399		
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027		U-1399		
	9198882	Jan 26, 2027		U-1399		
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP	U-1399		
	9925157	Jan 26, 2027	DP	U-1399		
	9925158	Jan 26, 2027	DP	U-1399		
<u>CYSTEAMINE HYDROCHLORIDE - CYSTADROPS</u>						
N 211302 001					>A> NP	Aug 19, 2023
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP	U-2752		
	10583155	Jan 15, 2039	DP	U-2752		
	10653719	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10478453	Jan 15, 2039	DP	U-2752		
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039		U-2722		
	10583155	Jan 15, 2039	DP	U-2752		
	10653719	Jan 15, 2039	DP			
	10702490	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001					ODE-287	Aug 03, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001 >A>	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002 >A>	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003 >A>	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004 >A>	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005 >A>	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002 >A>	6515117	Oct 04, 2025	DS DP U-493			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10711013	Oct 27, 2030	DS DP			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-263	Jul 23, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 001					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 002					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 003					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003					M-263	Jul 23, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	7049328	Jun 28, 2021	U-735			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	10702539	Jan 09, 2023	U-1597			
	10702539	Jan 09, 2023	U-2868			
	10702539	Jan 09, 2023	U-985			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10022502	Jun 22, 2034	U-2340			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP	U-2727		
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP	U-2727		
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP	U-2727		
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP	U-2727		
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286 001					CGT	Nov 18, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907 001					CGT	Nov 19, 2020
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210305 001					>A> PC	Feb 14, 2021
<u>DIMETHYL FUMARATE - DIMETHYL FUMARATE</u>						
A 210305 002					>A> PC	Feb 14, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					M-260	Feb 05, 2023
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					I-839	Aug 06, 2023
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10603281	Jun 08, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720		NPP	Apr 27, 2023
	10478601	Apr 25, 2035	DP U-2721			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
	10682351	Sep 01, 2036	U-2850			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	6872728	Jan 25, 2021	DS DP		NCE	Jul 23, 2023
	7056927	Sep 10, 2024	DS DP		NP	May 29, 2023
	7179815	Mar 07, 2021	U-2842			
	7419983	Jul 06, 2024	DS DP			
	7462625	Jan 25, 2021	DS DP U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10646481	Aug 13, 2029	DP			
	>A> 10758534	Oct 06, 2035	DS DP U-2645			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Jun 24, 2026	DS DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Jun 24, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7579449	Aug 01, 2028	DS		M-252	Mar 30, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7579449	Aug 01, 2028	DS		M-252	Mar 30, 2023
	8673927	May 04, 2027	U-1652	Y	M-258	Jul 03, 2022
	9173859	May 04, 2027	DP U-1772	Y		
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10610489	Sep 30, 2030	DP			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	7579449	Aug 01, 2028	DS			
<u>EMTRICITABINE - EMTRICITABINE</u>						
A 091168 001				>A> PC		Feb 27, 2021
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Apr 17, 2025	DS DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Apr 17, 2025	DS DP	>A> NPP		Sep 28, 2020
				ODE-284		Sep 28, 2024
				ODE-285		Sep 28, 2024
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	>A> 10772868	Mar 25, 2036	DP			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-826	Apr 08, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10258622	Nov 21, 2032	U-2802			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9474754	Aug 05, 2033	DP U-2802			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745	>A> ODE-313		Aug 15, 2026
	>A> 10738037	May 18, 2037	DS DP U-2946			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745	>A> ODE-313		Aug 15, 2026
	>A> 10738037	May 18, 2037	DS DP U-2946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10737028	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10737028	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10737028	Nov 23, 2024	DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001					I-840	Jul 31, 2023
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	8999932	Feb 07, 2031	DS DP U-2014			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039	U-2786			
	10632066	Feb 01, 2039	U-2787			
	>A> 10765628	Feb 01, 2039	U-2786			
	>A> 10765628	Feb 01, 2039	U-2787			
	>A> 10780047	Feb 01, 2039	U-2786			
	>A> 10780047	Feb 01, 2039	U-2787			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Oct 22, 2039	U-2859		NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		>A> ODE-312	Jun 25, 2027
	10478442	May 03, 2033	U-2860			
	10603290	Aug 02, 2037	U-2861			
	9549909	May 03, 2033	U-2858			
	9603814	May 03, 2033	U-2858			
	9603815	May 03, 2033	U-2858			
	9610260	May 03, 2033	U-2858			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLORTAUICIPIR F-18 - TAUVID</u>						
N 212123 001	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLORTAUICIPIR F-18 - TAUVID</u>						
N 212123 002	8932557	May 19, 2029	DS		NCE	May 28, 2025
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10716868	Dec 30, 2035	U-2450			
<u>FLUROESTRADIOL F-18 - CERIANNA</u>						
N 212155 001					NCE	May 20, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 6715485	Nov 03, 2020	DP			
	8978647	Dec 06, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	>A> 6715485	Nov 03, 2020	DP			
	8978647	Dec 06, 2030	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	>A> 10765820	May 19, 2025	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	10716753	May 28, 2030	DP U-2546			
<u>FOSFOMYCIN TROMETHAMINE - FOSFOMYCIN TROMETHAMINE</u>						
A 212548 001				>A> CGT		Apr 04, 2021
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10624911	Jun 02, 2037	DP			
	10717721	May 23, 2032	DS			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
	10624911	Jun 02, 2037	DP			
	10717721	May 23, 2032	DS			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
	8168615	Feb 25, 2025	DP			
	8461333	Feb 25, 2025	DS			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001					M-259	Apr 10, 2023
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10668040	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10688518	Nov 12, 2036	DP			
	10744277	Dec 07, 2036	DP U-2941			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP		NP	Jun 28, 2021
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NPP	Aug 31, 2023
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10722511	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10722511	Jul 25, 2033	U-1810			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
	10729720	Apr 21, 2035	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10752634	Jun 03, 2033	DP			
	>A> 8008309	Nov 13, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 8008309	Nov 13, 2027	DS DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10752634	Jun 03, 2033	DP			
	>A> 8008309	Nov 13, 2027	DS DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 8008309	Nov 13, 2027	DS DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 8008309	Nov 13, 2027	DS DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 8008309	Nov 13, 2027	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	10730879	Mar 05, 2033	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	10730879	Mar 05, 2033	DS DP			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	10631746	Aug 04, 2035	DP U-2815			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10722508	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					ODE-305 GAIN	Mar 06, 2022 Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					ODE-305 GAIN	Mar 06, 2022 Mar 06, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778			
	10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778			
	10646481	Aug 13, 2029	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784			
	10610125	Jun 21, 2030	U-2785			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001 >A>	10668072	Apr 04, 2037	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 001	RE46791	May 22, 2024	DS DP			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	May 22, 2024	DS DP			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LETTERMOVIR - PREVYMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP			
	RE46791	May 22, 2024	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	8470359	Oct 15, 2023	DS DP U-2940		I-829	May 01, 2023
	9539333	Nov 13, 2020	DS DP			
	9914802	Nov 13, 2020	DS DP U-2940			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001 >A>	10561524	Sep 16, 2029	U-2948		>A> D-181	Aug 20, 2023
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001 >A>	10561524	Sep 16, 2029	U-2948			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001 >A>	10561524	Sep 16, 2029	U-2948			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	>A> 10765640	May 10, 2031	DP			
	>A> 10765749	May 10, 2031	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
	>A> 10751305	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10675325	Aug 11, 2031	DP			
	10702576	Aug 11, 2031	U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927	May 04, 2027	U-1503	Y	M-252	Mar 30, 2023
	9173859	May 04, 2027	DP U-1503	Y	M-258	Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10555938	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10646437	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	10695345	Aug 30, 2039	DP U-543			
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	7763615	Dec 13, 2024	DS DP U-2836		NCE ODE-304	Jun 15, 2025 Jun 15, 2027
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	6667314	Aug 06, 2021	DS DP U-824			
	6667314*PED	Feb 06, 2022				
	7368460	Nov 25, 2022	U-824			
	7368460*PED	May 25, 2023				
	7576097	May 25, 2021	DS			
	7576097*PED	Nov 25, 2021				
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	10709713	May 26, 2030	U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003					M-244	Aug 12, 2022
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	10709844	Mar 10, 2029	DP			
	8814834	May 27, 2031	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10610485	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10617651	Mar 23, 2032				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10617651	Mar 23, 2032				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10617651	Mar 23, 2032				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10617651	Mar 23, 2032				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10617651	Mar 23, 2032				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP			U-2357
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038				U-2357
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP			U-2357
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038				U-2357

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	6770262	Mar 29, 2021	U-2843			
	8334281	May 16, 2030	DP U-2843			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10596155	Jun 28, 2032	DP			
<u>METYSOSINE - METYSOSINE</u>						
A 213734 001					CGT	Jan 20, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 001					CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 002					CGT	Jan 18, 2021
<u>MEXILETINE HYDROCHLORIDE - MEXILETINE HYDROCHLORIDE</u>						
A 213500 003					CGT	Jan 18, 2021
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 001					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 002					PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10660904	Apr 20, 2036	U-1643			
	>A> 10780097	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10213512	Oct 01, 2030	DP U-1631			
	10265404	Oct 01, 2030	DP			
	10322186	Oct 01, 2030	U-1631			
	8865139	Oct 01, 2030	DP U-1631			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-1631			
	9675700	Oct 01, 2030	DP U-1631			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			
	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10737028	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10737028	Nov 23, 2024	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Nov 10, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10676440	Sep 25, 2035	DS DP			
	6297375	Mar 17, 2023	DS			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002 >A>	10758616	Apr 18, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003 >A>	10758616	Apr 18, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004 >A>	10758616	Apr 18, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	001				NCE	Aug 07, 2025
<u>NIFURTIMOX - LAMPIT</u>						
N 213464	002				NCE	Aug 07, 2025
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	10342787	Apr 16, 2038	DP U-2804		
		10576070	Apr 16, 2038	DP U-2804		
		7070581	Jun 23, 2023	DP		
		8517997	May 14, 2024	DP		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001	>A> 6762180	Oct 01, 2025	DS DP	I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002	>A> 6762180	Oct 01, 2025	DS DP	I-825	Mar 09, 2023
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447	001				I-833 ODE-295	Apr 29, 2023 Apr 29, 2027
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860	001	10213572	Feb 12, 2036	DP		
		10737051	Oct 20, 2035	DP		
		6758214	Feb 23, 2022	DP		
		7560076	Apr 21, 2027	DP		
		7618594	Oct 17, 2026	DP		
		9604028	Aug 13, 2029	U-2793		
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999	001	10751349	Apr 26, 2036	DP		
	>A>	10758549	Apr 26, 2036	U-2945		
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999	002	10751349	Apr 26, 2036	DP		
	>A>	10758549	Apr 26, 2036	U-2945		
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232	001	10238709	Feb 03, 2036	U-2857	NP	Jun 26, 2023
		10695397	Feb 03, 2036	U-2857		
		8329198	Sep 17, 2029	DP		
		8535695	Sep 17, 2029	U-2857		
		9265812	Sep 17, 2029	DP		
		9566246	Sep 17, 2029	DP		
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224	001	10342850	May 15, 2038	DP		
<u>OLAPARIB - LYNPARZA</u>						
N 208558	001	8071579	Aug 12, 2027	U-2480	I-831	May 08, 2023
		8071579	Aug 12, 2027	U-2819	I-832	May 19, 2023
		8071579	Aug 12, 2027	U-2820	ODE-283	Dec 27, 2026
		8071579	Aug 12, 2027	U-2821	ODE-306	May 08, 2027
		8071579	Aug 12, 2027	U-2822		
		8071579	Aug 12, 2027	U-2823		
		8071579	Aug 12, 2027	U-2824		
		8071579	Aug 12, 2027	U-2832		
		8071579	Aug 12, 2027	U-2833		
		8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2103		
		8143241	Aug 12, 2027	U-2480		
		8143241	Aug 12, 2027	U-2481		
		8143241	Aug 12, 2027	U-2482		
		8143241	Aug 12, 2027	U-2483		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2480		I-831	May 08, 2023
	8071579	Aug 12, 2027	U-2819		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2820		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2821		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680			
	9533053	May 19, 2032	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246	002				M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	001	10143680	Jul 06, 2035	DP	NCE	Mar 06, 2025
		10709691	Oct 12, 2035	U-2770	ODE-286	Mar 06, 2027
		8314097	Mar 27, 2029	DS DP		
		8609862	Jan 13, 2031	U-2770		
		8835646	Aug 23, 2026	DS DP		
		9434754	Jan 13, 2031	DS		
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	002	10143680	Jul 06, 2035	DP	NCE	Mar 06, 2025
		10709691	Oct 12, 2035	U-2770	ODE-286	Mar 06, 2027
		8314097	Mar 27, 2029	DS DP		
		8609862	Jan 13, 2031	U-2770		
		8835646	Aug 23, 2026	DS DP		
		9434754	Jan 13, 2031	DS		
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801	003	10143680	Jul 06, 2035	DP	NCE	Mar 06, 2025
		10709691	Oct 12, 2035	U-2770	ODE-286	Mar 06, 2027
		8314097	Mar 27, 2029	DS DP		
		8609862	Jan 13, 2031	U-2770		
		8835646	Aug 23, 2026	DS DP		
		9434754	Jan 13, 2031	DS		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001	10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	002	10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	10646485	Sep 02, 2036	DP U-1556		
		10668060	Dec 10, 2030	DP U-1556		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	002	10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	004	10675278	Nov 20, 2023	DP		
		10696684	Mar 30, 2025	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	10751325	Jun 11, 2035		U-2921		
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	8357714	Aug 26, 2031		U-2849	NP	Jul 08, 2023
	9867808	Aug 26, 2031		U-2849		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	May 14, 2029	DS DP	U-2774	NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029		U-2774		
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001					>A> M-14	Dec 06, 2022
					>A> PED	Jun 06, 2023
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	>A> 9439906	Jan 26, 2031		U-1901		
	>A> 9439906	Jan 26, 2031		U-2757		
	>A> 9439906	Jan 26, 2031		U-2758		
	>A> 9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	>A> 9439906	Jan 26, 2031		U-1901		
	>A> 9439906	Jan 26, 2031		U-2757		
	>A> 9439906	Jan 26, 2031		U-2758		
	>A> 9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	>A> 9439906	Jan 26, 2031		U-1901		
	>A> 9439906	Jan 26, 2031		U-2757		
	>A> 9439906	Jan 26, 2031		U-2758		
	>A> 9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	>A> 9439906	Jan 26, 2031		U-1901		
	>A> 9439906	Jan 26, 2031		U-2757		
	>A> 9439906	Jan 26, 2031		U-2758		
	>A> 9439906	Jan 26, 2031		U-543		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	>A> 9439906	Jan 26, 2031		U-1901		
	>A> 9439906	Jan 26, 2031		U-2757		
	>A> 9439906	Jan 26, 2031		U-2758		
	>A> 9439906	Jan 26, 2031		U-543		
<u>PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM</u>						
A 213725 001					PC	Feb 09, 2021
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022		U-2728		
	7772209	May 24, 2022		U-2729		
	9604990	Oct 28, 2035	DS			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033		U-2809	NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033		U-2809	NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033		U-2809	NCE	Apr 17, 2025
	9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10730876	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10646480	Aug 27, 2038	DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	8354430	Feb 06, 2026	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	8354430	Feb 06, 2026	U-1101			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Jan 30, 2028	DS			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		ODE-296 ODE-297	May 14, 2027 May 14, 2027
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	>A> 10030005	Nov 01, 2036	DS DP U-2952		>A> NCE	Sep 08, 2025
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Jul 02, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	9421195	Jul 24, 2029	U-1481			
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	8188113	Jul 27, 2030	DS DP		NCE	May 15, 2025
	8461179	Jun 07, 2032	DS DP		ODE-298	May 15, 2027
	8940756	Jun 07, 2032	U-2829			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	>A> 9586955	Feb 08, 2033	DS DP		NCE	Aug 07, 2025
	>A> 9969754	May 11, 2035	DS DP U-1943			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406	004				I-824	Oct 11, 2021
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	001	10130636	Aug 17, 2035	U-2012	I-830	May 15, 2023
		10130636	Aug 17, 2035	U-2101		
		10130636	Aug 17, 2035	U-2273		
		10130636	Aug 17, 2035	U-2830		
		7351701	Jul 23, 2024	U-2012		
		7351701	Jul 23, 2024	U-2101		
		7351701	Jul 23, 2024	U-2273		
		7351701	Jul 23, 2024	U-2830		
		7531530	Jul 23, 2024	U-2012		
		7531530	Jul 23, 2024	U-2101		
		7531530	Jul 23, 2024	U-2273		
		7531530	Jul 23, 2024	U-2830		
		8071579	Aug 12, 2027	U-2012		
		8071579	Aug 12, 2027	U-2101		
		8071579	Aug 12, 2027	U-2273		
		8071579	Aug 12, 2027	U-2830		
		8143241	Aug 12, 2027	U-2012		
		8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2273		
		8143241	Aug 12, 2027	U-2830		
		8859562	Aug 04, 2031	U-2012		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2273		
		8859562	Aug 04, 2031	U-2830		
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	002	10130636	Aug 17, 2035	U-2012	I-830	May 15, 2023
		10130636	Aug 17, 2035	U-2101		
		10130636	Aug 17, 2035	U-2273		
		10130636	Aug 17, 2035	U-2830		
		7351701	Jul 23, 2024	U-2012		
		7351701	Jul 23, 2024	U-2101		
		7351701	Jul 23, 2024	U-2273		
		7351701	Jul 23, 2024	U-2830		
		7531530	Jul 23, 2024	U-2012		
		7531530	Jul 23, 2024	U-2101		
		7531530	Jul 23, 2024	U-2273		
		7531530	Jul 23, 2024	U-2830		
		8071579	Aug 12, 2027	U-2012		
		8071579	Aug 12, 2027	U-2101		
		8071579	Aug 12, 2027	U-2273		
		8071579	Aug 12, 2027	U-2830		
		8143241	Aug 12, 2027	U-2012		
		8143241	Aug 12, 2027	U-2101		
		8143241	Aug 12, 2027	U-2273		
		8143241	Aug 12, 2027	U-2830		
		8859562	Aug 04, 2031	U-2012		
		8859562	Aug 04, 2031	U-2101		
		8859562	Aug 04, 2031	U-2273		
		8859562	Aug 04, 2031	U-2830		
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115	003	10130636	Aug 17, 2035	U-2012	I-830	May 15, 2023
		10130636	Aug 17, 2035	U-2101		
		10130636	Aug 17, 2035	U-2273		
		10130636	Aug 17, 2035	U-2830		
		7351701	Jul 23, 2024	U-2012		
		7351701	Jul 23, 2024	U-2101		
		7351701	Jul 23, 2024	U-2273		
		7351701	Jul 23, 2024	U-2830		
		7531530	Jul 23, 2024	U-2012		
		7531530	Jul 23, 2024	U-2101		
		7531530	Jul 23, 2024	U-2273		
		7531530	Jul 23, 2024	U-2830		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10682338	Sep 04, 2035	U-2583			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		I-837	Jun 22, 2023
	10519139	Aug 14, 2035	DS DP U-2855		>A> ODE-310	Jun 22, 2027
	10544108	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	>A> 10335462	Jun 21, 2033	U-2580		I-822	Jan 16, 2023
	>A> 8114833	Aug 13, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	>A> 8129343	Jan 29, 2029	DS DP U-2202			
	>A> 8536122	Mar 20, 2026	DS DP U-2202			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003					M-252	Jan 16, 2023
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001					ODE-231 PED	Oct 26, 2025 Apr 26, 2026
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10695365	Oct 22, 2033	DS		M-261	Apr 24, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					NPP ODE-293	Mar 19, 2023 Mar 19, 2027
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034		U-1470	NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP	U-1470	ODE-293	Mar 19, 2027
	8334270	Mar 21, 2028	DS DP	U-1470		
	8575135	Nov 16, 2032	DS DP	U-1470		
	8580765	Mar 21, 2028	DS DP	U-1470		
	8618076	Dec 11, 2030	DS DP	U-1470		
	8633309	Mar 26, 2029	DS DP	U-1470		
	8735372	Mar 21, 2028		U-1470		
	8889159	Mar 26, 2029		DP U-1470		
	8921341	Nov 16, 2032	DS DP	U-1470		
	8940718	Nov 16, 2032	DS DP	U-1470		
	9085573	Mar 21, 2028	DS DP	U-1470		
	9284342	Sep 13, 2030	DS DP	U-1470		
	9757406	Jan 30, 2034		DP		
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001					NP PED	May 26, 2023 Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10512609	Sep 05, 2037		U-2548		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10512609	Sep 05, 2037		U-2548		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038		U-2769		
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10624906	Oct 28, 2036		DP		
	10660907	Oct 28, 2036		DP		
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034		DP		
	10682376	Nov 13, 2028		DP		
	10695367	Nov 13, 2028		DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10682376	Nov 13, 2028	DP			
	10695367	Nov 13, 2028	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	10722667	Dec 30, 2028	DP			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003					M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004					M-253	Jan 29, 2023
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003					ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001					ODE-294	May 24, 2025
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 001	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 002	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	8664239	Aug 30, 2028	U-2678			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610510	Jan 25, 2033	U-2805			
	10610511	Oct 10, 2034	U-2806			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		I-835	Jun 18, 2023
	10245269	Apr 11, 2033	U-2737		I-836	Jun 18, 2023
	10245269	Apr 11, 2033	U-2851		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2854		ODE-299	Jan 23, 2027
	10369155	Oct 16, 2035	U-2736		>A> ODE-314	Jun 18, 2027
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Apr 13, 2032	U-2736			
	10420775	Apr 13, 2032	U-2852			
	10420775	Apr 13, 2032	U-2853			
	8410088	Apr 13, 2032	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Apr 13, 2032	U-2852			
	8765732	Apr 13, 2032	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	9175331	Sep 12, 2031	U-2852			
	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			
	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9549931	Apr 13, 2032	U-2852			
	9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			
	9949999	Sep 12, 2031	U-2851			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2025	DS			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Jun 20, 2028	DS DP U-2507		NPP	Jun 19, 2023
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Jun 20, 2028	DS DP U-2507		NPP	Jun 19, 2023
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Apr 17, 2025	DS DP		M-255	Feb 04, 2023
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001 >A>	8338395	May 08, 2027	U-1500			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	10695308	Dec 16, 2024	U-2845			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	10695308	Dec 16, 2024	U-2845			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849			
	10716793	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724		ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724		ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724		ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724		ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724		ODE-308	Dec 20, 2020
	8747897	Aug 11, 2031	DP U-2725			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
<u>TRIHEPTANOIN - DOJOLVI</u>						
N 213687 001	>A> 8697748	Oct 03, 2025	DP		NCE	Jun 30, 2025
	>A> 9186344	Jul 01, 2025	DP		>A> ODE-311	Jun 30, 2027
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP		>A> ODE-309	Apr 17, 2027
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP		>A> ODE-309	Apr 17, 2027
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	10597400	Oct 17, 2036	U-2616			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10688046	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10730873	Nov 21, 2031	DS			
	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	9079934	Aug 31, 2031	DS DP		NCE	Aug 12, 2025
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm